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1 INTRODUCTION 
1.1 Pancreatic cancer 
1.1.1 Epidemiology of pancreatic cancer 
(This part has been partly published (Huang et al., 2018a; Huang et al., 2017; Huang et al., 2018b).) 
Pancreatic cancer (PaC) is one of the most deadly malignancies and constitutes a major global health 
burden. In 2018, ~459,000 patients are estimated to be newly diagnosed with PaC and ~432,000 
PaC-associated deaths are estimated to occur, accounting for 3% of all new cancer cases and 5% of all 
cancer-related deaths, respectively (Bray et al., 2018). It is the seventh leading cause of cancer-related 
mortality worldwide, with mortality closely paralleling incidence (Bray et al., 2018). The incidence of 
PaC is especially high in developed countries, being the fourth leading cause of cancer-related 
mortality in Western societies (Ferlay et al., 2013; Malvezzi et al., 2017; Siegel et al., 2017). In the 
European Union, the incidence of PaC has been stable or moderately increasing over the past decades, 
and was estimated to have caused 91,500 deaths in 2017, and to cause 111,500 deaths in 2025, 
potentially becoming the third leading cause of cancer-related deaths (Ferlay et al., 2016). In 2018, 
88,900 patients in Europe and 44,300 in the United States (US) are estimated to die from this 
malignancy (Malvezzi et al., 2018; Siegel et al., 2018). No particularly strong risk factors are 
universally accepted for PaC, which precludes timely intervention (Malvezzi et al., 2017; Siegel et al., 
2017; Vasen et al., 2016). PaC usually occurs at older ages, and more than half of the patients are 
diagnosed with advanced-stage diseases due to the lack of effective early screening methods and the 
usually unspecific early symptoms and signs (Canto et al., 2013; Ryan et al., 2014; Wolfgang et al., 
2013). Treatment for PaC is thus largely palliative. The long-term survival of PaC patients is poor, 
even in those with early-stage diseases (Ferlay et al., 2013; Malvezzi et al., 2017; Siegel et al., 2017; 
Sirri et al., 2016). With 5-year survival of only about 5%, advances in survival of PaC patients have 
been slow (Siegel et al., 2018), and the prognosis has not markedly improved over the past decades 
despite numerous efforts in therapeutic modification (Lepage et al., 2015b; Wolfgang et al., 2013). 
PaC is the only major cancer entity not showing declining mortality rates in both sexes in Europe 
(Malvezzi et al., 2017). 
1.1.2 Treatment for pancreatic cancer 
(This part except the last two paragraphs has been published (Huang et al., 2018a; Huang et al., 2017; 
Huang et al., 2018b).) 
Primary resection of the primary tumor and regional lymph nodes (LNs) remains the cornerstone of 
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potentially curative treatment which could markedly improve the long-term survival in selected 
patients, and is recommended for medically-fit patients with resectable locoregional PaC amenable to 
surgery, who however comprise only less than one-fifth of all diagnosed cases (Khorana et al., 2016; 
Khorana et al., 2017a; Khorana et al., 2017b; Wolfgang et al., 2013). Resectability is to a large extent 
determined by vascular involvement. Only patients with favorable conditions and high probability to 
achieve curative resection are deemed eligible candidates for resection (Ryan et al., 2014). While 
resection mostly aims at negative margins, notably, it currently remains controversial how 
clear-margin (R0) resection should be defined (Konstantinidis et al., 2013; Tempero et al., 2014) and 
whether and how strongly it is associated with survival (Butturini et al., 2008; Chandrasegaram et al., 
2015). The resectability criteria for PaC in the European Society for Medical Oncology (ESMO) 
guidelines (Ducreux et al., 2015b) follow the US National Comprehensive Cancer Network (NCCN) 
guidelines (Tempero et al., 2014). According to the current guidelines (Balaban et al., 2016; Ducreux 
et al., 2015b; Khorana et al., 2016; Sohal et al., 2016; Tempero et al., 2014), only American Joint 
Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) tumor-node-metastasis 
(TNM) stage I-II PaCs are usually resectable, while for locally-advanced PaCs involving major 
arteries (T4/stage III according to the TNM staging system) and metastatic (M1/stage IV) cancers, 
resection should be mostly avoided. However, the resectability criteria are differentially and arguably 
defined (Balaban et al., 2016; Evans et al., 2015; Wolfgang et al., 2013). Notably, even most of stage 
I-II PaCs are not curatively resectable. Large-scale investigations on surgical resection for PaC are rare 
(Balaban et al., 2016).  
The perioperative mortality is noteworthy. In Germany, it is 10% on the whole population basis 
and is volume-dependent (5%-6% even in the largest centers), which is mainly influenced by failure to 
rescue and surgical expertise (Krautz et al., 2017; Nimptsch et al., 2016). Furthermore, postsurgical 
morbidity remains relatively high (30%-40%) even in high-volume centers (Ceppa et al., 2015). 
Patients with resectable PaC who undergo resection have much better survival especially in the longer 
term than those who cannot undergo resection (Ducreux et al., 2015b; Khorana et al., 2016). When 
counseling a given PaC patient who is considering surgery or who has already undergone resection, it 
is important to well inform him/her with survival estimates especially for the resected subgroup so that 
he/she could decide whether or not to undergo resection. However, population-based survival 
estimates are only available for overall patients without differentiation by resection status or TNM 
stage (Lepage et al., 2015b), according to which survival however might vary greatly. Survival in 
resected PaC from institutional reports would be accompanied with relatively high patient selection, 
which makes the generalizability questionable. 
While resection offers the only chance to cure PaC, the 5-year postsurgical survival remains low 
(8%-16%) if no further adjuvant treatment is administered (Oettle et al., 2013; van der Geest et al., 
2016a), as tumors might quickly recur locally and/or distantly (Oettle et al., 2013). Chemotherapy 
further improves outcomes (Lutz et al., 2017; Neoptolemos et al., 2010; Oettle et al., 2013; Oettle et 
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al., 2007), while the safety and efficacy of adding radiation remains controversial (Hammel et al., 
2016; Liao et al., 2013). While chemotherapy has been routinely recommended for resected PaC 
(Ducreux et al., 2015b; Khorana et al., 2016; Tempero et al., 2017), it remains challenging to get 
many patients to adjuvant therapy after pancreatectomy (Huang et al., 2018b). Patients with 
locally-advanced or metastatic diseases are generally not considered candidates for surgery, and 
palliative treatment remains the mainstay (Sohal et al., 2016). Underuse of therapy with proven 
efficacies potentially greatly limits survival improvement (Tsai and Evans, 2016). Although the 
European and US evidence-based guidelines have clearly outlined the role of non-surgical treatment 
for PaC (Balaban et al., 2016; Ducreux et al., 2015b; Khorana et al., 2016; Sohal et al., 2016; 
Tempero et al., 2014), its application in the real-world clinical practice has rarely been investigated. 
While randomized controlled trials (RCTs) on chemotherapy and radiotherapy for PaC have been 
actively conducted (Hammel et al., 2016; Liao et al., 2013; Lutz et al., 2017; Neoptolemos et al., 2010; 
Oettle et al., 2007), the implementation of the evidence into the clinical routine remains largely 
unexplored.  
Studying survival-associated factors in patients with resected PaC receiving chemotherapy is 
difficult due to challenges in accruing adequate and sufficient numbers of operated patients with 
detailed information. While to date some studies have tried to identify the prognostic factors, most of 
them reported single institution-/hospital-based case series with <200 long-term survivors, revealing 
conflicting results (Erdmann et al., 2015; Jouffret et al., 2015; Pindak et al., 2017; Yamamoto et al., 
2015). Further insights into the survival-associated factors at the population level would have 
important implications for treatment and prognosis. 
Survival is heterogeneous in resected PaC patients undergoing chemotherapy, and there lacks a 
model predicting individualized survival for them. Stage is the major prognostic factor for PaC. 
Notably, survival of patients with disease of the same TNM stage might vary greatly (Jouffret et al., 
2015). Other prognostic factors such as patient age and tumor differentiation could improve 
individualized survival-prediction. A model incorporating all these factors can be intuitively illustrated 
using a nomogram (Balachandran et al., 2015). Resected patients who receive chemotherapy are 
selected and have characteristics distinct from those who do not (Huang et al., 2018b). Besides two 
institutional nomograms predicting postsurgical survival in overall patients (Brennan et al., 2004; Tol 
et al., 2015), population-based survival-predicting models specifically for resected PaC patients 
receiving chemotherapy with international validations and with robustness have not been found. 
1.1.3 Lymph node examination in pancreatic cancer 
PaC patients with LN metastases have higher risks of disease recurrence after resection. LN 
involvement is amongst the strongest indicators for long-term survival and impacts therapeutic 
decisions in resectable PaC (Khorana et al., 2016; Neoptolemos et al., 2017; Tempero et al., 2017). 
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LN sampling or dissection might play vital roles in precise nodal staging by identifying the presence 
of LN involvement and in possibly enhanced treatment effect by clearing potentially metastatic LNs. 
However, due to the low resection rates (Huang et al., 2017), large international population-based 
investigations on LN examination in resected PaC remain scarce.  
Previous studies have shown contradictory results regarding the association of examined LN 
(ELN) number with long-term survival in resected PaC (Ashfaq et al., 2014; Hellan et al., 2008; 
Huebner et al., 2012; Lahat et al., 2016; Michalski et al., 2007; Pedrazzoli et al., 1998; Riall et al., 
2005; Slidell et al., 2008; Sun et al., 2014; Tol et al., 2014b; Valsangkar et al., 2013; Wu et al., 2014; 
Yeo et al., 2002; Yeo et al., 1999). Some small retrospective studies suggested that more ELNs were 
associated with better prognosis especially in node-negative disease (Ashfaq et al., 2014; Hellan et al., 
2008; Huebner et al., 2012; Slidell et al., 2008; Valsangkar et al., 2013), while for node-positive 
cancer, ELN number was non-prognostic (Lahat et al., 2016; Vuarnesson et al., 2013). However, a 
secondary analysis of the Radiation Therapy Oncology Group (RTOG)-9704 trial showed that while 
overall more ELNs were associated with improved survival, there was not such an association in 
node-negative disease (Showalter et al., 2011). A recent systematic review did not demonstrate a 
significant association between ELN number and survival (Elshaer et al., 2017). Most previous studies, 
however, had potential important limitations such as lack of adjustment for confounders, absence of 
stratified analyses, and limited sample size, resulting in limited robustness. More robust evidence on 
this topic is therefore needed. 
In general, ELN number is considered an important metric for quality assessment in cancer care 
(Benson et al., 2017; Benson et al., 2018; Ettinger et al., 2017; Gradishar et al., 2018). In PaC, 
however, the minimum number of LNs which should be examined as a quality indicator especially to 
accurately stage cancer or to stratify patient survival has not yet been well-established. The NCCN has 
not suggested a specific threshold for ELNs in PaC. According to the AJCC and UICC, a minimum of 
10 LNs is recommended to be analyzed for nodal staging. The ESMO, however, recommends removal 
of ≥15 LNs to allow adequate pathologic staging (Ducreux et al., 2015b). The survival impact has not 
been emphasized in the guidelines. In several small retrospective single-institution univariable 
analyses, recommendations for ELN number in PaC varied greatly from 11 to 20, and the methods for 
identifying the cut-off values were not statistically robust (Ashfaq et al., 2014; Huebner et al., 2012; 
Valsangkar et al., 2013). Single institution/hospital-based findings might not be generalizable to the 
average real-world population level due to high case selection. The controversies between guidelines 
and studies need to be further addressed by large international population-based evidence. 
1.2 Gastric cancer 
1.2.1 Epidemiology of gastric cancer 
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Despite the overall declines in incidence and mortality (Arnold et al., 2015; Smyth et al., 2016), 
gastric cancer (GC) remains a significant cancer burden globally (Soerjomataram et al., 2012). 
Worldwide ~1,034,000 patients are estimated to be newly diagnosed with GC and ~783,000 
GC-associated deaths are estimated to occur in 2018, accounting for 6% of all new cancer cases and 8% 
of all cancer-related deaths and making it the fifth most commonly diagnosed malignancy and the third 
leading cause of cancer-related mortality (Bray et al., 2018). GC is the fourth leading cause of 
cancer-related mortality in Europe with ~107,000 deaths in 2012 (Ferlay et al., 2013). GC is 
anatomically categorized into cardia and non-cardia cancers, whose incidences have been trending in 
opposite directions over the past decades in Western countries (Colquhoun et al., 2015; Smyth et al., 
2016). Alarmingly, cardia cancer with an especially poor prognosis is showing an increasing incidence 
(Mariette et al., 2011; Torre et al., 2015). Most patients with early-stage GCs for which curative 
treatment is largely possible are asymptomatic, and many GC patients have advanced disease at 
diagnosis (Thrumurthy et al., 2013).  
1.2.2 Treatment for gastric cancer 
Adequate resection remains the cornerstone of potentially curative treatment which can assure 
long-term survival for medically fit patients with resectable non-metastatic GC (Ajani et al., 2016; 
Smyth et al., 2016; Songun et al., 2010). Notably, involvement of peri-stomach structures in 
non-metastatic cancers might preclude resection, while a proportion of patients with metastatic disease 
undergo resection partly due to detection of metastasis only during or after surgery or for palliative 
reasons. Regarding non-surgical therapies, the recommendation is perioperative chemotherapy in 
Europe (Smyth et al., 2016), while adjuvant chemoradiotherapy is preferred in the US (Ajani et al., 
2016) 
GC shows marked global variations in etiology, incidence, patient and tumor characteristics, 
management, and outcomes (Ferro et al., 2014; Macdonald, 2011; Strong et al., 2010). GC care has 
not been well-investigated in Western countries due to its being less prevalent, which potentially 
hampers the survival improvement. Real-world GC treatment patterns at the population level, which 
may be directly associated with the overall survival statistics, have remained largely unknown in most 
Western countries except the Netherlands (Dassen et al., 2013; Nelen et al., 2017). Notably, the 
application of resection, which is the fundamental treatment for GC, has been rarely studied. 
International analyses of treatment patterns could help to identify differences and potentially 
modifiable places in clinical practice, of potential relevance for guiding adequate health policy-making 
and resource allocation. 
1.3 Study questions and aims 
Using real-world data from multiple European national population-based cancer registries and the US 
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Surveillance, Epidemiology, and End Results (SEER) Program (SEER, 2018), this thesis/dissertation 
aims to investigate the treatment and outcomes for PaC and GC in Europe and the US in the early 21st 
century. The research questions are detailed as follows: 
1.3.1 Pancreatic cancer 
 To explore the application of surgical resection for PaC in various European countries and the US; 
 To assess chemotherapy and radiotherapy use across countries for resected and unresected PaC; 
 To comprehensively and robustly provide 1-month to 5-year overall survival estimates at the 
population level for overall (resected and unresected) and resected PaC patients in Europe and the 
US stratified by TNM stage and age; 
 To explore the survival trends over time in each country; 
 To investigate factors associated with survival in patients with resected TNM stage I-II PaC 
receiving chemotherapy;  
 To construct a population-based survival-predicting model with international validations; 
 To further investigate the association of ELN number with staging and survival in resected PaC 
through overall and stratified analyses of resected PaC patients from the US and the Netherlands; 
 To determine and to validate the minimal and optimal thresholds for the ELN number, using a 
multivariable approach. 
1.3.2 Gastric cancer 
 To investigate the application of resection for both non-metastatic and metastatic GCs and explore 
the treatment-associated factors; 
 To come up with some potential explanations for the observed trends. 
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2 MATERIALS AND METHODS 
2.1 Data sources and quality 
2.1.1 Data sources 
(This part has been published (Huang et al., 2018a; Huang et al., 2017; Huang et al., 2018b).) 
For robustness, only data from population-based cancer registries were included in the analyses for 
this thesis. Institution-based data were not included due to the relatively high risk of patient selection 
bias. An extensive attempt was made to find and contact population-based cancer registries, and 
formal invitations were sent to the population-based participants of the EUROpean CAncer 
REgistry-based study on survival and CARE of cancer patients (EUROCARE) project (Lepage et al., 
2015a) and other population-based registries based on extensive PubMed and internet search. The 
response rate was relatively high, but only national population-based registries able to provide high 
quality data on TNM staging, treatment (resection, chemotherapy, and radiotherapy), and survival 
were eligible. A list showing the selection of the contacted European national population-based cancer 
registries together with the reasons for exclusion is shown in Table 1. Finally, population-based data 
of PaC patients from seven European national population-based cancer registries (the Netherlands, 
Belgium, Norway, Denmark, Sweden, Slovenia, and Estonia) and the US SEER-18 Program database 
were obtained for this large international real-world observational study series. The participating 
European population-based national registries, located in Western, Northern, Southern, and Eastern 
Europe, respectively, were those able to provide data of relatively high quality according to a 
standardized uniform data-request sheet with variable lists, to ensure the robustness of the results. All 
variables were uniformly (re)coded across registries. All patient-level data were anonymous. No 
individual patient data were reported. This real-world observational study was approved by the Ethics 
Committee of the Medical Faculty Heidelberg, conducted according to the Declaration of Helsinki 
(World Medical, 2013), and reported following the Strengthening the Reporting of Observational 
Studies in Epidemiology (STROBE) guidelines. 
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Table 1. Selection of contacted European national population-based cancer registries1 (Huang et al., 2018a) 
Country of 
contacted registry 
Included in 
pancreatic 
cancer study 
Included in 
gastric 
cancer study 
Comment if not initially included 
Comment if initially included but 
not included in one or more further 
analyses 
Northern Europe     
Finland No No Surgical treatment not validated  
Sweden No Yes Pancreatic cancer: national data not statistically validated 
 
Norway Yes Yes   
Iceland No No No national population-based data on treatment 
 
Denmark Yes No Gastric cancer: required variables not readily prepared 
Pancreatic cancer: consent withdrawn 
due to legislation issues 
Western Europe     
The UK No No 
No ready-to-use national 
population-based data on treatment or 
TNM stage 
 
Ireland No No No further response after initial contact  
The Netherlands Yes Yes   
Belgium Yes Yes   
Southern Europe     
Bulgaria No No No national population-based data on treatment 
 
Serbia No No No response  
Slovenia Yes Yes   
Croatia No No No national population-based data on surgical treatment 
 
Eastern Europe     
Estonia Yes Yes  
Small number of resected cases and 
short incidence periods recorded not 
allowing for robust survival analysis 
Latvia No No No national population-based data on treatment 
 
Lithuania No No No response  
Ukraine No No Insufficient resources for data collection 
 
Slovakia No No No response  
Central Europe     
Poland No No No response  
Czech Republic No No No national population-based data on treatment 
 
Austria No No No national population-based data on treatment 
 
1For the other countries and regions in Europe (e.g., France, Italy, and Germany) not listed in this table, no corresponding national 
population-based registries were found through careful search. 
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2.1.2 Data quality 
(This part except the description of the Swedish registry has been published (Huang et al., 2017).) 
The included registries generally follow the international standards and classifications, and are 
controlled for quality using the International Agency for Research on Cancer (IARC) and International 
Association of Cancer Registries (IACR) rules. The data analyzed are generally of high quality. 
2.1.2.1 European population-based registries 
The European national population-based cancer registries included in this thesis participate in the 
EUROCARE, whose criteria for inclusion, quality checks, etc. have been extensively described (Rossi 
et al., 2015).  
The Netherlands Cancer Registry (NCR) 
The Netherlands Cancer Registry (NCR)/Netherlands Comprehensive Cancer Organization (IKNL) is 
a national organization and is the quality institute for oncologic research and practice. “The objective 
of IKNL is to serve the public interest by promoting the fight against cancer, particularly by helping 
those suffering from cancer.” The NCR/IKNL supports this objective through the following four main 
processes: 1) Record: Information about every patient with cancer in the Netherlands is gathered in the 
NCR. 2) Report: The data in NCR are then reported in three domains: the public (science), political 
(the Ministry of Health, Welfare and Sport, and the National Health Care Institute), and care domains 
(hospitals/care institutions, professionals, and patients). 3) Improve: The effect of all the improvement 
initiatives (e.g., training) is evaluated in the NCR/IKNL. The IKNL responds to developments in the 
field by shifting its focus from a general to a tumor-specific approach to oncologic care. 4) Regulate: 
Guidelines are deployed to improve quality and efficiency and to reduce unwanted variation in care 
(NCR, 2017).  
Belgian Cancer Registry (BCR) 
The Belgian Cancer Registry (BCR) is a national population-based registry which has covered the 
entire country since 2004 and which relies on two major data sources: oncologic care programs and 
pathology laboratories. It has a legal basis to use the national registration number which allows 
accurate linkage and follow-up. Detailed information about diagnostic and therapeutic procedures is 
obtained through linkage with administrative and clinical databases for an active involvement in 
quality of care studies. 
Cancer Registry of Norway (CRN) 
Records in the Cancer Registry of Norway (CRN) are complete and nationwide, and the CRN has 
since 1953 kept a complete registration of all new cases of malignancies. Regulated by the Norwegian 
law, medical practitioners are required to report cancerous and pre-cancerous lesions to the registry, 
and five sources of information are available: 1) copies of all pathology and autopsy reports from all 
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laboratories in Norway, 2) registration forms filled in by clinicians providing the location and extent of 
disease and treatment, 3) copies of all death certificates that mention neoplastic disease, 4) hospital 
discharge data and outpatient diagnoses from all hospitals, and 5) radiotherapy data from all treating 
centers. The CRN has documented a high degree of data quality including key aspects such as 
comparability, completeness, and validity (Larsen et al., 2009).  
Danish Pancreatic Cancer Database (DPCD) 
The Danish PaC data are based on the Danish national registries for pathology and treatment, which 
are well documented with a high data validity (Erichsen et al., 2010; Pedersen, 2011; Schmidt et al., 
2014; Schmidt et al., 2015). In Denmark, all hospitals are required to register diagnosis and treatment 
information for every patient contact in the Danish National Patient Registry. All histological and 
cytological specimens are likewise required to be registered in the National Pathology Register. The 
Danish Civil Registry keeps track of the vital status of all Danes. The Danish Pancreatic Cancer 
Database (DPCD) gets data from all these three registers and combines the data. The combined data 
for each patient are validated by the relevant surgical and oncological department regarding diagnosis 
and treatment. The completeness of clinical validation has been around 70%. The completeness 
regarding patients with a diagnosis of PaC is close to 100%.  
The Swedish National Register for Esophageal and Gastric Cancer (NREV) 
In 2006 The Swedish Association for Upper Gastro-Intestinal Surgery closed two previous registers, 
SWEGIR (https://www.swegir.com/) for GC and SECC, another research-based register for 
esophageal and cardia cancer, which later merged and formed The Swedish National Register for 
Esophageal and Gastric Cancer (NREV) on January 1st, 2006. NREV receives yearly financial support 
from the Swedish Government. The Steering Committee of the NREV consists of surgeons, 
oncologists, nurses, a pathologist, patients, and statisticians with representativeness from both 
university and regional/county hospitals. The Steering Committee of the NREV is also responsible for 
establishing the national guidelines of care for patients with esophageal and gastric cancer, which are 
updated every second year. The main objectives of the NREV are to compile data and information to 
monitor the diagnostic process, to evaluate the treatment regimens, and to improve the care of patients 
with esophageal cancer and/or GC. The NREV also serves to facilitate research, and yearly publishes 
the results for the previous year. The register has been validated and shown to have a high level of 
completeness, accuracy, and concordance compared to the mandatory Swedish Cancer Registry 
(Linder et al., 2016). 
Cancer Registry of Slovenia (CRS) 
The quality and completeness indices of the Cancer Registry of Slovenia (CRS) suggest that cancer 
registration in Slovenia adequately covers the entire population. To assure the completeness and to 
obtain additional information on registered cancer cases, the CRS is linked with several governmental 
and health databases. The synchronization of data between different sources is based on comparing the 
unique personal identification number which is assigned to every resident in Slovenia and recorded in 
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every state registry including the CRS. Using unique personal identification numbers guaranties data 
integrity and quality, and prevents data duplication. The CRS links with the Central Register of 
Population instantaneously through secure on-line connection (24/7 availability) and daily updates 
information on vital status and address for each person registered by the CRS. The electronic linkage 
to the national Mortality Database is performed several times every year (Zadnik et al., 2017).  
Estonian Cancer Registry (ECR) 
In Estonia, the overall completeness of reporting cancer cases has been estimated to be approximately 
95%-98%. The Estonian Cancer Registry (ECR) regularly performs data linkage with the Estonian 
Causes of Death Registry. Additionally, the ECR regularly compares its database with the databases of 
the two biggest hospitals responsible for PaC surgical treatment for assurance of the completeness. 
Data are received on clinical and pathology notification forms. Data input and coding are done within 
the registry. The registry has been regularly using the IARC Check Program for checking the internal 
consistency of data. The data quality is evaluated using standard indicators for population-based 
registries (Innos et al., 2014).  
2.1.2.2 The Surveillance, Epidemiology, and End Results Program 
The SEER Program of the National Cancer Institute (NCI) is an authoritative source of information on 
cancer epidemiology in the US, and collects data from population-based cancer registries. The SEER 
Program registries routinely collect data on patient demographics, primary tumor site, morphology, 
stage, the first course of treatment, and follow-up for vital status. The SEER Program is the only 
comprehensive source of population-based information in the US that includes stage of cancer at the 
time of diagnosis. The SEER data are updated annually and provided as a public service. The NCI 
staff work with the North American Association of Central Cancer Registries to guide all state 
registries to achieve data content and compatibility acceptable for pooling data and improving national 
estimates. 
The SEER Program is viewed as the standard for quality among cancer registries around the 
world. Each SEER Program registry has a contractual obligation to meet the specifically defined data 
quality goals on an ongoing basis. The SEER Program has also developed an extensive set of field 
edits which prevent and correct errors in the data. Electronic edits provide the means to authenticate 
codes, to check for missing data, and to check for interrelated data item errors. The joint efforts with 
national committees and national data standards contribute to the high data quality (SEER, 2018).  
2.2 Pancreatic cancer 
The overall inclusion and exclusion criteria and the overall collected information and definition are 
first described, and the study-specific methods are then detailed in each specific subsection with the 
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corresponding heading. Data in each country were analyzed separately and results were described for 
each country separately without pooling, considering the potential heterogeneity across countries and 
to avoid the impact of any single large patient cohort. Numeric data are presented as mean ± standard 
deviation and/or median (interquartile range) where appropriate, and categorical data as count 
(percentage). The SAS software (v. 9.4; SAS Institute Inc., Cary, NC) was used for analysis if not 
otherwise specified, and statistical significance was defined by two-sided P <0.05. 
2.2.1 Overall inclusion and exclusion criteria 
(This part has been partly published (Huang et al., 2018a; Huang et al., 2017; Huang et al., 2018b).) 
Only patients with diagnoses of primary invasive malignancies of the exocrine pancreas were selected. 
Cases were initially included regardless of being eligible for resection. Patients were initially included 
irrespective of being microscopically diagnosed or not in this real-world study following the 
EUROCARE studies (De Angelis et al., 2014; Lepage et al., 2015b), since consensus has been reached 
by the International Study Group of Pancreatic Surgery (ISGPS) that, in the presence of a solid mass 
suspicious for malignancy, biopsy proof has not been and is not required before proceeding with 
resection (Asbun et al., 2014). Patients with benign/premalignant tumors, non-pancreatic neoplasms 
involving the pancreas, neuroendocrine tumors/carcinoids, stromal tumors/sarcomas, germ-cell 
neoplasms, lymphomas, or peri-ampullar tumors were excluded (Table 2). Patients with diagnosis 
based on death certificate only (DCO) or autopsy were also excluded. As the fifth and prior editions of 
the TNM staging system were not compatible with the later versions (sixth or seventh) in effect during 
2003-2017 (Ducreux et al., 2015b), only patients with PaC diagnosed from 2003 or the first year when 
resection status was registered until 2016/2017 (depending on the year when the specific part of 
analyses were done) or the most recent year of registration were included in each registry. 
 
Table 2. Inclusion and exclusion codes for pancreatic cancer according to the International Classification of 
Diseases for Oncology, Third Edition (Huang et al., 2017) 
Category  Code 
Topography Inclusion C25.0 (head of pancreas), C25.1 (body of pancreas), C25.2 (tail of pancreas), C25.3 
(pancreas duct), C25.7 (other specified parts of pancreas), C25.8 (overlapping lesion of 
pancreas), C25.9 (pancreas, NOS) 
 Exclusion C25.4 
Morphology Inclusion1 8000-8009 (unspecified neoplasms), 8010-8049 (epithelial neoplasms, NOS), 8050-8089 
(squamous cell neoplasms), 8140-8389 (adenomas and adenocarcinomas), 8440-8499 
(cystic, mucinous, and serous neoplasms), 8500-8549 (ductal and lobular neoplasms), 
8550-8559 (acinar cell neoplasms), 8560-8579 (complex epithelial neoplasms) 
 Exclusion 8013, 8150-8153, 8155-8157, 8160, 8162, 8170, 8180, 8240-8243, 8246-8249, 8312, 8680, 
8700, 8800-8802, 8810, 8825, 8830, 8851, 8852, 8858, 8890, 8891, 8900, 8920, 8936, 8982, 
9043, 9100, 9120, 9250, 9364, 9473, 9500, 9591, 9673, 9680, 9687, 9691, 9695, 9702 
Behavior Inclusion 3 (invasive malignant tumor) 
 Exclusion 0, 1, 2 
1Based on the Surveillance, Epidemiology, and End Results (SEER) Program broad groupings. 
NOS, not otherwise specified. 
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2.2.2 Overall collected information and definition 
(This part has been partly published (Huang et al., 2018a; Huang et al., 2017; Huang et al., 2018b).) 
Information on patient (year of diagnosis/surgery, sex, and age) and cancer characteristics 
(microscopic confirmation, topography, morphology, TNM stages, and differentiation), treatment 
(resection and (neo)adjuvant/palliative chemotherapy and radiotherapy), and outcome variables 
(follow-up time and survival status) was obtained from all participating countries. 
Specific covariates were only available in certain national population-based registries. 
Race/ethnicity and marital status were available in SEER-18. Tumor size was available in the US. 
Comorbidity information at diagnosis was recorded in the Eindhoven Cancer Registry (EiCR), which 
is part of the national Netherlands Cancer Registry and which contributes to more than one-tenth of 
the records in the Netherlands Cancer Registry. Belgium and Denmark provided Eastern Cooperative 
Oncology Group (ECOG) performance status score. Chemotherapy information was not available in 
SEER-18 for the 2015 submission. For the 2016 and 2017 SEER-18 submission, non-surgical 
therapies were reported with low sensitivity. Neoadjuvant and adjuvant chemotherapy/radiotherapy 
was not distinguishable in Estonia, and neoadjuvant and adjuvant chemotherapy was not 
distinguishable in the US in the submission versions with available information. Information on 
neoadjuvant chemotherapy and radiotherapy was not available in Norway. Time intervals between 
diagnosis/surgery and chemotherapy/radiotherapy application were available in the Netherlands, 
Belgium, and Slovenia. Information on hospital type was available in the Netherlands and Belgium. In 
resected patients, data on positive and harvested lymph node numbers and resection type were 
retrievable in the US and the Netherlands. Data on resection margin were available in the Netherlands 
and Slovenia. For SEER-18, sub-registry information was additionally retrieved. 
Tumor stage was defined according to the AJCC/UICC TNM staging system, Sixth or Seventh 
Edition (both editions are identical to each other) (Ducreux et al., 2015b). Tumor topography, 
morphology, and behavior were coded based on the International Classification of Diseases for 
Oncology, Third Edition (ICD-O-3) (WHO, 2018). Tumor location included pancreas head (C25.0), 
body (C25.1), tail (C25.2), overlapping lesion (C25.8), and other (pancreas duct, overlapping lesion, 
or not otherwise specified (NOS) tumor). Tumor histology was categorized into adenocarcinoma, not 
otherwise specified (8140-8389), ductal/lobular neoplasms (8500-8549), cystic/mucinous/serous 
cancers (8440-8499), and other based on the SEER broad grouping (SEER, 2018), and all histology 
types were malignant and invasive. Lymph node ratio (LNR) was calculated by dividing positive LN 
(PLN) by examined LN (ELN) number. 
Resection was defined as surgical removal of the primary tumor, regardless of being curative or 
palliative and extents of excision and lymphadenectomy. A patient was considered to have received 
chemotherapy/radiotherapy if ≥1 cycle was administered, regardless of the detailed regimen, dosage, 
and administration method. In operated patients, neoadjuvant therapy referred to the non-surgical 
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treatment supplied before resection, and adjuvant treatment was that given post-operation. 
Chemotherapy/radiotherapy was considered palliative if resection was not conducted. Survival status 
was obtained from official population registers and/or valid national mortality registrations. 
2.2.3 Resection of pancreatic cancer in Europe and the US 
(This part has been published (Huang et al., 2017).) 
Data from the national population-based cancer registries of the Netherlands, Belgium, Norway, 
Denmark, Slovenia, and Estonia and from the US SEER-18 Program (the 2015 submission (SEER, 
2016)) was used for this part of analyses (Table 1).  
Patient age was divided into four groups (<60, 60-69, 70-79, and ≥80 years). Age-standardized 
resection rates were computed for each population-based registry using the age distribution of the US 
patients, the largest group of patients included. Trends of standardized resection rates over years were 
evaluated for each country and, for simplicity, rates over two-calendar year periods (2003-2004 until 
2013-2014) were displayed. 
Multivariable logistic regression was used to investigate the associations of resection with sex, 
age group, tumor location, and cTNM stage in overall patients, with female, <60 years, pancreas head 
tumor, and stage I-II as the reference category, respectively. Year of diagnosis was also included in the 
models. Sensitivity analyses were conducted by repeating association analyses after imputing missing 
stages using multiple imputations (Moons et al., 2015) (variables applied: year of diagnosis, sex, age, 
tumor location, resection, chemotherapy, radiotherapy, and survival time and status; routine: PROC 
MI). In additional analyses, associations were investigated for tumor subgroups according to tumor 
stage and location, respectively, and were reassessed after adding tumor size, ECOG score, 
comorbidity, or hospital type one by one into the models.  
2.2.4 Non-surgical therapies for resected and unresected pancreatic cancer in Europe and the 
US 
(This part has been published (Huang et al., 2018b).) 
Data from the national population-based cancer registries of the Netherlands, Belgium, Norway 
(2003-2011, the period 2012-2014 was not included in this part of analyses due to low sensitivity of 
reporting), Slovenia, and Estonia and from the US SEER-18 Program (the 2015 submission (SEER, 
2016)) was used for this part of analyses (Table 1). 
A combination of cTNM and pTNM stages was used with priority given to pTNM staging. To 
explore the chemotherapy and radiotherapy utilization, age-standardized rates for resected and 
unresected PaC were computed using the age distribution in the cancer population from the US, the 
largest dataset in this study, as standard. Age was divided into the following groups: <60, 60-69, 70-79, 
and ≥80 years. Treatment rates were tested for linear trends, and rates over two-calendar year periods 
MATERIALS AND METHODS 
15 
 
(2003-2004 until 2013-2014) were depicted. Rates of chemotherapy and radiotherapy application 
according to age group, tumor location, and TNM stage in resected and unresected patients, and 
geographic disparities across the US registries during 2012-2014 were further explored. Utilization of 
combination therapies regarding neoadjuvant and adjuvant chemotherapy and radiotherapy in the 
common period 2011-2013 was assessed in the Netherlands, Belgium, and Slovenia, where 
information on both neoadjuvant and adjuvant treatment was available. Due to the very low rates of 
neoadjuvant treatment, neoadjuvant and adjuvant therapies were combined in the other analyses. 
Multivariable logistic regression was used to evaluate the associations of chemotherapy and 
radiotherapy utilization with year of diagnosis, sex, age, tumor location, and TNM stage for resected 
and unresected patients in the main analyses. Additional variables (hospital type, lymph node ratio 
(LNR, the proportion of metastatic to harvested nodes), ECOG score, resection type, and comorbidity 
type and number) were included one by one into the main models in further analyses in countries with 
available information. Sensitivity analyses were conducted by limiting patients receiving 
chemotherapy or radiotherapy to those undergoing the treatment ≤90 days after diagnosis in countries 
with available time interval information, and by restricting the total patients to those surviving >90 
days after diagnosis in all countries to control for the impact of short-term mortality on treatment 
reception. 
2.2.5 Stratified survival of resected and overall pancreatic cancer patients in Europe and the US 
(This part has been published (Huang et al., 2018a).) 
Data from the national population-based cancer registries of the Netherlands, Belgium, Norway, and 
Slovenia and from the US SEER-18 Program (the 2015 submission (SEER, 2016)) was used for this 
part of analyses (Table 1). 
Patients with unknown diagnosis/follow-up date or survival status or without TNM staging 
information were further excluded. In stage classification, pTNM stages were prioritized over cTNM 
ones. Complete-case analysis was performed for patients with known TNM stages. Overall survival 
was defined as the months between diagnosis and death from any cause/last follow-up, and was 
estimated for overall and resected PaC patients stratified by TNM stage (I-II and III-IV) and age group 
(<60, 60-69, and ≥70 years) using the Kaplan-Meier method, with the 1-, 3-, 6-, 12-, 24-, 36-, and 
60-month survival rates calculated. Cancer stage was divided into stage I-II and III-IV considering the 
former to be clearly-resectable and the latter mostly-unresectable, and to ensure adequate numbers for 
assessment in each subgroup. When describing survival for resected stage III-IV PaC, the subgroups 
<60 and 60-69 years were combined considering the small size of either. All categories were 
predefined. Sensitivity analyses were conducted by limiting the overall patients to those with 
microscopic confirmation. Survival trends over three calendar-year periods (2003-2005, 2006-2008, 
and 2009-2011) in each country were further reported. Changes in survival rates of overall and 
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operated patients diagnosed between 2003-2005 and 2009-2011 were examined using the log-rank 
test.  
2.2.6 Prognostic factors and development and international validation of a benchmark 
population-based survival-predicting model in patients with resected stage I-II pancreatic 
adenocarcinoma receiving chemotherapy 
Data from the national population-based cancer registries of the Netherlands, Belgium, Norway, and 
Slovenia and from the US SEER-18 Program (the 2017 submission (SEER, 2018)) was used for this 
part of analyses (Table 1). 
2.2.6.1 Patients 
Only patients with microscopically-confirmed diagnoses of primary invasive TNM stage I-II 
adenocarcinomas of the exocrine pancreas who underwent surgical resection in 2003 until 2014 were 
selected. Since chemotherapy is standard for resected PaC patients (Ducreux et al., 2015b; Khorana et 
al., 2016; Tempero et al., 2017), only those receiving chemotherapy were included. Patients with 
unknown/obscure follow-up time or vital status were excluded. Individuals with 
cystic/mucinous/serous or acinar cell tumors were further excluded. To minimize the effect of the 
potential heterogeneity in surgery quality and perioperative care, cases surviving <3 months were 
excluded. Since resection is not routinely recommended for stage III or IV PaC patients (Ducreux et 
al., 2015b; Khorana et al., 2016; Tempero et al., 2017), they were also excluded. Stage was a 
combination of pathologic and clinical stages with priority given to pathologic staging.  
2.2.6.2 Prognostic factors 
The Kaplan-Meier method was applied to calculate survival time and rates. To assess the independent 
impact of potential prognostic factors on survival, Cox proportional hazards regression was used. 
Variables including year of diagnosis, age, sex, tumor location, T and N stages, and differentiation 
were included as covariates in the main multivariable models. For complete-case analysis, patients 
with missing data were excluded in multivariable analyses. In the US, results for the white patients 
were computed for comparison with the total patients, for whom main analyses were performed. In 
registries with available information, resection margin, hospital type, tumor size, positive and 
harvested lymph node numbers, lymph node ratio, T and N stages according to the eighth edition 
following Kamarajah et al. (Kamarajah et al., 2017), ECOG score, resection type, and comorbidities 
were incorporated one by one into the main models to examine the survival association for each of 
them. The proportional hazards assumption was verified for all variables by plotting the logarithm of 
the negative logarithm of the survival function against the logarithm of survival time (Hess, 1995).  
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2.2.6.3 Nomogram construction and validation 
The SEER-18 dataset, the largest among the included ones, was used as the training set for nomogram 
construction (models based on the other cohorts did not reveal markedly better performance). Age, sex, 
tumor location, T and N stages, and differentiation were entered as potentially relevant prognostic 
factors, and the final model was selected using a backward step-down process with the Akaike 
information criterion (AIC) as a stopping rule (Harrell et al., 1996). To permit nonlinear associations, 
continuous variables were modeled using restricted cubic splines where appropriate (Harrell et al., 
1996).  
The nomogram was subjected to 1,000 bootstrap resamples for internal validation of the training 
US cohort, and was externally validated using the European datasets to assess the international 
generalizability of the model. The model performance and discrimination ability for predicting 
survival was numerically evaluated by computing Harrell’s concordance index (C-index) (Harrell et 
al., 1996). Comparison of C-indexes of different models followed Hanley et al. (Hanley and McNeil, 
1983). Calibration of the nomogram for 1, 2, 3-, and 5-year survival was done by comparing the 
predicted with the observed survival. Bootstrapping was used for bias correction (Harrell et al., 1996).  
In sensitivity analyses for the training US cohort, C-indexes were re-calculated after replacing 
continuous age with age group, N stage with positive lymph node number or lymph node ratio, and 
sixth/seventh edition of cancer stages with the eighth version, after adding harvested lymph node 
number and/or tumor size, after limiting patients to those diagnosed after 2009 or white patients, and 
after stratifying patients by tumor location. The survival and rms packages in R 3.4.1 
(http://www.r-project.org) were used. 
2.2.7 Significance of examined lymph node number in accurate staging and long-term survival in 
resected stage I-II pancreatic cancer 
Data from the national population-based cancer registries of the Netherlands and the US SEER-18 
Program (the 2017 submission (SEER, 2018)) was used for this part of analyses. 
2.2.7.1 Patients 
Population-based data on PaC patients from the US SEER-18 Program (SEER, 2018) and the national 
Netherlands Cancer Registry (NCR) were used. The SEER Program of the National Cancer Institute is 
an authoritative source of information on cancer epidemiology in the US, and the NCR of the 
Netherlands Comprehensive Cancer Organization is the quality institute for oncological research and 
practice in the Netherlands. Patient-level data on patients with incident PaC were consecutively 
collected in both registries.  
Patients undergoing resection for first TNM stage I-II primary invasive malignancy of the 
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exocrine pancreas during 2003-2015 were eligible. Patients with unknown follow-up period or 
survival status were excluded. Those with tumors originating from islets of Langerhans, with ineligible 
histology, or with benign or in situ tumors were also excluded (Table 2). Patients with stage III (T4) or 
IV (M1) disease were not eligible because resection is not routinely recommended as the standard of 
care for them (Ducreux et al., 2015a; Ducreux et al., 2015b). Patients with 0 or missing recorded 
ELNs were excluded, considering that lymphadenectomy is part of PaC resection and that the ELN 
number is required to be reported (Ducreux et al., 2015a; Tol et al., 2014a). The US patients diagnosed 
in 2003 were excluded because of the unavailability of TNM stage.  
2.2.7.2 Statistical analyses 
Based on the hypothesis that more ELNs confer a greater chance to identify PLNs, stage migration 
was evaluated by investigating the association of the ELN count with the proportion of node-positive 
versus node-negative status with logistic regression models, adjusting for confounders potentially 
associated with the ELN count and/or nodal stage before and/or during resection (year of diagnosis, 
sex, age, tumor location, histology, differentiation, T stage, and resection type). The association of 
ELN count with overall survival was investigated and visualized using multivariable Cox proportional 
hazards regression models, with adjustment for potential prognostic factors including year of diagnosis, 
sex, age, tumor location, histology, differentiation, T stage, metastatic LN number, and resection type. 
Interactions between ELN number and other factors were tested by adding the interaction terms one by 
one. Sensitivity analyses were performed by stratifying the models by demographic, clinical, and 
pathologic characteristics and by entering the additional variables available in only one cohort (e.g., 
comorbidities in NCR) into the models. In the NCR, neoadjuvant and/or adjuvant chemotherapy 
and/or radiotherapy were included as static or time-varying covariates in the models for sensitivity 
analysis. Considering the low sensitivity of the non-surgical variables (Noone et al., 2016) and the 
unavailability of the intervals between diagnosis/resection and non-surgical treatment, chemotherapy 
or radiotherapy was not further included in the multivariable models in SEER-18. Before performing 
survival analyses, the proportional hazards assumption was validated by plotting the logarithm of the 
negative logarithm of the survival function against the logarithm of survival time (Hess, 1995). 
Disease-specific survival, which was available in the US, was used as an additional endpoint for 
sensitivity analysis. 
The associations of increasing ELN number with serial odds ratios (ORs) for stage migration and 
hazard ratios (HRs) for survival, the logarithms of both ratios, the mean PLN number, and LNR were 
depicted by curves, which were fitted using the LOWESS smoother with the default bandwidth of 2/3 
(Borkowf et al., 2003). The most frequent ELN counts (12 in SEER-18 and 10 in NCR) were used as 
the references. Structural breakpoints for the smoothed parameters in the overall and stratified US 
patients were then determined by the Chow test (F-test). Given that survival outcomes are the most 
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important, the breakpoint for smoothed HRs in the whole US derivation cohort was considered as the 
optimal threshold, and the breakpoint for smoothed ORs for stage migration as the minimal threshold. 
The whole US and Dutch cohorts were then used for internal and external cutoff validation, 
respectively, by assessing survival and stage migration associated with ≥ versus < identified threshold 
number of ELNs with multivariable adjustment in overall and stratified analyses.  
A mathematic model involving the ELN count was additionally generated following Robinson et 
al. (Robinson et al., 2016), and was used to assess the accuracy of declared node-negative disease, 
namely, the possibility of having ≥1 undetected PLNs in reported node-negative disease with different 
ELN numbers. Data were managed using the SAS (version 9.4, SAS Institute Inc.) and R 3.4.1 
software (http://www.r-project.org).  
2.3 Gastric cancer 
2.3.1 Patients 
Individual-level data of GC patients from national population-based cancer registries of the 
Netherlands, Belgium, Sweden, Norway, Slovenia, and Estonia, and the US SEER-18 Program were 
included (Table 1).  
Only patients with microscopically-confirmed primary invasive malignancies of the stomach 
(C16) registered in 2003 to 2017 were selected (Table 3), irrespective of distant metastasis status. 
Both cardia and non-cardia GCs were included. Individuals with non-invasive benign/premalignant/in 
situ tumors, non-GC neoplasms involving the stomach, gastrointestinal stromal tumors/sarcomas, 
neuroendocrine tumors/carcinoids, lymphomas, or germ-cell neoplasms were excluded. Cases 
diagnosed based on DCO/autopsy were also excluded. 
 
Table 3. Inclusion and exclusion codes for gastric cancer according to International Classification of Diseases 
for Oncology, Third Edition1 
Category  Code 
Topology Inclusion C16, C16.0, C16.1, C16.2, C16.3, C16.4, C16.5, C16.6, C16.8, C16.9 
 Exclusion - 
Morphology Inclusion2 8000-8009 (unspecified neoplasms), 8010-8049 (epithelial neoplasms, NOS), 8050-8089 
(squamous cell neoplasms), 8140-8389 (adenomas and adenocarcinomas), 8440-8499 
(cystic, mucinous and serous neoplasms), 8500-8549 (ductal and lobular neoplasms), 
8550-8559 (acinar cell neoplasms), 8560-8579 (complex epithelial neoplasms) 
 Exclusion 8013, 8152, 8153, 8156, 8160, 8170, 8240-8243, 8246, 8249, 8252, 8390, 8590, 8680, 
8700, 8711, 8720, 8800-8805, 8810, 8811, 8830, 8840, 8850-8852, 8858, 8890, 8891, 
8895-8897, 8900, 8902, 8910, 8912, 8920, 8930, 8931, 8935, 8936, 8960, 9040, 9041, 
9064, 9071, 9080, 9090, 9100, 9120, 9364, 9380, 9490, 9500, 9540, 9560, 9580 
Behavior Inclusion 3 
 Exclusion 0, 2 
1http://codes.iarc.fr/ 
2Based on Surveillance, Epidemiology, and End Results Program broad groupings. 
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Data on patient (year of diagnosis, sex, and age), cancer (location, differentiation, histology, and 
stage), treatment (resection, chemotherapy, and radiotherapy), and follow-up variables (survival time 
and status) (re)coded following a uniform data-request sheet were obtained. Non-surgical therapies 
were registered with low sensitivity in the US and Estonia. Neoadjuvant and adjuvant therapies could 
not be differentiated in Norway or Estonia, and adjuvant therapies were not available in Sweden. 
Information on hospital type (the Netherlands, Belgium, and Sweden), volume (the Netherlands and 
Sweden), tumor size (the US), ECOG performance status score (Belgium and Sweden), American 
Society of Anesthesiologists (ASA) score (Sweden), and comorbidities (Eindhoven, the Netherlands 
and Belgium) were only available in certain registries. 
Resection was defined as removal of the primary tumor irrespective of being curative or palliative, 
of the type, extent, and radicality of excision and lymphadenectomy, and of the method, approach, 
procedure, and technique of management. Cancer topography and morphology followed the 
International Classification of Diseases for Oncology, Third Edition (WHO, 2018). Tumors were 
categorized into adenocarcinoma, signet ring cell carcinoma (SRC), and other. Tumor local invasion 
and lymph node metastasis were derived from the AJCC/UICC TNM staging, and were reclassified 
into categories consistent across the investigated period when the sixth/seventh edition was in effect. 
2.3.2 Statistics 
Considering the potential heterogeneity across registries, data were analyzed and presented separately 
in each country without pooling. Given that patients without and with distant metastasis are different 
clinical entities, they were analyzed separately. Patient age was categorized into four groups (<60, 
60-69, 70-79, and ≥80 years). Age-standardized treatment rates were calculated using the age 
distribution of the US patients, the largest group of patients analyzed, as the standard. Temporal trends 
of the standardized rates were assessed using linear regression, and rates over two-calendar-year 
periods are shown graphically. Subgroup analyses according to patient age and tumor location were 
further conducted, and age- and location-specific rates in 2010 or later were shown. 
Multivariable logistic regression models were constructed to investigate the associations of 
resection with patient and tumor characteristics with adjustment for year of diagnosis, patient sex, age 
group, tumor location, and histology in main analyses. Subgroup analyses according to age and 
location and in SRC and cancers invading adjacent structures were further conducted. Associations 
with additional variables (adjacent structure invasion, hospital type and volume, tumor size, adjacent 
structure invasion, ECOG and ASA scores, and comorbidities) were evaluated by adding them one by 
one into the main models in countries with available information. Cases with missing values were 
excluded from analyses.  
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3 RESULTS 
3.1 Pancreatic cancer 
3.1.1 Resection of pancreatic cancer in Europe and the US  
(This part has been published (Huang et al., 2017).) 
3.1.1.1 Characteristics of overall patients 
A total of 147,700 patients from seven population-based registries were analyzed (Table 4). In the US, 
the Netherlands, Belgium, Norway, and Slovenia, patients diagnosed between 2003/2004 and 
2013/2014 were included. In Denmark and Estonia, included patients were diagnosed during 
2011-2016 and 2009-2014, respectively. Patient characteristics are shown in Table 5. The mean ages 
were 70-72 years, with patients ≥70 years comprising 52.6%-59.5% of the diagnosed cases. Around 
half of the patients (47.2%-52.6%) were female. Most patients had pancreatic head tumors 
(67.8%-74.7%). Metastatic diseases were most commonly diagnosed with proportions between 54.5% 
(the US) and 72.8% (Slovenia), whereas stage I-II cancers only comprised 18.8% (Slovenia) to 36.2% 
(the US). Stage was missing for 10.5%-26.5% of patients in investigated countries except Belgium 
(40.1%), and the missingness was mostly associated with patient age and tumor location (Table 6). 
Overall, resection rates ranged from 13.0% (Estonia) to 21.7% (Belgium). Chemotherapy was 
administered to 15.0% (Estonia) to 57.3% (Belgium) of patients. Radiotherapy was less frequently 
used (1.9% (Slovenia) to 6.9% (Belgium)). 
 
Table 4. General information on participating registries for Chapter 3.1.1 (Huang et al., 2017) 
Source Country Year of diagnosis Registered primary cases1
Excluded cases2 Analyzed 
cases DCO/autopsy TNM stage 0 
SEER-183 The US Jan. 2004-Dec. 2013 99582 2972 (3.0) 37 (0.0) 96573 
NCR The Netherlands Jan. 2003-Dec. 2014 22579 99 (0.4) 2 (0.0) 22478 
BCR Belgium Jan. 2004-Dec. 2013 12146 NA 1 (0.0) 12145 
CRN Norway Jan. 2003-Dec. 2014 8022 333 (4.2) 3 (0.0) 7686 
DPCD Denmark May 2011-May 2016 4088 NA 2 (0.0) 4086 
CRS Slovenia Jan. 2003-Dec. 2013 3376 54 (1.6) 0 (0.0) 3322 
ECR Estonia Jan. 2009-Dec. 2014 1509 99 (6.6) 0 (0.0) 1410 
1A preliminary data-cleaning process had been performed to exclude cases with ineligible histology types. 
2Shown as n (percentage [%]). 
3Data of the year 2003 were not analyzed, as the TNM stage (version 6/7) information was unavailable. 
SEER, Surveillance, Epidemiology, and End Results Program; NCR, Netherlands Cancer Registry; BCR, Belgian Cancer Registry; CRN, 
Cancer Registry of Norway; DPCD, Danish Pancreatic Cancer Database; CRS, Cancer Registry of Slovenia; ECR, Estonian Cancer Registry; 
DCO, death certificate only; NA, not applicable due to not routinely registered. 
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Table 5. Demographic and clinical characteristics of overall pancreatic cancer patients1 (Huang et al., 2017) 
Parameter The US The Netherlands Belgium Norway Denmark Slovenia Estonia 
Incidence period 2004-2013 2003-2014 2004-2013 2003-2014 2011-2016 2003-2013 2009-2014
n 96573 22478 12145 7686 4086 3322 1410 
Sex, female 48317 (50.0) 11184 (49.8) 5902 (48.6) 3973 (51.7) 2149 (52.6) 1691 (50.9) 665 (47.2) 
Age [year] 70 ± 12 70 ± 11 70 ± 11 72 ± 12 70 ± 10 70 ± 11 71 ± 11 
Age group        
< 60 years 19676 (20.4) 4199 (18.7) 2207 (18.2) 1155 (15.0) 619 (15.2) 625 (18.8) 230 (16.3) 
60-69 years 24334 (25.2) 6425 (28.6) 3176 (26.2) 1956 (25.5) 1319 (32.3) 810 (24.4) 370 (26.2) 
70-79 years 27073 (28.0) 7320 (32.6) 4192 (34.5) 2268 (29.5) 1490 (36.5) 1120 (33.7) 493 (35.0) 
≥ 80 years 25490 (26.4) 4534 (20.2) 2570 (21.2) 2307 (30.0) 658 (16.1) 767 (23.1) 317 (22.5) 
Tumor location2        
Pancreas head 46734 (67.8) 13997 (72.3) 4087 (68.9) 2673 (72.9) 2134 (68.8) 1445 (74.7) 754 (68.3) 
Pancreas body 10769 (15.6) 2288 (11.8) 815 (13.7) 492 (13.4) 508 (16.3) 226 (11.7) 213 (19.3) 
Pancreas tail 11453 (16.6) 3079 (15.9) 1034 (17.4) 490 (13.4) 462 (14.9) 264 (13.6) 137 (12.4) 
Other 27617 (28.6) 3114 (13.8) 6209 (51.1) 4021 (52.4) 982 (24.0) 1387 (41.8) 306 (21.7) 
cTNM stage3        
I-II 31313 (36.2) 5184 (27.2) 2123 (29.2) 1545 (25.0) 801 (26.7) 457 (18.8) 283 (25.2) 
III 8033 (9.3) 1937 (10.1) 936 (12.9) 395 (6.4) 419 (13.9) 205 (8.4) 118 (10.5) 
IV 47120 (54.5) 11993 (62.7) 4217 (58.0) 4238 (68.6) 1785 (59.4) 1773 (72.8) 721 (64.3) 
Resection 15628 (16.2) 2945 (13.1) 2630 (21.7) 1005 (13.1) 690 (16.9) 602 (18.1) 183 (13.0) 
Chemotherapy NA 5061 (22.5) 6958 (57.3) 1567 (20.4) 2164 (53.0) 581 (17.5) 211 (15.0) 
Radiotherapy 5282 (5.5) 510 (2.3) 836 (6.9) 319 (4.2) 149 (3.7) 64 (1.9) 34 (2.4) 
1Enumeration data are shown as count (percentage [%]), and measurement data as mean ± standard deviation. Records are complete 
otherwise specified below.  
2The percentages of pancreas head, body, and tail are the proportions compared to the total tumor cases of pancreas head, body, and tail; 
other: pancreas duct, overlapping lesion, NOS, and other specified parts. 
3Unknown cTNM stage: the US, 10107 (10.5%); the Netherlands, 3364 (15.0%); Belgium, 4869 (40.1%); Norway, 1508 (19.6%); Denmark, 
1081 (26.5%); Slovenia, 887 (26.5%); and Estonia, 288 (20.4%). For the US, Norway, and Estonia, the stage is a combination of clinical and 
pathological ones. The summary stage was used to help retrieve missing TNM stages. 
NOS, not otherwise specified; NA, not available. 
 
Table 6. Association of missing versus available TNM stages with demographic, clinical, and therapeutic 
parameters for pancreatic cancer patients estimated by multivariable logistic regression (Huang et al., 2017) 
Parameter The US (n = 96573) 
The Netherlands 
(n = 22478) 
Belgium 
(n = 12145) 
Norway 
(n = 7686) 
Denmark 
(n = 4086) 
Slovenia 
(n = 3322) 
Estonia 
(n = 1410) 
 OR (95% CI)1 OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) 
Year of diagnosis 0.94 (0.94-0.95) 0.89 (0.88-0.90) 0.94 (0.93-0.95) 1.02 (1.00-1.04) 1.26 (1.20-1.32) 0.97 (0.95-1.00) 0.83 (0.77-0.90)
Sex        
Female 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Male 0.91 (0.87-0.95) 1.04 (0.97-1.13) 1.01 (0.94-1.09) 1.06 (0.95-1.19) 1.06 (0.92-1.22) 0.89 (0.76-1.05) 0.79 (0.59-1.04)
Age group        
< 60 years 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
60-69 years 1.20 (1.10-1.31) 1.23 (1.08-1.39) 0.84 (0.75-0.94) 1.15 (0.94-1.42) 1.10 (0.87-1.38) 1.10 (0.86-1.41) 0.95 (0.58-1.53)
70-79 years 1.75 (1.62-1.90) 1.71 (1.52-1.93) 0.89 (0.80-0.99) 1.41 (1.16-1.72) 1.27 (1.01-1.59) 1.01 (0.80-1.27) 1.57 (1.01-2.43)
≥ 80 years 4.54 (4.22-4.89) 2.49 (2.20-2.83) 0.93 (0.83-1.05) 2.14 (1.77-2.60) 1.90 (1.47-2.44) 1.46 (1.14-1.87) 3.61 (2.29-5.71)
Tumor location        
Pancreas head 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Pancreas body 0.54 (0.48-0.60) 0.46 (0.39-0.54) 0.60 (0.50-0.71) 0.57 (0.43-0.75) 1.09 (0.87-1.36) 0.45 (0.32-0.64) 0.62 (0.40-0.96)
Pancreas tail 0.35 (0.30-0.39) 0.24 (0.20-0.28) 0.68 (0.59-0.79) 0.38 (0.28-0.53) 0.88 (0.69-1.12) 0.26 (0.18-0.38) 0.58 (0.33-1.00)
Other2 4.13 (3.94-4.33) 0.70 (0.63-0.78) 1.39 (1.28-1.51) 0.89 (0.79-1.00) 1.30 (1.09-1.54) 0.52 (0.44-0.62) 1.03 (0.74-1.43)
1Odds ratios and 95% confidence intervals for missing versus available TNM stages were calculated using multivariable logistic regression 
models adjusting for year of diagnosis, sex, age group, and tumor location. ORs shown in bold are statistically significant. 
2Other: pancreas duct, overlapping lesion, NOS, and other specified parts. 
OR, odds ratio; CI, confidence interval; NOS, not otherwise specified. 
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3.1.1.2 Characteristics of resected patients 
Together only 16.0% (23,683/147,700) of the investigated PaC patients underwent resection (Table 7). 
Resected patients were younger (mean age, 65-67 years) than the overall patients. Only 36.9%-43.8% 
were ≥70 years. Most patients had stage I-II cancers (75.1% (Slovenia) to 92.4% (Denmark)). 
Pancreatic head cancers were more frequent among resected patients (78.7%-87.7%). Patients with 
pancreatic head cancers had the greatest proportion of stage I-II tumors, and those with tail cancers 
had the largest proportion of metastatic lesions. Neoadjuvant chemotherapy (0.3%-4.2%) and 
radiotherapy (0.1%-4.3%) were rarely administered in countries with available information. 
Pancreatoduodenectomy was the most common surgical approach (68.6% (Denmark) to 83.9% (the 
Netherlands)). Adjuvant chemotherapy use varied strongly with proportions between 12.0% (Estonia) 
and 55.7% (Denmark). Adjuvant radiotherapy was more frequently used in the US (29.5%) than in 
Europe, where the proportions ranged from 0.1% (Denmark) to 8.9% (Belgium). 
 
Table 7. Demographic and clinical characteristics of resected pancreatic cancer patients1 (Huang et al., 2017) 
Parameter The US The Netherlands Belgium Norway Denmark Slovenia Estonia 
n 15628 2945 2630 1005 690 602 183 
Sex, female 7738 (49.5) 1387 (47.1) 1217 (46.3) 471 (46.9) 358 (51.9) 293 (48.7) 87 (47.5)
Age [year] 66 ± 11 65 ± 10 66 ± 10 66 ± 11 67 ± 9 65 ± 10 66 ± 10 
Age group        
< 60 years 4290 (27.5) 773 (26.3) 691 (26.3) 253 (25.2) 129 (18.7) 175 (29.1) 37 (20.2)
60-69 years 4982 (31.9) 1086 (36.9) 848 (32.2) 367 (36.5) 259 (37.5) 201 (33.4) 69 (37.7)
70-79 years 4708 (30.1) 969 (32.9) 915 (34.8) 323 (32.1) 252 (36.5) 197 (32.7) 68 (37.2)
≥ 80 years 1648 (10.5) 117 (4.0) 176 (6.7) 62 (6.2) 50 (7.3) 29 (4.8) 9 (4.9) 
Tumor location2        
Pancreas head 10730 (78.7) 2375 (87.7) 1374 (79.6) 729 (83.3) 521 (85.3) 435 (85.8) 128 (79.5)
Pancreas body 1065 (7.8) 106 (3.9) 127 (7.3) 65 (7.4) 19 (3.1) 38 (7.5) 17 (10.6)
Pancreas tail 1845 (13.5) 228 (8.4) 226 (13.1) 81 (9.3) 71 (11.6) 34 (6.7) 16 (9.9) 
Other 1988 (12.7) 236 (8.0) 903 (34.3) 130 (12.9) 79 (11.5) 95 (15.8) 22 (12.0)
TNM stage3        
I-II 13303 (86.9) 2675 (91.9) 2155 (87.9) 526 (83.0) 635 (92.4) 406 (75.1) 159 (89.8)
III 767 (5.0) 148 (5.1) 146 (6.0) 30 (4.7) 37 (5.4) 46 (8.5) 11 (6.2) 
IV 1231 (8.1) 89 (3.1) 152 (6.2) 78 (12.3) 15 (2.2) 89 (16.5) 7 (4.0) 
Neoadjuvant chemotherapy NA 65 (2.2) 82 (3.1) NA 29 (4.2) 2 (0.3) NA 
Neoadjuvant radiotherapy 677 (4.3) 39 (1.3) 32 (1.2) NA 6 (0.9) 1 (0.2) NA 
Resection type        
Pancreatoduodenectomy 10759 (68.8) 2472 (83.9) NA NA 473 (68.6) NA NA 
Distal pancreatectomy 2208 (14.1) 298 (10.1) NA NA 90 (13.0) NA NA 
Total pancreatectomy 1855 (11.9) 48 (1.6) NA NA 127 (18.4) NA NA 
Other4 806 (5.2) 127 (4.3) NA NA 0 (0.0) NA NA 
Adjuvant chemotherapy NA 1167 (39.6) 1446 (55.0) 193 (19.2) 384 (55.7) 172 (28.6) 22 (12.0)
Adjuvant radiotherapy 4610 (29.5) 40 (1.4) 234 (8.9) 33 (3.3) 1 (0.1) 14 (2.3) 12 (6.6) 
1Enumeration data are shown as count (percentage [%]), and measurement data as mean ± standard deviation. Records are complete 
otherwise specified below.  
2The percentages of pancreas head, body, and tail are the proportions compared to the total tumor cases of pancreas head, body, and tail; 
other: pancreas duct, overlapping lesion, NOS, and other specified parts. 
3Unkown TNM stage: the US, 327 (2.1%); the Netherlands, 33 (1.1%); Belgium, 177 (6.7%); Norway, 371 (36.9%); Denmark, 3 (0.4%); 
Slovenia, 61 (10.1%); and Estonia, 6 (3.3%). 
4Pancreatectomy (NOS) and local resection. 
NOS, not otherwise specified; NA, not available. 
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 Characteristics of resected patients by cancer stage were further described (Tables 8-11). 
Operated patients with stage I-II cancers were mostly older than those with stage III-IV tumors (mean 
age, 65-68 vs. 64-66 years). There was generally a greater proportion of pancreatic head tumors in 
stage I-II PaCs than in stage III-IV diseases (79.4%-88.6% vs. 66.1%-85.3%). Compared to stage IV 
cancer, resected stage III PaC was more often located in pancreas head (75.4%-94.1% vs. 
59.0%-75.8%). Accordingly, pancreatoduodenectomy was more frequently performed for stage III 
PaC than for stage IV disease (66.9%-80.4% vs. 50.9%-66.3%). 
 
Table 8. Demographic and clinical characteristics of resected stage I-II cancer patients1 (Huang et al., 2017) 
Parameter The US Netherlands Belgium Norway Denmark Slovenia Estonia 
n 13303 2675 2155 526 635 406 159 
Sex, female 6604 (49.6) 1268 (47.4) 993 (46.1) 261 (49.6) 33.0 (52.0) 209 (51.5) 76 (47.8)
Age [year] 66 ± 11 65 ± 10 66 ± 10 65 ± 11 68 ± 9 65 ± 10 67 ± 10 
Age group        
< 60 years 3574 (26.9) 693 (25.9) 546 (25.3) 134 (25.5) 112 (17.6) 122 (30.1) 32 (20.1)
60-69 years 4272 (32.1) 978 (36.6) 698 (32.4) 195 (37.1) 239 (37.6) 131 (32.3) 60 (37.7)
70-79 years 4073 (30.6) 892 (33.4) 762 (35.4) 170 (32.3) 235 (37.0) 138 (34.0) 58 (36.5)
≥ 80 years 1384 (10.4) 112 (4.2) 149 (6.9) 27 (5.1) 49 (7.7) 15 (3.7) 9 (5.7) 
Tumor location2        
Pancreas head 9573 (80.4) 2187 (88.6) 1207 (79.6) 394 (83.3) 479 (85.4) 321 (87.2) 112 (79.4)
Pancreas body 890 (7.5) 91 (3.7) 100 (7.3) 33 (7.4) 17 (3.0) 26 (7.1) 16 (11.4)
Pancreas tail 1448 (12.2) 191 (7.7) 169 (13.1) 41 (9.3) 65 (11.6) 21 (5.7) 13 (9.2) 
Other 1392 (10.5) 206 (7.7) 679 (31.5) 58 (11.0) 74 (11.7) 38 (9.4) 18 (11.3)
Neoadjuvant chemotherapy NA 50 (1.9) 53 (2.5) NA 26 (4.1) 2 (0.5) NA 
Neoadjuvant radiotherapy 522 (3.9) 34 (1.3) 20 (0.9) NA 6 (0.9) 1 (0.3) NA 
Resection type        
Pancreatoduodenectomy 9479 (71.3) 2269 (84.8) NA NA 436 (68.7) NA NA 
Distal pancreatectomy 1878 (14.1) 256 (9.6) NA NA 82 (12.9) NA NA 
Total pancreatectomy 1629 (12.3) 42 (1.6) NA NA 117 (18.4) NA NA 
Other3 317 (2.4) 108 (4.0) NA NA 0 (0.0) NA NA 
Adjuvant chemotherapy NA 1078 (40.3) 1200 (55.7) 127 (24.1) 355 (55.9) 120 (29.6) 18 (11.3)
Adjuvant radiotherapy 4193 (31.5) 33 (1.2) 190 (8.8) 17 (3.2) 1 (0.2) 8 (2.0) 11 (6.9) 
1Enumeration data are shown as count (percentage [%]), and measurement data as mean ± standard deviation. Records are complete 
otherwise specified below.  
2The percentages of pancreas head, body, and tail are the proportions compared to the total tumor cases of pancreas head, body, and tail; 
other: pancreas duct, overlapping lesion, NOS, and other specified parts. 
3Pancreatectomy (NOS) and local resection. 
SEER, Surveillance, Epidemiology, and End Results Program; NCR, Netherlands Cancer Registry; BCR, Belgian Cancer Registry; CRN, 
Cancer Registry of Norway; DPCD, Danish Pancreatic Cancer Database; CRS, Cancer Registry of Slovenia; NOS, not otherwise specified; 
NA, not available. 
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Table 9. Demographic and clinical characteristics of resected stage III-IV cancer patients1 (Huang et al., 2017) 
Parameter The US Netherlands Belgium Norway Denmark Slovenia Estonia 
n 1998 237 298 108 52 135 18 
Sex, female 969 (48.5) 106 (44.7) 154 (51.9) 47 (43.5) 28 (53.9) 56 (41.5) 9 (50.0) 
Age [year] 65 ± 12 64 ± 10 64 ± 10 64 ± 10 64 ± 10 65 ± 10 66 ± 8 
Age group        
< 60 years 636 (31.8) 69 (29.1) 92 (30.9) 32 (29.6) 15 (28.9) 40 (29.6) 3 (16.7) 
60-69 years 622 (31.1) 96 (40.5) 103 (34.6) 43 (39.8) 19 (36.5) 45 (33.3) 8 (44.4) 
70-79 years 550 (27.5) 68 (28.7) 90 (30.2) 26 (24.1) 17 (32.7) 43 (31.9) 7 (38.9) 
≥ 80 years 190 (9.5) 4 (1.7) 13 (4.4) 7 (6.5) 1 (1.9) 7 (5.2) 0 (0.0) 
Tumor location2        
Pancreas head 1069 (66.1) 166 (78.7) 126 (69.2) 57 (66.3) 42 (85.3) 80 (78.4) 12 (75.0)
Pancreas body 168 (10.4) 11 (5.2) 19 (10.4) 8 (9.3) 1 (3.1) 12 (11.8) 1 (6.3) 
Pancreas tail 381 (23.5) 34 (16.1) 37 (20.3) 21 (24.4) 5 (11.6) 10 (9.8) 3 (18.8) 
Other 380 (19.0) 26 (11.0) 116 (38.9) 22 (20.4) 4 (7.7) 33 (24.4) 2 (11.1) 
Neoadjuvant chemotherapy NA 15 (6.3) 24 (8.1) NA 2 (3.9) 0 (0.0) NA 
Neoadjuvant radiotherapy 139 (7.0) 5 (2.1) 9 (3.0) NA 0 (0.0) 0 (0.0) NA 
Resection type        
Pancreatoduodenectomy 1140 (57.1) 178 (75.1) NA NA 37 (71.2) NA NA 
Distal pancreatectomy 295 (14.8) 39 (16.5) NA NA 7 (13.5) NA NA 
Total pancreatectomy 211 (10.6) 5 (2.1) NA NA 8 (15.4) NA NA 
Other3 352 (17.6) 15 (6.3) NA NA 0 (0.0) NA NA 
Adjuvant chemotherapy NA 81 (34.2) 195 (65.4) 25 (23.2) 28 (53.9) 39 (28.9) 4 (22.2) 
Adjuvant radiotherapy 383 (19.2) 7 (3.0) 35 (11.7) 4 (3.7) 0 (0.0) 5 (3.7) 1 (5.6) 
1Enumeration data are shown as count (percentage [%]), and measurement data as mean ± standard deviation. Records are complete 
otherwise specified below.  
2The percentages of pancreas head, body, and tail are the proportions compared to the total tumor cases of pancreas head, body, and tail; 
other: pancreas duct, overlapping lesion, NOS, and other specified parts. 
3Pancreatectomy (NOS) and local resection. 
SEER, Surveillance, Epidemiology, and End Results Program; NCR, Netherlands Cancer Registry; BCR, Belgian Cancer Registry; CRN, 
Cancer Registry of Norway; DPCD, Danish Pancreatic Cancer Database; CRS, Cancer Registry of Slovenia; NOS, not otherwise specified; 
NA, not available. 
 
Table 10. Demographic and clinical characteristics of resected stage III cancer patients1 (Huang et al., 2017) 
Parameter The US Netherlands Belgium Norway Denmark Slovenia Estonia
n 767 148 146 30 37 46 11 
Sex, female 364 (47.5) 65 (43.9) 73 (50.0) 13 (43.3) 19 (51.4) 21 (45.7) 7 (63.6)
Age [year] 65 ± 11 65 ± 10 64 ± 10 66 ± 7 66 ± 9 63 ± 11 66 ± 9 
Age group        
< 60 years 229 (29.9) 40 (27.0) 50 (34.3) 5 (16.7) 8 (21.6) 16 (34.8) 2 (18.2)
60-69 years 262 (34.2) 58 (39.2) 43 (29.5) 16 (53.3) 15 (40.5) 13 (28.3) 4 (36.4)
70-79 years 215 (28.0) 46 (31.1) 48 (32.9) 8 (26.7) 13 (35.1) 16 (34.8) 5 (45.5)
≥ 80 years 61 (8.0) 4 (2.7) 5 (3.4) 1 (3.3) 1 (2.7) 1 (2.2) 0 (0.0) 
Tumor location2        
Pancreas head 487 (75.4) 112 (84.8) 70 (76.1) 21 (84.0) 32 (94.1) 33 (82.5) 8 (80.0)
Pancreas body 68 (10.5) 4 (3.0) 11 (12.0) 2 (8.0) 0 (0.0) 4 (10.0) 0 (0.0) 
Pancreas tail 91 (14.1) 16 (12.1) 11 (12.0) 2 (8.0) 2 (5.9) 3 (7.5) 2 (20.0)
Other 121 (15.8) 16 (10.8) 54 (37.0) 5 (16.7) 3 (8.1) 6 (13.0) 1 (9.1) 
Neoadjuvant chemotherapy NA 12 (8.1) 17 (11.6) NA 2 (5.4) 0 (0.0) NA 
Neoadjuvant radiotherapy 116 (15.1) 5 (3.4) 8 (5.5) NA 0 (0.0) 0 (0.0) NA 
Resection type        
Pancreatoduodenectomy 513 (66.9) 119 (80.4) NA NA 28 (75.7) NA NA 
Distal pancreatectomy 82 (10.7) 18 (12.2) NA NA 3 (8.1) NA NA 
Total pancreatectomy 93 (12.1) 2 (1.4) NA NA 6 (16.2) NA NA 
Other3 79 (10.3) 9 (6.1) NA NA 0 (0.0) NA NA 
Adjuvant chemotherapy NA 59 (39.9) 96 (65.8) 7 (23.3) 18 (48.7) 13 (28.3) 1 (9.1) 
Adjuvant radiotherapy 257 (33.5) 6 (4.1) 28 (19.2) 1 (3.3) 0 (0.0) 3 (6.5) 1 (9.1) 
1Enumeration data are shown as count (percentage [%]), and measurement data as mean ± standard deviation. Results for stage IV cancers in 
Estonia are not presented due to limited case number (n = 7). Records are complete otherwise specified below.  
2The percentages of pancreas head, body, and tail are the proportions compared to the total tumor cases of pancreas head, body, and tail; 
other: pancreas duct, overlapping lesion, NOS, and other specified parts. 
3Pancreatectomy (NOS) and local resection. 
SEER, Surveillance, Epidemiology, and End Results Program; NCR, Netherlands Cancer Registry; BCR, Belgian Cancer Registry; CRN, 
Cancer Registry of Norway; DPCD, Danish Pancreatic Cancer Database; CRS, Cancer Registry of Slovenia; NOS, not otherwise specified; 
NA, not available. 
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Table 11. Demographic and clinical characteristics of resected stage IV cancer patients1 (Huang et al., 2017) 
Parameter The US Netherlands Belgium Norway Denmark Slovenia
n 1231 89 152 78 15 89 
Sex, female 605 (49.2) 41 (46.1) 81 (53.3) 34 (43.6) 9 (60.0) 35 (39.3)
Age [year] 65 ± 12 63 ± 9 64 ± 10 64 ± 11 61 ± 11 66 ± 10
Age group       
< 60 years 407 (33.1) 29 (32.6) 42 (27.6) 27 (34.6) 7 (46.7) 24 (27.0)
60-69 years 360 (29.2) 38 (42.7) 60 (39.5) 27 (34.6) 4 (26.7) 32 (36.0)
70-79 years 335 (27.2) 22 (24.7) 42 (27.6) 18 (23.1) 4 (26.7) 27 (30.3)
≥ 80 years 129 (10.5) 0 (0.0) 8 (5.3) 6 (7.7) 0 (0.0) 6 (6.7) 
Tumor location2       
Pancreas head 582 (59.9) 54 (68.4) 56 (62.2) 36 (59.0) 10 (71.4) 47 (75.8)
Pancreas body 100 (10.3) 7 (8.9) 8 (8.9) 6 (9.8) 1 (7.1) 8 (12.9)
Pancreas tail 290 (29.8) 18 (22.8) 26 (28.9) 19 (31.1) 3 (21.4) 7 (11.3)
Other 259 (21.0) 10 (11.2) 62 (40.8) 17 (21.8) 1 (6.7) 27 (30.3)
Neoadjuvant chemotherapy NA 3 (3.4) 7 (4.6) NA 0 (0.0) 0 (0.0) 
Neoadjuvant radiotherapy 23 (1.9) 0 (0.0) 1 (0.7) NA 0 (0.0) 0 (0.0) 
Resection type       
Pancreatoduodenectomy 627 (50.9) 59 (66.3) NA NA 9 (60.0) NA 
Distal pancreatectomy 213 (17.3) 21 (23.6) NA NA 4 (26.7) NA 
Total pancreatectomy 118 (9.6) 3 (3.4) NA NA 2 (13.3) NA 
Other3 273 (22.2) 6 (6.7) NA NA 0 (0.0) NA 
Adjuvant chemotherapy NA 22 (24.7) 99 (65.1) 18 (23.1) 10 (66.7) 26 (29.2)
Adjuvant radiotherapy 126 (10.2) 1 (1.1) 7 (4.6) 3 (3.9) 0 (0.0) 2 (2.3) 
1Enumeration data are shown as count (percentage [%]), and measurement data as mean ± standard deviation. Results for stage IV cancers in 
Estonia are not presented due to limited case number (n = 7). Records are complete otherwise specified below.  
2The percentages of pancreas head, body, and tail are the proportions compared to the total tumor cases of pancreas head, body, and tail; 
other: pancreas duct, overlapping lesion, NOS, and other specified parts. 
3Pancreatectomy (NOS) and local resection. 
SEER, Surveillance, Epidemiology, and End Results Program; NCR, Netherlands Cancer Registry; BCR, Belgian Cancer Registry; CRN, 
Cancer Registry of Norway; DPCD, Danish Pancreatic Cancer Database; CRS, Cancer Registry of Slovenia; NOS, not otherwise specified; 
NA, not available. 
3.1.1.3 Resection trends and rates 
As shown in Figure 1, overall resection rates increased over time in the US (2003-2004 to 2013-2014: 
14.1% to 17.0%; Ptrend<0.001), the Netherlands (2003-2004 to 2013-2014: 8.2% to 17.9%; 
Ptrend<0.001), and Denmark (2011-2012 to 2013-2014: 12.0% to 17.6%; Ptrend=0.007), while no 
significant trends were observed in Belgium (Ptrend=0.270), Norway (Ptrend=0.102), Slovenia 
(Ptrend=0.092), or Estonia (Ptrend=0.406). Starting from as early as 1973 and 1953, respectively, trends 
of increasing resection rates were observed in the US (5.5%-17.8%) and Norway (5.1%-18.4%) in 
overall patients (results not shown). When focusing on the period 2012-2014, resection rates ranged 
from 13.2% (Estonia) to 21.2% (Slovenia). For the subgroup of stage I-II tumors, increasing trends 
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were observed in the US (2003-2004 to 2013-2014: 39.4% to 44.0%; Ptrend<0.001), the Netherlands 
(2003-2004 to 2013-2014: 32.6% to 58.2%; Ptrend<0.001), and Denmark (2011-2012 to 2013-2014: 
60.5% to 70.1%; Ptrend=0.017), while no significant trends were observed in Belgium (Ptrend=0.726), 
Norway (Ptrend=0.675), Slovenia (Ptrend=0.596), or Estonia (Ptrend=0.406). In 2012-2014, the 
proportions of resected patients ranged from 34.8% (Norway) to 68.7% (Denmark). 
 
 
Figure 1. Age-standardized resection trends for overall pancreatic cancer patients (A) and those with TNM stage 
I-II tumors (B). The US cancer population was used for age standardization. (Huang et al., 2017) 
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3.1.1.4 Association of resection with demographic and clinical parameters 
Association of resection with demographic and clinical variables in each country was investigated 
using a multivariable model including year of diagnosis, patient sex, age, cancer location, and stage 
(Table 12). While resection was not significantly associated with sex, it was less frequently conducted 
with increasing age and more advanced cTNM stage. Specifically, compared to patients <60 years, the 
ORs for resection among patients aged 70-79 and ≥80 years ranged between 0.37 (the Netherlands) 
and 0.63 (Estonia) and between 0.03 (the Netherlands) and 0.16 (the US), respectively. Compared to 
stage I-II cancers, the ORs of stages III and IV cancers were 0.05-0.18 and 0.01-0.06, respectively. 
Resection was significantly less frequently conducted in pancreatic body cancers than head tumors in 
all countries except Slovenia and Estonia, with ORs ranging from 0.22 (Denmark) to 0.65 (the US). 
Pancreatic tail cancers were significantly more often resected than pancreatic head tumors in the US 
(OR=1.99), the Netherlands (OR=1.47), Norway (OR=1.70), Denmark (OR=2.46), and Estonia 
(OR=3.18), while no significant associations were observed in Belgium. In Slovenia, even an opposite 
pattern was detected (OR=0.49). After multiple imputations for missing stages, patterns remained 
unchanged (Table 13). 
 
Table 12. Association of resection versus non-resection with demographic and clinical parameters for pancreatic 
cancer patients estimated by multivariable logistic regression (Huang et al., 2017) 
Parameter The US  (n = 86466)1 
The Netherlands 
(n = 19114) 
Belgium  
(n = 7276) 
Norway  
(n = 6178) 
Denmark  
(n = 3005) 
Slovenia  
(n = 2435) 
Estonia 
(n = 1122) 
 OR (95% CI)2 OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) 
Year of diagnosis 1.01 (1.01-1.02) 1.15 (1.13-1.17) 1.01 (0.98-1.04) 0.98 (0.95-1.01) 1.14 (1.03-1.26) 1.04 (1.00-1.09) 1.01 (0.88-1.16) 
Sex        
Female 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
Male 0.97 (0.93-1.01) 1.02 (0.91-1.15) 1.08 (0.91-1.27) 1.18 (0.95-1.46) 1.10 (0.82-1.47) 0.99 (0.74-1.32) 1.05 (0.65-1.68) 
Age group        
< 60 years 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
60-69 years 0.84 (0.80-0.89) 0.76 (0.64-0.89) 0.72 (0.57-0.91) 0.82 (0.61-1.09) 0.71 (0.45-1.13) 0.82 (0.56-1.19) 1.14 (0.58-2.25) 
70-79 years 0.59 (0.56-0.63) 0.37 (0.32-0.44) 0.43 (0.34-0.54) 0.44 (0.33-0.59) 0.56 (0.35-0.88) 0.46 (0.32-0.67) 0.63 (0.32-1.22) 
≥ 80 years 0.16 (0.15-0.17) 0.03 (0.03-0.04) 0.08 (0.06-0.12) 0.05 (0.04-0.08) 0.15 (0.09-0.26) 0.05 (0.03-0.09) 0.08 (0.03-0.19)
Tumor location        
Pancreas head 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
Pancreas body 0.65 (0.60-0.70) 0.49 (0.38-0.64) 0.60 (0.43-0.83) 0.52 (0.35-0.78) 0.22 (0.12-0.41) 0.77 (0.47-1.27) 0.92 (0.43-1.95) 
Pancreas tail 1.99 (1.85-2.14) 1.47 (1.17-1.86) 1.07 (0.78-1.47) 1.70 (1.16-2.50) 2.46 (1.36-4.47) 0.49 (0.28-0.87) 3.18 (1.20-8.45) 
Other3 0.67 (0.63-0.71) 0.63 (0.51-0.78) 0.46 (0.38-0.56) 0.15 (0.12-0.20) 0.59 (0.39-0.89) 0.29 (0.20-0.41) 0.60 (0.30-1.20) 
cTNM stage4        
I-II 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
III 0.12 (0.11-0.13) 0.05 (0.04-0.06) 0.12 (0.09-0.15) 0.12 (0.08-0.19) 0.05 (0.04-0.07) 0.18 (0.12-0.29) 0.06 (0.03-0.13) 
IV 0.03 (0.03-0.03) 0.01 (< 0.01-0.01) 0.02 (0.01-0.02) 0.03 (0.02-0.04) NE 0.06 (0.04-0.08) 0.01 (<0.01-0.01)
1Numbers in table heads indicate numbers of cases available for analyses after excluding the missing.  
2Odds ratios and 95% confidence intervals for surgical resection versus non-resection were calculated using multivariable logistic regression 
models adjusting for year of diagnosis, sex, age group, tumor location, and cTNM stage. ORs shown in bold are statistically significant. 
3Other: pancreas duct, overlapping lesion, NOS, and other specified parts. 
4For the US, Norway, and Estonia, TNM stage is a combination of clinical and pathological stages; NOS, not otherwise specified. 
OR, odds ratio; CI, confidence interval; NE, not estimable due to small case number. 
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Table 13. Association of resection versus non-resection with demographic and clinical parameters for pancreatic 
cancer patients estimated by multivariable logistic regression after multiple imputations for missing TNM stages1 
(Huang et al., 2017) 
Parameter The US  (n = 96573) 
The Netherlands
(n = 22478) 
Norway 
(n = 7686) 
Denmark 
(n = 4086) 
Slovenia 
(n = 3322) 
Estonia 
(n = 1410) 
 OR (95% CI)2 OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) 
Year of diagnosis 1.01 (1.01-1.02) 1.15 (1.13-1.17) 1.00 (0.97-1.03) 1.12 (1.01-1.24) 1.07 (1.03-1.12) 1.02 (0.90-1.17) 
Sex       
Female 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
Male 0.98 (0.94-1.02) 1.08 (0.97-1.21) 1.18 (0.98-1.41) 1.08 (0.81-1.44) 0.91 (0.71-1.15) 1.11 (0.70-1.76) 
Age group       
< 60 years 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
60-69 years 0.83 (0.78-0.88) 0.73 (0.63-0.85) 0.75 (0.58-0.97) 0.69 (0.44-1.08) 0.82 (0.60-1.12) 1.14 (0.58-2.21) 
70-79 years 0.57 (0.54-0.60) 0.34 (0.29-0.40) 0.43 (0.33-0.55) 0.50 (0.32-0.79) 0.40 (0.29-0.54) 0.60 (0.32-1.14) 
≥ 80 years 0.15 (0.14-0.16) 0.03 (0.03-0.04) 0.06 (0.04-0.08) 0.15 (0.09-0.25) 0.04 (0.03-0.07) 0.06 (0.02-0.15)
Tumor location       
Pancreas head 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
Pancreas body 0.66 (0.61-0.72) 0.47 (0.37-0.61) 0.53 (0.38-0.76) 0.20 (0.11-0.36) 0.68 (0.44-1.07) 0.91 (0.43-1.93) 
Pancreas tail 2.04 (1.90-2.19) 1.44 (1.16-1.80) 1.62 (1.14-2.30) 1.73 (0.97-3.06) 0.63 (0.39-1.00) 2.70 (1.10-6.67) 
Other3 0.67 (0.63-0.71) 0.78 (0.64-0.94) 0.16 (0.13-0.20) 0.25 (0.18-0.36) 0.35 (0.26-0.46) 0.69 (0.35-1.34) 
Imputed TNM stage4       
I-II 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
III 0.12 (0.11-0.13) 0.04 (0.03-0.05) 0.08 (0.06-0.12) 0.03 (0.02-0.04) 0.14 (0.10-0.20) 0.05 (0.02-0.09) 
IV 0.03 (0.03-0.03) 0.01 (< 0.01-0.01) 0.02 (0.02-0.03) NE 0.04 (0.03-0.05) <0.01 (<0.01-0.01) 
1Variables applied in imputation of missing cTNM stages were: year of diagnosis, sex, age, tumor location, resection, chemotherapy, 
radiotherapy, and survival status and time. 
2Odds ratios and 95% confidence intervals for surgical resection versus non-resection were calculated using multivariable logistic regression 
models adjusting for year of diagnosis, sex, age group, tumor location, and cTNM stage. Multiple imputation was not performed for Belgium 
due to >30% missing TNM stages. ORs shown in bold are statistically significant. 
3Other: pancreas duct, overlapping lesion, NOS, and other specified parts. 
4For the US, Norway, and Estonia, TNM stage is a combination of clinical and pathological stages. 
OR, odds ratio; CI, confidence interval; NE, not estimable due to small case number. 
 
Association patterns for stage I-II PaCs were mostly consistent with those for overall cancers 
(Table 14). Within stage III-IV PaCs, pancreatic tail cancers were significantly less frequently resected 
compared to pancreatic head tumors in the US (OR=0.83), the Netherlands (OR=0.63), and Belgium 
(OR=0.53); in Norway, Denmark, and Estonia, the original significant associations disappeared. 
Moreover, in the US male patients were significantly less often resected (OR=0.89). Resection rates 
were higher for stage III PaC than for stage IV disease in all countries (Figure 2). Resection patterns 
were mostly similar for stages III and IV cancers (Table 15). In the US (OR=2.28) and the 
Netherlands (OR=2.18), pancreatic tail cancers were more often resected compared to head tumors in 
stage III PaCs, but not in stage IV diseases. In Slovenia, pancreatic tail PaCs were less frequently 
resected compared to head tumors in stage IV cancers (OR=0.39), but not in stage III diseases. 
Association patterns were similar for pancreatic head, body, and tail cancers (data not shown). 
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Table 14. Association of resection versus non-resection with demographic and clinical variables for patients with 
cTNM stage I-II and III-IV pancreatic cancers estimated by multivariable logistic regression (Huang et al., 2017) 
Variable The US The Netherlands Belgium Norway Denmark Slovenia Estonia 
 OR (95% CI)1 OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) 
cTNM stage I-II2 n3 = 31313 n = 5184 n = 2123 n = 1545 n = 801 n = 457 n = 283 
Year of diagnosis 1.02 (1.01-1.03) 1.17 (1.15-1.19) 1.04 (1.00-1.07) 0.98 (0.95-1.02) 1.18 (1.05-1.32) 1.00 (0.92-1.07) 1.04 (0.89-1.23)
Sex        
Female 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Male 1.00 (0.95-1.05) 1.03 (0.90-1.17) 1.12 (0.93-1.36) 1.16 (0.90-1.50) 1.09 (0.78-1.51) 0.72 (0.45-1.15) 0.97 (0.57-1.67)
Age group        
< 60 years 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
60-69 years 0.85 (0.80-0.91) 0.74 (0.61-0.90) 0.74 (0.56-0.99) 0.84 (0.58-1.21) 0.79 (0.46-1.35) 0.74 (0.37-1.47) 0.99 (0.44-2.24)
70-79 years 0.57 (0.53-0.60) 0.35 (0.29-0.41) 0.43 (0.33-0.56) 0.44 (0.31-0.63) 0.68 (0.40-1.14) 0.29 (0.15-0.54) 0.51 (0.23-1.12)
≥ 80 years 0.14 (0.13-0.15) 0.03 (0.02-0.04) 0.08 (0.06-0.12) 0.05 (0.03-0.07) 0.16 (0.09-0.30) 0.01 (< 0.01-0.04) 0.07 (0.03-0.20)
Tumor location        
Pancreas head 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Pancreas body 0.72 (0.66-0.79) 0.52 (0.39-0.71) 0.57 (0.38-0.86) 0.56 (0.34-0.91) 0.24 (0.12-0.49) 1.44 (0.51-4.13) 1.52 (0.59-3.94)
Pancreas tail 2.79 (2.52-3.08) 1.62 (1.22-2.16) 1.17 (0.78-1.74) 2.47 (1.31-4.66) 2.65 (1.21-5.77) 0.58 (0.20-1.69) NE 
Other4 0.70 (0.65-0.75) 0.58 (0.46-0.74) 0.46 (0.37-0.57) 0.14 (0.10-0.19) 0.54 (0.35-0.85) 0.22 (0.12-0.39) 0.69 (0.32-1.50)
cTNM stage III-IV2 n = 55153 n = 13930 n = 5153 n = 4633 n = 2204 n = 1978 n = 839 
Year of diagnosis 0.99 (0.97-1.01) 1.06 (1.01-1.11) 0.93 (0.88-0.98) 0.97 (0.92-1.03) 1.07 (0.88-1.30) 1.07 (1.00-1.14) 0.99 (0.76-1.30)
Sex        
Female 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Male 0.89 (0.81-0.97) 0.92 (0.69-1.22) 0.85 (0.61-1.18) 1.20 (0.81-1.78) 1.18 (0.67-2.09) 1.18 (0.80-1.74) 1.16 (0.45-2.99)
Age group        
< 60 years 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
60-69 years 0.81 (0.73-0.91) 0.73 (0.52-1.03) 0.70 (0.46-1.04) 0.80 (0.50-1.28) 0.84 (0.41-1.74) 0.78 (0.48-1.25) 1.87 (0.48-7.26)
70-79 years 0.69 (0.61-0.78) 0.52 (0.36-0.75) 0.49 (0.32-0.74) 0.43 (0.26-0.74) 0.48 (0.22-1.07) 0.56 (0.34-0.90) 1.20 (0.30-4.77)
≥ 80 years 0.31 (0.26-0.36) 0.02 (< 0.01-0.14) 0.10 (0.04-0.25) 0.13 (0.06-0.30) 0.27 (0.08-0.98) 0.24 (0.11-0.50) NE 
Tumor location        
Pancreas head 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Pancreas body 0.41 (0.35-0.48) 0.37 (0.21-0.66) 0.60 (0.33-1.08) 0.45 (0.21-0.95) 0.08 (0.01-0.60) 0.65 (0.35-1.21) 0.17 (0.02-1.33)
Pancreas tail 0.83 (0.74-0.94) 0.63 (0.42-0.94) 0.53 (0.30-0.91) 1.08 (0.64-1.83) 0.58 (0.24-1.40) 0.35 (0.18-0.70) 0.78 (0.22-2.84)
Other4 0.44 (0.39-0.50) 0.61 (0.39-0.95) 0.36 (0.25-0.53) 0.16 (0.10-0.27) 0.37 (0.16-0.83) 0.26 (0.17-0.41) 0.28 (0.06-1.29)
1Odds ratios and 95% confidence intervals for surgical resection versus non-resection were calculated using multivariable logistic regression 
models adjusting for year of diagnosis, sex, age group, and tumor location. ORs shown in bold are statistically significant. 
2For the US, Norway, and Estonia, TNM stage is a combination of clinical and pathological stages. 
3Indicate numbers of cases available for analyses.  
4Other: pancreas duct, overlapping lesion, NOS, and other specified parts. 
OR, odds ratio; CI, confidence interval; NE, not estimable due to small case number. 
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Figure 2. TNM stage-specific resection proportions for pancreatic cancer (Huang et al., 2017) 
 
Table 15. Association of resection versus non-resection with demographic and clinical variables for patients with 
cTNM stage III and IV pancreatic cancers estimated by multivariable logistic regression (Huang et al., 2017) 
Variable Value The US The Netherlands Belgium Norway Denmark Slovenia 
  OR (95% CI)1 OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) 
cTNM stage III2  N3 = 8033 n = 1937 n = 936 n = 395 n = 419 n = 205 
Year of diagnosis  1.03 (1.00-1.06) 1.09 (1.02-1.16) 0.95 (0.88-1.04) 0.90 (0.80-1.02) 1.03 (0.84-1.27) 1.22 (1.05-1.41) 
Sex Female 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
 Male 1.01 (0.87-1.17) 1.17 (0.80-1.72) 1.11 (0.70-1.75) 1.73 (0.78-3.85) 1.18 (0.64-2.18) 1.25 (0.56-2.79) 
Age group < 60 years 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
 60-69 years 0.93 (0.77-1.13) 0.79 (0.50-1.26) 0.76 (0.43-1.36) 1.87 (0.63-5.61) 0.56 (0.25-1.26) 0.41 (0.14-1.20) 
 70-79 years 0.76 (0.62-0.92) 0.73 (0.45-1.17) 0.44 (0.24-0.81) 0.67 (0.20-2.23) 0.31 (0.13-0.75) 0.69 (0.27-1.77) 
 ≥ 80 years 0.32 (0.24-0.43) 0.07 (0.01-0.49) 0.10 (0.03-0.34) 0.11 (0.01-0.96) 0.16 (0.04-0.60) 0.22 (0.04-1.13) 
Tumor location Pancreas head 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
 Pancreas body 0.44 (0.38-0.57) 0.36 (0.16-0.78) 1.06 (0.51-2.17) 0.28 (0.06-1.27) 0.10 (0.01-0.74) 0.54 (0.17-1.77) 
 Pancreas tail 2.28 (1.77-2.93) 2.18 (1.16-4.10) 1.07 (0.35-3.25) 1.57 (0.29-8.64) 2.16 (0.79-5.93) 1.74 (0.21-14.41)
 Other4 0.58 (0.47-0.72) 0.98 (0.54-1.77) 0.54 (0.32-0.92) 0.19 (0.07-0.54) 0.80 (0.33-1.95) 0.16 (0.05-0.58)
cTNM stage IV2  n = 47120 n = 11993 n = 4217 n = 4238 - n = 1773 
Year of diagnosis  0.97 (0.95-0.99) 0.99 (0.93-1.06) 0.93 (0.85-1.01) 0.99 (0.92-1.06)  1.06 (0.98-1.14) 
Sex Female 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) - 1.00 (reference) 
 Male 0.85 (0.76-0.95) 0.81 (0.51-1.26) 0.76 (0.46-1.24) 1.16 (0.73-1.83) - 1.24 (0.78-1.95) 
Age group < 60 years 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) - 1.00 (reference) 
 60-69 years 0.74 (0.64-0.86) 0.77 (0.46-1.28) 0.58 (0.31-1.06) 0.59 (0.34-1.03) - 1.01 (0.57-1.76) 
 70-79 years 0.65 (0.56-0.76) 0.36 (0.19-0.66) 0.47 (0.25-0.86) 0.37 (0.20-0.68) - 0.58 (0.32-1.05) 
 ≥ 80 years 0.31 (0.26-0.38) NE 0.08 (0.02-0.35) 0.13 (0.05-0.33) - 0.28 (0.12-0.69) 
Tumor location Pancreas head 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) - 1.00 (reference) 
 Pancreas body 0.43 (0.35-0.54) 0.50 (0.21-1.19) 0.30 (0.09-1.01) 0.54 (0.22-1.29) - 0.73 (0.34-1.54) 
 Pancreas tail 0.98 (0.85-1.13) 0.92 (0.53-1.61) 0.81 (0.40-1.61) 1.38 (0.78-2.46) - 0.39 (0.18-0.86) 
 Other4 0.50 (0.43-0.57) 0.68 (0.34-1.35) 0.39 (0.22-0.69) 0.19 (0.10-0.33) - 0.35 (0.21-0.57)
1Odds ratios and 95% confidence intervals for surgical resection versus non-resection were calculated using multivariable logistic regression 
models adjusting for year of diagnosis, sex, age group, and tumor location. For subgroups with resected cases <30 (stage IV in Denmark, 15; 
stage III in Estonia, 11; stage IV in Estonia, 7), results are not shown due to insufficient statistical power. ORs shown in bold are statistically 
significant. 
2For the US, Norway, and Estonia, TNM stage is a combination of clinical and pathological stages. 
3Indicate numbers of cases available for analyses.  
4Other: pancreas duct, overlapping lesion, NOS, and other specified parts. 
OR, odds ratio; CI, confidence interval; NE, not estimable due to small case number; -, not shown due to insufficient statistical power. 
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Associations of resection with tumor size, performance status, comorbidities, and hospital type 
were further explored by adding these factors one by one into the main models with the covariates of 
year of diagnosis, sex, age, cancer location, and stage (Table 16). Resection was significantly less 
frequently conducted with increasing tumor size in the US. In countries where performance status was 
available (Belgium and Denmark), tumors were less frequently resected with increasing ECOG scores. 
In the Netherlands (OR=2.81) and Belgium (OR=2.13), patients managed in academic hospitals 
underwent more often resection. Detailed information on comorbidity was available in the EiCR in the 
Netherlands. Cardiac, vascular, neurological, and pulmonary diseases were associated with less 
frequent resection. Patients with ≥2 comorbidities underwent less often resection compared to those 
without comorbidities (OR=0.60). Additional analyses were further performed for stage I-II and III-IV 
tumors, respectively. Patterns for both stage groups were mostly consistent with the overall ones.  
 
Table 16. Association of resection versus non-resection with tumor size, performance status, comorbidities, and 
hospital type in pancreatic cancer patients in registries with available information estimated by multivariable 
logistic regression (Huang et al., 2017) 
Variable The US The Netherlands Belgium Denmark n OR (95% CI)1 n OR (95% CI) n OR (95% CI) n OR (95% CI) 
Tumor size         
< 20 mm 4648 1.00 (reference) NA NA NA NA NA NA 
20-29 mm 13350 0.70 (0.64-0.76) NA NA NA NA NA NA 
30-39 mm 17743 0.56 (0.51-0.61) NA NA NA NA NA NA 
40-49 mm 13855 0.48 (0.43-0.52) NA NA NA NA NA NA 
≥ 50 mm 18386 0.49 (0.45-0.54) NA NA NA NA NA NA 
ECOG score         
0 NA NA NA NA 756 1.00 (reference) 609 1.00 (reference)
1 NA NA NA NA 5162 0.63 (0.49-0.82) 939 0.57 (0.37-0.89)
2 NA NA NA NA 1246 0.36 (0.26-0.52) 523 0.25 (0.14-0.45)
3 NA NA NA NA 445 0.16 (0.07-0.36) 294 0.18 (0.09-0.36)
4 NA NA NA NA 146 0.06 (0.01-0.47) 70 0.17 (0.04-0.71)
Comorbidity2         
Cardiac disease NA NA 757 0.59 (0.41-0.87) NA NA NA NA 
Vascular disease NA NA 530 0.59 (0.38-0.91) NA NA NA NA 
Hypertension NA NA 935 0.99 (0.71-1.38) NA NA NA NA 
Neurological disease NA NA 174 0.47 (0.23-0.97) NA NA NA NA 
Diabetes NA NA 832 0.95 (0.69-1.33) NA NA NA NA 
Pulmonary disease NA NA 335 0.59 (0.35-0.99) NA NA NA NA 
Comorbidity number         
0 NA NA 1332 1.00 (reference) NA NA NA NA 
1 NA NA 1122 0.91 (0.63-1.32) NA NA NA NA 
≥ 2 NA NA 1591 0.60 (0.41-0.87) NA NA NA NA 
Hospital type         
Non-academic NA NA 17866 1.00 (reference) 7004 1.00 (reference) NA NA
Academic NA NA 4612 2.81 (2.46-3.20) 4767 2.13 (1.80-2.52) NA NA
1Odds ratios and 95% confidence intervals for surgical resection versus non-resection were calculated using multivariable logistic regression 
models adjusting for year of diagnosis, sex, age group, tumor location, and cTNM stage, with the respective variable added in the models. 
Results for each new model revealed consistent patterns in associations of resection with sex, age group, tumor location, and stage compared 
to the main analyses. ORs shown in bold are statistically significant. 
2In the Netherlands, comorbidity information at diagnosis was available in the Eindhoven Cancer Registry. Patients without the respective 
comorbidities were referenced.  
HR, hazard ratio; CI, confidence interval; ECOG, Eastern Collaborative Oncology Group; NA, not available. 
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3.1.2 Non-surgical therapies for resected and unresected pancreatic cancer in Europe and the 
US 
(This part has been published (Huang et al., 2018b).) 
3.1.2.1 Patient characteristics 
Totally 145,056 PaC cases from six population-based databases during 2003-2014 were initially 
included (Table 17). After excluding DCO/autopsy-diagnosed patients (n=3483, 2.4%) and TNM stage 
0 tumor patients (n=40, <0.1%), finally 141,533 (97.7%) records were analyzed. Between 12.6% 
(Norway) and 21.7% (Belgium) of the cancers were resected (Table 18). Among the resected cancer 
patients, the mean age was 65-67 years. Most of the resected cancers were in pancreas head 
(78.7%-87.7%) and stage I-II (75.1%-91.9%). Stage proportions remained stable over time. Only 
small minorities of the cancers (5.8%-17.0%) were well-differentiated. Compared to resected PaC 
patients, unresected cancer patients were older (mean age, 70-73 years; Table 19). Pancreatic head 
cancers were less common (64.5%-70.7%), and most tumors were metastatic (64.5%-79.9%). 
 
Table 17. General information on participating registries for Chapter 3.1.2 (Huang et al., 2018b) 
Source Country Diagnosis period Registered primary cases1
Excluded cases2 Analyzed 
cases DCO/autopsy TNM stage 0 
SEER183 the US Jan. 2004-Dec. 2013 99582 2972 (3.0) 37 (0.0) 96573 
NCR The Netherlands Jan. 2003-Dec. 2014 22579 99 (0.4) 2 (0.0) 22478 
BCR Belgium Jan. 2004-Dec. 2013 12146 NA 1 (0.0) 12145 
CRN Norway Jan. 2003-Dec. 2011 5864 259 (4.4) 0 (0.0) 5605 
CRS Slovenia Jan. 2003-Dec. 2013 3376 54 (1.6) 0 (0.0) 3322 
ECR Estonia Jan. 2009-Dec. 2014 1509 99 (6.6) 0 (0.0) 1410 
1A preliminary data-cleaning process had been performed to exclude cases with ineligible histology types. 
2Shown as n (percentage [%]). 
3Data of the year 2003 was not analyzed, as the TNM stage (version 6/7) information was unavailable. 
SEER, Surveillance, Epidemiology, and End Results Program; NCR, Netherlands Cancer Registry; BCR, Belgian Cancer Registry; CRN, 
Cancer Registry of Norway; CRS, Cancer Registry of Slovenia; ECR, Estonian Cancer Registry; DCO, death certificate only; NA, not 
available. 
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Table 18. Demographic and clinical characteristics of resected pancreatic cancer patients (Huang et al., 2018b) 
Parameter the US The Netherlands Belgium Norway Slovenia Estonia5
Diagnosis period 2004-2013 2003-2014 2004-2013 2003-2011 2003-2013 2009-2014
n1 15628 (16.2) 2945 (13.1) 2630 (21.7) 709 (12.6) 602 (18.1) 183 (13.0) 
Sex, female 7738 (49.5) 1387 (47.1) 1217 (46.3) 326 (46.0) 293 (48.7) 87 (47.5) 
Age (year) 66 ± 11 65 ± 10 66 ± 10 65 ± 11 65 ± 10 67 ± 10 
Age group       
< 60 years 4290 (27.5) 773 (26.3) 691 (26.3) 193 (27.2) 175 (29.1) 37 (20.2) 
60-69 years 4982 (31.9) 1086 (36.9) 848 (32.2) 251 (35.4) 201 (33.4) 69 (37.7) 
70-79 years 4708 (30.1) 969 (32.9) 915 (34.8) 220 (31.0) 197 (32.7) 68 (37.2) 
≥ 80 years 1648 (10.5) 117 (4.0) 176 (6.7) 45 (6.4) 29 (4.8) 9 (4.9) 
Tumor location2       
Pancreas head 10730 (78.7) 2375 (87.7) 1374 (79.6) 532 (87.1) 435 (85.8) 128 (79.5) 
Pancreas body 1065 (7.8) 106 (3.9) 127 (7.3) 31 (5.1) 38 (7.5) 17 (10.6) 
Pancreas tail 1845 (13.5) 228 (8.4) 226 (13.1) 48 (7.9) 34 (6.7) 16 (9.9) 
Other 1988 (12.7) 236 (8.0) 903 (34.3) 98 (13.8) 95 (15.8) 22 (12.0) 
TNM stage3       
I-II 13303 (86.9) 2675 (91.9) 2155 (87.9) 381 (82.1) 406 (75.1) 159 (89.8) 
III 767 (5.0) 148 (5.1) 146 (5.9) 23 (5.0) 46 (8.5) 11 (6.2) 
IV 1231 (8.1) 89 (3.1) 152 (6.2) 60 (12.9) 89 (16.5) 7 (4.0) 
Differentiation4       
Well 1606 (11.9) 267 (11.1) 360 (17.0) 33 (5.8) 46 (9.6) 22 (15.6) 
Intermediate 6732 (49.9) 1247 (52.1) 1039 (49.1) 357 (63.0) 177 (36.8) 80 (56.7) 
Poor/undifferentiated 5156 (38.2) 881 (36.8) 717 (34.9) 177 (31.2) 258 (53.6) 39 (27.7) 
Neoadjuvant chemotherapy NA 65 (2.2) 82 (3.1) NA 2 (0.3) NA
Neoadjuvant radiotherapy 677 (4.3) 39 (1.3) 32 (1.2) NA 1 (0.2) NA
Adjuvant/palliative chemotherapy NA 1167 (39.6) 1446 (55.0) 139 (19.6) 172 (28.6) 22 (12.0) 
Adjuvant/palliative radiotherapy 4610 (29.5) 40 (1.4) 234 (8.9) 31 (4.4) 14 (2.3) 12 (6.6) 
Enumeration data are shown as count (percentage [%]), and measurement data as mean ± standard deviation. Records are complete otherwise 
specified below. 
1Proportions in brackets are relative to the number of total incident cases in respective country. 
2The percentages of pancreas head, body, and tail cancers are the proportions compared to the total tumor cases of the 3 locations; ‘other’ 
includes pancreas duct, overlapping lesion, NOS, and other specified parts, and its proportion is relative to the whole cases. 
3Unkown TNM stage: the US: 327 (2.1%); The Netherlands: 33 (1.1%); Belgium: 177 (6.7%); Norway: 245 (34.6%); Slovenia: 61 (10.1%); 
Estonia: 6 (3.3%). 
4Unknown differentiation: the US, 2134 (13.7%); The Netherlands, 550 (18.7%); Belgium, 514 (19.5%); Norway, 142 (20.0%); Slovenia, 
121 (20.1%); Estonia, 42 (23.0%).  
5Underreporting of non-surgical treatment data might exist in the Estonian Cancer Registry. 
NOS, not otherwise specified; NA, not available. 
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Table 19. Demographic and clinical characteristics of unresected pancreatic cancer patients (Huang et al., 
2018b) 
Parameter the US The Netherlands Belgium Norway Slovenia Estonia4
Diagnosis period 2004-2013 2003-2014 2004-2013 2003-2011 2003-2013 2009-2014 
n1 80945 (83.8) 19533 (86.9) 9515 (78.3) 4896 (87.4) 2720 (81.9) 1227 (87.0)
Sex, female 40579 (50.1) 9797 (50.2) 4685 (49.2) 2576 (52.6) 1398 (51.4) 578 (47.1) 
Age (year) 71 ± 12 70 ± 11 71 ± 11 73 ± 12 71 ± 11 71 ± 11 
Age group       
< 60 years 15386 (19.0) 3426 (17.5) 1516 (15.9) 677 (13.8) 450 (16.5) 193 (15.7) 
60-69 years 19352 (23.9) 5339 (27.3) 2328 (24.5) 1119 (22.9) 609 (22.4) 301 (24.5) 
70-79 years 22365 (27.6) 6351 (32.5) 3277 (34.4) 1413 (28.9) 923 (33.9) 425 (34.6) 
≥ 80 years 23842 (29.5) 4417 (22.6) 2394 (25.2) 1687 (34.5) 738 (27.1) 308 (25.1) 
Tumor location2       
Pancreas head 36004 (65.1) 11622 (69.8) 2713 (64.5) 1417 (68.7) 1010 (70.7) 626 (66.4) 
Pancreas body 9704 (17.5) 2182 (13.1) 688 (16.3) 297 (14.4) 188 (13.2) 196 (20.8) 
Pancreas tail 9608 (17.4) 2851 (17.1) 808 (19.2) 291 (14.1) 230 (16.1) 121 (12.8) 
Other 25629 (31.7) 2878 (14.7) 5306 (55.8) 2834 (57.9) 1292 (47.5) 284 (23.1) 
TNM stage3       
I-II 18010 (25.3) 3035 (18.1) 1282 (19.4) 745 (18.1) 261 (12.3) 124 (13.1) 
III 7266 (10.2) 1821 (10.9) 879 (13.3) 259 (6.3) 166 (7.8) 107 (11.3) 
IV 45889 (64.5) 11916 (71.1) 4455 (67.3) 3103 (75.6) 1696 (79.9) 714 (75.6) 
Adjuvant/palliative chemotherapy NA 3894 (19.9) 5512 (57.9) 970 (19.8) 409 (15.0) 189 (15.4) 
Adjuvant/palliative radiotherapy 953 (1.2) 470 (2.4) 602 (6.3) 248 (5.1) 50 (1.8) 22 (1.8) 
Enumeration data are shown as count (percentage [%]), and measurement data as mean ± standard deviation. Records are complete otherwise 
specified below. Results of tumor differentiation for the unresected were not shown due to great proportions of missing values. 
1Proportions in brackets are relative to the number of total incident cases in respective country. 
2The percentages of pancreas head, body, and tail cancers are the proportions compared to the total tumor cases of the 3 locations; ‘other’ 
includes pancreas duct, overlapping lesion, NOS, and other specified parts, and its proportion is relative to the whole cases. 
3Unkown TNM stage: the US: 9780 (12.1%); The Netherlands: 2761 (14.1%); Belgium: 2899 (30.5 %); Norway: 789 (16.1%); Slovenia: 597 
(21.9%); Estonia: 282 (23.0%). 
4Underreporting of non-surgical treatment data might exist in the Estonian Cancer Registry. 
NOS, not otherwise specified; NA, not available. 
 
3.1.2.2 Non-surgical therapy combinations 
The Netherlands, Belgium, and Slovenia provided information on both pre- and post-surgical therapies, 
and were analyzed concerning the combination of non-surgical therapies (Table 20). Briefly, most 
patients did not receive any non-surgical treatment. For those receiving ≥1 non-surgical therapies, 
chemotherapy alone was the most common modality. Neoadjuvant treatment was rarely administered. 
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Table 20. Non-surgical therapy combinations for pancreatic cancer in Europe, 2011-2013 (Huang et al., 2018b) 
Neoadjuvant therapy Adjuvant/palliative therapy The Netherlands Belgium Slovenia 
Resected n = 1039 n = 940 n = 202
None None 467 (45.0) 359 (38.2) 133 (65.8) 
None  Chemotherapy 544 (52.4) 488 (51.9) 63 (31.2) 
None  Radiotherapy 0 (0.0) 8 (0.9) 0 (0.0) 
None  Chemoradiotherapy 1 (0.1) 46 (4.9) 5 (2.5) 
Chemotherapy None 3 (0.3) 5 (0.3) 1 (0.5) 
Chemotherapy  Chemotherapy 2 (0.2) 19 (2.0) 0 (0.0) 
Chemotherapy  Radiotherapy 0 (0.0) 2 (0.2) 0 (0.0)
Chemotherapy  Chemoradiotherapy 0 (0.0) 1 (0.1) 0 (0.0)
Radiotherapy None 0 (0.0) 0 (0.0)  0 (0.0)
Radiotherapy  Chemotherapy 0 (0.0) 0 (0.0)  0 (0.0)
Radiotherapy  Radiotherapy 0 (0.0) 0 (0.0)  0 (0.0)
Radiotherapy  Chemoradiotherapy 0 (0.0) 0 (0.0) 0 (0.0)
Chemoradiotherapy None 10 (1.0) 8 (0.9) 0 (0.0) 
Chemoradiotherapy  Chemotherapy 12 (1.2) 2 (0.2) 0 (0.0) 
Chemoradiotherapy  Radiotherapy 0 (0.0) 2 (0.2) 0 (0.0)
Chemoradiotherapy  Chemoradiotherapy 0 (0.0) 0 (0.0)  0 (0.0)
Unresected n = 5280 n = 3358 n = 805
None  None 3907 (74.0) 1439 (42.9) 670 (83.2) 
None  Chemotherapy 1261 (23.9) 1732 (51.6) 118 (14.7) 
None  Radiotherapy 27 (0.5) 30 (0.9) 9 (1.1) 
None  Chemoradiotherapy 85 (1.6) 157 (4.7) 8 (1.0) 
Data are shown as n (percentage [%]). 
 
Within the subgroup of resected PaC patients, significant proportions did not receive any 
non-surgical treatment (38.2% (Belgium) to 65.8% (Slovenia)). Among those who received ≥1 
non-surgical therapy, adjuvant chemotherapy alone was the most common modality (31.2% (Slovenia) 
to 52.4% (the Netherlands)). Adjuvant chemoradiation was administered for 0.1%, 4.9%, and 2.5% of 
the patients in the Netherlands, Belgium, and Slovenia, respectively. All the other treatment 
combinations were used in <2.5% of the patients in all the registries. 
For unresected cancer patients, the plurality or majority of patients remained untreated (42.9% 
(Belgium) to 83.2% (Slovenia)). Among the treated patients, most of them received chemotherapy 
(14.7% (Slovenia) to 51.6% (Belgium)), followed by chemoradiation (1.0% (Slovenia) to 4.7% 
(Belgium)) and radiotherapy alone (0.5% (the Netherlands) to 1.1% (Slovenia)). 
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3.1.2.3 Time between diagnosis/surgery and chemotherapy/radiotherapy use 
Information on the time interval between diagnosis/resection and chemotherapy/radiotherapy 
administration was available in the Netherlands, Belgium, and Slovenia (Table 21). Among resected 
patients receiving chemotherapy, the mean time intervals between diagnosis and chemotherapy and 
between surgery and chemotherapy were 66-71 and 51-52 days, respectively. As many as 81.5%-85.5% 
and 93.5%-99.7% of resected patients received chemotherapy ≤90 days after diagnosis and after 
surgery, respectively. Compared to chemotherapy, it took longer for resected patients to receive 
radiotherapy after diagnosis (81-114 days) and after surgery (75-85 days), and smaller proportions of 
patients received radiotherapy ≤90 days after diagnosis (46.2%-62.5%) and ≤90 days after resection 
(58.6%-75.0%). 
 
Table 21. Time between diagnosis/surgery and chemotherapy/radiotherapy use in resected and unresected 
pancreatic cancer patients receiving chemotherapy/radiotherapy in registries with available information (Huang 
et al., 2018b) 
Interval The Netherlands Belgium 
 n 
Mean ± 
standard 
deviation 
Median 
(interquartile 
range) 
Administered 
≤90 days n 
Mean ± 
standard 
deviation 
Median 
(interquartile 
range) 
Administered 
≤90 days 
Resected         
Diagnosis-chemotherapy 964 66 ± 33 58 (43-82) 786 (81.5) 1446 71 ± 34 64 (50-83) 1199 (82.9) 
Surgery-chemotherapy 964 51 ± 18 48 (39-60) 928 (96.3) 1446 51 ± 15 50 (41-61) 1442 (99.7) 
Diagnosis-radiotherapy 8 81 ± 40 70 (52-103) 5 (62.5) 234 105 ± 56 98 (62-142) 108 (46.2) 
Surgery-radiotherapy 8 75 ± 33 70 (52-90) 6 (75.0) 234 85 ± 43 75 (49-115) 137 (58.6) 
Unresected         
Diagnosis-chemotherapy 2882 38 ± 37 28 (17-48) 2683 (93.1) 5512 26 ± 19 20 (12-35) 5491 (99.6) 
Diagnosis-radiotherapy 313 47 ± 38 40 (23-60) 279 (89.1) 602 71 ± 52 55 (25-112) 387 (64.3) 
Intervals are shown in days. 
 
Table 21. Time between diagnosis/surgery and chemotherapy/radiotherapy use in resected and unresected 
pancreatic cancer patients receiving chemotherapy/radiotherapy in registries with available information (Huang 
et al., 2018b) (continued) 
Interval Slovenia 
 n Mean ± standard deviation 
Median (interquartile 
range) 
Administered 
≤90 days 
Resected     
Diagnosis-chemotherapy 172 69 ± 39 63 (50-81) 147 (85.5) 
Surgery-chemotherapy 168 52 ± 33 46 (38-56) 157 (93.5) 
Diagnosis-radiotherapy 14 114 ± 82 89 (51-133) 7 (50.0) 
Surgery-radiotherapy 13 82 ± 63 58 (33-91) 9 (69.2) 
Unresected     
Diagnosis-chemotherapy 409 46 ± 52 34 (15-60) 372 (91.0) 
Diagnosis-radiotherapy 50 106 ± 114 64 (32-153) 33 (66.0) 
Intervals are shown in days. 
 
 In unresected patients receiving chemotherapy/radiotherapy, the time between diagnosis and 
chemotherapy (26-46 days) and between diagnosis and radiotherapy (47-106 days) was shorter with 
larger international variations. 91.0%-99.6% of unresected patients received chemotherapy ≤90 days 
after diagnosis, and 64.3%-89.1% of patients underwent radiotherapy within the post-diagnosis period. 
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3.1.2.4 Temporal trends of chemotherapy and radiotherapy use 
The application trends from 2003-2004 to 2013-2014 are illustrated in Figure 3. For resected PaC, 
chemotherapy was most commonly administered in Belgium in all periods with an increasing trend 
(2003-2004: 29.1%, 2013-2014: 62.9%; Ptrend=0.001). The Netherlands showed the strongest increase 
over the periods (2003-2004: 7.6%, 2013-2014: 56.2%; Ptrend<0.001). Chemotherapy rates also 
increased in Norway (2003-2004: 2.3%, 2011-2012: 30.2%; Ptrend<0.001) and Slovenia (2003-2004: 
14.8%, 2013-2014: 33.4%; Ptrend=0.009). Estonia showed the lowest rates with an insignificant trend 
(2009-2010: 8.8%, 2013-2014: 12.8%; Ptrend=0.165). For unresected cancer, chemotherapy was again 
most frequently used in Belgium, where the proportions were stable (2003-2004: 53.2%, 2013-2014: 
57.2%; Ptrend=0.188). Chemotherapy use increased in the Netherlands (2003-2004: 10.7%, 2013-2014: 
27.9%; Ptrend<0.001), Norway (2003-2004: 14.3%, 2011-2012: 25.1%; Ptrend=0.002), Slovenia 
(2003-2004: 11.6%, 2013-2014: 16.7%; Ptrend=0.010), and Estonia (2009-2010: 11.6%, 2013-2014: 
19.4%; Ptrend=0.002). Rates changed most dramatically from 2003-2004 to 2009-2010 for both 
resected and unresected PaCs in most countries. 
 
 
 
Figure 3. Age-standardized trends of chemotherapy administration for resected (A) and unresected (B) 
pancreatic cancer patients and of radiotherapy administration for resected (C) and unresected (D) patients. 
(Huang et al., 2018b) 
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From 2003-2004 to 2013-2014 in Belgium, among patients receiving chemotherapy the 
utilization of combination regimens increased from 1.5% to 2.8% for resected PaC (Ptrend=0.005), and 
from 2.9% to 10.5% for unresected tumor (Ptrend<0.001). The proportion of fluorouracil-based 
regimens decreased from 25.0% to 7.6% (Ptrend=0.046), with the proportion of gemcitabine-based 
regimens increasing from 64.6% to 89.8% (Ptrend=0.039) for resected PaC. For unresected cancers, 
While with statistical insignificances, reverse, statistically insignificant trends were observed 
concerning the proportions of fluorouracil-based (6.8% to 11.6%, Ptrend=0.062) and gemcitabine-based 
regimens (90.3% to 85.5%, Ptrend=0.053). 
 For resected PaC, radiotherapy was much more frequently administered in the US compared to 
Europe in all study periods, with a decreasing rate (2003-2004: 40.4%, 2013-2014: 32.0%; 
Ptrend<0.001). Belgium overall ranked first in radiotherapy administration in Europe, but the rate 
decreased from 14.6% in 2003-2004 to 7.3% in 2013-2014 (Ptrend=0.003). In the Netherlands, a similar 
trend was observed (2003-2004: 5.4%, 2013-2014: 2.9%; Ptrend=0.024). In Norway (Ptrend=0.470) and 
Slovenia (Ptrend=0.835), radiotherapy was rarely administered with stable rates <5.0%. In Estonia, no 
significant trends were observed (2009-2010: 5.3%, 2013-2014: 4.8%; Ptrend=0.738). For unresected 
cancer, radiotherapy use was rare in all countries during 2003-2014 (<8.5% across periods; 
Ptrend=0.011 (the US), 0.021 (the Netherlands), 0.124 (Belgium), 0.573 (Norway), 0.119 (Slovenia), 
and 0.693 (Estonia)). In 2013-2014, radiotherapy was administered in 0.9% (the US) to 4.9% 
(Belgium) of unresected patients. 
Great variations across different geographical areas within the US were observed regarding 
radiotherapy use during 2012-2013 (Figure 4). For resected cancer patients, radiotherapy rates were 
generally higher in the eastern than the western US, and were markedly higher than the average level 
of the total SEER-18 registries (32.9%) in Iowa (43.3%), Louisiana (42.8%), Kentucky (39.3%), 
Atlanta (46.5%), Georgia (41.5%), and Detroit (45.5%), but markedly lower in Connecticut (18.8%) 
and Los Angeles (18.0%). For unresected cancer patients, radiotherapy rates were very low 
(0.5%-2.9%) across all the US sub-registries. 
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Figure 4. Age-standardized rates of radiotherapy administration for resected (A) and unresected (B) pancreatic 
cancer in 2012-2013 in the US. Geographical disparities of radiotherapy administration in the US are shown. The 
total registry is marked in red, the western US sub-registries in green, and the eastern sub-registries in blue. 
(Huang et al., 2018b) 
 
In 2012-2014, chemotherapy and radiotherapy use decreased with increasing age for both 
resected and unresected PaCs (Figure 5). For unresected cancers, those in pancreas body and those of 
stage III mostly received more frequently chemotherapy. Radiotherapy was more often used for stage 
III PaCs in both resected and unresected cancers. 
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3.1.2.5 Factors associated with chemotherapy and radiotherapy use in resected pancreatic 
cancer 
Using multivariable logistic regression, for resected PaC, chemotherapy was less frequently 
administered with increasing age, especially among patients aged 70-79 (OR=0.25-0.52 across 
countries) and ≥80 years (OR=0.02-0.08) compared to those <60 years (Table 22). Compared to stage 
I-II cancers, chemotherapy was less frequently administered in metastatic PaCs in the Netherlands 
(OR=0.50), while in Belgium, it was more often used in stage III (OR=1.94) and IV (OR=1.52) 
cancers. Radiotherapy was more frequently administered for male patients in the US (OR=1.08; Table 
23). A decreasing frequency of radiotherapy administration with increasing age was observed in all 
countries, with ORs in patients aged 70-79 and ≥80 years versus those <60 years of 0.27-0.55 and 
0.05-0.25, respectively. In the US, patients with pancreatic tail cancers received less frequently 
radiotherapy than those with head tumors (OR=0.72). Compared to patients with stage I-II PaCs, those 
with stage III tumors received more often radiotherapy (OR=1.68-3.20), while patients with metastatic 
cancers underwent less frequently radiotherapy (OR=0.25-0.47). 
 
Table 22. Association of chemotherapy use with demographic and clinical variables in resected pancreatic 
cancer estimated by multivariable logistic regression (Huang et al., 2018b) 
Variable The Netherlands Belgium Norway Slovenia 
 OR (95% CI)1 OR (95% CI) OR (95% CI)  OR (95% CI)
Resected (treated/total) 1194/2912 1431/2453 108/464 161/541 
Year of diagnosis 1.34 (1.30-1.38) 1.15 (1.11-1.19) 1.51 (1.36-1.69) 1.14 (1.07-1.22)
Sex (ref.: female)     
Male 0.91 (0.77-1.08) 0.90 (0.76-1.07) 1.26 (0.77-2.05) 1.29 (0.87-1.91)
Age group (ref.: < 60 years)     
60-69 years 0.62 (0.50-0.76) 0.63 (0.50-0.80) 1.26 (0.71-2.26) 0.73 (0.46-1.15)
70-79 years 0.25 (0.20-0.31) 0.29 (0.23-0.37) 0.52 (0.26-1.00) 0.26 (0.15-0.43)
≥ 80 years 0.02 (0.01-0.05) 0.06 (0.04-0.10) 0.08 (0.01-0.69) NE 
Tumor location (ref.: pancreas head)     
Pancreas body 0.84 (0.54-1.32) 1.02 (0.67-1.55) 0.22 (0.05-1.06) 0.89 (0.40-1.96)
Pancreas tail 0.74 (0.54-1.01) 1.13 (0.81-1.57) 1.39 (0.59-3.28) 0.94 (0.40-2.20)
Other2 0.71 (0.52-0.97) 0.79 (0.65-0.95) 1.29 (0.63-2.63) 1.29 (0.71-2.35)
TNM stage (ref.: I-II)     
III 1.21 (0.84-1.77) 1.94 (1.31-2.87) 1.33 (0.44-4.08) 0.81 (0.40-1.65)
IV 0.50 (0.30-0.84) 1.52 (1.04-2.20) 1.50 (0.73-3.08) 0.86 (0.49-1.49)
1Odds ratios and 95% confidence intervals for chemotherapy versus non-chemotherapy and radiotherapy versus non-radiotherapy were 
calculated using multivariable logistic regression models adjusting for year of diagnosis, sex, age group, tumor location, and TNM stage. 
Results for countries with number of patients receiving indicated therapy < 50 (Estonia, 22) were not reported. ORs shown in bold are 
statistically significant. 
2Other: pancreas duct, overlapping lesion, and not otherwise specified (NOS) parts. 
OR, odds ratio; CI, confidence interval; NE, not estimable due to small case number; NA, not available. 
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Table 23. Association of radiotherapy use with demographic and clinical variables in resected pancreatic cancer 
estimated by multivariable logistic regression (Huang et al., 2018b) 
Variable The US The Netherlands Belgium 
 OR (95% CI) OR (95% CI) OR (95% CI) 
Resected (treated/total) 5205/14923 78/2912 250/2453 
Year of diagnosis 0.96 (0.95-0.97) 0.92 (0.86-0.98) 0.87 (0.83-0.91) 
Sex (ref.: female)    
Male 1.08 (1.00-1.15) 0.82 (0.52-1.29) 1.19 (0.90-1.56) 
Age group (ref.: < 60 years)    
60-69 years 0.90 (0.83-0.98) 0.38 (0.22-0.64) 1.00 (0.73-1.36) 
70-79 years 0.55 (0.51-0.61) 0.27 (0.15-0.50) 0.44 (0.30-0.63) 
≥ 80 years 0.25 (0.22-0.29) 0.17 (0.02-1.24) 0.05 (0.01-0.35) 
Tumor location (ref.: pancreas head)    
Pancreas body 0.92 (0.80-1.06) 1.64 (0.58-4.66) 1.43 (0.80-2.53) 
Pancreas tail 0.72 (0.64-0.81) 0.62 (0.22-1.74) 0.62 (0.35-1.12) 
Other2 0.73 (0.65-0.82) 0.85 (0.36-2.01) 0.93 (0.69-1.26) 
TNM stage (ref.: I-II)    
III 1.68 (1.45-1.96) 3.20 (1.63-6.27) 2.91 (1.92-4.41) 
IV 0.25 (0.21-0.30) 0.38 (0.05-2.81) 0.47 (0.23-0.98) 
1Odds ratios and 95% confidence intervals for chemotherapy versus non-chemotherapy and radiotherapy versus non-radiotherapy were 
calculated using multivariable logistic regression models adjusting for year of diagnosis, sex, age group, tumor location, and TNM stage. 
Results for countries with number of patients receiving indicated therapy < 50 (Norway, 19; Slovenia, 11; Estonia, 12) were not reported. 
ORs shown in bold are statistically significant. 
2Other: pancreas duct, overlapping lesion, and not otherwise specified (NOS) parts. 
OR, odds ratio; CI, confidence interval; NE, not estimable due to small case number; NA, not available. 
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In countries with available information on the time interval between diagnosis and treatment, 
association patterns and trends remained similar after limiting patients receiving chemotherapy or 
radiotherapy to those undergoing the treatment ≤90 days after diagnosis (Table 24). After restricting 
the total patients to those surviving >90 days after diagnosis in all countries, association patterns and 
trends also remained mostly similar with only a few exceptions mostly reflected by the changes in 
significance (Tables 25-26). 
 
Table 24. Associations of chemotherapy or radiotherapy administered ≤ 90 days after diagnosis versus not 
administered with demographic and clinical variables for resected pancreatic cancer estimated by multivariable 
logistic regression (Huang et al., 2018b) 
Variable Chemotherapy  Radiotherapy 
Country Netherlands Belgium Slovenia  Belgium 
 OR (95% CI)1 OR (95% CI) OR (95% CI)   OR (95% CI)
Resected (treated ≤ 90 days/untreated) 781/1718 1160/1012 127/356  102/2203 
Year of diagnosis 1.48 (1.43-1.54) 1.15 (1.11-1.18) 1.17 (1.08-1.25)  0.83 (0.77-0.89)
Sex (ref.: female)      
Male 0.87 (0.71-1.06) 0.89 (0.74-1.07) 1.13 (0.73-1.74)  1.22 (0.80-1.84)
Age group (ref.: < 60 years)      
60-69 years 0.69 (0.54-0.88) 0.63 (0.49-0.80) 0.74 (0.45-1.21)  1.32 (0.82-2.12)
70-79 years 0.24 (0.18-0.31) 0.27 (0.21-0.34) 0.20 (0.11-0.37)  0.48 (0.27-0.85)
≥ 80 years 0.02 (0.01-0.05) 0.06 (0.04-0.10) NE  0.14 (0.02-1.07)
Tumor location (ref.: pancreas head)      
Pancreas body 0.67 (0.38-1.17) 0.79 (0.50-1.24) 0.78 (0.29-2.07)  1.22 (0.47-3.19)
Pancreas tail 0.84 (0.59-1.20) 1.19 (0.84-1.68) 0.77 (0.28-2.09)  0.63 (0.24-1.63)
Other2 0.65 (0.45-0.95) 0.78 (0.63-0.95) 1.59 (0.82-3.07)  1.23 (0.80-1.90)
TNM stage (ref.: I-II)      
III 1.05 (0.67-1.66) 1.79 (1.18-2.72) 0.81 (0.37-1.73)  3.58 (2.03-6.30)
IV 0.27 (0.13-0.55) 1.55 (1.05-2.29) 0.76 (0.38-1.49)  0.27 (0.07-1.13)
1Odds ratios and 95% confidence intervals for chemotherapy administered ≤ 90 days after diagnosis versus non-chemotherapy and 
radiotherapy administered ≤ 90 days after diagnosis versus non-radiotherapy were calculated using multivariable logistic regression models 
adjusting for year of diagnosis, sex, age group, tumor location, and TNM stage. Results for countries with number of patients receiving 
indicated therapy within 90 days after diagnosis < 50 (radiotherapy: the Netherlands, 5; Slovenia, 6) were not reported. ORs shown in bold 
are statistically significant. 
2Other: pancreas duct, overlapping lesion, and not otherwise specified (NOS) parts. 
OR, odds ratio; CI, confidence interval; NE, not estimable due to small case number; NA, not available. 
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Table 25. Associations of chemotherapy use with demographic and clinical variables for resected pancreatic 
cancer patients surviving >90 days after diagnosis estimated by multivariable logistic regression (Huang et al., 
2018b) 
Variable The Netherlands Belgium Norway Slovenia 
 OR (95% CI)1 OR (95% CI) OR (95% CI)  OR (95% CI)
Resected (treated/total) 1160/2656 1420/2275 107/437 152/456 
Year of diagnosis 1.37 (1.33-1.41) 1.17 (1.13-1.21) 1.52 (1.36-1.70) 1.16 (1.08-1.24)
Sex (ref.: female)     
Male 0.93 (0.78-1.10) 0.94 (0.79-1.13) 1.34 (0.82-2.20) 1.35 (0.88-2.05)
Age group (ref.: < 60 years)     
60-69 years 0.64 (0.52-0.80) 0.64 (0.50-0.82) 1.33 (0.74-2.39) 0.72 (0.45-1.17)
70-79 years 0.25 (0.20-0.32) 0.31 (0.24-0.40) 0.56 (0.29-1.10) 0.25 (0.15-0.44)
≥ 80 years 0.02 (0.01-0.06) 0.06 (0.04-0.09) 0.11 (0.01-0.93) NE 
Tumor location (ref.: pancreas head)     
Pancreas body 0.84 (0.52-1.35) 1.02 (0.66-1.60) 0.25 (0.05-1.21) 0.92 (0.39-2.19)
Pancreas tail 0.71 (0.51-0.98) 1.01 (0.72-1.42) 1.40 (0.58-3.34) 0.63 (0.24-1.62)
Other2 0.70 (0.50-0.97) 0.80 (0.65-0.98) 1.29 (0.62-2.66) 1.75 (0.88-3.48)
TNM stage (ref.: I-II)     
III 1.50 (1.00-2.25) 2.30 (1.48-3.57) 1.73 (0.54-5.54) 0.86 (0.41-1.78)
IV 0.49 (0.28-0.85) 1.84 (1.21-2.80) 1.51 (0.71-3.20) 1.12 (0.57-2.21)
1Odds ratios and 95% confidence intervals for chemotherapy versus non-chemotherapy and radiotherapy versus non-radiotherapy in 
pancreatic cancer patients surviving > 90 days after diagnosis were calculated using multivariable logistic regression models adjusting for 
year of diagnosis, sex, age group, tumor location, and TNM stage. Results for countries with number of patients receiving indicated therapy 
< 50 (Estonia, 19) were not reported. ORs shown in bold are statistically significant. 
2Other: pancreas duct, overlapping lesion, and not otherwise specified (NOS) parts. 
OR, odds ratio; CI, confidence interval; NE, not estimable due to small case number; NA, not available. 
 
Table 26. Associations of radiotherapy use with demographic and clinical variables for resected pancreatic 
cancer patients surviving >90 days after diagnosis estimated by multivariable logistic regression (Huang et al., 
2018b) 
Variable the US The Netherlands Belgium 
 OR (95% CI) OR (95% CI) OR (95% CI) 
Resected (treated/total) 5090/13761 76/2656 249/2275 
Year of diagnosis 0.96 (0.94-0.97) 0.92 (0.86-0.99) 0.87 (0.83-0.91) 
Sex (ref.: female)    
Male 1.10 (1.02-1.18) 0.79 (0.49-1.25) 1.20 (0.91-1.58) 
Age group (ref.: < 60 years)    
60-69 years 0.93 (0.85-1.02) 0.39 (0.23-0.66) 1.03 (0.75-1.40) 
70-79 years 0.61 (0.55-0.66) 0.25 (0.13-0.47) 0.47 (0.32-0.67) 
≥ 80 years 0.29 (0.25-0.34) 0.19 (0.03-1.43) 0.05 (0.01-0.38) 
Tumor location (ref.: pancreas head)    
Pancreas body 0.92 (0.80-1.06) 1.76 (0.61-5.03) 1.43 (0.80-2.55) 
Pancreas tail 0.73 (0.65-0.82) 0.63 (0.22-1.77) 0.61 (0.34-1.10) 
Other2 0.74 (0.66-0.83) 0.70 (0.28-1.79) 0.95 (0.70-1.28) 
TNM stage (ref.: I-II)    
III 1.77 (1.51-2.07) 3.46 (1.75-6.84) 3.09 (2.02-4.72) 
IV 0.32 (0.26-0.38) 0.43 (0.06-3.15) 0.49 (0.23-1.02) 
1Odds ratios and 95% confidence intervals for chemotherapy versus non-chemotherapy and radiotherapy versus non-radiotherapy in 
pancreatic cancer patients surviving > 90 days after diagnosis were calculated using multivariable logistic regression models adjusting for 
year of diagnosis, sex, age group, tumor location, and TNM stage. Results for countries with number of patients receiving indicated therapy 
< 50 (Norway, 18; Slovenia, 11; Estonia, 11) were not reported. ORs shown in bold are statistically significant. 
2Other: pancreas duct, overlapping lesion, and not otherwise specified (NOS) parts. 
OR, odds ratio; CI, confidence interval; NE, not estimable due to small case number; NA, not available. 
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3.1.2.6 Factors associated with chemotherapy and radiotherapy use in unresected pancreatic 
cancer 
For unresected PaC, chemotherapy was more frequently administered to male patients in Belgium 
(OR=1.18), but less often in Slovenia (OR=0.75; Table 27). Decreasing chemotherapy use rates with 
increasing ages were observed in all countries, with ORs in patients aged 70-79 and ≥80 years versus 
those <60 years of 0.19-0.44 and 0.03-0.10, respectively. Compared to pancreatic head cancers, body 
(OR=1.43-3.30) and tail tumors (OR=1.28-1.95) were more frequently treated with chemotherapy in 
all countries except Norway. Compared to patients with stage I-II PaCs, those with stage III 
(OR=1.90-5.70) and IV tumors (OR=1.35-5.18) received more frequently chemotherapy, and the 
association strengths were weaker for metastatic cancers. Radiotherapy was again less often used with 
increasing age (70-79 vs. <60 years, OR=0.24-0.46; ≥80 vs. <60 years, OR=0.03-0.18; Table 28). In 
the US, patients with pancreatic body (OR=0.74) and tail cancers (OR=0.42) received radiotherapy 
less often compared to those with head cancers. In the Netherlands, patients with pancreas tail cancers 
received less frequently radiation (OR=0.36). Compared to stage I-II PaCs, stage III cancers were 
treated with more often radiotherapy in the US (OR=1.22), the Netherlands (OR=2.93), and Belgium 
(OR=1.51), while patients with metastatic cancers received less often radiotherapy (OR=0.18-0.53). 
 
Table 27. Association of chemotherapy use with demographic and clinical parameters for unresected pancreatic 
cancer estimated by multivariable logistic regression (Huang et al., 2018b) 
Variable The Netherlands Belgium Norway Slovenia Estonia 
 OR (95% CI)1 OR (95% CI) OR (95% CI) OR (95% CI)  OR (95% CI) 
Unresected (treated/total) 3708/16772 4062/6616 888/4107 340/2123 175/945 
Year of diagnosis 1.13 (1.12-1.15) 1.02 (1.00-1.04) 1.12 (1.08-1.16) 1.08 (1.04-1.13) 1.20 (1.09-1.33) 
Sex (ref.: female)      
Male 1.02 (0.94-1.11) 1.18 (1.05-1.32) 0.95 (0.81-1.12) 0.75 (0.57-0.97) 1.26 (0.88-1.81) 
Age group (ref.: < 60 years)      
60-69 years 0.64 (0.58-0.70) 0.76 (0.63-0.92) 0.70 (0.57-0.86) 0.62 (0.46-0.84) 0.68 (0.4.-1.09) 
70-79 years 0.23 (0.21-0.26) 0.42 (0.35-0.50) 0.30 (0.24-0.38) 0.19 (0.14-0.27) 0.44 (0.28-0.71) 
≥ 80 years 0.03 (0.02-0.03) 0.09 (0.07-0.11) 0.04 (0.03-0.06) 0.03 (0.01-0.06) 0.10 (0.04-0.22) 
Tumor location (ref.: pancreas head)      
Pancreas body 1.50 (1.33-1.69) 1.56 (1.25-1.95) 1.22 (0.88-1.68) 1.43 (0.92-2.24) 3.30 (2.08-5.23) 
Pancreas tail 1.28 (1.14-1.43) 1.51 (1.23-1.86) 0.85 (0.61-1.18) 1.95 (1.31-2.90) 1.84 (1.04-3.25) 
Other2 1.04 (0.92-1.17) 1.01 (0.89-1.15) 0.71 (0.59-0.85) 0.74 (0.55-1.00) 1.97 (1.24-3.11)
TNM stage (ref.: I-II)      
III 2.26 (1.92-2.66) 1.90 (1.56-2.31) 1.91 (1.32-2.78) 5.49 (2.64-11.41) 5.70 (1.83-17.76)
IV 1.35 (1.18-1.55) 1.52 (1.32-1.75) 1.43 (1.12-1.84) 2.77 (1.45-5.29) 5.18 (1.83-14.68)
1Odds ratios and 95% confidence intervals for chemotherapy versus non-chemotherapy and radiotherapy versus non-radiotherapy were 
calculated using multivariable logistic regression models adjusting for year of diagnosis, sex, age group, tumor location, and TNM stage. 
ORs shown in bold are statistically significant. 
2Other: pancreas duct, overlapping lesion, and not otherwise specified (NOS) parts. 
OR, odds ratio; CI, confidence interval; NE, not estimable due to small case number; NA, not available. 
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Table 28. Association of radiotherapy use with demographic and clinical parameters for unresected pancreatic 
cancer estimated by multivariable logistic regression (Huang et al., 2018b) 
Variable the US The Netherlands Belgium Norway 
 OR (95% CI) OR (95% CI) OR (95% CI)  OR (95% CI) 
Unresected (treated/total) 908/70415 408/16772 459/6616 206/4107 
Year of diagnosis 0.96 (0.94-0.98) 0.96 (0.93-0.99) 0.97 (0.94-1.01) 1.06 (1.00-1.13)
Sex (ref.: female)     
Male 1.08 (0.95-1.24) 1.04 (0.85-1.28) 0.92 (0.76-1.13) 1.16 (0.87-1.55)
Age group (ref.: < 60 years)     
60-69 years 0.79 (0.68-0.93) 0.78 (0.61-0.99) 0.72 (0.56-0.93) 0.60 (0.43-0.85)
70-79 years 0.46 (0.38-0.55) 0.34 (0.26-0.45) 0.39 (0.30-0.50) 0.24 (0.16-0.36)
≥ 80 years 0.18 (0.14-0.22) 0.03 (0.02-0.08) 0.13 (0.09-0.20) 0.08 (0.04-0.14)
Tumor location (ref.: pancreas head)     
Pancreas body 0.74 (0.60-0.92) 0.94 (0.69-1.28) 1.00 (0.69-1.45) 1.07 (0.60-1.92)
Pancreas tail 0.42 (0.31-0.58) 0.36 (0.21-0.62) 1.01 (0.69-1.48) 0.93 (0.49-1.76)
Other2 0.79 (0.67-0.94) 0.72 (0.51-1.01) 0.95 (0.76-1.19) 1.03 (0.74-1.43)
TNM stage (ref.: I-II)     
III 1.22 (1.03-1.45) 2.93 (2.25-3.82) 1.51 (1.17-1.95) 1.19 (0.70-2.05)
IV 0.29 (0.24-0.34) 0.18 (0.13-0.25) 0.24 (0.19-0.31) 0.53 (0.37-0.77)
1Odds ratios and 95% confidence intervals for chemotherapy versus non-chemotherapy and radiotherapy versus non-radiotherapy were 
calculated using multivariable logistic regression models adjusting for year of diagnosis, sex, age group, tumor location, and TNM stage. 
Results for countries with number of patients receiving indicated therapy < 50 (Slovenia, 42; Estonia, 19) were not reported. ORs shown in 
bold are statistically significant. 
2Other: pancreas duct, overlapping lesion, and not otherwise specified (NOS) parts. 
OR, odds ratio; CI, confidence interval; NE, not estimable due to small case number; NA, not available. 
 
 In countries with available information on the time interval between diagnosis and treatment, 
association patterns and trends remained mostly similar after limiting patients to those receiving the 
treatment ≤90 days after diagnosis, with only a few exceptions mostly reflected by the changes in 
significance (Table 29). After limiting the total patients to those surviving >90 days after diagnosis, 
association patterns and trends also remained similar overall with only a few exceptions mostly 
reflected by the changes in significance (Tables 30-31). 
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Table 29. Associations of chemotherapy or radiotherapy administered ≤90 days after diagnosis versus not 
administered with demographic and clinical variables for unresected pancreatic cancer estimated by 
multivariable logistic regression (Huang et al., 2018b) 
Variable Chemotherapy Radiotherapy 
Country The Netherlands Belgium Slovenia The Netherlands Belgium 
Unresected OR (95% CI)1 OR (95% CI) OR (95% CI) OR (95% CI)  OR (95% CI)
Treated ≤ 90 days/untreated 2593/13064 4044/2554 204/961 260/16364 292/6157 
Year of diagnosis 1.29 (1.27-1.31) 1.02 (1.00-1.04) 1.12 (1.06-1.19) 1.10 (1.06-1.15) 0.91 (0.88-0.95)
Sex (ref.: female)      
Male 0.97 (0.88-1.06) 1.17 (1.05-1.31) 0.97 (0.69-1.36) 1.20 (0.93-1.54) 1.00 (0.79-1.28)
Age group (ref.: < 60 years)      
60-69 years 0.66 (0.58-0.73) 0.76 (0.63-0.92) 0.54 (0.36-0.81) 0.84 (0.63-1.12) 0.92 (0.67-1.25)
70-79 years 0.24 (0.21-0.27) 0.42 (0.35-0.50) 0.22 (0.15-0.34) 0.37 (0.26-0.52) 0.41 (0.29-0.57)
≥ 80 years 0.02 (0.02-0.03) 0.09 (0.08-0.11) 0.03 (0.01-0.08) 0.02 (<0.01-0.07) 0.18 (0.11-0.29)
Tumor location (ref.: pancreas head)      
Pancreas body 1.47 (1.28-1.69) 1.57 (1.26-1.96) 1.03 (0.57-1.88) 0.91 (0.63-1.33) 0.93 (0.57-1.52)
Pancreas tail 1.34 (1.18-1.52) 1.52 (1.23-1.86) 1.83 (1.09-3.07) 0.39 (0.21-0.73) 1.03 (0.64-1.66)
Other2 1.16 (1.02-1.33) 1.01 (0.89-1.15) 0.72 (0.49-1.06) 0.77 (0.51-1.15) 1.01 (0.77-1.33)
TNM stage (ref.: I-II)      
III 2.15 (1.76-2.63) 1.91 (1.57-2.32) 2.73 (1.16-6.41) 2.56 (1.84-3.56) 1.54 (1.13-2.11)
IV 1.41 (1.19-1.67) 1.53 (1.33-1.76) 1.45 (0.65-3.21) 0.19 (0.13-0.27) 0.26 (0.19-0.35)
1Odds ratios and 95% confidence intervals for chemotherapy administered ≤ 90 days after diagnosis versus non-chemotherapy and 
radiotherapy administered ≤ 90 days after diagnosis versus non-radiotherapy were calculated using multivariable logistic regression models 
adjusting for year of diagnosis, sex, age group, tumor location, and TNM stage. Results for countries with number of patients receiving 
indicated therapy within 90 days after diagnosis < 50 (radiotherapy: Slovenia, 14) were not reported. ORs shown in bold are statistically 
significant. 
2Other: pancreas duct, overlapping lesion, and not otherwise specified (NOS) parts. 
OR, odds ratio; CI, confidence interval; NE, not estimable due to small case number; NA, not available. 
 
Table 30. Associations of chemotherapy use with demographic and clinical parameters for unresected pancreatic 
cancer patients surviving >90 days after diagnosis estimated by multivariable logistic regression (Huang et al., 
2018b) 
Variable The Netherlands Belgium Norway Slovenia Estonia 
 OR (95% CI)1 OR (95% CI) OR (95% CI) OR (95% CI)  OR (95% CI) 
Unresected (treated/total) 3006/8079 3239/4304 714/2022 191/534 118/447 
Year of diagnosis 1.14 (1.12-1.16) 1.04 (1.01-1.07) 1.13 (1.09-1.18) 1.16 (1.07-1.25) 1.22 (1.06-1.40) 
Sex (ref.: female)      
Male 1.18 (1.06-1.31) 1.38 (1.18-1.62) 1.02 (0.83-1.25) 1.25 (0.83-1.87) 1.31 (0.82-2.08) 
Age group (ref.: < 60 years)      
60-69 years 0.67 (0.59-0.76) 1.00 (0.77-1.31) 0.84 (0.65-1.10) 0.58 (0.35-0.95) 0.82 (0.45-1.51) 
70-79 years 0.26 (0.23-0.30) 0.55 (0.43-0.70) 0.39 (0.30-0.52) 0.18 (0.11-0.31) 0.51 (0.28-0.93) 
≥ 80 years 0.03 (0.02-0.04) 0.11 (0.09-0.15) 0.07 (0.04-0.10) 0.04 (0.01-0.13) 0.12 (0.04-0.38) 
Tumor location (ref.: pancreas head)      
Pancreas body 1.68 (1.44-1.96) 1.65 (1.20-2.26) 1.25 (0.84-1.85) 0.98 (0.49-1.93) 3.08 (1.68-5.67) 
Pancreas tail 1.83 (1.56-2.15) 1.41 (1.04-1.91) 0.95 (0.61-1.47) 2.33 (1.17-4.62) 1.69 (0.78-3.63) 
Other2 1.32 (1.13-1.54) 1.11 (0.93-1.33) 0.73 (0.58-0.91) 0.88 (0.56-1.39) 2.50 (1.39-4.49)
TNM stage (ref.: I-II)      
III 2.16 (1.81-2.59) 2.29 (1.81-2.90) 2.29 (1.52-3.45) 2.81 (1.15-6.86) 3.76 (1.14-12.38)
IV 2.38 (2.04-2.77) 3.07 (2.57-3.67) 2.29 (1.74-3.02) 2.52 (1.08-5.89) 4.92 (1.68-14.39)
1Odds ratios and 95% confidence intervals for chemotherapy versus non-chemotherapy and radiotherapy versus non-radiotherapy in 
pancreatic cancer patients surviving > 90 days after diagnosis were calculated using multivariable logistic regression models adjusting for 
year of diagnosis, sex, age group, tumor location, and TNM stage. ORs shown in bold are statistically significant. 
2Other: pancreas duct, overlapping lesion, and not otherwise specified (NOS) parts. 
OR, odds ratio; CI, confidence interval; NE, not estimable due to small case number; NA, not available. 
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Table 31. Associations of radiotherapy use with demographic and clinical parameters for unresected pancreatic 
cancer patients surviving >90 days after diagnosis estimated by multivariable logistic regression (Huang et al., 
2018b) 
Variable the US The Netherlands Belgium Norway 
 OR (95% CI) OR (95% CI) OR (95% CI)  OR (95% CI) 
Unresected (treated/total) 825/37825 368/8079 413/4304 161/2022 
Year of diagnosis 0.95 (0.93-0.98) 0.95 (0.92-0.98) 0.97 (0.93-1.01) 1.04 (0.98-1.12)
Sex (ref.: female)     
Male 1.12 (0.97-1.29) 1.12 (0.90-1.39) 0.95 (0.77-1.17) 1.28 (0.92-1.78)
Age group (ref.: < 60 years)     
60-69 years 0.82 (0.69-0.98) 0.77 (0.60-1.00) 0.72 (0.55-0.94) 0.62 (0.42-0.90)
70-79 years 0.55 (0.45-0.66) 0.39 (0.29-0.52) 0.46 (0.35-0.61) 0.28 (0.18-0.44)
≥ 80 years 0.27 (0.21-0.35) 0.03 (0.01-0.09) 0.15 (0.10-0.24) 0.07 (0.03-0.16)
Tumor location (ref.: pancreas head)     
Pancreas body 0.69 (0.55-0.87) 1.01 (0.73-1.40) 1.01 (0.68-1.49) 1.01 (0.53-1.95)
Pancreas tail 0.44 (0.31-0.63) 0.38 (0.20-0.70) 1.09 (0.73-1.64) 0.86 (0.39-1.91)
Other2 0.82 (0.68-0.98) 0.75 (0.51-1.10) 0.96 (0.76-1.22) 1.16 (0.80-1.68)
TNM stage (ref.: I-II)     
III 1.15 (0.96-1.37) 2.81 (2.13-3.71) 1.57 (1.21-2.05) 1.21 (0.69-2.13)
IV 0.38 (0.32-0.45) 0.21 (0.15-0.30) 0.25 (0.19-0.33) 0.55 (0.37-0.82)
1Odds ratios and 95% confidence intervals for chemotherapy versus non-chemotherapy and radiotherapy versus non-radiotherapy in 
pancreatic cancer patients surviving > 90 days after diagnosis were calculated using multivariable logistic regression models adjusting for 
year of diagnosis, sex, age group, tumor location, and TNM stage. Results for countries with number of patients receiving indicated therapy 
< 50 (Slovenia, 20; Estonia, 16) were not reported. ORs shown in bold are statistically significant. 
2Other: pancreas duct, overlapping lesion, and not otherwise specified (NOS) parts. 
OR, odds ratio; CI, confidence interval; NE, not estimable due to small case number; NA, not available. 
 
3.1.2.7 Associations of chemotherapy and radiotherapy use with additional variables 
For resected cancer patients (Tables 32-33), those treated in academic hospitals were more likely to 
receive chemotherapy (OR=1.39) and radiotherapy (OR=2.05). Increasing ECOG scores were 
associated with less frequent use of radiotherapy in Belgium. Patients received less often radiotherapy 
after total pancreatectomy versus pancreatoduodenectomy (OR=0.88). For unresected PaC (Tables 
34-35), patients managed in academic hospitals received more frequently chemotherapy (OR=1.51) 
and radiotherapy (OR=7.94) in the Netherlands, and more often radiotherapy in Belgium (OR=1.54). 
In Belgium, chemotherapy and radiotherapy were less commonly used with increasing ECOG scores. 
Cardiac (OR=0.74), vascular (OR=0.64), and neurological diseases (OR=0.45) and multiple 
comorbidities (OR=0.65) were associated with less frequent chemotherapy administration in 
Eindhoven, the Netherlands. 
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Table 32. Associations of chemotherapy use with hospital type, lymph node ratio, performance status, resection 
type, and comorbidities for resected pancreatic cancer in countries with available information estimated by 
adjusted multivariable logistic regression (Huang et al., 2018b) 
Variable The Netherlands Belgium 
 n OR (95% CI) n OR (95% CI) 
Hospital type     
Non-academic 1633 1.00 (reference) 1127 1.00 (reference) 
Academic 1312 1.39 (1.17-1.64) 1502 0.84 (0.70-1.00) 
Lymph node ratio (as continuous) 2725 1.31 (0.91-1.88) - - 
ECOG score     
0 - - 302 1.00 (references) 
1 - - 1434 0.98 (0.74-1.29) 
≥ 2 - - 182 0.78 (0.52-1.18) 
Resection type      
Pancreatoduodenectomy 2472 1.00 (reference) - - 
Distal pancreatectomy 298 0.92 (0.56-1.52) - - 
Total pancreatectomy 48 0.60 (0.30-1.21) - - 
Other 127 0.39 (0.18-0.85)   
Comorbidity type     
Cardiac disease (yes vs. no) 74 1.21 (0.67-2.17) - - 
Vascular disease (yes vs. no) 46 0.99 (0.48-2.06) - - 
Hypertension (yes vs. no) 127 0.91 (0.56-1.49) - - 
Neurological disease (yes vs. no) 11 0.35 (0.06-1.98) - - 
Diabetes (yes vs. no) 107 0.72 (0.43-1.21) - - 
Pulmonary disease (yes vs. no) 38 0.77 (0.35-1.70) - - 
Comorbidity number     
0 168 1.00 (reference) - - 
1 140 0.90 (0.51-1.57) - - 
≥ 2 158 0.88 (0.49-1.57) - - 
The main logistic regression models adjusted for year of diagnosis, age, sex, tumor location, and TNM stage. ORs were calculated after the 
additionally investigated variables were included one by one into the main models. Statistically significant ORs are shown in bold. 
OR, odds ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; -, not available; NE, not estimable. 
 
Table 33. Associations of radiotherapy use with hospital type, lymph node ratio, performance status, resection 
type, and comorbidities for resected pancreatic cancer in countries with available information estimated by 
adjusted multivariable logistic regression (Huang et al., 2018b) 
Variable the US The Netherlands Belgium 
 n OR (95% CI) n OR (95% CI) n OR (95% CI) 
Hospital type       
Non-academic -  - 1633 1.00 (reference) 1127 1.00 (reference) 
Academic -  - 1312 2.05 (1.28-3.27) 1502 1.13 (0.86-1.50) 
Lymph node ratio (as continuous) 14086 1.04 (0.87-1.24) 2725 0.46 (0.15-1.41) -  -
ECOG score       
0 -  - - - 302 1.00 (references)
1 -  - - - 1434 0.65 (0.44-0.97)
≥ 2 -  - - - 182 0.64 (0.34-1.20) 
Resection type        
Pancreatoduodenectomy 10759 1.00 (reference) 2472 1.00 (reference) -  -
Distal pancreatectomy 2208 0.95 (0.83-1.09) 298 0.46 (0.11-1.88) -  -
Total pancreatectomy 1855 0.88 (0.79-0.98) 48 0.63 (0.08-4.95) -  -
Other 806 0.83 (0.68-1.02) 127 0.40 (0.11-1.40)   
Comorbidity type       
Cardiac disease (yes vs. no) -  - 74 0.57 (0.07-4.99) -  -
Vascular disease (yes vs. no) -  - 46 NE -  -
Hypertension (yes vs. no) -  - 127 0.61 (0.12-3.05) -  -
Neurological disease (yes vs. no) -  - 11 NE -  -
Diabetes (yes vs. no) -  - 107 1.10 (0.27-4.44) -  -
Pulmonary disease (yes vs. no) -  - 38 NE -  -
Comorbidity number       
0 -  - 168 1.00 (reference) -  -
1 -  - 140 2.26 (0.65-7.81) -  -
≥ 2 -  - 158 0.81 (0.13-4.96) -  -
The main logistic regression models adjusted for year of diagnosis, age, sex, tumor location, and TNM stage. ORs were calculated after the 
additionally investigated variables were included one by one into the main models. Statistically significant ORs are shown in bold. 
OR, odds ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; -, not available; NE, not estimable. 
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Table 34. Associations of chemotherapy use with hospital type, lymph node ratio, performance status, resection 
type, and comorbidities for unresected pancreatic cancer in countries with available information estimated by 
adjusted multivariable logistic regression (Huang et al., 2018b) 
Variable The Netherlands Belgium 
 n OR (95% CI) n OR (95% CI) 
Hospital type     
Non-academic 16233 1.00 (reference) 5877 1.00 (reference) 
Academic 3300 1.51 (1.37-1.66) 3265 0.98 (0.87-1.11) 
ECOG score     
0 - - 537 1.00 (reference) 
1 - - 4415 0.80 (0.63-1.01) 
2 - - 1295 0.42 (0.32-0.55) 
≥ 3 - - 569 0.11 (0.08-0.16) 
Comorbidity type     
Cardiac disease (yes vs. no) 807 0.74 (0.57-0.96) - - 
Vascular disease (yes vs. no) 559 0.64 (0.48-0.85) - - 
Hypertension (yes vs. no) 942 1.00 (0.80-1.25) - - 
Neurological disease (yes vs. no) 198 0.45 (0.26-0.79) - - 
Diabetes (yes vs. no) 846 0.91 (0.73-1.14) - - 
Pulmonary disease (yes vs. no) 361 0.74 (0.53-1.05) - - 
Comorbidity number     
0 1164 1.00 (reference) - - 
1 982 0.97 (0.76-1.23) - - 
≥ 2 1433 0.65 (0.51-0.83) - - 
The main logistic regression models adjusted for year of diagnosis, age, sex, tumor location, and TNM stage. ORs were calculated after the 
additionally investigated variables were included one by one into the main models. Statistically significant ORs are shown in bold. 
OR, odds ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; -, not available; NE, not estimable. 
 
Table 35. Associations of radiotherapy use with hospital type, lymph node ratio, performance status, resection 
type, and comorbidities for unresected pancreatic cancer in countries with available information estimated by 
adjusted multivariable logistic regression (Huang et al., 2018b) 
Variable The Netherlands Belgium 
 n OR (95% CI) n OR (95% CI) 
Hospital type     
Non-academic 16233 1.00 (reference) 5877 1.00 (reference) 
Academic 3300 7.94 (6.27-10.05) 3265 1.54 (1.26-1.88) 
ECOG score     
0 - - 537 1.00 (reference) 
1 - - 4415 0.52 (0.38-0.70) 
2 - - 1295 0.38 (0.26-0.57) 
≥ 3 - - 569 0.29 (0.16-0.55) 
Comorbidity type     
Cardiac disease (yes vs. no) 807 1.46 (0.72-2.95) - - 
Vascular disease (yes vs. no) 559 1.51 (0.70-3.28) - - 
Hypertension (yes vs. no) 942 1.17 (0.60-2.29) - - 
Neurological disease (yes vs. no) 198 0.77 (0.18-3.32) - - 
Diabetes (yes vs. no) 846 1.61 (0.87-2.99) - - 
Pulmonary disease (yes vs. no) 361 0.79 (0.21-3.32) - - 
Comorbidity number     
0 1164 1.00 (reference) - - 
1 982 1.75 (0.85-3.59) - - 
≥ 2 1433 1.17 (0.54-2.56) - - 
The main logistic regression models adjusted for year of diagnosis, age, sex, tumor location, and TNM stage. ORs were calculated after the 
additionally investigated variables were included one by one into the main models. Statistically significant ORs are shown in bold. 
OR, odds ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; -, not available; NE, not estimable. 
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3.1.3 Stratified survival of resected and overall pancreatic cancer patients in Europe and the US 
(This part has been published (Huang et al., 2018a).) 
3.1.3.1 Patient characteristics 
Data on a total of 125,183 PaC patients (stage I-II, 42,955 (34%); stage III-IV, 82,228 (66%)) were 
analyzed (Table 36). Patients were diagnosed in comparable periods across all countries (2003/2004 
through 2013/2014). Demographic and clinical characteristics for the overall and resected cancer 
patients with stages I-II and III-IV PaCs are shown in Tables 37-38. Within overall PaCs, 66% 
(Norway) to 91% (Belgium) of stage I-II cancers and 53% (Slovenia) to 86% (Belgium) of stage 
III-IV tumors were microscopically confirmed. Nearly all resected PaCs were microscopically 
confirmed (stage I-II, 99%->99%; stage III-IV, 92%-100%).  
 
Table 36. General information on participating registries for Chapter 3.1.3 (Huang et al., 2018a) 
Source Country Diagnosis period 
Censoring 
date 
Registered 
malignant 
cases1 
Excluded cases2  Analyzed cases
DCO 
/autopsy
Unknown stage
/stage 0 
Unknown 
survival3 
 Stage 
I-II 
Stage 
III-IV
SEER184 The US Jan. 2004- Dec. 2013 
Dec. 31, 
2013 99582 2972 (3) 10144 (10) 0 (0) 
 31313 55153
NCR The Netherlands 
Jan. 2003- 
Dec. 2014 
Feb 1, 
2015 22579 99 (<1) 2796 (12) 0 (0) 
 5710 13974
BCR Belgium Jan. 2004- Dec. 2013 
Jul. 1, 
2015 12146 -5 3077 (25) 0 (0) 
 3437 5632
CRN Norway Jan. 2003- Dec. 2014 
Jun. 30, 
2015 8022 333 (4) 1509 (19) 2 (<1) 
 1545 4633
CRS Slovenia Jan. 2003- Dec. 2013 
May 25, 
2016 3376 54 (2) 658 (20) 0 (0) 
 667 1997
1A preliminary data-cleaning process had been performed to exclude cases with ineligible histology types. 
2Shown as n (percentage [%]). 
3Unknown survival time and/or vital status. 
4Data of the year 2003 was not analyzed, as the TNM stage (version 6/7) information was unavailable. 
5Not routinely registered. 
SEER, Surveillance, Epidemiology, and End Results Program; NCR, The Netherlands Cancer Registry; BCR, Belgian Cancer Registry; CRN, 
Cancer Registry of Norway; CRS, Cancer Registry of Slovenia; DCO, death certificate only. 
 
In stage I-II PaCs (Table 37), 49%-55% of the overall patients were female. The mean age was 
69-72 years. Most cancers were located in pancreas head (81%-89%). Only 10%-18% of the tumors 
were well-differentiated. Chemotherapy was administered for 17% (Norway) to 52% (Belgium) of the 
European patients. Radiotherapy was more frequently applied in the US (14%) than in Europe (1% 
(Slovenia) to 10% (Belgium)). Resection rates were 34% (Norway) to 63% (Belgium). Compared to 
overall patients, resected cancer patients were less frequently female and mostly younger. Tumor 
location was comparable, but slightly fewer cancers were well-differentiated (6%-17%). Neoadjuvant 
chemotherapy (1%-3%) and radiotherapy (0%-4%) were rarely used. Resected cancer patients 
received more frequently adjuvant chemotherapy (24%-56%), but less often radiotherapy (1%-9%) 
compared to the overall patient groups in Europe. In the US, resected patients received markedly more 
often radiotherapy (32%) compared to the overall US or the resected European patients.  
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Table 37. Demographic and clinical characteristics of stage I-II pancreatic cancer patients (Huang et al., 2018a) 
Parameter The US (2004-2013) Netherlands (2003-2014) Belgium (2004-2013) 
Group Overall Resected Overall Resected Overall Resected 
n 31313 13303 (43) 5710 2675 (47) 3437 2155 (63) 
Microscopically confirmed1 27290 (87) 13290 (>99) 4046 (71) 2673 (>99) 3127 (91) 2148 (>99) 
Gender, female 16193 (52) 6604 (50) 2951 (52) 1268 (47) 1684 (49) 993 (46) 
Age [year] 70 ± 12 66 ± 11 71 ± 11 65 ± 10 69 ± 11 66 ± 10 
Age group       
< 60 years 6100 (20) 3574 (27) 981 (17) 693 (26) 686 (20) 546 (25) 
60-69 years 7817 (25) 4272 (32) 1477 (26) 978 (37) 937 (27) 698 (32) 
≥ 70 years 17396 (56) 5457 (41) 3252 (57) 1004 (38) 1814 (53) 911 (42) 
Tumor location1       
Pancreas head 22412 (83) 9573 (80) 4666 (89) 2187 (89) 1807 (81) 1207 (82) 
Pancreas body 2502 (9) 890 (8) 255 (5) 91 (4) 179 (8) 100 (7) 
Pancreas tail 2196 (8) 1448 (12) 296 (6) 191 (8) 244 (11) 169 (11) 
Other 4203 (13) 1392 (11) 493 (9) 206 (8) 1207 (35) 679 (32) 
Differentiation2       
Well 2145 (13) 1428 (12) 283 (12) 244 (11) 389 (18) 302 (17) 
Intermediate 7574 (47) 6026 (51) 1225 (51) 1138 (52) 1072 (48) 901 (50) 
Poor/undifferentiated 6264 (39) 4464 (38) 920 (38) 802 (37) 762 (34) 608 (34) 
Neoadjuvant chemotherapy - NA - 50 (2) - 53 (3) 
Neoadjuvant radiotherapy - 522 (4) - 34 (1) - 20 (1) 
Resection type       
Pancreatoduodenectomy - 9479 (71) - 2269 (85) - NA 
Distal pancreatectomy - 1878 (14) - 256 (10) - NA 
Total pancreatectomy - 1629 (12) - 42 (2) - NA 
Other3 - 314 (2) - 108 (4) - NA 
Adjuvant/palliative chemotherapy NA NA 1392 (24) 1078 (40) 1796 (52) 1200 (56) 
Adjuvant/palliative radiotherapy 4460 (14) 4193 (32) 120 (2) 33 (1) 326 (10) 190 (9) 
Enumeration data are shown as count (percentage [%]), and measurement data as mean ± standard deviation. Records are complete otherwise 
specified below. 
1The percentages of pancreas head, body, and tail are the proportions compared to the total tumor cases of the 3 locations; ‘other’ includes 
pancreas duct, overlapping lesion, NOS, and other specified parts, and its proportion is relative to the whole cases. 
2Unknown differentiation: the US, overall: 15330 (49%), resected: 1385 (10%); The Netherlands, overall: 3282 (58%), resected: 491 (18%); 
Belgium, overall: 1214 (35%), resected: 344 (16%); Norway, overall: 909 (59%), resected: 100 (19%); Slovenia, overall: 252 (38%), 
resected: 35 (9%); Estonia, overall: 134 (47%), resected: 32 (20%). 
3Pancreatectomy (NOS) and local resection. 
NOS, not otherwise specified; NA, not available; -, not applicable.  
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Table 37. Demographic and clinical characteristics of stage I-II pancreatic cancer patients (Huang et al., 2018a) 
(continued) 
Parameter Norway (2003-2014) Slovenia (2003-2013) 
Group Overall Resected Overall Resected 
n 1545 526 (34) 667 406 (61) 
Microscopically confirmed1 1017 (66) 520 (99) 475 (71) 401 (99) 
Gender, female 853 (55) 261 (50) 361 (54) 209 (52) 
Age [year] 72 ± 12 65 ± 11 69 ± 11 65 ± 10 
Age group     
< 60 years 234 (15) 134 (26) 144 (22) 122 (30) 
60-69 years 375 (24) 195 (37) 166 (25) 131 (32) 
≥ 70 years 936 (61) 197 (37) 357 (54) 153 (38) 
Tumor location1     
Pancreas head 851 (85) 394 (84) 471 (88) 321 (87) 
Pancreas body 87 (9) 33 (7) 35 (7) 26 (7) 
Pancreas tail 62 (6) 41 (9) 32 (6) 21 (6) 
Other 545 (35) 58 (11) 129 (19) 38 (9) 
Differentiation2     
Well 61 (10) 27 (6) 41 (10) 37 (10) 
Intermediate 352 (55) 259 (61) 153 (37) 142 (38) 
Poor/undifferentiated 223 (35) 135 (32) 221 (53) 192 (52) 
Neoadjuvant chemotherapy - NA - 2 (1) 
Neoadjuvant radiotherapy - 0 (0) - 1 (<1) 
Resection type     
Pancreatoduodenectomy - NA - NA 
Distal pancreatectomy - NA - NA 
Total pancreatectomy - NA - NA 
Other3 - NA - NA 
Adjuvant/palliative chemotherapy 265 (17) 127 (24) 131 (20) 120 (30) 
Adjuvant/palliative radiotherapy 64 (4) 17 (3) 9 (1) 8 (2) 
Enumeration data are shown as count (percentage [%]), and measurement data as mean ± standard deviation. Records are complete otherwise 
specified below. 
1The percentages of pancreas head, body, and tail are the proportions compared to the total tumor cases of the 3 locations; ‘other’ includes 
pancreas duct, overlapping lesion, NOS, and other specified parts, and its proportion is relative to the whole cases. 
2Unknown differentiation in stage I-II cancer: the US, overall: 15330 (49%), resected: 1385 (10%); The Netherlands, overall: 3282 (58%), 
resected: 491 (18%); Belgium, overall: 1214 (35%), resected: 344 (16%); Norway, overall: 909 (59%), resected: 100 (19%); Slovenia, 
overall: 252 (38%), resected: 35 (9%); Estonia, overall: 134 (47%), resected: 32 (20%). 
3Pancreatectomy (NOS) and local resection. 
NOS, not otherwise specified; NA, not available; -, not applicable. 
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Compared to patients with stage I-II PaCs, overall patients with stage III-IV cancers were less 
frequently women (48%-50%), and were younger (mean age, 68-71 years; Table 38). Pancreatic head 
cancers comprised smaller proportions (56%-64%), and well-differentiated tumors were rarer 
(8%-17%). Chemotherapy was more often used (18% (Slovenia) to 65% (Belgium)), while 
radiotherapy was less frequently administered (1% (the US) to 6% (Belgium)). Resection rates ranged 
from 2% (the Netherlands) to 7% (Slovenia). The comparison patterns of resected versus overall 
cancer patients with stage III-IV PaCs were similar to those with stage I-II tumors regarding patient 
sex, age, tumor differentiation, and chemotherapy application. However, the proportions of pancreatic 
head cancers among resected tumor patients were greater (66%-79%). Neoadjuvant chemotherapy 
(0%-8%) and radiotherapy rates (0%-7%) remained low. Radiotherapy was used for 3%-19% of 
resected cancer patients, and was again more frequently administered in the US. 
 
Table 38. Demographic and clinical characteristics of stage III-IV pancreatic cancer patients (Huang et al., 
2018a) 
Parameter The US (2004-2013) Netherlands (2003-2014) Belgium (2004-2013) 
Group Overall Resected Overall Resected Overall Resected 
n 55153 1998 (4) 13974 237 (2) 5632 298 (5) 
Microscopically confirmed1 46973 (85) 1994 (>99) 10375 (74) 237 (100) 4837 (86) 297 (>99) 
Gender, female 26427 (48) 969 (49) 6755 (48) 106 (45) 2700 (48) 154 (52) 
Age [year] 69 ± 12 65 ± 12 68 ± 11 64 ± 10 69 ± 11 64 ± 10 
Age group       
< 60 years 12582 (23) 636 (32) 2938 (21) 69 (29) 1043 (19) 92 (31) 
60-69 years 15081 (27) 622 (31) 4412 (32) 96 (41) 1608 (29) 103 (35) 
≥ 70 years 27490 (50) 740 (37) 6624 (47) 72 (30) 2981 (53) 103 (35) 
Tumor location1       
Pancreas head 21244 (56) 1069 (66) 7202 (62) 166 (79) 1585 (58) 126 (69) 
Pancreas body 7893 (21) 168 (10) 1844 (16) 11 (5) 508 (19) 19 (10) 
Pancreas tail 9003 (24) 381 (24) 2666 (23) 34 (16) 649 (24) 37 (20) 
Other 17013 (31) 380 (19) 2262 (16) 26 (11) 2890 (51) 116 (39) 
Differentiation2       
Well 1213 (10) 173 (11) 222 (9) 20 (11) 425 (17) 42 (17) 
Intermediate 4518 (35) 680 (45) 833 (35) 98 (51) 962 (39) 113 (47) 
Poor/undifferentiated 6795 (56) 670 (44) 1340 (56) 73 (38) 1082 (44) 88 (36) 
Neoadjuvant chemotherapy - NA - 15 (6) - 24 (8) 
Neoadjuvant radiotherapy - 139 (7) - 5 (2) - 9 (3) 
Resection type       
Pancreatoduodenectomy - 1140 (57) - 178 (75) - NA 
Distal pancreatectomy - 295 (15) - 39 (17) - NA 
Total pancreatectomy - 211 (11) - 5 (2) - NA 
Other3 - 352 (18) - 15 (6) - NA 
Adjuvant/palliative chemotherapy NA NA 3475 (25) 81 (34) 3661 (65) 195 (65) 
Adjuvant/palliative radiotherapy 770 (1) 383 (19) 328 (2) 7 (3) 358 (6) 35 (12) 
Enumeration data are shown as count (percentage [%]), and measurement data as mean ± standard deviation. Records are complete otherwise 
specified below. 
1The percentages of pancreas head, body, and tail are the proportions compared to the total tumor cases of the 3 locations; ‘other’ includes 
pancreas duct, overlapping lesion, NOS, and other specified parts, and its proportion is relative to the whole cases. 
2Unknown differentiation: the US, overall: 42627 (77%), resected: 475 (24%); The Netherlands, overall: 11579 (83%), resected: 46 (19%); 
Belgium, overall: 3163 (56%), resected:55 (19%); Norway, overall: 3150 (68%), resected: 26 (24%); Slovenia, overall: 1555 (78%), resected: 
47 (35%); Estonia, overall: 718 (86%), resected: 5 (28%). 
3Pancreatectomy (NOS) and local resection. 
NOS, not otherwise specified; NA, not available; -, not applicable. 
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Table 38. Demographic and clinical characteristics of stage III-IV pancreatic cancer patients (Huang et al., 
2018a) (continued) 
Parameter Norway (2003-2014) Slovenia (2003-2013) 
Group Overall Resected Overall Resected 
n 4633 108 (2) 1997 135 (7) 
Microscopically confirmed1 3224 (70) 105 (97) 1056 (53) 124 (92) 
Gender, female 2332 (50) 47 (44) 967 (48) 56 (42) 
Age [year] 71 ± 12 64 ± 10 69 ± 11 65 ± 10 
Age group     
< 60 years 759 (16) 32 (30) 393 (20) 40 (30) 
60-69 years 1268 (27) 43 (40) 513 (26) 45 (33) 
≥ 70 years 2606 (56) 26 (24) 1091 (55) 43 (32) 
Tumor location1     
Pancreas head 1245 (63) 57 (66) 653 (64) 80 (78) 
Pancreas body 340 (17) 8 (9) 160 (16) 12 (12) 
Pancreas tail 382 (19) 21 (24) 215 (21) 10 (10) 
Other 2666 (58) 22 (20) 969 (49) 33 (24) 
Differentiation3     
Well 122 (8) 6 (7) 33 (8) 6 (7) 
Intermediate 596 (40) 50 (61) 112 (25) 30 (34) 
Poor/undifferentiated 765 (52) 26 (32) 297 (67) 52 (59) 
Neoadjuvant chemotherapy - NA - 0 (0) 
Neoadjuvant radiotherapy - 0 (0) - 0 (0) 
Resection type     
Pancreatoduodenectomy - NA - NA 
Distal pancreatectomy - NA - NA 
Total pancreatectomy - NA - NA 
Other3 - NA - NA 
Adjuvant/palliative chemotherapy 1159 (25) 25 (23) 368 (18) 39 (29) 
Adjuvant/palliative radiotherapy 198 (4) 4 (4) 46 (2) 5 (4) 
Enumeration data are shown as count (percentage [%]), and measurement data as mean ± standard deviation. Records are complete otherwise 
specified below. 
1The percentages of pancreas head, body, and tail are the proportions compared to the total tumor cases of the 3 locations; ‘other’ includes 
pancreas duct, overlapping lesion, NOS, and other specified parts, and its proportion is relative to the whole cases. 
2 Unknown differentiation: the US, overall: 42627 (77%), resected: 475 (24%); The Netherlands, overall: 11579 (83%), resected: 46 (19%); 
Belgium, overall: 3163 (56%), resected:55 (19%); Norway, overall: 3150 (68%), resected: 26 (24%); Slovenia, overall: 1555 (78%), resected: 
47 (35%); Estonia, overall: 718 (86%), resected: 5 (28%). 
3Pancreatectomy (NOS) and local resection. 
NOS, not otherwise specified; NA, not available; -, not applicable.
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3.1.3.2 Survival of overall and resected stage I-II pancreatic cancer patients 
Survival of overall and resected stage I-II cancer patients is shown in Figures 6-7, and the 
corresponding 1-month to 5-year survival rates are detailed in Table 39. For overall cancer patients, 
survival was lower in older patients and decreased strongly after diagnosis, with 3-year survival rates 
of 20%-34% (<60 years), 14%-25% (60-69 years), and 9%-13% (≥70 years), respectively. The 
subgroup of resected cancer patients of all age groups in all countries had higher survival estimates, 
with 1-month (perioperative) survival rates of 98%-100% (<60 years), 97%-99% (60-69 years) and 
94%-99% (≥70 years), and 3-year survival rates of 23%-39% (<60 years), 16%-31% (60-69 years) and 
17%-30% (≥70 years), respectively. Again, younger patients had better survival than older ones. 
However, age-specific differences were smaller, especially between those aged 60-69 and ≥70 years. 
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Table 39. Unadjusted survival proportions of overall and resected stage I-II pancreatic cancer patients (Huang et 
al., 2018a) 
Time The US The Netherlands Belgium 
 Overall Resected Overall Resected Overall Resected 
 OS (95% CI)1 OS (95% CI) OS (95% CI) OS (95% CI) OS (95% CI) OS (95% CI) 
1 month       
< 60 years 95 (94-95) 98 (98-99) 97 (96-98) 98 (97-99) 98 (97-99) 99 (97-99) 
60-69 years 92 (91-93) 97 (96-97) 95 (94-96) 97 (96-98) 97 (96-98) 98 (97-99) 
≥ 70 years 79 (78-79) 94 (93-94) 88 (87-89) 96 (95-97) 93 (92-94) 96 (94-97) 
3 months       
< 60 years 89 (88-90) 96 (95-97) 92 (90-94) 97 (95-98) 95 (93-96) 96 (94-98) 
60-69 years 84 (84-85) 94 (93-95) 87 (85-89) 94 (93-96) 93 (91-94) 94 (92-96) 
≥ 70 years 65 (64-66) 89 (88-90) 72 (70-73) 91 (89-92) 83 (81-84) 90 (88-92) 
6 months       
< 60 years 80 (79-81) 91 (90-92) 81 (78-83) 92 (90-94) 90 (87-92) 93 (90-95) 
60-69 years 73 (72-74) 88 (86-89) 76 (74-78) 89 (86-91) 86 (83-88) 89 (87-91) 
≥ 70 years 51 (50-51) 80 (79-81) 53 (51-55) 81 (78-83) 67 (65-69) 80 (77-83) 
12 months       
< 60 years 59 (57-60) 75 (73-76) 60 (56-63) 74 (70-77) 73 (70-76) 78 (75-82) 
60-69 years 52 (51-53) 71 (69-72) 53 (50-55) 68 (65-71) 65 (62-68) 72 (68-75) 
≥ 70 years 31 (31-32) 61 (59-62) 30 (29-32) 61 (57-64) 43 (40-45) 58 (55-62) 
24 months       
< 60 years 35 (34-37) 50 (48-52) 30 (27-33) 40 (36-44) 47 (43-51) 53 (49-57) 
60-69 years 29 (28-30) 44 (42-45) 28 (25-30) 38 (35-42) 38 (35-41) 45 (41-48) 
≥ 70 years 16 (15-16) 37 (35-38) 14 (13-15) 33 (30-37) 21 (19-23) 33 (30-36) 
36 months       
< 60 years 26 (24-27) 37 (36-39) 20 (18-23) 27 (24-31) 34 (30-37) 39 (35-43) 
60-69 years 20 (19-21) 31 (29-32) 18 (16-20) 25 (22-28) 25 (22-28) 30 (27-34) 
≥ 70 years 10 (10-11) 26 (24-27) 9 (8-11) 24 (21-27) 13 (11-14) 21 (19-24) 
60 months       
< 60 years 19 (18-20) 28 (26-30) 14 (12-17) 19 (16-23) 23 (19-26) 26 (22-30) 
60-69 years 13 (12-14) 21 (20-23) 11 (9-13) 16 (13-19) 16 (14-19) 20 (17-23) 
≥ 70 years 6 (6-7) 16 (15-17) 5 (4-6) 13 (10-16) 7 (6-8) 12 (10-15) 
1Data are shown as survival proportion (95% confidence interval) [%].  
OS, overall survival; CI, confidence interval. 
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Table 39. Unadjusted survival proportions of overall and resected stage I-II pancreatic cancer patients (Huang et 
al., 2018a) (continued) 
Time Norway Slovenia 
 Overall Resected Overall Resected 
 OS (95% CI) OS (95% CI) OS (95% CI) OS (95% CI) 
1 month     
< 60 years 98 (96-99) 100 (100-100) 97 (93-99) 98 (93-99) 
60-69 years 97 (94-98) 99 (95-100) 96 (92-98) 99 (94-100) 
≥ 70 years 89 (86-90) 99 (95-100) 85 (81-89) 99 (95-100) 
3 months     
< 60 years 95 (92-97) 99 (95-100) 92 (86-95) 94 (88-97) 
60-69 years 90 (86-93) 97 (93-99) 90 (84-94) 96 (91-98) 
≥ 70 years 68 (65-71) 95 (91-98) 66 (61-71) 88 (82-92) 
6 months     
< 60 years 86 (81-90) 96 (90-98) 88 (81-92) 89 (82-94) 
60-69 years 77 (72-81) 91 (86-95) 78 (71-84) 85 (77-90) 
≥ 70 years 50 (47-53) 88 (83-92) 50 (45-55) 82 (75-88) 
12 months     
< 60 years 64 (57-70) 82 (75-88) 60 (52-68) 63 (54-71) 
60-69 years 52 (47-57) 73 (66-79) 55 (48-63) 62 (53-70) 
≥ 70 years 28 (25-31) 70 (63-76) 31 (26-36) 60 (51-67) 
24 months     
< 60 years 38 (32-45) 58 (48-66) 33 (25-41) 36 (27-44) 
60-69 years 29 (24-34) 48 (40-55) 23 (17-30) 28 (20-35) 
≥ 70 years 13 (10-15) 38 (31-45) 16 (12-20) 30 (23-37) 
36 months     
< 60 years 26 (20-32) 39 (30-48) 22 (16-29) 23 (16-31) 
60-69 years 18 (14-23) 31 (24-38) 14 (9-19) 16 (11-23) 
≥ 70 years 9 (7-11) 30 (23-37) 9 (7-13) 17 (11-23) 
60 months     
< 60 years 17 (12-23) 25 (17-34) 15 (9-21) 15 (9-23) 
60-69 years 13 (9-17) 23 (16-30) 8 (5-13) 10 (5-16) 
≥ 70 years 6 (4-7) 17 (11-24) 5 (3-8) 10 (6-16) 
1Data are shown as survival proportion (95% confidence interval) [%].  
OS, overall survival; CI, confidence interval.
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3.1.3.3 Survival of overall and resected stage III-IV pancreatic cancer patients 
Considering the potential varying proportions of underreporting of advanced-stage cancers, survival 
results for stage III-IV PaC patients should be interpreted with caution. The survival of the overall and 
resected stage III-IV cancer patients is shown in Figures 8-9, and the corresponding 1-month to 5-year 
survival rates are detailed in Table 40. Generally, patients with stage III-IV cancers had much lower 
survival than those with stage I-II tumors, and already had high mortality shortly after diagnosis. In the 
overall patient group, survival decreased with increasing age, with 3-year survival rates of 2%-5% 
(<60 years), 1%-2% (60-69 years), and 1%-1% (≥70 years), respectively. The resected cancer patient 
subgroups showed higher survival estimates than the overall in all countries and all age groups 
(perioperative survival rates: <70 years, 94%-99%; ≥70 years, 81%-96%; 3-year survival rates: <70 
years, 5%-19%; ≥70 years, 2%-14%). The differences between age groups were smaller in the resected 
cancer patient subgroups than the overall patient population. 
 
RESULTS 
63 
 
 F
igu
re 
8. 
Ka
pla
n-M
eie
r c
urv
es 
(so
lid
 lin
es)
 of
 ag
e g
rou
p-s
pec
ific
 su
rvi
val
 of
 ov
era
ll c
anc
er 
pat
ien
ts w
ith
 TN
M 
sta
ge 
III-
IV
 pa
ncr
eat
ic c
anc
ers
. T
he 
das
hed
 lin
es 
ind
ica
te 
the
 95
% 
con
fid
enc
e l
im
its 
and
 th
e s
had
ow
s r
epr
ese
nt 
the
 H
all-
We
lln
er 
con
fid
enc
e b
and
s. T
he 
num
ber
s o
f p
atie
nts
 at
 ris
k a
re 
als
o s
how
n. 
Me
dia
n s
urv
iva
l is
 in
 m
on
ths
. 
IQ
R, 
int
erq
uar
tile
 ra
nge
. (H
uan
g e
t a
l., 
20
18a
)  
RESULTS 
64 
 
 F
igu
re 
9. 
Ka
pla
n-M
eie
r c
urv
es 
(so
lid
 lin
es)
 of
 ag
e g
rou
p-s
pec
ific
 su
rvi
val
 of
 re
sec
ted
 ca
nce
r p
atie
nts
 wi
th 
TN
M 
sta
ge 
III-
IV
 pa
ncr
eat
ic c
anc
ers
. T
he 
das
hed
 lin
es 
ind
ica
te 
the
 95
% 
con
fid
enc
e l
im
its 
and
 th
e s
had
ow
s r
epr
ese
nt 
the
 H
all-
We
lln
er 
con
fid
enc
e b
and
s. T
he 
num
ber
s o
f p
atie
nts
 at
 ris
k a
re 
als
o s
how
n. 
Me
dia
n s
urv
iva
l is
 in
 m
on
ths
. 
IQ
R, 
int
erq
uar
tile
 ra
nge
. (H
uan
g e
t a
l., 
20
18a
) 
RESULTS 
65 
 
Table 40. Unadjusted survival proportions of overall and resected stage III-IV pancreatic cancer patients (Huang 
et al., 2018a) 
Time The US The Netherlands Belgium 
 Overall Resected2 Overall Resected Overall Resected 
 OS (95% CI)1 OS (95% CI) OS (95% CI) OS (95% CI) OS (95% CI) OS (95% CI) 
1 month       
< 60 years 75 (74-76) 94 (93-96) 86 (85-87) 94 (89-97) 93 (92-95) 99 (95-100) 60-69 years 69 (68-70) 81 (80-82) 89 (88-91) 
≥ 70 years 53 (53-54) 81 (78-84) 69 (68-70) 96 (88-99) 81 (80-83) 96 (90-99) 
3 months       
< 60 years 58 (57-58) 86 (84-88) 59 (57-61) 90 (84-93) 78 (75-80) 93 (89-96) 60-69 years 51 (50-52) 52 (50-53) 69 (67-71) 
≥ 70 years 34 (34-35) 68 (64-71) 36 (35-37) 89 (79-94) 55 (53-56) 85 (77-91) 
6 months       
< 60 years 40 (39-41) 71 (68-73) 34 (32-36) 76 (68-82) 59 (56-62) 85 (79-89) 60-69 years 34 (33-35) 29 (28-31) 50 (48-53) 
≥ 70 years 21 (20-21) 53 (49-56) 18 (17-18) 72 (60-82) 34 (32-35) 66 (56-74) 
12 months       
< 60 years 20 (19-21) 47 (44-50) 13 (11-14) 48 (40-56) 31 (28-34) 57 (50-64) 60-69 years 16 (16-17) 11 (10-12) 24 (22-26) 
≥ 70 years 9 (9-9) 32 (28-35) 6 (5-7) 42 (30-53) 14 (13-15) 36 (27-45) 
24 months       
< 60 years 7 (6-7) 21 (19-24) 4 (3-5) 21 (15-28) 10 (9-12) 23 (17-29) 60-69 years 5 (5-6) 2 (2-3) 6 (5-7) 
≥ 70 years 3 (2-3) 13 (11-16) 1 (1-2) 19 (10-30) 4 (3-4) 12 (6-19) 
36 months       
< 60 years 3 (3-4) 11 (9-13) 2 (2-3) 11 (7-17) 5 (4-7) 12 (8-17) 60-69 years 2 (2-2) 1 (1-1) 2 (1-3) 
≥ 70 years 1 (1-1) 8 (5-10) 1 (1-1) 14 (7-24) 1 (1-2) 5 (2-11) 
60 months       
< 60 years 2 (2-2) 8 (6-10) 1 (1-1) 9 (5-14) 2 (1-4) 4 (2-8) 60-69 years 1 (1-1) 1 (<1-1) 1 (<1-1) 
≥ 70 years 1 (1-1) 5 (3-7) <1 (<1-1) 9 (3-19) 1 (<1-1) 4 (1-10) 
1Data are shown as survival proportion (95% confidence interval) [%].  
2For the resected group in each center, the age groups ‘< 60 years’ and ‘60-69 years’ were combined to the group ‘< 70 years’ due to limited 
case numbers. 
OS, overall survival; CI, confidence interval; NA, not available. 
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Table 40. Unadjusted survival proportions of overall and resected stage III-IV pancreatic cancer patients (Huang 
et al., 2018a) (continued) 
Time Norway Slovenia 
 Overall Resected Overall Resected 
 OS (95% CI) OS (95% CI) OS (95% CI) OS (95% CI) 
1 month     
< 60 years 91 (89-93) 97 (90-99) 83 (79-86) 99 (92-100) 60-69 years 84 (82-86) 79 (75-82) 
≥ 70 years 73 (71-74) 91 (74-97) 67 (64-70) 90 (78-96) 
3 months     
< 60 years 65 (62-68) 89 (80-95) 55 (50-60) 81 (71-88) 60-69 years 57 (54-59) 49 (44-53) 
≥ 70 years 37 (35-39) 76 (57-87) 33 (30-35) 68 (53-79) 
6 months     
< 60 years 41 (38-45) 72 (60-81) 38 (33-42) 68 (57-77) 60-69 years 35 (32-38) 32 (28-36) 
≥ 70 years 18 (16-19) 49 (31-64) 14 (12-16) 42 (28-55) 
12 months     
< 60 years 19 (16-22) 45 (33-56) 14 (11-18) 32 (22-42) 60-69 years 13 (11-14) 15 (12-18) 
≥ 70 years 6 (5-7) 39 (22-55) 5 (4-7) 16 (8-27) 
24 months     
< 60 years 7 (5-9) 25 (15-35) 5 (3-7) 11 (5-18) 60-69 years 3 (2-4) 3 (1-4) 
≥ 70 years 2 (1-2) 19 (7-34) 1 (1-2) 4 (1-12) 
36 months     
< 60 years 4 (3-6) 19 (11-29) 2 (1-4) 5 (2-11) 60-69 years 1 (1-2) 1 (<1-2) 
≥ 70 years 1 (1-1) 7 (1-21) 1 (<1-1) 2 (<1-9) 
60 months     
< 60 years 1 (1-3) 3 (1-10) 1 (1-3) 4 (1-9) 60-69 years 1 (<1-1) 1 (<1-2) 
≥ 70 years <1 (<1-1) NA <1 (<1-1) NA 
1Data are shown as survival proportion (95% confidence interval) [%].  
2For the resected group in each center, the age groups ‘< 60 years’ and ‘60-69 years’ were combined to the group ‘< 70 years’ due to limited 
case numbers. 
OS, overall survival; CI, confidence interval; NA, not available.
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3.1.3.4 Survival of overall stage I-II and III-IV pancreatic cancer patients with microscopic 
confirmation 
Considering the relatively high proportions of overall PaC patients without microscopic confirmation, 
sensitivity analyses were conducted by limiting the overall stage I-II and III-IV cancer patients to 
those with microscopically confirmed cancers (Figures 10-11 and Table 41). Patients with 
microscopically confirmed stage I-II and III-IV cancers generally had higher survival especially in 
those ≥70 years and within 24 months after diagnosis, in all participating countries except Belgium, 
where microscopic confirmation rates were high and where survival remained very similar. The 3-year 
survival rates remained mostly similar to the results of the main analyses, and were 21%-34% (<60 
years), 14%-25% (60-69 years), and 12%-14% (≥70 years) for stage I-II PaC, and 2%-5% (<60 years), 
1%-2% (60-69 years), and 1%-1% (≥70 years) for stage III-IV tumor. 
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Table 41. Unadjusted survival proportions of overall patients with microscopically confirmed stages I-II and 
III-IV pancreatic cancers (Huang et al., 2018a) 
Time The US The Netherlands Belgium 
 Stage I-II Stage III-IV Stage I-II Stage III-IV Stage I-II Stage III-IV 
 OS (95% CI)1 OS (95% CI) OS (95% CI) OS (95% CI) OS (95% CI) OS (95% CI) 
1 month       
< 60 years 96 (95-96) 77 (76-78) 98 (97-99) 87 (86-89) 98 (97-99) 93 (91-95) 
60-69 years 93 (92-93) 72 (71-72) 96 (95-97) 83 (82-84) 97 (96-98) 89 (87-91) 
≥ 70 years 84 (84-85) 60 (59-61) 92 (90-93) 74 (72-75) 93 (92-94) 81 (80-83) 
3 months       
< 60 years 90 (90-91) 59 (58-60) 93 (91-94) 61 (59-63) 95 (93-96) 78 (75-80) 
60-69 years 86 (85-87) 53 (53-54) 89 (87-91) 55 (53-57) 92 (91-94) 69 (67-71) 
≥ 70 years 71 (71-72) 40 (39-40) 79 (77-81) 42 (41-44) 83 (81-84) 55 (53-56) 
6 months       
< 60 years 81 (80-82) 41 (40-42) 83 (81-86) 36 (34-37) 90 (87-92) 59 (56-62) 
60-69 years 74 (73-75) 35 (35-36) 79 (77-81) 32 (31-34) 86 (83-88) 50 (48-53) 
≥ 70 years 57 (56-57) 24 (24-25) 63 (61-66) 22 (21-23) 67 (65-69) 34 (32-35) 
12 months       
< 60 years 60 (58-61) 20 (20-21) 62 (59-65) 13 (12-15) 72 (69-76) 31 (28-34) 
60-69 years 54 (52-55) 17 (17-18) 57 (54-59) 12 (11-13) 65 (62-68) 24 (22-26) 
≥ 70 years 36 (35-36) 10 (10-11) 40 (38-42) 7 (7-8) 43 (40-45) 14 (13-15) 
24 months       
< 60 years 36 (34-37) 7 (6-7) 31 (28-34) 4 (4-5) 47 (43-51) 10 (9-12) 
60-69 years 30 (29-31) 5 (5-6) 30 (27-33) 3 (2-3) 38 (35-41) 6 (4-7) 
≥ 70 years 18 (17-19) 3 (3-3) 20 (18-22) 2 (1-2) 21 (19-22) 3 (3-4) 
36 months       
< 60 years 26 (24-27) 3 (3-4) 21 (18-24) 2 (2-3) 34 (30-37) 5 (4-7) 
60-69 years 20 (19-21) 2 (2-3) 19 (17-22) 1 (1-2) 25 (22-28) 2 (1-3) 
≥ 70 years 12 (11-12) 1 (1-2) 14 (12-16) 1 (<1-1) 13 (11-14) 1 (1-2) 
60 months       
< 60 years 19 (18-20) 2 (1-2) 14 (12-17) 1 (1-1) 23 (19-26) 2 (1-3) 
60-69 years 13 (12-14) 1 (1-1) 12 (10-14) <1 (<1-1) 16 (14-19) 1 (<1-1) 
≥ 70 years 7 (7-8) 1 (<1-1) 7 (6-9) <1 (<1-1) 7 (6-8) 1 (<1-1) 
1Data are shown as survival proportion (95% confidence interval) [%].  
OS, overall survival; CI, confidence interval; NA, not available.
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Table 41. Unadjusted survival proportions of overall patients with microscopically confirmed stages I-II and 
III-IV pancreatic cancers (Huang et al., 2018a) (continued) 
Time Norway Slovenia 
 Stage I-II Stage III-IV Stage I-II Stage III-IV 
 OS (95% CI) OS (95% CI) OS (95% CI) OS (95% CI) 
1 month     
< 60 years 99 (96-100) 92 (90-94) 98 (93-99) 87 (82-90) 
60-69 years 97 (94-98) 87 (85-89) 97 (92-99) 82 (77-86) 
≥ 70 years 96 (94-98) 80 (78-82) 94 (90-97) 67 (63-72) 
3 months     
< 60 years 96 (93-98) 67 (63-70) 95 (90-98) 61 (55-67) 
60-69 years 91 (88-94) 59 (56-62) 93 (88-96) 54 (48-59) 
≥ 70 years 85 (82-88) 44 (42-47) 81 (75-86) 39 (35-44) 
6 months     
< 60 years 88 (82-91) 43 (39-46) 92 (85-95) 44 (38-49) 
60-69 years 79 (74-83) 37 (34-40) 82 (74-87) 40 (34-45) 
≥ 70 years 67 (63-71) 22 (20-24) 70 (63-76) 19 (16-23) 
12 months     
< 60 years 65 (58-71) 20 (17-23) 65 (56-72) 17 (13-22) 
60-69 years 55 (49-60) 13 (11-15) 59 (50-66) 19 (15-24) 
≥ 70 years 42 (37-46) 7 (6-9) 49 (42-56) 7 (5-10) 
24 months     
< 60 years 39 (32-46) 7 (5-9) 35 (27-43) 6 (3-9) 
60-69 years 30 (25-35) 3 (2-4) 24 (18-31) 4 (2-6) 
≥ 70 years 19 (16-23) 2 (1-3) 25 (19-31) 2 (1-4) 
36 months     
< 60 years 25 (19-32) 4 (2-6) 23 (16-30) 2 (1-4) 
60-69 years 19 (14-24) 1 (<1-2) 14 (9-20) 2 (1-3) 
≥ 70 years 13 (10-17) 1 (<1-1) 14 (9-19) 1 (<1-2) 
60 months     
< 60 years 16 (11-22) 1 (<1-2) 15 (9-23) 2 (1-4) 
60-69 years 13 (9-18) <1 (<1-1) 8 (4-14) 1 (<1-3) 
≥ 70 years 8 (5-11) <1 (<1-1) 8 (5-13) <1 (<1-1) 
1Data are shown as survival proportion (95% confidence interval) [%].  
OS, overall survival; CI, confidence interval; NA, not available. 
  
RESULTS 
72 
 
3.1.3.5 Temporal trends of survival in overall and resected pancreatic cancers by TNM stage 
The trends of the 1-month to 5-year survival of PaC patients diagnosed in 2003-2005, 2006-2008, and 
2009-2011 are shown in Table 42 and Figures 12-16. Significant survival changes between 
2003-2005 and 2009-2011 are described in detail as follows. 
Short-term survival 
Significant increases in 1-month survival for overall PaC patients were observed in the US and the 
Netherlands, with 3 and 3% units increase for stage I-II cancers and 2 and 3% units increase for stage 
III-IV tumors. In Slovenia, an increase by 6% units in 1-month survival was observed among overall 
stage III-IV cancer patients. For the subgroup of resected cancer patients, a significant survival 
increase was only observed for stage I-II cancer patients in the US (by 2% units). Improvements in 
3-month survival were mostly larger and also significant among overall cancer patients in the US and 
the Netherlands, with 4 and 6% units increase in stage I-II cancers and 3 and 3% units increase in 
stage III-IV tumors, respectively. In Norway, an increase by 6% units was observed for stage I-II 
cancer patients. In Slovenia, a significant increase by 8% units persisted for patients with stage III-IV 
cancers. Within the resected cancer patient subgroup, significant increasing trends were observed in 
both stage I-II (by 2% units) and III-IV cancer patients (by 7% units) in the US, and in patients with 
stage III-IV cancers in Slovenia (by 10% units). 
 
Longer-term survival 
While in all countries 1-year survival increased for patients with stage I-II PaCs, the increases were 
only significant in the US (by 6% units), the Netherlands (by 12% units), and Norway (by 10% units). 
For the subgroup of resected cancer patients, again 1-year survival increased in all countries, but the 
changes were only significant in the US (by 5% units) and Norway (by 11% units). For overall 
patients with stage III-IV cancers, 1-year survival increased significantly in the US (by 3% units), the 
Netherlands (by 1% unit), Norway (by 2% units), and Slovenia (by 6% units). For patients with 
resected stage III-IV PaCs, significant increases were only observed in the US (by 13% units). 
Improvements in 3-year survival for overall patients with stage I-II cancers were mostly smaller and 
were significant in the US (by 4% units), the Netherlands (by 8% units), and Norway (by 2% units). 
For the subgroup of patients with resected stage I-II tumors, significant increases were observed in the 
US (by 5% units), the Netherlands (by 11% units), and Belgium (by 5% units). Changes in 3-year 
survival of patients with stage III-IV PaCs were minor and significant only in the US (by <1% unit 
increase) and the Netherlands (by <1% unit increase). Significant changes for the subgroup of patients 
with resected stage III-IV cancers were observed only in the US (by 5% unit increase). Regarding 
5-year survival, significant increases were observed only in patients with stage I-II tumors. Survival 
rates increased by 6 and 1% unit in the Netherlands and Norway respectively for overall cancer 
patients, and by 8% units in the Netherlands for the resected tumor patients.  
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Table 42. Unadjusted survival rates of overall and resected pancreatic cancer patients diagnosed in 2003-2005, 
2006-2008, and 2009-2011 (Huang et al., 2018a) 
Survival Period Stage The US The Netherlands Belgium 
   Overall Resected Overall Resected Overall Resected 
   OS (95% CI)1 OS (95% CI) OS (95% CI) OS (95% CI) OS (95% CI) OS (95% CI)
1-month 2003-2005 I-II 83 (82-84) 95 (94-96) 89 (87-91) 96 (93-97) 94 (92-96) 97 (94-98) 
  III-IV 61 (60-62) 86 (82-89) 73 (71-75) 88 (74-95) 88 (85-90) 96 (86-99) 
 2006-2008 I-II 84 (84-85) 96 (95-96) 92 (91-94) 97 (95-98) 95 (94-97) 97 (95-98) 
  III-IV 62 (61-63) 89 (86-91) 77 (75-78) 100 (100-100) 86 (85-88) 98 (91-99) 
 2009-2011 I-II 86 (85-87) 96 (96-97) 92 (90-93) 97 (96-98) 96 (95-97) 98 (97-99) 
  III-IV 63 (62-64) 90 (88-92) 76 (75-78) 91 (81-96) 85 (84-87) 100 (100-100)
 %unit change2, P I-II +3, 0.006 +2, 0.004 +3, 0.021 +1, 0.257 +2, 0.116 +1, 0.577 
  III-IV +2, 0.002 +4, 0.989 +3, 0.001 +3, 0.635 -2, 0.086 +4, 0.189 
3-month 2003-2005 I-II 72 (71-73) 91 (90-92) 74 (71-76) 92 (89-94) 86 (83-89) 93 (90-96) 
  III-IV 42 (41-43) 74 (69-78) 42 (40-43) 84 (69-92) 66 (62-69) 93 (82-97) 
 2006-2008 I-II 73 (72-74) 92 (91-92) 78 (76-81) 93 (91-95) 87 (85-89) 92 (90-94) 
  III-IV 44 (43-44) 79 (76-82) 46 (44-47) 98 (88-100) 63 (61-65) 85 (95-91) 
 2009-2011 I-II 76 (75-77) 93 (92-94) 80 (78-82) 93 (91-95) 89 (87-91) 94 (92-96) 
  III-IV 45 (44-46) 81 (78-84) 45 (43-46) 85 (74-92) 63 (60-65) 93 (85-96) 
 %unit change2, P I-II +4, <0.001 +2, <0.001 +6, 0.001 +1, 0.546 +3, 0.118 +1, 0.508 
  III-IV +3, <0.001 +7, 0.017 +3, 0.001 +1, 0.831 -3, 0.087 -<1, 0.972 
12-month 2003-2005 I-II 38 (36-39) 64 (62-66) 33 (30-36) 64 (59-68) 52 (48-57) 62 (56-67) 
  III-IV 11 (11-12) 34 (29-39) 8 (7-9) 49 (33-63) 19 (17-22) 45 (31-57) 
 2006-2008 I-II 40 (39-41) 65 (64-67) 36 (33-38) 64 (60-68) 56 (53-60) 69 (65-73) 
  III-IV 12 (12-13) 35 (31-39) 8 (7-9) 53 (38-64) 19 (17-21) 47 (36-57) 
 2009-2011 I-II 44 (43-45) 70 (68-71) 45 (43-48) 69 (65-72) 55 (52-57) 68 (65-71) 
  III-IV 14 (14-15) 47 (42-51) 9 (8-10) 41 (29-52) 20 (18-22) 53 (42-62) 
 %unit change2, P I-II +6, < 0.001 +5, <0.001 +12, <0.001 +5, 0.066 +3, 0.297 +6, 0.057 
  III-IV +3, < 0.001 +13, <0.001 +1, 0.001 -8, 0.496 +1, 0.476 +8, 0.548 
36-month 2003-2005 I-II 13 (13-14) 27 (25-29) 8 (7-10) 18 (14-22) 17 (14-21) 24 (19-29) 
  III-IV 2 (2-2) 7 (5-10) 1 (1-2) 14 (6-26) 2 (2-4) 8 (2-16) 
 2006-2008 I-II 14 (14-15) 29 (27-30) 12 (10-13) 24 (20-28) 21 (18-23) 28 (25-32) 
  III-IV 2 (2-2) 9 (7-11) 1 (1-1) 11 (5-21) 2 (2-3) 7 (3-14) 
 2009-2011 I-II 17 (16-18) 33 (31-34) 16 (15-18) 29 (26-32) 20 (18-22) 30 (26-33) 
  III-IV 2 (2-2) 11 (9-14) 1 (1-1) 12 (6-21) 2 (1-3) 10 (5-16) 
 %unit change2, P I-II +4, <0.001 +5, <0.001 +8, <0.001 +11, <0.001 +3, 0.076 +5, 0.035 
  III-IV +<1, <0.001 +5, <0.001 +<1, 0.005 -2, 0.886 -1, 0.285 +2, 0.317 
60-month 2003-2005 I-II 9 (8-10) 18 (17-20) 4 (3-5) 10 (7-13) 11 (8-14) 16 (12-21) 
  III-IV 1 (1-1) 4 (2-6) 1 (<1-1) 9 (3-20) 1 (<1-2) 4 (1-11) 
 2006-2008 I-II 10 (9-11) 20 (19-21) 7 (6-9) 15 (12-19) 13 (11-15) 18 (15-21) 
  III-IV 1 (1-1) 6 (5-9) <1 (<1-1) 6 (2-14) 1 (1-2) 5 (2-11) 
 2009-2011 I-II NA NA 10 (8-12) 18 (15-21) 12 (10-14) 18 (15-21) 
  III-IV NA NA 1 (<1-1) 12 (6-21) 1 (<1-1) 2 (<1-7) 
 %unit change2, P I-II NA, NA NA, NA +6, <0.001 +8, <0.001 +1, 0.109 +2, 0.090 
  III-IV NA, NA NA, NA +<1, 0.004 +3, 0.935 -<1, 0.290 -2, 0.409 
1Data are shown as survival rate (95% confidence interval) [%].  
2%changes are shown by comparing average survival of patients diagnosed in 2009-2011 to those in 2003-2005. Significant changes 
according to P values calculated using the log-rank test are highlighted in bold. 
OS, overall survival; NA, not available as follow-up was not long enough. 
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Table 42. Unadjusted survival rates of overall and resected pancreatic cancer patients diagnosed in 2003-2005, 
2006-2008, and 2009-2011 (Huang et al., 2018a) (continued) 
Survival Period Stage Norway Slovenia 
   Overall Resected Overall Resected 
   OS (95% CI) OS (95% CI) OS (95% CI) OS (95% CI)
1-month 2003-2005 I-II 91 (88-94) 99 (94-100) 89 (84-93) 96 (90-98) 
  III-IV 78 (75-80) 100 (100-100) 69 (65-74) 92 (71-98) 
 2006-2008 I-II 90 (83-96) 99 (93-100) 93 (88-96) 99 (93-100) 
  III-IV 79 (76-81) 96 (75-99) 75 (71-78) 97 (80-100) 
 2009-2011 I-II 94 (91-96) 98 (95-99) 90 (85-94) 99 (94-100) 
  III-IV 78 (75-80) 96 (77-100) 75 (72-79) 98 (86-100) 
 %unit change2, P I-II +3, 0.175 -1, 0.473 +1, 0.851 +4, 0.083 
  III-IV +<1, 0.972 -4, 0.301 +6, 0.024 +6, 0.229 
3-month 2003-2005 I-II 76 (71-80) 98 (93-99) 76 (69-82) 87 (79-92) 
  III-IV 44 (41-47) 87 (68-95) 36 (31-40) 58 (36-75) 
 2006-2008 I-II 72 (67-76) 94 (86-97) 80 (73-86) 92 (85-96) 
  III-IV 48 (46-51) 84 (63-94) 43 (39-47) 85 (67-93) 
 2009-2011 I-II 82 (78-85) 96 (92-98) 76 (70-82) 97 (91-99) 
  III-IV 47 (44-49) 86 (66-94) 44 (40-48) 76 (61-86) 
 %unit change2, P I-II +6, 0.035 -1, 0.562 +<1, 0.909 +10, 0.005 
  III-IV +3, 0.225 -1, 0.890 +8, 0.007 +18, 0.085 
12-month 2003-2005 I-II 34 (29-39) 66 (57-74) 38 (30-45) 51 (41-60) 
  III-IV 8 (6-10) 37 (20-53) 5 (3-8) 13 (3-29) 
 2006-2008 I-II 33 (29-38) 71 (60-79) 51 (43-59) 67 (57-76) 
  III-IV 11 (10-13) 56 (35-73) 12 (10-15) 39 (23-55) 
 2009-2011 I-II 44 (39-49) 77 (70-83) 42 (35-48) 60 (50-68) 
  III-IV 10 (8-11) 46 (28-63) 11 (9-14) 17 (8-30) 
 %unit change2, P I-II +10, 0.003 +11 0.025 +4, 0.577 +9, 0.101 
  III-IV +2, 0.027 +100.689 +6, <0.001 +5, 0.238 
36-month 2003-2005 I-II 12 (9-16) 28 (20-36) 9 (6-14) 11 (6-17) 
  III-IV 1 (1-2) 10 (3-24) 1 (<1-2) NA 
 2006-2008 I-II 10 (7-14) 32 (22-41) 19 (14-26) 27 (19-37) 
  III-IV 2 (1-2) 24 (10-42) 2 (1-3) 12 (4-26) 
 2009-2011 I-II 15 (12-18) 30 (23-37) 12 (8-16) 17 (11-24) 
  III-IV 1 (1-2) 14 (5-30) 1 (<1-1) NA 
 %unit change2, P I-II +2, 0.025 +2, 0.205 +2, 0.468 +6, 0.069 
  III-IV -<1, 0.062 +4, 0.785 +<1, 0.002 NA, NA 
60-month 2003-2005 I-II 9 (6-12) 18 (12-25) 7 (3-11) 9 (5-15) 
  III-IV 1 (<1-1) 3 (<1-15) <1 (<1-1) NA 
 2006-2008 I-II 7 (4-9) 20 (12-28) 9 (5-14) 13 (7-21) 
  III-IV 1 (<1-1) 4 (<1-17) 2 (1-3) 12 (4-26) 
 2009-2011 I-II 10 (7-13) 20 (14-27) 8 (5-12) 11 (6-17) 
  III-IV <1 (<1-1) NA <1 (<1-1) NA 
 %unit change2, P I-II +1, 0.043 +2, 0.262 +2, 0.469 +2, 0.113 
  III-IV -<1, 0.069 NA, NA +<1, 0.002 NA, NA 
1Data are shown as survival rate (95% confidence interval) [%].  
2%changes are shown by comparing average survival of patients diagnosed in 2009-2011 to those in 2003-2005. Significant changes 
according to P values calculated using the log-rank test are highlighted in bold. 
OS, overall survival; NA, not available as follow-up was not long enough. 
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Figure 12. Changes in 1-month survival over calendar periods among overall and resected patients with stages 
I-II and III-IV pancreatic cancers (Huang et al., 2018a) 
 
 
Figure 13. Changes in 3-month survival over calendar periods among overall and resected patients with stages 
I-II and III-IV pancreatic cancers (Huang et al., 2018a) 
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Figure 14. Changes in 12-month survival over calendar periods among overall and resected patients with stages 
I-II and III-IV pancreatic cancers (Huang et al., 2018a) 
 
 
Figure 15. Changes in 36-month survival over calendar periods among overall and resected patients with stages 
I-II and III-IV pancreatic cancers (Huang et al., 2018a) 
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Figure 16. Changes in 60-month survival over calendar periods among overall and resected patients with stages 
I-II and III-IV pancreatic cancers (Huang et al., 2018a) 
3.1.4 Prognostic factors and development and international validation of a benchmark 
population-based survival-predicting model in patients with resected stage I-II pancreatic 
adenocarcinoma receiving chemotherapy 
3.1.4.1 Patient characteristics 
A total of 168,949 PaC patients were registered in the population-based registries during 
2003/2004-2013/2014 with follow-up until 2014-2016. After excluding patients diagnosed based on 
DCO/autopsy (n=4,403), unresected (n=137,605), receiving no/unknown chemotherapy (n=11,465), 
without microscopically-confirmed tumors or with tumors of ineligible pathology (n=1,418), with 
stage 0/III/IV/unknown tumors (n=1,856), and with survival <3 months or unknown (n=365), finally 
11,837 patients were eligible for analysis (Table 43). Of the analyzed patients (Table 44), 52%-76% 
were diagnosed in 2010 or later. The proportion of women was 42%-51%, and the mean age was 
61-65 years. Most patients were 50-69 years (58%-71%). Tumors were most commonly located at 
pancreas head (82%-92%). A minority of patients had T1 (0%-8%) or T2 cancers (7%-26%) compared 
to T3 tumors (66%-93%). N1 tumors comprised 55%-84%. Most patients had either moderately- 
(40%-63%) or poorly-differentiated/undifferentiated tumors (34%-50%). 
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Table 43. General information on participating registries for Chapter 3.1.4 
Source Diagnosis period 
Censoring 
date 
Registered 
primary 
cases2 
Excluded cases1 
Analyzed 
cases 
Follow-up 
months3 DCO/ autopsy 
Not resected/ 
no/unknown 
chemotherapy
Not microscopically 
confirmed/ineligible 
pathology 
Stage 
0/III/IV/ 
unknown 
Survival <3 
months/ 
unknown 
SEER-
184 
Jan. 2004- 
Dec. 2015 
Dec. 31, 
2015 122826 3917 106524 1102 1436 328 9519 
56 
(28-89) 
BCR Jan. 2004- Dec. 2013 Jul. 1, 2015 12146 NA 10658 142 233 8 1105 
64 
(40-89) 
NCR Jan. 2003- Dec. 2014 
Feb. 1, 
2015 22579 99 21277 106 86 29 982 
36 
(20-59) 
CRS Jan. 2003- Dec. 2013 
May 25, 
2016 3376 54 3140 22 42 0 118 
75 
(51-87) 
CRN Jan. 2003- Dec. 2014 
Jun. 30, 
2015 8022 333 7471 46 59 0 113 
40 
(32-65) 
1Data exclusion followed this sequence: DCO/autopsy, not resected, no/unknown chemotherapy, stage 0/III/IV, not 
microscopically-confirmed/ineligible pathology, and survival <3 months/unknown (from left to right). 
2A preliminary data-cleaning process had been performed to exclude cases with ineligible histology types except cystic, mucinous, and 
serous malignancies. 
3Shown as median (interquartile range), and computed using the reverse Kaplan-Meier method.  
4Data of the year 2003 was not analyzed, as the TNM stage (version 6/7) information was unavailable. 
SEER, Surveillance, Epidemiology, and End Results Program; NCR, Netherlands Cancer Registry; BCR, Belgian Cancer Registry; CRN, 
Cancer Registry of Norway; CRS, Cancer Registry of Slovenia; DCO, death certificate only; NA, not available. 
 
Table 44. Demographic and clinical characteristics of resected pancreas cancer patients receiving chemotherapy1 
Variable The US Belgium The Netherlands Slovenia Norway 
n 9519 1105 982 118 113 
Incidence period 2004-2015 2004-2013 2003-2014 2003-2013 2003-2014
Diagnosis in 2010 or later 5635 (59) 579 (52) 747 (76) 67 (57) 79 (70) 
Sex, female 4671 (49) 522 (47) 483 (49) 50 (42) 58 (51) 
Age (years)      
Mean ± standard deviation 65 ± 10 64 ± 10 62 ± 9 61 ± 9 64 ± 8 
Median (interquartile range) 65 (58-72) 65 (58-71) 64 (57-69) 61 (54-68) 63 (59-70)
< 50 706 (7) 90 (8) 92 (9) 11 (9) 4 (4) 
50-59 2101 (22) 264 (24) 235 (24) 38 (32) 29 (26) 
60-69 3464 (36) 406 (37) 417 (42) 46 (39) 50 (44) 
≥ 70 3248 (34) 345 (31) 238 (24) 23 (19) 30 (27) 
Tumor location2      
Pancreas head 7314 (83) 658 (82) 820 (90) 97 (92) 91 (88) 
Pancreas body 622 (7) 58 (7) 31 (3) 5 (5) 4 (4) 
Pancreas tail 845 (10) 86 (11) 63 (7) 3 (3) 8 (8) 
Other 738 (8) 303 (27) 68 (7) 13 (11) 10 (9) 
T stage3      
T1 494 (5) 56 (5) 72 (7) 0 (0) 8 (8) 
T2 1192 (13) 185 (17) 182 (19) 8 (7) 28 (26) 
T3 7815 (82) 860 (78) 727 (74) 108 (93) 70 (66) 
N stage, N14 6339 (67) 805 (73) 703 (72) 97 (84) 60 (55) 
Differentiation5      
Well 858 (10) 149 (15) 91 (11) 12 (11) 3 (3) 
Intermediate 4540 (52) 511 (52) 423 (51) 44 (40) 64 (63) 
Poor/undifferentiated 3266 (38) 326 (33) 319 (38) 55 (50) 35 (34) 
1Categorical data are shown as count (percentage [%]). For brevity, results for the counterparts in dichotomous variables are omitted. Records 
are complete otherwise specified below. 
2The percentages of pancreas head, body, tail, and overlapping cancers are the proportions compared to the total cases of the four locations; 
‘other’ includes overlapping lesion, pancreas duct, and not otherwise specified location, and its proportion is relative to the whole cases. 
3Missing T stage: the US: 18 (<1%); Belgium: 4 (<1%); the Netherlands: 1 (<1%); Slovenia: 2 (2%); Norway: 7 (6%). 
4Missing N stage: the US: 0 (0%); Belgium: 7 (1%); the Netherlands: 0 (0%); Slovenia: 2 (2%); Norway: 3 (3%). 
5Missing differentiation: the US: 855 (9%); Belgium: 119 (11%); the Netherlands: 149 (15%); Slovenia: 7 (6%); Norway: 11 (10%). 
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3.1.4.2 Survival-associated factors 
The median overall survival time was 18 (Slovenia) to 23 months (the US), and the 3-year survival 
rate was 21% (Slovenia) to 31% (the US; Figure 17). Results from multivariable Cox regression are 
shown in Table 45, and only significant results are described. Increasing age was associated with 
worse survival in the US (HR per year=1.01), Belgium (HR=1.02), and Norway (HR=1.04). Survival 
was significantly worse in men only in the US (HR=1.10) and in pancreas body compared to head 
tumors in Norway (HR=2.67). Compared to T3 cancers, T1 cancers were associated with higher 
survival in all investigated countries (HR=0.17-0.70), while T2 cancers were associated with better 
survival only in the US (HR=0.86). Negative nodal status was associated with significantly higher 
survival in the US (HR=0.65), Belgium (HR=0.78), and the Netherlands (HR=0.51). Better 
differentiation was significantly associated with higher survival in all countries except Slovenia and 
Norway, and the HRs for well- and intermediately- versus poorly-/un-differentiated tumors were 
0.48-0.68 and 0.61-0.81, respectively. Association patterns and strengths were similar between white 
and overall US patients.  
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Table 45. Association of demographic and clinical variables with overall survival for resected pancreatic cancer 
patients estimated by adjusted multivariable Cox proportional hazards regression 
Variable The US The US (white) Belgium The Netherlands Slovenia Norway 
Used no. 8657 7170 979 833 109 96 
 HR (95% CI)1 HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)  HR (95% CI)
Year of diagnosis 
(per year; continuous) 0.97 (0.96-0.98) 0.97 (0.96-0.98) 0.98 (0.95-1.01) 0.99 (0.95-1.03) 0.96 (0.89-1.03) 0.80 (0.69-0.93)
Age (per year; 
continuous) 1.01 (1.01-1.01) 1.01 (1.01-1.01) 1.02 (1.01-1.02) 1.00 (0.99-1.01) 1.01 (0.99-1.04) 1.04 (1.00-1.08)
Sex       
Female 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Male 1.10 (1.05-1.16) 1.12 (1.06-1.18) 0.93 (0.80-1.07) 1.08 (0.91-1.29) 1.49 (0.96-2.32) 1.14 (0.67-1.95)
Tumor location       
Pancreas head 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Pancreas body 1.03 (0.92-1.15) 1.04 (0.92-1.17) 1.34 (0.99-1.82) 1.19 (0.69-2.04) 1.33 (0.47-3.81) 0.40 (0.05-2.98)
Pancreas tail 1.02 (0.93-1.12) 1.03 (0.93-1.14) 1.00 (0.76-1.30) 0.85 (0.57-1.26) 0.39 (0.09-1.66) 2.67 (1.09-6.53)
Other2 1.02 (0.93-1.13) 1.03 (0.93-1.15) 0.95 (0.80-1.12) 0.92 (0.65-1.38) 0.83 (0.37-1.84) 0.89 (0.30-2.65)
T stage       
T1 0.66 (0.57-0.75)  0.70 (0.61-0.81) 0.68 (0.47-0.97) 0.48 (0.33-0.71) -  0.17 (0.04-0.72)
T2 0.86 (0.79-0.93) 0.88 (0.81-0.97) 0.89 (0.74-1.08) 1.02 (0.82-1.26) 0.70 (0.29-1.67) 0.89 (0.49-1.61)
T3 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
N stage       
N0 0.65 (0.61-0.69) 0.65 (0.61-0.69) 0.78 (0.66-0.92) 0.51 (0.41-0.64) 0.77 (0.40-1.51) 0.71 (0.39-1.29)
N1 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Differentiation       
Well 0.60 (0.55-0.66) 0.59 (0.53-0.65) 0.68 (0.55-0.85) 0.48 (0.35-0.67) 0.57 (0.27-1.22) 0.31 (0.04-2.58)
Intermediate 0.77 (0.73-0.81) 0.78 (0.73-0.82) 0.81 (0.69-0.94) 0.61 (0.50-0.73) 0.82 (0.51-1.32) 0.93 (0.54-1.61)
Poor/undifferentiated 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
1HRs were calculated by Cox proportional hazard regression with adjustment for year of diagnosis, age, sex, tumor location, T, N, and M 
stages, histology, and differentiation. In stratified analyses, the stratification factor was omitted from the model. Statistically significant HRs 
are shown in bold. 
2Other: pancreas duct, overlapping lesion, and not otherwise specified location. 
HR, hazard ratio; CI, confidence interval; -, not available. 
 
Associations with further variables were explored in countries with available relevant information 
(Table 46). In the Netherlands, positive resection margin was associated with worse survival in 
(HR=1.36), and resection in academic hospital was associated with better survival (HR=0.79). In the 
US, larger tumor size was associated with inferior survival, and replacing T stage according to the 
sixth/seventh edition with the eighth edition revealed similar association patterns and strengths. In the 
US and the Netherlands, while increasing metastatic node number (HR per positive lymph node=1.05 
and 1.07) and lymph node ratio (HR=2.60 and 3.15) were associated with inferior survival, more 
harvested nodes suggested better survival (both HR per harvested node=0.99). Following the eighth 
version of TNM staging, N1 (HR=1.42 and 1.68) and N2 stages (HR=1.84 and 2.43) were associated 
with worse survival compared to N0 stage in the US and the Netherlands. In Eindhoven, the 
Netherlands, more comorbidities were associated with inferior survival (e.g., HR≥2 vs. 0 comorbidities=1.86). 
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Table 46. Association of survival with potential prognostic factors available in at least one registry for resected 
pancreatic cancer estimated by adjusted Cox proportional hazard regression 
Variable The US Belgium The Netherlands Slovenia n HR (95% CI) n HR (95% CI) n HR (95% CI) n HR (95% CI) 
Resection margin         
Negative -  -  - - 637 1.00 (reference) 51 1.00 (reference)
Positive -  -  - - 291 1.36 (1.12-1.65) 34 1.54 (0.82-2.88)
Hospital type         
Non-academic -  -  497 1.00 (reference) 510 1.00 (reference) -  -
Academic -  -  608 0.89 (0.77-1.03) 472 0.79 (0.66-0.94) -  -
Tumor size         
≤2 cm 1490 1.00 (reference) - - - -  -  -
2-3 cm 3146 1.23 (1.12-1.35) - - - -  -  -
3-4 cm 2487 1.38 (1.25-1.52) - - - -  -  -
4-5 cm 1229 1.60 (1.44-1.78) - - - -  -  -
>5 cm 938 1.56 (1.39-1.75) - - - -  -  -
T stage (8th version)         
T1 1490 0.62 (0.57-0.68) - - - -  -  -
T2 5633 0.81 (0.76-0.87) - - - -  -  -
T3 2167 1.00 (reference) - - - -  -  -
Positive LN number2 9426 1.05 (1.04-1.06) - - 974 1.07 (1.04-1.10) -  -
N stage (8th version)         
N0 (0 positive LNs) 3180 1.00 (reference) - - 280 1.00 (reference) -  -
N1 (1-3 positive LNs) 3885 1.42 (1.33-1.51) - - 416 1.68 (1.33-2.13) -  -
N2 (≥4 positive LNs) 2244 1.84 (1.72-1.98) - - 278 2.43 (1.89-3.12) -  -
Harvested LN number2 9484 0.99 (0.99-0.99) - - 959 0.99 (0.98-1.00) -  -
LN ratio2 9138 2.60 (2.26-3.00) - - 945 3.15 (2.05-4.84) -  -
ECOG score         
0 -  -  140 1.00 (reference) - -  -  -
1 -  -  662 0.96 (0.76-1.20) - -  -  -
≥2 -  -  63 1.04 (0.73-1.47) - -  -  -
Resection type          
Pancreatoduodenectomy 7108 1.00 (reference) - - 877 1.00 (reference)  -  -
Distal pancreatectomy 1142 1.02 (0.92-1.14) - - 88 1.33 (0.61-2.91) -  -
Total pancreatectomy 1102 1.07 (0.99-1.15) - - 10 0.98 (0.36-2.65) -  -
Comorbidity (yes v no)         
Cardiovascular disease  -  -  - - 30/119 1.33 (0.69-2.57) -  -
Hypertension  -  -  - - 39/110 1.01 (0.59-1.75) -  -
Diabetes  -  -  - - 33/116 1.34 (0.76-2.38) -  -
Pulmonary disease  -  -  - - 14/135 1.96 (0.88-4.36) -  -
Number of comorbidities         
0 -  -  - - 52 1.00 (reference) -  -
1 -  -  - - 48 1.48 (0.84-2.62) -  -
≥ 2 -  -  - - 49 1.86 (1.00-3.46) -  -
1The main Cox proportional hazard regression models adjusted for year of diagnosis, age, sex, tumor location, T, N, and M stages, histology, 
and differentiation. HRs were calculated after N stage was replaced by metastatic node number (group) or lymph node ratio, or after the other 
investigated variables were included one by one into the main models. Statistically significant HRs are shown in bold. 
2As continuous. 
HR, hazard ratio; CI, confidence interval; LN, lymph node; ECOG, Eastern Cooperative Oncology Group; -, not available. 
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Sensitivity analyses of the main models by incorporation of the further prognostic covariates did 
not change the association patterns or markedly alter the association strengths for the variables 
included in the main models (data not shown). 
3.1.4.3 Prognostic nomogram 
Construction 
A nomogram incorporating prognostic factors remaining after backward selection in the US (sex, age, 
T and N stages, and differentiation) was established (Figure 18). The nomogram illustrated age and 
differentiation to have the largest contributions to prognosis. T and N stages showed moderate impacts 
on survival. Each number/category of these variables is assigned a score on the Points scale. After 
summing up the total score and locating it on the Total Points scale, a line drawn straight down to the 
Median Survival or 1-/2-/3-/5-Year Survival Probability scale shows the estimated survival time or 
probability at each time point. Score assignment for specific categories of the variables and survival 
for different accumulated scores are shown in Table 47. The layout of an online version of the model 
is shown in Figure 19. 
 
 
 
Figure 18. Prognostic nomogram for patients with resected stage I-II pancreatic cancer receiving chemotherapy 
derived from the US cohort. Each number/category of the prognostic variables is assigned a score on the Points 
scale. After summing up the total score and locating it on the Total Points scale, a line drawn straight down to the 
Median Survival or 1-/2-/3-/5-Year Survival scale shows the median survival time and estimated survival 
probability at each time point. Age is in years.  
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Table 47. Score assignment for specific categories of the variables included in the nomogram 
Prognostic factors   1-year survival  
Variable Category Score Total score 1-year survival probability
Sex Female 0 345 0.60 
 Male 18 313 0.65 
Age (years) 25 42 277 0.70 
 30 34 236 0.75 
 35 27 187 0.80 
 40 19 126 0.85 
 45 11 44 0.90 
 50 4 2-year survival  
 55 0 Total score 2-year survival probability
 60 5 358 0.20 
 65 18 329 0.25 
 70 24 302 0.30 
 75 33 276 0.35 
 80 46 250 0.40 
 85 59 224 0.45 
 90 73 197 0.50 
 95 86 169 0.55 
 100 100 138 0.60 
T stage T1 0 106 0.65 
 T2 53 70 0.70 
 T3 78 29 0.75 
N stage N0 0 3-year survival  
 N1 82 Total score 3-year survival probability
Differentiation Well 0 342 0.10 
 Intermediate 47 305 0.15 
 Poor/undifferentiated 97 273 0.20 
Median survival   245 0.25 
Total score Median survival (months)  218 0.30 
251 20  192 0.35 
152 30  166 0.40 
99 40  139 0.45 
64 50  112 0.50 
43 60  84 0.55 
27 70  54 0.60 
13 80  21 0.65 
0 90  5-year survival  
   Total score 5-year survival probability
   323 0.05 
   272 0.10 
   235 0.15 
   204 0.20 
   175 0.25 
   148 0.30 
   122 0.35 
   96 0.40 
   70 0.45 
   43 0.50 
   15 0.55 
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Figure 19. Layout of a potential online version of the developed nomogram with Evidencio 
(www.evidencio.com; not public yet) 
 
Model function 
Reference values: sex="Female", t="T1", n="N0", dgrade="Well" (the variable names “age”, “sex”, 
“t”, “n”, and “dgrade” are for “Age”, “Sex”, “T Stage”, “N Stage”, and “Differentiation” in the 
nomogram (Figure 18), respectively) 
Function:-0.71148656+0.09222951*(sex=="Male")-0.0080361358*age+4.0504221e-05*pmax(ag
e-47,0)^3-0.00019415844*pmax(age-59,0)^3+0.00026940813*pmax(age-65,0)^3-0.00014449267*p
max(age-71,0)^3+2.8738757e-05*pmax(age-80,0)^3+0.27621944*(t=="T2")+0.410323*(t=="T3")+0.
42855775*(n=="N1")+0.24623505*(dgrade=="Intermediate")+0.50857222*(dgrade=="Poor/undiffer
entiated") 
The function pmax() take one or more vectors as arguments, recycle them to common length, and 
return a single vector giving the ‘parallel’ maxima of the argument vectors. 
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Calibration and validation 
The nomogram was applied to the US and the European countries for internal and external validations, 
respectively. The calibration plots presented very good agreement between nomogram-predicted and 
actual survival in the US, Belgium, and the Netherlands (Figure 20; plots were not shown in Slovenia 
or Norway where case number was too small to generate meaningful calibration). Generally the 
calibration was best for 2- and 3-year survival. In the training US cohort, the C-index for the 
established nomogram was significantly higher than that for the model based on both T and N stages 
(0.60, 95% CI=0.59-0.61 vs. 0.56, 95% CI=0.56-0.57). In the validation cohorts, C-indexes were also 
significantly higher for the nomogram than for the T and N stage-based model (Table 48). 
 
 
 
Figure 20. Calibration curves for 1-, 2-, 3-, and 5-year overall survival prediction in the primary training (the US) 
and validation cohorts (Belgium, the Netherlands, Slovenia, and Norway). Nomogram-predicted survival is 
plotted on the x axis, and actual survival on the y axis. The vertical bars at the top represent the frequency of the 
predicted probability of survival. A plot along the 45-degree line indicates a perfect calibration model where the 
predicted probabilities are identical to the actual proportions. 
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Table 48. Concordance indexes for resected pancreatic cancer in training and validation cohorts and in 
sensitivity analyses for the training US cohort 
Model modification/subgroup Concordance index 95% confidence interval
Training cohort   
The US, nomogram 0.60 0.59-0.61 
The US, model based on both T and N stages 0.56 0.56-0.57 
Validation cohorts   
Belgium, nomogram 0.58 0.55-0.60 
Belgium, model based on both T and N stages 0.54 0.52-0.56 
The Netherlands, nomogram 0.62 0.59-0.65 
The Netherlands, model based on both T and N stages 0.56 0.54-0.59 
Slovenia, nomogram 0.58 0.51-0.65 
Slovenia, model based on both T and N stages 0.52 0.47-0.57 
Norway, nomogram 0.63 0.55-0.71 
Norway, model based on both T and N stages 0.61 0.54-0.68 
Sensitivity analyses for the training US cohort   
Replacement   
Age group in place of continuous age 0.59 0.59-0.60 
Metastatic lymph node number in place of N stage 0.60 0.59-0.61 
Lymph node ratio in place of N stage 0.61 0.61-0.62 
The 8th version of T stage in place of the original stage 0.61 0.60-0.61 
The 8th version of N stage in place of the original stage 0.60 0.59-0.61 
The 8th version of T & N stages in place of the original stages 0.61 0.60-0.62 
Addition   
Harvested lymph node added 0.60 0.60-0.61 
Tumor size added 0.61 0.60-0.61 
Harvested lymph node & tumor size added 0.61 0.60-0.62 
Subgroup   
Diagnosis after 2009 0.60 0.59-0.61 
White ethnicity 0.60 0.59-0.61 
Pancreas head 0.60 0.59-0.61 
Pancreas body & tail 0.61 0.59-0.63 
Concordance indexes in sensitivity analyses greater than that for the overall nomogram in the US are highlighted in bold. 
 
Sensitivity analyses 
Sensitivity analyses were performed for the derivative US cohort (Table 48). Using positive lymph 
node number or lymph node ratio instead of N stage in the nomogram did not obviously change the 
C-index (by 0.00 and +0.01, respectively). Replacing the sixth/seventh version of both T and N stages 
with the eighth version also had minimal impact on the C-index (by +0.01). After including examined 
lymph node number, tumor size, or both, the C-index only changed by 0.0, +0.01, and +0.01, 
respectively. Limiting the sample to patients diagnosed after 2009 or white people did not change the 
C-index. Within subgroups according to tumor location, C-index was slightly higher than the overall 
one in body/tail cancer (0.61). 
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3.1.5 Significance of examined lymph node number in accurate staging and long-term survival in 
resected stage I-II pancreatic cancer 
3.1.5.1 Patient characteristics  
A total of 15,791 eligible PaC patients in the US cohort (2004-2015) and 2,512 in the Netherlands 
cohort (2003-2014) undergoing cancer-directed resection were analyzed. Reasons for exclusion are 
detailed in Table 49. The proportion of females was 50% in SEER-18 and 47% in NCR. The mean age 
was 66 and 65 years in the SEER-18 and NCR cohorts, respectively (Table 50). Most resected tumors 
were located in pancreatic head (SEER-18, 73%; NCR, 82%), were not-otherwise-specified 
adenocarcinoma or ductal/lobular cancers (SEER-18, 88%; NCR, 90%), were of stage T3 (SEER-18, 
78%; NCR, 69%), and were declared node-positive (SEER-18, 63%; NCR, 67%). 
Pancreatoduodenectomy was the most common type of resection (SEER-18, 73%; NCR, 86%). The 
mean ELN number was 16 in the US cohort and 11 in the Netherlands cohort, and in both countries 
the mean ELN number increased over time during the investigated periods (SEER-18, 11 to 18; NCR, 
7 to 15; Figure 21). The mean PLN number was 2 in both cohorts. Median follow-up time was 58 
months in the US cohort and 48 months in the Netherlands cohort.  
 
Table 49. General information on the US and the Netherlands population-based pancreatic cancer cohorts 
Source Diagnosis period 
Censoring 
date 
Registered primary 
cases with eligible 
histology1 
Excluded cases2 Eligible 
cases with 
≥ 1 ELN 
DCO/ 
autopsy
Unknown 
survival 
Not 
resected
Stage 0/III/ 
IV/missing 
ELN 
missing 
0 
ELNs
SEER-183 Jan. 2004- Dec. 2015 
Dec. 31, 
2015 122826 3917 (3) 0 (0) 
99448 
(81) 2802 (2) 68 (<1) 
800 
(1) 15791 
NCR Jan. 2003- Dec. 2014 
Feb. 1, 
2015 22579 99 (<1) 0 (0) 
19534 
(87) 271 (1) 103 (<1) 
60 
(<1) 2512 
1A preliminary data-cleaning process had been performed to exclude cases with ineligible histology types. 
2Shown as n (percentage [%]). 
3Data of the year 2003 were not analyzed, as the TNM stage (version 6/7) information was unavailable. 
SEER, Surveillance, Epidemiology, and End Results Program; NCR, the Netherlands Cancer Registry; ELN, examine lymph node; DCO, 
death certificate only. 
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Table 50. Demographic and clinical characteristics of patients with resected stage I-II pancreatic cancer and with 
≥ 1 examined lymph node1 
Parameter  SEER-18, the US NCR, the Netherlands 
n  15791 2512 
Sex Female 7823 (50) 1192 (47) 
Age (years)  66 ± 11, 67 (59-74) 65 ± 10, 66 (59-73) 
Age group < 50 years 1185 (8) 159 (6) 
 50-59 years 2943 (19) 486 (19) 
 60-69 years 5231 (33) 917 (37) 
 70-79 years 4815 (30) 842 (34) 
 ≥ 80 years 1617 (10) 108 (4) 
Tumor location2 Pancreas head 11589 (73) 2070 (82) 
 Pancreas body 1110 (7) 82 (3) 
 Pancreas tail 1659 (11) 171 (7) 
 Overlapping lesion 672 (4) 64 (3) 
 Other 761 (5) 125 (5) 
Tumor histology3 Adenocarcinoma, NOS 7952 (50) 1504 (60) 
 Ductal/lobular 6043 (38) 742 (30) 
 Cystic/mucinous/serous 1151 (7) 212 (8) 
 Other 645 (4) 54 (2) 
T stage4 T1 1114 (7) 220 (9) 
 T2 2278 (14) 571 (23) 
 T3 12375 (78) 1721 (69) 
N stage N1 9910 (63) 1676 (67) 
Differentiation5 Well 1661 (12) 226 (11) 
 Intermediate 7309 (51) 1067 (52) 
 Poor/undifferentiated 5355 (37) 770 (37) 
Neoadjuvant chemotherapy7 Yes NA 49 (2) 
Neoadjuvant radiotherapy7 Yes 632 (4) 34 (1) 
Resection type Pancreatoduodenectomy 11462 (73) 2151 (86) 
 Distal pancreatectomy 2206 (14) 234 (9) 
 Total pancreatectomy 1906 (12) 39 (2) 
 Other6 217 (1) 88 (4) 
Examined lymph node count  16 ± 10, 14 (9-21) 11 ± 7, 10 (6-15) 
Positive lymph node count  2 ± 3, 1 (0-3) 2 ± 3, 1 (0-3) 
Lymph node ratio  0.16 ± 0.20, 0.08 (0.00-0.24) 0.21 ± 0.24, 0.14 (0.00-0.33)
Adjuvant chemotherapy7 Yes 10293 (65) 1040 (41) 
Adjuvant radiotherapy7 Yes 4751 (30) 29 (1) 
Follow up month8  58 (27-95) 48 (24-74) 
1Enumeration data are shown as count (percentage [%]), and measurement data as mean ± standard deviation, median (interquartile range). 
Records are complete otherwise specified below.  
2Pancreas duct and pancreas (NOS). 
3Based on SEER broad groupings. Other: squamous cell, transitional cell, acinar cell, mucoepidermoid, complex, unspecified, and epithelial 
(NOS) neoplasms. 
4Unkown T stage: the US, 24 (< 1%); the Netherlands, 0 (0%). 
5Unknown differentiation: the US, 1466 (9%); the Netherlands, 449 (18%). 
6Pancreatectomy (NOS) and local resection. 
7In the US, neoadjuvant and adjuvant chemotherapy could not be differentiated from each other; the other category for the non-surgical 
variables was “No/unknown”, considering the low sensitivity. 
8Shown as median (interquartile range), and computed using the reverse Kaplan-Meier method.  
SEER, Surveillance, Epidemiology, and End Results Program; NCR, the Netherlands Cancer Registry; NOS, not otherwise specified; NA, 
not available. 
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Figure 21. Distribution (A and B) and temporal trends (C and D) of examined lymph node (ELN) number in the 
United States (US) and the Netherlands databases. The yearly ELN number is shown as mean ± 95% confidence 
interval in blue. Patients with ≥1 ELN were included. 
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3.1.5.2 Examined lymph node number and stage migration 
In both countries, the PLN number increased with more ELNs (Figures 22A-B). Accordingly, the odds 
for nodal stage migration increased with more ELNs, also after multivariable adjustment, both overall 
(per 1 additional ELN: ORSEER-18=1.05, 95% CI=1.04-1.05; ORNCR=1.10, 95% CI=1.08-1.12) and in 
most subgroups by sex, age group, tumor location, histology, T stage, differentiation, resection type, 
and chemotherapy and radiotherapy administration (Table 51). Interaction tests suggested that the 
association with stage migration was weaker in T1 and cystic/mucinous tumors in SEER-18 and in 
patients undergoing distal pancreatectomy in both cohorts, and stronger in male patients in NCR. 
Sensitivity analyses by inclusion of further potentially ELN-/PLN-associated covariates (SEER-18: 
tumor size; NCR: hospital type, neoadjuvant treatment, and comorbidities), by replacing the 7th edition 
TNM staging with the 8th edition in SEER-18 following Kamarajah et al. (Kamarajah et al., 2017), by 
limiting the study period to 2010 or later, and by limiting patients to those with pancreatic 
adenocarcinoma only or to those survived ≥1 or 3 months did not change the association patterns (data 
not shown). 
 
Figure 22. Associations of examined lymph node (ELN) number with positive lymph node number (A and B), 
hazard ratio for overall survival (C and D), and odds ratio for stage migration (E and F) in the United States (US) 
and the Netherlands cohorts. The point estimates and corresponding 95% confidence intervals for the variables 
associated with ELN number are shown in blue. LOWESS smoother-fitted curves with a fitting bandwidth of 2/3 
are shown in red. The structural breaks determined by the Chow test for survival association in the US cohort are 
shown in green. Hazard ratio for survival was computed using multivariable Cox proportional hazards regression 
model adjusting for sex, age, tumor T stage, histology, and resection type. Odds ratio for stage migration was 
computed using multivariable logistic regression adjusting for T stage, histology, location, and resection type. 
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Table 51. Association of examined lymph node number (entered as a continuous variable) with nodal stage 
migration in resected pancreatic cancer patients with ≥ 1 examined lymph node1 
Stratification The US The Netherlands 
 OR 95% CI POR Pinteraction OR 95% CI POR Pinteraction
Overall 1.05 1.04-1.05 < 0.001  1.10 1.08-1.12 < 0.001  
Sex    0.829    0.028 
Female 1.05 1.04-1.05 < 0.001  1.07 1.05-1.10 < 0.001  
Male 1.05 1.04-1.05 < 0.001  1.12 1.09-1.15 < 0.001  
Age group    0.359    0.589 
< 50 years 1.04 1.02-1.05 < 0.001  1.10 1.02-1.18 0.010  
50-59 years 1.05 1.04-1.06 < 0.001  1.12 1.07-1.17 < 0.001  
60-69 years 1.04 1.03-1.05 < 0.001  1.11 1.08-1.15 < 0.001  
70-79 years 1.05 1.04-1.06 < 0.001  1.07 1.04-1.10 < 0.001  
≥ 80 years 1.05 1.04-1.07 < 0.001  1.24 1.02-1.51 0.031  
Tumor location    0.220    0.099 
Pancreas head 1.05 1.04-1.05 < 0.001  1.11 1.09-1.13 < 0.001   
Pancreas body 1.04 1.02-1.05 < 0.001  1.08 0.94-1.23 0.282   
Pancreas tail 1.06 1.04-1.07 < 0.001  1.09 1.02-1.16 0.014   
Overlapping lesion 1.04 1.02-1.06 < 0.001  1.05 0.94-1.18 0.420   
Other2 1.05 1.03-1.07 < 0.001  1.02 0.96-1.08 0.501   
Tumor histology3    0.013    0.084 
Adenocarcinoma, NOS 1.05 1.04-1.05 < 0.001  1.08 1.06-1.11 < 0.001   
Ductal/lobular 1.05 1.04-1.06 < 0.001  1.13 1.09-1.17 < 0.001   
Cystic/mucinous/serous 1.03 1.02-1.05 < 0.001  1.15 1.06-1.25 0.001   
Other 1.04 1.02-1.07 < 0.001  0.94 0.41-2.17 0.893   
T stage    0.006    0.655 
T1 1.03 1.01-1.05 < 0.001  1.05 0.98-1.12 0.164  
T2 1.05 1.04-1.06 < 0.001  1.10 1.06-1.15 < 0.001  
T3 1.05 1.04-1.05 < 0.001  1.10 1.08-1.13 < 0.001  
Differentiation    0.952    0.593 
Well 1.05 1.04-1.06 < 0.001  1.11 1.04-1.18 0.001   
Intermediate 1.05 1.04-1.05 < 0.001  1.10 1.07-1.13 < 0.001   
Poor/undifferentiated 1.05 1.04-1.05 < 0.001  1.09 1.06-1.12 < 0.001   
Resection type    0.049    0.014 
Pancreatoduodenectomy 1.05 1.04-1.06 < 0.001  1.10 1.08-1.12 < 0.001   
Distal pancreatectomy 1.04 1.02-1.05 < 0.001  1.05 1.00-1.11 0.042   
Total pancreatectomy 1.05 1.04-1.07 < 0.001  1.23 0.91-1.64 0.175   
Other4 1.04 1.00-1.08 0.039  1.44 1.14-1.81 0.003   
Chemotherapy, yes 1.05 1.04-1.05 < 0.001  1.09 1.06-1.13 < 0.001  
Radiotherapy, yes 1.05 1.04-1.06 < 0.001  1.57 1.01-2.44 0.045  
1Odds ratios for association of examined lymph node number with positive versus negative nodal status overall and in stratifications were 
calculated using multivariable logistic regression models adjusting for year of diagnosis, sex, age, tumor location, histology, T stage, 
differentiation, and resection type. In stratified analyses, the stratification factor was omitted from the model. Interactions between examined 
lymph node number and the stratification factors were also tested, where age group, tumor T stage, and differentiation were regarded as 
ordinal. Statistically significant P values are shown in bold. 
2Pancreas duct and pancreas (NOS). 
3Based on SEER broad groupings. Other: squamous cell, transitional cell, acinar cell, mucoepidermoid, complex, unspecified, and epithelial 
(NOS) neoplasms. 
4Pancreatectomy (NOS) and local resection. 
SEER, Surveillance, Epidemiology, and End Results Program; OR, odds ratio; CI, confidence interval; NOS, not otherwise specified. 
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LNR firstly decreased with more ELNs in both countries, and then the declining trend weakened 
in the US and disappeared in the Netherlands (Figures 23A-B). In both cohorts, more ELNs were 
associated with a lower probability of having ≥1 undetected PLN in patients who were considered to 
have node-negative disease (Figure 24). The association curves became less steep with more ELNs. 
 
 
Figure 23. Associations of examined lymph node number (ELN) with lymph node ratio (A and B) and the 
logarithms of hazard ratio for survival (C and D) and odds ratio for stage migration (E and F) in the United 
States (US) and the Netherlands cohorts. The point estimates and corresponding 95% confidence intervals for the 
variables associated with ELN number are shown in blue. LOWESS smoother-fitted curves with a fitting 
bandwidth of 2/3 are shown in red. The structural breaks determined by the Chow test for the association with 
the hazard ratio for survival in the US cohort (19 ELNs) are shown in green. 
 
 
Figure 24. Associations of examined lymph node (ELN) number with probability of undetected positive lymph 
nodes in the United States (US) and the Netherlands cohorts. The point estimates and corresponding 95% 
confidence intervals for the variables associated with ELN number are shown in blue. LOWESS smoother-fitted 
curves with a fitting bandwidth of 2/3 are shown in red. The structural breaks determined by the Chow test for 
the association with the hazard ratio for survival in the US cohort (19 ELNs) are shown in green. 
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3.1.5.3 Examined lymph node number and overall survival 
After controlling for other prognostic factors including sex, age, tumor location, histology, T stage, N 
stage, differentiation, and resection type, more ELNs were associated with better OS both overall 
(HRSEER-18=0.98, 95% CI=0.98-0.99; HRNCR=0.98, 95% CI=0.97-0.99) and in most subgroups (Table 
52). Notably, the significant association persisted in both declared node-negative (HRSEER-18=0.99, 95% 
CI=0.98-0.99; HRNCR=0.98, 95% CI=0.96-1.00) and node-positive diseases (HRSEER-18=0.98, 95% 
CI=0.98-0.99; HRNCR=0.98, 95% CI=0.97-0.99). Association strengths in subgroups according to the 
same stratification factors were very similar despite a few significant interaction test results. 
Sensitivity analyses by inclusion of further potentially prognostic covariates (SEER-18: ethnicity, 
marital status, and tumor size; NCR: hospital type, resection margin, non-surgical treatment as static or 
time-dependent, and comorbidities), by replacing the 7th edition TNM staging with the 8th edition in 
SEER-18 following Kamarajah et al. (Kamarajah et al., 2017), by limiting the study period to 2010 or 
later, by limiting patients to those with pancreatic adenocarcinoma only or to those survived ≥1 or 3 
months, and by use of disease-specific survival as the endpoint in SEER-18 did not change the 
association patterns (data not shown). 
3.1.5.4 Cut-point analysis and validation 
The fitting curves for associations of ELN number with PLN number, HR for survival, and OR for 
stage migration are shown in Figure 22, and the curves for associations with LNR and with the 
logarithms of the HR and OR in Figure 23. Based on the US cohort, the determined structural 
breakpoints for the various associations in the whole cohort and for the association with HR in various 
stratifications are listed in Table 53. Because survival is the most crucial endpoint and for 
representativeness and generalizability, the structural breakpoint for survival derived from the 
SEER-18 database (19 ELNs) was used as the optimal cut-point. While most of the identified 
breakpoints for survival were essentially in agreement with each other, notably the breakpoint was 
markedly smaller in observed node-negative (13) than node-positive disease (19), and in patients <60 
years (12) than those aged 60-69 (18) or ≥70 years (19).  
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Table 52. Association of examined lymph node number (entered as a continuous variable) with overall survival 
in resected pancreatic cancer patients with ≥ 1 examined lymph node1 
Stratification The US The Netherlands 
 HR 95% CI PHR Pinteraction HR 95% CI PHR Pinteraction
Overall 0.98 0.98-0.99 < 0.001  0.98 0.97-0.99 < 0.001  
Sex    0.023    0.028 
Female 0.99 0.98-0.99 < 0.001  0.97 0.96-0.98 < 0.001  
Male 0.98 0.98-0.99 < 0.001  0.98 0.97-1.00 0.009  
Age group    0.058    0.149 
< 50 years 0.98 0.98-0.99 0.001  0.97 0.93-1.01 0.106  
50-59 years 0.99 0.98-0.99 < 0.001  0.98 0.96-1.01 0.129  
60-69 years 0.99 0.98-0.99 < 0.001  0.98 0.97-1.00 0.017  
70-79 years 0.98 0.98-0.99 < 0.001  0.97 0.95-0.98 < 0.001  
≥ 80 years 0.98 0.97-0.99 < 0.001  0.92 0.86-0.98 0.009  
Tumor location    < 0.001    0.576 
Pancreas head 0.98 0.98-0.99 < 0.001  0.98 0.97-0.99 < 0.001  
Pancreas body 0.99 0.98-1.00 0.005  0.96 0.91-1.03 0.261  
Pancreas tail 0.99 0.98-1.00 0.006  0.94 0.89-0.98 0.004  
Overlapping lesion 0.99 0.98-1.00 0.144  0.94 0.88-1.00 0.048  
Other2 0.98 0.97-0.99 < 0.001  0.98 0.94-1.03 0.440  
Tumor histology3    0.037    0.182 
Adenocarcinoma, NOS 0.99 0.98-0.99 < 0.001  0.98 0.97-0.99 0.001  
Ductal/lobular 0.98 0.98-0.99 < 0.001  0.97 0.95-0.98 < 0.001  
Cystic/mucinous/serous 0.98 0.97-0.99 < 0.001  0.98 0.95-1.02 0.370  
Other 1.00 0.98-1.01 0.539  0.91 0.72-1.15 0.427  
T stage    0.062    0.568 
T1 0.99 0.97-1.00 0.010  0.96 0.92-1.01 0.113  
T2 0.99 0.98-0.99 < 0.001  0.97 0.95-0.99 0.001  
T3 0.98 0.98-0.99 < 0.001  0.98 0.97-0.99 < 0.001  
N stage    0.524    0.997 
N0 0.99 0.98-0.99 < 0.001  0.98 0.96-1.00 0.025  
N1 0.98 0.98-0.99 < 0.001  0.98 0.97-0.99 < 0.001  
Differentiation    0.289    0.863 
Well 0.99 0.98-1.00 0.029  0.99 0.96-1.02 0.442  
Intermediate 0.98 0.98-0.99 < 0.001  0.97 0.96-0.99 < 0.001  
Poor/undifferentiated 0.99 0.98-0.99 < 0.001  0.98 0.97-0.99 0.006  
Resection type    0.517    0.455 
Pancreatoduodenectomy 0.98 0.98-0.99 < 0.001  0.98 0.97-0.99 < 0.001  
Distal pancreatectomy 0.99 0.98-0.99 < 0.001  0.96 0.93-0.99 0.013  
Total pancreatectomy 0.99 0.98-0.99 < 0.001  0.99 0.88-1.11 0.815  
Other4 0.98 0.96-1.01 0.113  0.98 0.90-1.07 0.656  
Chemotherapy, yes 0.99 0.98-0.99 < 0.001  0.97 0.96-0.99 < 0.001  
Radiotherapy, yes 0.99 0.98-0.99 < 0.001  0.82 0.65-1.03 0.086  
1Hazard ratios for associations of examined lymph node number with survival were calculated by Cox proportional hazards regression with 
adjustment for year of diagnosis, sex, age, tumor location, histology, T stage, metastatic lymph node number, differentiation, and resection 
type. In stratified analyses, the stratification factor was omitted from the model. Interactions between examined lymph node number and the 
stratification factors were also tested, where age group, tumor T stage, N stage, and differentiation were regarded as ordinal. Statistically 
significant P values are shown in bold. 
2Pancreas duct and pancreas (NOS). 
3Based on SEER broad groupings. Other: squamous cell, transitional cell, acinar cell, mucoepidermoid, complex, unspecified, and epithelial 
(NOS) neoplasms. 
4Pancreatectomy (NOS) and local resection. 
SEER, Surveillance, Epidemiology, and End Results Program; HR, hazard ratio; CI, confidence interval; NOS, not otherwise specified. 
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Table 53. Structural breakpoints of examined lymph node number based on different parameters and based on 
hazard ratio for overall survival in different stratifications in the US cohort1 
Parameter/subgroup Comment/category Structural breakpoint F P
4 
Based on different parameters 
  Hazard ratio for survival  19 1036.6 < 0.001
Hazard ratio for survival The Netherlands 19 165.1 < 0.001
  ln(hazard ratio for survival)  19 1799.1 < 0.001
  Odds ratio for stage migration  12 331.4 < 0.001
Odds ratio for stage migration The Netherlands 14 127.9 < 0.001
  ln(odds ratio for stage migration)  10 722.5 < 0.001
  Positive lymph node number  14 298.1 < 0.001
  Lymph node ratio  15 764.5 < 0.001
Based on hazard ratio for survival in different subgroups 
Sex Female 19 986.9 < 0.001
 Male 17 558.1 < 0.001
Age group < 60 years 12 1184.4 < 0.001
 60-69 years 18 711.3 < 0.001
 ≥ 70 years 19 50.5 < 0.001
Tumor location Pancreas head 17 372.0 < 0.001
 Pancreas body/tail 16 331.6 < 0.001
 Overlapping lesion/other2 21 919.5 < 0.001
Tumor histology Adenocarcinoma, NOS/ductal/lobular 19 859.0 < 0.001
 Cystic/mucinous/serous 15 158.7 < 0.001
 Other3 19 652.3 < 0.001
T stage T1 16 7215.1 < 0.001
 T2 17 31.0 < 0.001
 T3 18 633.3 < 0.001
N stage N0 13 1212.5 < 0.001
 N1 19 1215.6 < 0.001
Differentiation Well 18 93.3 < 0.001
 Intermediate 21 1763.4 < 0.001
 Poor/undifferentiated 17 382.3 < 0.001
Resection type Pancreatoduodenectomy 17 538.9 < 0.001
 Distal pancreatectomy 20 2317.8 < 0.001
 Total pancreatectomy 21 1066.8 < 0.001
Chemotherapy Yes 17 590.9 < 0.001
Radiotherapy Yes 18 924.9 < 0.001
1Results are derived from the US cohort if not otherwise specified in the “Comment/category” column. Structure breakpoints were 
determined by Chow test for the LOWESS smoother-fitted associations of examined lymph node number with the indicated parameters 
overall and in stratifications. Odds ratios for association of examined lymph node number with positive versus negative nodal status overall 
and in stratifications were calculated using multivariable logistic regression models adjusting for year of diagnosis, sex, age, tumor location, 
histology, T stage, differentiation, and resection type. Hazard ratios for associations of examined lymph node number with survival were 
calculated by Cox proportional hazards regression with adjustment for year of diagnosis, sex, age, tumor location, histology, T stage, 
metastatic lymph node number, differentiation, and resection type. In stratified analyses, the stratification factor was omitted from the model. 
Statistically significant P values are shown in bold. 
2Pancreas duct and pancreas (NOS). 
3Based on SEER broad groupings. Other: squamous cell, transitional cell, acinar cell, mucoepidermoid, complex, unspecified, and epithelial 
(NOS) neoplasms. 
4The P values are for the Chow Test (F Test) at the given structural breakpoints. 
SEER, Surveillance, Epidemiology, and End Results Program; NOS, not otherwise specified. 
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The chosen optimal cut-point was validated internally in the US cohort where it was generated 
and externally in the independent Netherlands cohort: Cox regression analysis confirmed significantly 
decreased all-cause mortality hazard for patients with ≥19 ELNs after multivariable adjustment, 
overall (HRSEER-18=0.80, 95% CI=0.76-0.83; HRNCR=0.74, 95% CI=0.62-0.88) and in most 
stratifications by sex, age group, tumor location, histology, T stage, differentiation, resection type, and 
chemotherapy and radiotherapy administration (Table 54). Notably, while the association remained 
significant in both declared node-negative (HR=0.80, 95% CI=0.73-0.88) and node-positive PaCs 
(HR=0.80, 95% CI=0.75-0.84) in the US, it was only significant in node-positive cancer in the 
Netherlands (HR=0.71, 95% CI=0.59-0.85; Figure 25). Furthermore, the odds for nodal stage 
migration significantly increased with ≥19 ELNs in multivariable analyses, both overall 
(ORSEER-18=1.82, 95% CI=1.67-1.98; HRNCR=2.87, 95% CI=2.03-4.06) and in nearly all of the 
subgroups (Table 55). Changes of HR, OR, the corresponding logarithms, lymph node ratio, and 
false-negative LN probability with more ELNs all became markedly less steep with more than 19 
ELNs in both cohorts (Figures 22-24). 
Twelve ELNs were further selected as the minimal threshold based on the ORs for stage 
migration (Table 53), which was validated using an approach similar with that for the optimal 
threshold in both overall (survival: HRSEER-18=0.79, 95% CI=0.76-0.83; HRNCR=0.84, 95% 
CI=0.75-0.95; stage migration: ORSEER-18=1.99, 95% CI=1.84-2.15; ORNCR=2.70, 95% CI=2.17-3.35) 
and stratified analyses (data not shown). 
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Table 54. Association of ≥ versus < 19 examined lymph nodes with overall survival in resected pancreatic cancer 
patients with ≥ 1 examined lymph node1 
Stratification The US The Netherlands 
 HR 95% CI PHR Pinteraction HR 95% CI PHR Pinteraction
Overall 0.80 0.76-0.83 < 0.001  0.74 0.62-0.88 0.001  
Sex    0.140    0.276 
Female 0.80 0.74-0.85 < 0.001  0.68 0.53-0.87 0.003  
Male 0.79 0.74-0.85 < 0.001  0.78 0.61-0.99 0.040  
Age group    0.006    0.917 
< 50 years 0.80 0.67-0.96 0.019  0.41 0.19-0.89 0.023  
50-59 years 0.85 0.77-0.95 0.004  0.60 0.40-0.91 0.016  
60-69 years 0.83 0.76-0.89 < 0.001  0.88 0.66-1.17 0.364  
70-79 years 0.77 0.71-0.83 < 0.001  0.70 0.51-0.95 0.021  
≥ 80 years 0.70 0.60-0.81 < 0.001  0.24 0.05-1.22 0.086  
Tumor location    0.129    0.347 
Pancreas head 0.79 0.75-0.83 < 0.001  0.77 0.64-0.93 0.006  
Pancreas body/tail 0.83 0.73-0.94 0.004  0.64 0.32-1.27 0.200  
Overlapping lesion/other2 0.80 0.68-0.94 0.005  0.61 0.32-1.17 0.134  
Tumor histology3    0.019    0.786 
Adenocarcinoma, NOS 0.79 0.74-0.84 < 0.001  0.80 0.64-1.00 0.051  
Ductal/lobular 0.79 0.74-0.85 < 0.001  0.71 0.52-0.96 0.027  
Cystic/mucinous/serous 0.74 0.59-0.94 0.012  0.53 0.26-1.10 0.088  
T stage    0.082    0.688 
T1-2 0.82 0.73-0.93 0.001  0.68 0.48-0.96 0.028  
T3 0.79 0.75-0.83 < 0.001  0.77 0.63-0.94 0.010  
N stage    < 0.001    < 0.001 
N0 0.80 0.73-0.88 < 0.001  1.04 0.67-1.63 0.848  
N1 0.80 0.75-0.84 < 0.001  0.71 0.59-0.85 < 0.001  
Differentiation    0.193    0.908 
Well/intermediate 0.75 0.71-0.80 < 0.001  0.74 0.59-0.93 0.009  
Poor/undifferentiated 0.84 0.79-0.91 < 0.001  0.81 0.62-1.06 0.123  
Resection type    0.953    0.225 
Pancreatoduodenectomy 0.80 0.76-0.84 < 0.001  0.74 0.62-0.89 0.001  
Distal pancreatectomy 0.80 0.70-0.92 0.002  0.53 0.26-1.08 0.080  
Total pancreatectomy 0.78 0.69-0.89 < 0.001  - - -  
Chemotherapy, yes 0.83 0.78-0.87 < 0.001  0.74 0.58-0.96 0.021  
Radiotherapy, yes 0.84 0.78-0.91 < 0.001  0.43 0.04-5.03 0.501  
1Hazard ratios for associations of ≥ versus < 19 examined lymph nodes with survival were calculated by Cox proportional hazards regression 
with adjustment for year of diagnosis, sex, age, tumor location, histology, T stage, metastatic lymph node number, differentiation, and 
resection type. In stratified analyses, the stratification factor was omitted from the model. Interactions between examined lymph node 
number and the stratification factors were also tested, where age group were regarded as ordinal. Significant P values are shown in bold. 
2Pancreas duct and pancreas (NOS). 
3Based on SEER broad groupings. 
SEER, Surveillance, Epidemiology, and End Results Program; HR, hazard ratio; CI, confidence interval; NOS, not otherwise specified; -, not 
estimable due to small case number. 
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Table 55. Association of ≥ versus < 19 examined lymph nodes with nodal stage migration in resected pancreatic 
cancer patients with ≥ 1 examined lymph node1 
Stratification The US The Netherlands 
 OR 95% CI POR Pinteraction OR 95% CI POR Pinteraction
Overall 1.82 1.67-1.98 < 0.001  2.87 2.03-4.06 < 0.001  
Sex    0.549    0.036 
Female 1.88 1.68-2.12 < 0.001  1.98 1.26-3.11 0.003  
Male 1.75 1.55-1.97 < 0.001  4.44 2.54-7.76 < 0.001  
Age group    0.421    0.697 
< 50 years 1.52 1.09-2.10 0.013  2.32 0.71-7.55 0.162  
50-59 years 2.26 1.85-2.78 < 0.001  3.69 1.65-8.26 0.002  
60-69 years 1.68 1.46-1.93 < 0.001  5.00 2.51-9.97 < 0.001  
≥ 70 years 1.82 1.60-2.07 < 0.001  1.93 1.10-3.39 0.022  
Tumor location    0.976    0.526 
Pancreas head 1.80 1.63-1.99 < 0.001  3.00 2.01-4.47 < 0.001   
Pancreas body/tail 1.90 1.55-2.33 < 0.001  4.16 1.42-12.22 0.009  
Overlapping lesion/other2 1.84 1.39-2.42 < 0.001  1.22 0.44-3.39 0.703   
Tumor histology3    0.179    0.447 
Adenocarcinoma, NOS 1.82 1.61-2.04 < 0.001  2.56 1.64-4.01 < 0.001   
Ductal/lobular 1.92 1.68-2.19 < 0.001  4.18 2.21-7.89 < 0.001   
Cystic/mucinous/serous 1.77 1.23-2.53 0.002   3.49 0.80-15.29 0.098   
T stage    0.784    0.093 
T1-2 1.89 1.57-2.29 < 0.001  2.00 1.10-3.62 0.023  
T3 1.80 1.64-1.98 < 0.001  3.57 2.30-5.52 < 0.001  
Differentiation    0.869    0.932 
Well/intermediate 1.85 1.66-2.05 < 0.001  2.87 1.84-4.47 < 0.001   
Poor/undifferentiated 1.78 1.55-2.05 < 0.001  2.93 1.68-5.14 < 0.001   
Resection type    0.174    0.729 
Pancreatoduodenectomy 1.86 1.69-2.06 < 0.001  3.06 2.08-4.49 < 0.001   
Distal pancreatectomy 1.52 1.21-1.91 < 0.001  2.15 0.82-5.64 0.119   
Total pancreatectomy 1.93 1.51-2.47 < 0.001  - - -   
Chemotherapy, yes 1.81 1.63-2.01 < 0.001  3.29 2.00-5.42 < 0.001  
Radiotherapy, yes 2.05 1.76-2.38 < 0.001  - - -  
1Odds ratios for association of examined lymph node number (≥ versus < 19) with nodal status (positive versus negative) overall and in 
stratifications were calculated using multivariable logistic regression models adjusting for year of diagnosis, sex, age, tumor location, 
histology, T stage, differentiation, and resection type. In stratified analyses, the stratification factor was omitted from the model. Interactions 
between examined lymph node number and the stratification factors were also tested, where age group were regarded as ordinal. Statistically 
significant P values are shown in bold. 
2Pancreas duct and pancreas (NOS). 
3Based on SEER broad groupings. Other: squamous cell, transitional cell, acinar cell, mucoepidermoid, complex, unspecified, and epithelial 
(NOS) neoplasms. 
4Pancreatectomy (NOS) and local resection. 
SEER, Surveillance, Epidemiology, and End Results Program; OR, odds ratio; CI, confidence interval; NOS, not otherwise specified; -, not 
estimable due to small case number. 
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3.2 Gastric cancer 
3.2.1 Characteristics of overall and resected gastric cancer patients 
Overall, 133,321 GC patients registered in the population-based registries were initially included 
(Table 56). Patients with DCO/autopsy-based diagnosis (1%), without microscopically-confirmed or 
eligible pathology (11%), with non-invasive diseases (1%), and without information on distant 
metastasis status (8%) were excluded. Exclusion of patients with unknown metastasis status affected 
overall resection rates by only 0-2% in the US, the Netherlands, Sweden, and Norway, but markedly 
increased the resection rate in Belgium (51% to 61%), where the proportion of unknown metastasis 
was high (22%; Table 57). Finally 105,922 patients were analyzed, among whom 65,707 (62%) had 
non-metastatic disease. Characteristics of overall and resected cancer patients without and with distant 
metastasis are shown in Tables 58-59. 
 
Table 56. General information on participating population-based registries for Chapter 3.2.1 
Source Country Diagnosis period 
Registered 
cases 
Excluded cases1 Analyzed 
cases DCO/ autopsy
Not pathologically 
diagnosed/eligible2
Precancerous 
/in situ 
Unknown 
metastasis
SEER-183 the US Jan. 2004- Dec. 2014 79091 855 (1) 11003 (14) 780 (1) 5344 (7) 61109 
NCR Netherlands Jan. 2005- Dec. 2014 18346 48 (<1) 387 (2) 343 (2) 711 (4) 16857 
BCR Belgium Jan. 2004- Dec. 2013 14122 NA 1750 (12) 23 (<1) 3076 (22) 9273 
SCR Sweden Jan. 2006- Aug. 2016 7909 NA 169 (2) 0 (0) 471 (6) 7269 
CRN Norway Jan. 2003- Dec. 2014 6194 53 (1) 737 (12) 5 (<1) 362 (6) 5037 
CRS Slovenia Jan. 2003- Dec. 2013 5265 NA 472 (9) 9 (<1) 236 (4) 4548 
ECR Estonia Jan. 2009- Dec. 2014 2394 67 (3) 253 (11) 0 (0) 245 (10) 1829 
1Shown as n (percentage [%]). 
2Preliminary case selection according to cancer histology had been performed by the national cancer registries of Netherlands and Sweden. 
3Data of the year 2003 was not analyzed, as the TNM stage (version 6/7) information was unavailable. 
SEER, Surveillance, Epidemiology, and End Results Program; NCR, Netherlands Cancer Registry; BCR, Belgian Cancer Registry; SCR, 
Swedish Cancer Registry; CRN, Cancer Registry of Norway; CRS, Cancer Registry of Slovenia; ECR, Estonian Cancer Registry; DCO, 
death certificate only; NA, not available. 
 
Table 57. Overall resection rates of all gastric cancer patients and patients after exclusion of non-pathologically 
diagnosed/eligible cases, those with unknown metastasis status, and both 
Patients The US The Netherlands Belgium Sweden Norway Slovenia Estonia 
 Rate (%) Rate (%) Rate (%) Rate (%) Rate (%)  Rate (%) Rate (%)
All patients 46 45 51 36 43 51 50 
After exclusion of non-pathologically 
diagnosed/eligible cases 44 46 50 36 44 52 52 
After exclusion of those with 
unknown metastasis status 49 47 61 38 45 54 56 
After exclusion of both 47 47 61 38 45 55 57 
Patients finally included 46 46 61 38 45 55 57 
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Table 58. Demographic and clinical characteristics of total and resected non-metastatic gastric cancer patients1 
Variable Category the US The Netherlands Belgium Sweden 
Year of diagnosis  2004-2015 2005-2014 2004-2013 2006-2016 
Without metastasis  Total Resected Total Resected Total Resected Total Resected
n  37829 25070 (66) 9745 6605 (68) 6468 5096 (79) 4486 2501 (56)
Sex Male 24063 (64) 15989 (64) 6287 (65) 4367 (66) 4274 (66) 3420 (67) 2821 (63) 1587 (63)
Age at diagnosis Year; as continuous 69 ± 13 67 ± 13 71 ± 12 68 ± 12 70 ± 13 69 ± 12 72 ± 12 69 ± 11 
Age group < 60 years 8672 (23) 6603 (26) 1699 (17) 1423 (22) 1274 (20) 1110 (22) 714 (16) 506 (20)
 60-69 years 8865 (23) 6559 (26) 2280 (23) 1815 (27) 1390 (22) 1191 (23) 1043 (23) 720 (29)
 70-79 years 10528 (28) 7286 (29) 3144 (32) 2230 (34) 2122 (33) 1733 (34) 1394 (31) 831 (33)
 ≥ 80 years 9764 (26) 4622 (18) 2622 (27) 1137 (17) 1682 (26) 1062 (21) 1335 (30) 444 (18)
Tumor location2 Gastric cardia 12731 (48) 7387 (42) 2630 (37) 1622 (33) 2024 (55) 1520 (54) 1387 (39) 737 (35)
 Gastric fundus/body 4461 (17) 2992 (17) 1576 (22) 1132 (23) 483 (13) 368 (13) 1018 (28) 611 (29)
 Gastric antrum/pylorus 9578 (36) 7208 (41) 2957 (41) 2236 (45) 1152 (32) 939 (33) 1196 (33) 762 (36)
 Other 11059 (29) 7483 (30) 2582 (27) 1615 (24) 2809 (43) 2269 (45) 885 (20) 391 (16)
Histology Adenocarcinoma 28795 (76) 19231 (77) 7316 (75) 4869 (74) 5100 (79) 3979 (78) NA NA 
 Signet ring cell carcinoma 6780 (18) 4586 (18) 1850 (19) 1333 (20) 972 (15) 802 (16) NA NA 
 Other3 2254 (6) 1253 (5) 579 (6) 403 (6) 396 (6) 315 (6) NA NA 
Differentiation4 Well 1923 (6) 1487 (6) 261 (4) 211 (4) 60 (12) 479 (11) - - 
 Moderate 9737 (29) 6753 (29) 1738 (28) 1369 (29) 1729 (31) 1371 (31) - - 
 Poor/undifferentiated 21399 (65) 14968 (65) 4310 (68) 3163 (67) 3158 (57) 2590 (58) - - 
Local invasion5 Lamina propria/submucosa 11585 (34) 7070 (29) 1335 (17) 1219 (19) 1426 (23) 1114 (22) 545 (15) 432 (18)
 Muscularis propria/subserosa 14824 (43) 11791 (48) 4278 (53) 3509 (55) 2887 (47) 2451 (49) 1950 (53) 1199 (51)
 Serosa 5071 (15) 4373 (18) 1509 (19) 1283 (20) 1609 (26) 1326 (26) 804 (22) 570 (24)
 Adjacent structures 3032 (9) 1569 (6) 910 (11) 368 (6) 268 (4) 157 (3) 383 (10) 144 (6) 
Positive lymph node6 0 20041 (54) 11631 (47) 4030 (47) 2955 (46) 2787 (46) 2228 (45) 2274 (55) 1275 (51)
 1-6 12359 (33) 9040 (36) 3414 (40) 2418 (37) 2381 (39) 1908 (38) 1385 (34) 849 (34)
 ≥ 7 4507 (12) 4335 (17) 1138 (13) 1081 (17) 948 (16) 856 (17) 464 (11) 361 (15)
Harvested node no.  \ 15 ± 13 \ 16 ± 16 \ NA \ 18 ± 14 
Resection type7 Partial/subtotal gastrectomy \  16764 (67) \ 4564 (69) \  NA  \ 860 (62)
 Total/near-total gastrectomy \  5075 (20) \ 1656 (25) \  NA  \ 475 (34)
 Other \  3231 (13) \ 385 (6) \  NA  \ 50 (4) 
Resection margin8 Positive \  NA \ 886 (15) \  NA  \ 338 (15)
Neoadjuvant CHT9 Yes \  NA \ 2326 (35) \  1155 (23) \ 840 (34)
Neoadjuvant RT9 Yes \  2509 (10) \ 183 (3) \  204 (4) \ 188 (8) 
Total/adjuvant CHT9 Yes 16872 (45) 11694 (47) 3176 (33) 1251 (19) 2543 (39) 1646 (32) NA NA
Total/adjuvant RT9 Yes 12071 (32) 5766 (23) 810 (8) 215 (3) 1037 (16) 645 (13) NA NA 
1Categorical data are shown as count (percentage [%]), and numeric data as mean ± standard deviation. Records are complete otherwise 
specified below. 
2The percentages of gastric cardia, fundus/body, and antrum/pylorus cancers are the proportions compared to the total tumor cases of the 3 
locations; ‘other’ includes lesser curvature, greater curvature, and overlapping lesion of stomach and stomach (NOS), and its proportion is 
relative to the whole cases. 
3Cystic/mucinous/serous (excluding signet ring cell), squamous cell, ductal/lobular, complex, unspecified, and epithelial (NOS) neoplasms. 
4Unknown differentiation: total patients: the US, 4770 (13%); the Netherlands, 3436 (35%); Belgium, 941 (15%); Sweden, 3507 (78%); 
Norway, 804 (25%); Slovenia, 680 (24%); Estonia, 159 (15%); resected patients: the US, 1862 (7%); the Netherlands, 1862 (28%); 
Belgium, 656 (13%); Sweden, 1552 (62%); Norway, 399 (19%); Slovenia, 348 (16%); Estonia, 104 (13%). 
5Unknown tumor local invasion: total patients: the US, 3317 (9%); the Netherlands, 1713 (18%); Belgium, 278 (4%); Sweden, 804 (18%); 
Norway, 1544 (47%); Slovenia, 437 (15%); Estonia, 108 (11%); resected patients: the US, 267 (1%); the Netherlands, 226 (3%); Belgium, 
48 (1%); Sweden, 156 (6%); Norway, 780 (38%); Slovenia, 40 (2%); Estonia, 38 (5%). Invasion of serosa and adjacent structures could not 
be differentiated from each other in Norway or Slovenia. 
6Unknown positive lymph node: total patients: the US, 922 (2%); the Netherlands, 1163 (12%); Belgium, 352 (5%); Sweden, 363 (8%); 
Norway, 794 (24%); Slovenia, 319 (11%); Estonia, 90 (9%); resected patients: the US, 64 (<1%); the Netherlands, 151 (2%); Belgium, 104 
(2%); Sweden, 16 (1%); Norway, 564 (27%); Slovenia, 19 (1%); Estonia, 95 (12%). 
7Gastrectomy (NOS) or local resection. Available in Sweden since 2010. 
8Unkown resection margin for resected non-metastatic cancer: the Netherlands, 628 (10%); Sweden, 286 (11%); Slovenia, 26 (3%). In 
Slovenia margin status was not available before 2009. 
9Non-surgical therapies in the US and Estonia had low sensitivity, and the counterpart category of “Yes” was “No/unknown”. In Norway and 
Estonia, neoadjuvant and adjuvant therapies could not be distinguished from each other. Total CHT/RT is for total patients, and (neo)adjuvant 
CHT/RT for resected patients. 
CHT, chemotherapy; RT, radiotherapy; NOS, not otherwise specified; \, resection-specific variables not applicable for total patients; -, not 
shown due to > 60% missing values; NA, not available. 
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Table 58. Demographic and clinical characteristics of total and resected non-metastatic gastric cancer patients1 
(continued) 
Variable Category Norway Slovenia Estonia 
Year of diagnosis  2003-2014 2003-2013 2009-2014 
Without metastasis  Total Resected Total Resected Total Resected
n  3258 2057 (63) 2893 2172 (75) 1028 807 (79)
Sex Male 2036 (62) 1323 (64) 1821 (63) 1384 (64) 568 (55) 445 (55)
Age at diagnosis Year; as continuous 72 ± 12 70 ± 12 69 ± 12 67 ± 12 68 ± 12 67 ± 12 
Age group < 60 years 520 (16) 379 (18) 642 (22) 56 (26) 223 (22) 194 (24)
 60-69 years 725 (22) 530 (26) 662 (23) 553 (25) 273 (27) 222 (28)
 70-79 years 968 (30) 664 (32) 1000 (35) 770 (35) 332 (32) 261 (32)
 ≥ 80 years 1045 (32) 484 (24) 589 (20) 282 (13) 200 (19) 130 (16)
Tumor location2 Gastric cardia 857 (39) 480 (32) 461 (27) 314 (23) 96 (12) 70 (11) 
 Gastric fundus/body 486 (22) 322 (22) 459 (27) 414 (30) 423 (52) 342 (53)
 Gastric antrum/pylorus 865 (39) 678 (46) 779 (46) 654 (47) 291 (36) 237 (37)
 Other 1050 (32) 577 (28) 1194 (41) 790 (36) 218 (21) 158 (20)
Histology Adenocarcinoma 2785 (85) 1771 (86) 2693 (93) 2069 (95) 626 (61) 503 (62)
 Signet ring cell carcinoma 278 (9) 178 (9) 74 (3) 48 (2) 283 (28) 221 (27)
 Other3 195 (6) 108 (5) 126 (4) 55 (3) 119 (12) 83 (10) 
Differentiation4 Well 101 (4) 68 (4) 223 (10) 184 (10) 66 (8) 53 (8) 
 Moderate 694 (28) 491 (30) 594 (27) 501 (27) 249 (29) 203 (29)
 Poor/undifferentiated 1659 (68) 1099 (66) 1396 (63) 1139 (62) 554 (64) 447 (64)
Local invasion5 Lamina propria/submucosa 250 (15) 195 (15) 483 (20) 447 (21) 182 (20) 164 (21)
 Muscularis propria/subserosa 669 (39) 540 (42) 1061 (43) 978 (46) 515 (56) 424 (55)
 Serosa 582 (34) 417 (33) 722 (29) 614 (29) 184 (20) 157 (20)
 Adjacent structures 213 (12) 125 (10) 190 (8) 93 (4) 39 (4) 24 (3) 
Positive lymph node6 0 1793 (73) 991 (66) 1128 (44) 855 (40) 503 (54) 401 (52)
 1-6 545 (22) 408 (27) 808 (31) 720 (33) 332 (35) 282 (36)
 ≥ 7 126 (5) 94 (6) 638 (25) 578 (27) 103 (11) 95 (12) 
Harvested node no.  \ NA \ NA  \ NA 
Resection type7 Partial/subtotal gastrectomy \ NA \ NA  \  NA
 Total/near-total gastrectomy \ NA \ NA  \  NA
 Other \ NA \ NA  \  NA
Resection margin8 Positive \ NA \ 68 (7) \  NA
Neoadjuvant CHT9 Yes \ NA \ 124 (6) \  NA 
Neoadjuvant RT9 Yes \ NA \ 61 (3) \  NA 
Total/adjuvant CHT9 Yes 614 (19) 453 (22) 813 (28) 620 (29) 177 (17) 134 (17)
Total/adjuvant RT9 Yes 188 (6) 88 (4) 695 (24) 563 (26) 36 (4) 34 (4)
1Categorical data are shown as count (percentage [%]), and numeric data as mean ± standard deviation. Records are complete otherwise 
specified below. 
2The percentages of gastric cardia, fundus/body, and antrum/pylorus cancers are the proportions compared to the total tumor cases of the 3 
locations; ‘other’ includes lesser curvature, greater curvature, and overlapping lesion of stomach and stomach (NOS), and its proportion is 
relative to the whole cases. 
3Cystic/mucinous/serous (excluding signet ring cell), squamous cell, ductal/lobular, complex, unspecified, and epithelial (NOS) neoplasms. 
4Unknown differentiation: total patients: the US, 4770 (13%); the Netherlands, 3436 (35%); Belgium, 941 (15%); Sweden, 3507 (78%); 
Norway, 804 (25%); Slovenia, 680 (24%); Estonia, 159 (15%); resected patients: the US, 1862 (7%); the Netherlands, 1862 (28%); 
Belgium, 656 (13%); Sweden, 1552 (62%); Norway, 399 (19%); Slovenia, 348 (16%); Estonia, 104 (13%). 
5Unknown tumor local invasion: total patients: the US, 3317 (9%); the Netherlands, 1713 (18%); Belgium, 278 (4%); Sweden, 804 (18%); 
Norway, 1544 (47%); Slovenia, 437 (15%); Estonia, 108 (11%); resected patients: the US, 267 (1%); the Netherlands, 226 (3%); Belgium, 
48 (1%); Sweden, 156 (6%); Norway, 780 (38%); Slovenia, 40 (2%); Estonia, 38 (5%). Invasion of serosa and adjacent structures could not 
be differentiated from each other in Norway or Slovenia. 
6Unknown positive lymph node: total patients: the US, 922 (2%); the Netherlands, 1163 (12%); Belgium, 352 (5%); Sweden, 363 (8%); 
Norway, 794 (24%); Slovenia, 319 (11%); Estonia, 90 (9%); resected patients: the US, 64 (<1%); the Netherlands, 151 (2%); Belgium, 104 
(2%); Sweden, 16 (1%); Norway, 564 (27%); Slovenia, 19 (1%); Estonia, 95 (12%). 
7Gastrectomy (NOS) or local resection. Available in Sweden since 2010. 
8Unkown resection margin for resected non-metastatic cancer: the Netherlands, 628 (10%); Sweden, 286 (11%); Slovenia, 26 (3%). In 
Slovenia margin status was not available before 2009. 
9Non-surgical therapies in the US and Estonia had low sensitivity, and the counterpart category of “Yes” was “No/unknown”. In Norway and 
Estonia, neoadjuvant and adjuvant therapies could not be distinguished from each other. Total CHT/RT is for total patients, and (neo)adjuvant 
CHT/RT for resected patients. 
CHT, chemotherapy; RT, radiotherapy; NOS, not otherwise specified; \, resection-specific variables not applicable for total patients; -, not 
shown due to > 60% missing values; NA, not available. 
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Table 59. Demographic and clinical characteristics of total and resected metastatic gastric cancer patients1 
Variable Category the US The Netherlands Belgium Sweden 
Year of diagnosis  2004-2015 2005-2014 2004-2013 2006-2016 
Without metastasis  Total Resected Total Resected Total Resected Total Resected
n  23280 3232 (14) 7112 1201 (17) 2805 598 (21) 2783 254 (9) 
Sex Male 14864 (64) 1914 (59) 4637 (65) 750 (62) 1894 (68) 385 (64) 1711 (61) 144 (57)
Age at diagnosis Year; as continuous 65 ± 14 64 ± 14 68 ± 12 67 ± 12 69 ± 13 67 ± 13 70 ± 12 68 ± 11 
Age group < 60 years 8071 (35) 1211 (37) 1574 (22) 283 (24) 648 (23) 176 (29) 483 (17) 54 (21) 
 60-69 years 5763 (25) 795 (25) 1948 (27) 338 (28) 690 (25) 138 (23) 752 (27) 74 (29) 
 70-79 years 5585 (24) 764 (24) 2345 (33) 399 (33) 879 (31) 179 (30) 902 (32) 85 (33) 
 ≥ 80 years 3861 (17) 462 (14) 1245 (18) 181 (15) 588 (21) 105 (18) 646 (23) 41 (16) 
Tumor location2 Gastric cardia 7145 (50) 518 (27) 2143 (47) 266 (34) 889 (60) 175 (54) 856 (44) 52 (25) 
 Gastric fundus/body 3165 (22) 395 (21) 1116 (24) 194 (25) 289 (19) 52 (16) 629 (32) 57 (28) 
 Gastric antrum/pylorus 3950 (28) 981 (52) 1352 (29) 329 (42) 315 (21) 99 (30) 458 (24) 98 (47) 
 Other 9020 (39) 1338 (41) 2501 (35) 412 (34) 1312 (47) 272 (46) 840 (30) 47 (19) 
Histology Adenocarcinoma 16181 (70) 2160 (67) 5445 (77) 890 (74) 2226 (79) 443 (74) NA NA 
 Signet ring cell carcinoma 5129 (22) 860 (27) 1221 (17) 248 (21) 414 (15) 120 (20) NA NA 
 Other3 1970 (8) 212 (7) 446 (6) 63 (5) 165 (6) 35 (6) NA NA 
Differentiation4 Well 374 (2) 46 (2) 65 (2) 14 (2) 173 (7) 24 (5) - 5 (4) 
 Intermediate 4021 (22) 552 (19) 847 (22) 167 (21) 635 (27) 123 (23) - 21 (17) 
 Poor/undifferentiated 13715 (76) 2383 (80) 3010 (77) 603 (77) 1532 (66) 390 (73) - 95 (79) 
Local invasion5 Lamina propria/submucosa 3875 (28) 182 (6) 111 (3) 19 (2) 90 (5) 14 (2) 48 (2) 10 (4) 
 Muscularis propria/subserosa 3797 (28) 1073 (35) 1805 (53) 409 (49) 641 (36) 192 (33) 797 (38) 86 (35) 
 Serosa 1773 (13) 1023 (33) 586 (17) 265 (32) 742 (42) 284 (49) 418 (20) 102 (42)
 Adjacent structures 4256 (31) 788 (26) 878 (26) 147 (18) 291 (17) 95 (16) 819 (39) 46 (19) 
Positive lymph node6 0 7743 (44) 554 (18) 1002 (18) 160 (15) 268 (15) 62 (11) 504 (24) 49 (20) 
 1-6 8308 (47) 1288 (42) 4150 (76) 700 (67) 1067 (58) 252 (44) 1127 (54) 107 (43)
 ≥ 7 1630 (9) 1237 (40) 287 (5) 187 (18) 519 (28) 262 (46) 470 (22) 95 (38) 
Harvested node no.  \ 13 ± 13 \ 9 ± 17 \ NA \ 19 ± 17 
Resection type7 Partial/subtotal gastrectomy \  1914 (59) \ 847 (71) \  NA  \ 91 (62) 
 Total/near-total gastrectomy \  755 (23) \ 299 (25) \  NA  \ 47 (32) 
 Other \  563 (17) \ 55 (5) \  NA  \ 9 (6) 
Neoadjuvant CHT8 Yes \  NA \ 225 (19) \  172 (29) \ 62 (24) 
Neoadjuvant RT8 Yes \  148 (5) \ 17 (1) \  32 (5) \ 6 (2) 
Total/adjuvant CHT8 Yes 12501 (54) 1724 (53) 2732 (38) 338 (28) 1745 (62) 284 (48) NA NA
Total/adjuvant RT8 Yes 3714 (16) 380 (12) 519 (7) 62 (5) 279 (10) 54 (9) NA NA 
1Categorical data are shown as count (percentage [%]), and numeric data as mean ± standard deviation. Records are complete otherwise 
specified below. 
2The percentages of gastric cardia, fundus/body, and antrum/pylorus cancers are the proportions compared to the total tumor cases of the 3 
locations; ‘other’ includes lesser curvature, greater curvature, and overlapping lesion of stomach and stomach (NOS), and its proportion is 
relative to the whole cases. 
3Cystic/mucinous/serous (excluding signet ring cell), squamous cell, ductal/lobular, complex, unspecified, and epithelial (NOS) neoplasms. 
4Unknown differentiation: total patients: the US, 5170 (22%); the Netherlands, 3190 (45%); Belgium, 465 (17%); Sweden, 2614 (94%); 
Norway, 597 (34%); Slovenia, 712 (43%); Estonia, 209 (26%); resected patients: the US, 251 (8%); the Netherlands, 417 (35%); Belgium, 
61 (10%); Sweden, 133 (52%); Norway, 45 (20%); Slovenia, 48 (15%); Estonia, 19 (16%). 
5Unknown tumor local invasion: total patients: the US, 9579 (41%); the Netherlands, 3732 (53%); Belgium, 1041 (37%); Sweden, 701 
(25%); Norway, 1162 (65%); Slovenia, 825 (50%); Estonia, 243 (30%); resected patients: the US, 166 (5%); the Netherlands, 361 (30%); 
Belgium, 13 (2%); Sweden, 903 (4%); Norway, 107 (48%); Slovenia, 26 (8%); Estonia, 15 (13%). Invasion of serosa and adjacent structures 
could not be differentiated from each other in Norway or Slovenia. 
6Unknown positive lymph node: total patients: the US, 5599 (24%); the Netherlands, 1673 (24%); Belgium, 951 (34%); Sweden, 682 (25%); 
Norway, 1263 (71%); Slovenia, 1037 (63%); Estonia, 473 (59%); resected patients: the US, 153 (5%); the Netherlands, 154 (13%); 
Belgium, 22 (4%); Sweden, 3 (1%); Norway, 123 (55%); Slovenia, 36 (11%); Estonia, 28 (24%). 
7Gastrectomy (NOS) or local resection. Available in Sweden since 2010. 
8Non-surgical therapies in the US and Estonia had low sensitivity, and the counterpart category of “Yes” was “No/unknown”. In Norway and 
Estonia, neoadjuvant and adjuvant therapies could not be distinguished from each other. Total CHT/RT is for total patients, and (neo)adjuvant 
CHT/RT for resected patients. 
CHT, chemotherapy; RT, radiotherapy; NOS, not otherwise specified; \, resection-specific variables not applicable for total patients; -, not 
shown due to > 60% missing values; NA, not available. 
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Table 59. Demographic and clinical characteristics of total and resected metastatic gastric cancer patients1 
(continued) 
Variable Category Norway Slovenia Estonia 
Year of diagnosis  2003-2014 2003-2013 2009-2014 
Without metastasis  Total Resected Total Resected Total Resected
n  1779 222 (12) 1655 323 (20) 801 119 (15)
Sex Male 1083 (61) 121 (55) 1057 (64) 200 (62) 471 (59) 68 (57) 
Age at diagnosis Year; as continuous 69 ± 13 68 ± 14 67 ± 12 64 ± 12 68 ± 13 65 ± 14 
Age group < 60 years 398 (22) 58 (26) 424 (26) 110 (34) 199 (25) 37 (31) 
 60-69 years 415 (23) 47 (21) 424 (26) 91 (28) 213 (27) 33 (28) 
 70-79 years 517 (29) 65 (29) 561 (34) 100 (31) 260 (32) 35 (29) 
 ≥ 80 years 449 (25) 52 (23) 246 (15) 22 (7) 129 (16) 14 (12) 
Tumor location2 Gastric cardia 465 (46) 30 (22) 240 (37) 29 (19) 70 (14) 5 (6) 
 Gastric fundus/body 257 (25) 37 (27) 171 (26) 54 (36) 296 (61) 41 (53) 
 Gastric antrum/pylorus 289 (29) 70 (51) 236 (36) 66 (44) 123 (25) 31 (40) 
 Other 768 (43) 85 (38) 1008 (61) 174 (54) 312 (39) 42 (35) 
Histology Adenocarcinoma 1454 (82) 177 (80) 1393 (84) 289 (89) 425 (53) 69 (58) 
 Signet ring cell carcinoma 174 (10) 28 (13) 101 (6) 19 (6) 249 (31) 36 (30) 
 Other3 151 (8) 17 (8) 161 (10) 15 (5) 127 (16) 14 (12) 
Differentiation4 Well 30 (3) 2 (1) 48 (5) 11 (4) 27 (5) 4 (4) 
 Intermediate 248 (21) 43 (24) 214 (23) 55 (20) 154 (26) 26 (26) 
 Poor/undifferentiated 904 (76) 132 (75) 681 (72) 209 (76) 411 (69) 70 (70) 
Local invasion5 Lamina propria/submucosa - 4 (3) 20 (2) 5 (2) 3 (1) 1 (1) 
 Muscularis propria/subserosa - 39 (34) 163 (20) 69 (23) 260 (47) 44 (42) 
 Serosa - 72 (63) 377 (45) 169 (57) 228 (41) 48 (46)  Adjacent structures - 270 (33) 54 (18) 67 (12) 11 (11) 
Positive lymph node6 0 - 16 (16) - 19 (7) 18 (5) 5 (5) 
 1-6 - 50 (51) - 75 (26) 233 (71) 44 (48) 
 ≥ 7 - 33 (33) - 193 (67) 77 (23) 42 (46) 
Harvested node no.  \ NA \ NA  \ NA 
Resection type7 Partial/subtotal gastrectomy \ NA \ NA  \  NA
 Total/near-total gastrectomy \ NA \ NA  \  NA
 Other \ NA \ NA  \  NA
Neoadjuvant CHT8 Yes \ NA \ 27 (8) \  NA 
Neoadjuvant RT8 Yes \ NA \ 7 (2) \  NA 
Total/adjuvant CHT8 Yes 522 (29) 58 (26) 408 (25) 120 (37) 254 (32) 36 (30) 
Total/adjuvant RT8 Yes 140 (8) 10 (5) 114 (7) 34 (11) 19 (2) 5 (4) 
1Categorical data are shown as count (percentage [%]), and numeric data as mean ± standard deviation. Records are complete otherwise 
specified below. 
2The percentages of gastric cardia, fundus/body, and antrum/pylorus cancers are the proportions compared to the total tumor cases of the 3 
locations; ‘other’ includes lesser curvature, greater curvature, and overlapping lesion of stomach and stomach (NOS), and its proportion is 
relative to the whole cases. 
3Cystic/mucinous/serous (excluding signet ring cell), squamous cell, ductal/lobular, complex, unspecified, and epithelial (NOS) neoplasms. 
4Unknown differentiation: total patients: the US, 5170 (22%); the Netherlands, 3190 (45%); Belgium, 465 (17%); Sweden, 2614 (94%); 
Norway, 597 (34%); Slovenia, 712 (43%); Estonia, 209 (26%); resected patients: the US, 251 (8%); the Netherlands, 417 (35%); Belgium, 
61 (10%); Sweden, 133 (52%); Norway, 45 (20%); Slovenia, 48 (15%); Estonia, 19 (16%). 
5Unknown tumor local invasion: total patients: the US, 9579 (41%); the Netherlands, 3732 (53%); Belgium, 1041 (37%); Sweden, 701 
(25%); Norway, 1162 (65%); Slovenia, 825 (50%); Estonia, 243 (30%); resected patients: the US, 166 (5%); the Netherlands, 361 (30%); 
Belgium, 13 (2%); Sweden, 903 (4%); Norway, 107 (48%); Slovenia, 26 (8%); Estonia, 15 (13%). Invasion of serosa and adjacent structures 
could not be differentiated from each other in Norway or Slovenia. 
6Unknown positive lymph node: total patients: the US, 5599 (24%); the Netherlands, 1673 (24%); Belgium, 951 (34%); Sweden, 682 (25%); 
Norway, 1263 (71%); Slovenia, 1037 (63%); Estonia, 473 (59%); resected patients: the US, 153 (5%); the Netherlands, 154 (13%); 
Belgium, 22 (4%); Sweden, 3 (1%); Norway, 123 (55%); Slovenia, 36 (11%); Estonia, 28 (24%). 
7Gastrectomy (NOS) or local resection. Available in Sweden since 2010. 
8Non-surgical therapies in the US and Estonia had low sensitivity, and the counterpart category of “Yes” was “No/unknown”. In Norway and 
Estonia, neoadjuvant and adjuvant therapies could not be distinguished from each other. Total CHT/RT is for total patients, and (neo)adjuvant 
CHT/RT for resected patients. 
CHT, chemotherapy; RT, radiotherapy; NOS, not otherwise specified; \, resection-specific variables not applicable for total patients; -, not 
shown due to > 60% missing values; NA, not available. 
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3.2.1.1 Non-metastatic gastric cancer patients 
Among overall patients with non-metastatic disease, most were males (55%-66%), and the mean ages 
were 68-72 years, with patients ≥70 years comprising the majority (51%-62%). Gastric cardia was the 
most common cancer site across countries (37%-55%), except in Slovenia (27%) and Estonia (12%). 
Most tumors were adenocarcinomas followed by SRCs. Except Slovenia with a particularly low 
proportion of reported SRCs (3%) and Estonia with a particularly high proportion of SRCs (28%), the 
proportions of non-SRC adenocarcinomas were 75%-85% in the other countries. Most cancers were 
poorly-/undifferentiated (57%-68%). Approximately half of the cancers invaded muscularis 
propria/subserosa (39%-56%), and did not involve lymph nodes (44%-73%). Only 4%-12% of cancers 
invaded adjacent structures. Over the studied period, resection rates were 56% (Sweden) to 79% 
(Belgium and Slovenia). In the investigated countries except the US and Estonia where non-surgical 
therapies had low sensitivity, chemotherapy was administered to 19% (Norway) to 39% (Belgium) of 
the patients, and radiotherapy was less often applied (6% (Norway) to 24% (Slovenia)). 
Resected patients were younger (mean ages, 67-70 years), with smaller proportions of patients 
≥70 years (47%-56%). Cardia cancers comprised smaller proportions (11%-54%), and smaller 
proportions of cancers invaded adjacent structures (3%-10%) or spared lymph nodes (40%-66%). On 
average, 15-18 lymph nodes were harvested. Partial/subtotal gastrectomy was the most common 
resection type (62%-69%), and proportions of positive resection margin were 15% in the Netherlands 
and Sweden and 7% in Slovenia. In countries with available information of high sensitivity, 
neoadjuvant chemotherapy was administered for 6% (Slovenia) to 35% of the patients (the 
Netherlands), while neoadjuvant radiotherapy was rarely administered (3% (the Netherlands and 
Slovenia) to 8% (Sweden)); adjuvant chemotherapy was used for 19%-32% of patients, while adjuvant 
radiotherapy was less frequently administered (3%-26%). 
3.2.1.2 Metastatic gastric cancer patients 
Compared to those with non-metastatic disease, patients with metastatic cancers were younger (mean 
age, 65-70 years) with smaller proportions of patients ≥70 years (41%-55%). Metastatic cancers were 
more frequently located in the cardia (37%-60%; Estonia, 14%) and poorly-/undifferentiated 
(66%-77%). They more often invaded adjacent structures (12%-39%) and less often spared lymph 
nodes (5%-24%; the US, 44%). Notably, 9% (Sweden) to 21% (Belgium) of metastatic cancers were 
resected. In countries with available non-surgical treatment data of high sensitivity, chemotherapy was 
administered to 25% (Slovenia) to 62% (Belgium) of patients, and radiotherapy was less often applied 
(7%-10%). 
Resected metastatic cancer patients were less often males compared to overall patients with 
metastatic diseases (55%-64% vs. 59%-68%), and were 1-3 years younger on average. Resected 
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metastatic cancers were much less frequently located in the cardia (6%-54%), and less often invaded 
adjacent structures (11%-26%). On average, 9-19 lymph nodes were harvested. In countries with 
high-quality non-surgical therapy information, neoadjuvant chemotherapy was administered for 8% 
(Slovenia) to 29% of patients (Belgium), while neoadjuvant radiotherapy was rarely administered 
(1%-5%); adjuvant chemotherapy was used for 26% (Norway) to 48% of patients (Belgium), while 
adjuvant radiotherapy was much less frequently administered (5%-11%). 
3.2.2 Resection trends for gastric cancer 
For non-metastatic cancer, age-standardized resection rates decreased over time in all countries 
(Figure 26). The largest average decreases were observed in Norway (2003-2004 to 2013-2014: 78% 
to 54%; Ptrend<0.001) and Sweden (2005-2006 to 2013-2014: 69% to 54%; Ptrend<0.001). Moderate 
decreases were observed in the US (2003-2004 to 2013-2014: 72% to 60%; Ptrend<0.001) and Estonia 
(2009-2010 to 2013-2014: 80% to 74%; Ptrend=0.020). Netherlands (2005-2006 to 2013-2014: 72% to 
68%; Ptrend=0.005), Belgium (2003-2004 to 2013-2014: 80% to 75%; Ptrend<0.001), and Slovenia 
(2003-2004 to 2013-2014: 77% to 70%; Ptrend=0.002) showed the slightest decreases. When limiting 
the cancers to those without adjacent structure invasion and those invading beyond submucosa and/or 
with positive lymph nodes, the decreasing trends remained in all countries (data not shown).  
 
RESULTS 
108 
 
 
Figure 26. Age-standardized resection rates for non-metastatic and metastatic gastric cancers. In the US and 
Norway, the decreasing trends started from as early as the 1980s and the 1960s, respectively (data not shown). 
 
For metastatic cancers (Figure 26), significant decreasing trends were observed in all countries 
except the Netherlands (Ptrend=0.132), Slovenia (Ptrend=0.139), and Estonia (Ptrend=0.329). The 
strongest decrease was observed in Norway (2003-2004 to 2013-2014: 19% to 5%; Ptrend<0.001), and 
the slightest decrease in Sweden (2005-2006 to 2013-2014: 14% to 9%; Ptrend=0.004). In the US 
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(2003-2004 to 2013-2014: 19% to 10%; Ptrend<0.001) and Belgium (2003-2004 to 2013-2014: 24% to 
16%; Ptrend=0.001), moderate decreases were observed. 
Subgroup analyses according to age group and tumor location were further conducted for 
non-metastatic cancers (Figure 27). Resection rates were higher in younger patients, and the 
decreasing trends were weaker or disappeared in patients <70 years compared to those ≥70 years in the 
Netherlands (2005-2006 to 2013-2014: 83% to 83%, Ptrend=0.915 vs. 63% to 54%, Ptrend<0.001), 
Sweden (2005-2006 to 2013-2014: 80% to 66%, Ptrend=0.011 vs. 60% to 43%, Ptrend<0.001), and 
Slovenia (2003-2004 to 2013-2014: 84% to 84%, Ptrend=0.807 vs. 71% to 58%, Ptrend=0.002). The 
decreasing trends were stronger in patients <70 years in Norway (2003-2004 to 2013-2014: 90% to 
60%, Ptrend<0.001 vs. 68% to 48%, Ptrend=0.001) and Estonia (2009-2010 to 2013-2014: 89% to 80%, 
Ptrend=0.011 vs. 72% to 68%, Ptrend=0.149). The magnitudes of decrease were similar in both age 
groups in Belgium (2003-2004 to 2013-2014: 86% to 80%, Ptrend=0.010 vs. 75% to 70%, Ptrend<0.001). 
 
 
Figure 27. Age-standardized resection rates for non-metastatic gastric cancer by age and tumor location  
 
Resection rates for cardia cancers were lower than those for non-cardia tumors. The magnitude of 
decrease was weaker in cardia cancers than non-cardia ones in Sweden (2005-2006 to 2013-2014: 63% 
to 56%, Ptrend=0.008 vs. 75% to 56%, Ptrend<0.001). The trends were only significant in non-cardia 
cancers in Belgium (2003-2004 to 2013-2014: 82% to 78%; Ptrend=0.016), Slovenia (2003-2004 to 
2013-2014: 90% to 82%; Ptrend=0.006), and Estonia (2009-2010 to 2013-2014: 82% to 75%; 
Ptrend=0.035). Similar decreasing trends in cardia and non-cardia cancers were observed in the US 
(2003-2004 to 2013-2014: 64% to 54%, Ptrend<0.001 vs. 78% to 69%, Ptrend<0.001), the Netherlands 
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(2005-2006 to 2013-2014: 66% to 58%, Ptrend<0.001 vs. 78% to 73%, Ptrend=0.016), and Norway 
(2003-2004 to 2013-2014: 67% to 46%, Ptrend=0.001 vs. 85% to 65%, Ptrend<0.001). 
3.2.3 Recent resection rates for gastric cancer by age group and tumor location 
The patients were limited to those diagnosed in 2010 or later, a recent period when all countries had 
data, to calculate the resection rates according to age group and tumor location (Figure 28). For 
non-metastatic cancers, resection rates decreased with increasing ages in all countries. The rates were 
markedly lower in patients ≥80 years (27% (Sweden) to 66% (Estonia)) compared to the other age 
groups (<60 years: 65% (Norway) to 88% (Slovenia); 60-69 years: 63% (Norway) to 87% (Slovenia); 
70-79 years: 55% (Sweden) to 79% (Belgium)), with large variations across countries. In most 
countries, resection rates were lower for cardia cancers (49% (Sweden) to 74% (Belgium)) than for 
fundus/body (54% (Sweden) to 88% (Slovenia)) or pylorus/antrum cancers (58% (Sweden) to 81% 
(Slovenia)). 
 
 
Figure 28. Resection rates for non-metastatic and metastatic gastric cancers by age group and tumor location in 
2010 or later 
 
For metastatic cancers, while the resection rates were markedly lower, the stratified patterns were 
similar to those for non-metastatic tumors, but with more fluctuations. In most countries, resection 
rates were markedly lower in patients ≥80 years (4% (Norway) to 17% (Belgium)) than in others (<60 
years: 8% (Norway) to 25% (Slovenia); 60-69 years: 8% (Sweden and Norway) to 18% (Slovenia); 
70-79 years: 7% (Norway) to 20% (Slovenia)). Also, resection rates were mostly lower in cardia 
cancers (3% (Norway) to 17% (Belgium)) than in fundus/body (7% (Sweden) to 34% (Slovenia)) or 
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pylorus/antrum cancers (13% (Norway) to 30% (Belgium)).  
3.2.4 Factors associated with resection 
Variables associated with resection were further investigated in each country using 
multivariable-adjusted models (Table 60), which further supported the decreasing resection rates in 
both non-metastatic (odds ratio per year (OR)=0.86-0.96 across countries) and metastatic cancers 
(OR=0.88-0.98, except Slovenia and Estonia).  
 
Table 60. Association of demographic and clinical parameters with resection for gastric cancer without and with 
distant metastasis using multivariable logistic regression 
Variable Category the US The Netherlands Belgium Sweden 
  OR (95% CI)1 OR (95% CI)1 OR (95% CI)1  OR (95% CI)1
Without metastasis      
Year of diagnosis Per 1 year 0.94 (0.93-0.94) 0.96 (0.94-0.97) 0.94 (0.92-0.97) 0.91 (0.89-0.93)
Sex Female vs. male 0.96 (0.92-1.01) 0.85 (0.77-0.94) 0.87 (0.76-0.99) 0.94 (0.83-1.08)
Age group 60-69 years 0.93 (0.87-1.00) 0.75 (0.64-0.89) 0.88 (0.70-1.10) 0.92 (0.74-1.14)
    < 60 years as reference 70-79 years 0.68 (0.64-0.73) 0.44 (0.38-0.51) 0.62 (0.50-0.75) 0.60 (0.49-0.73)
 ≥ 80 years 0.24 (0.23-0.26) 0.13 (0.11-0.15) 0.23 (0.19-0.28) 0.18 (0.15-0.23)
Tumor location Gastric fundus/body 1.77 (1.64-1.91) 2.08 (1.79-2.41) 1.39 (1.09-1.78) 1.62 (1.36-1.94)
    Gastric cardia as reference Gastric antrum/pylorus 2.79 (2.62-2.98) 2.77 (2.43-3.14) 2.05 (1.69-2.48) 2.03 (1.70-2.41)
 Other2 1.78 (1.68-1.89) 1.29 (1.14-1.46) 1.73 (1.49-2.01) 0.87 (0.72-1.04)
Tumor histology SRC vs. non-SRC 0.80 (0.76-0.85) 0.99 (0.88-1.12) 1.03 (0.86-1.24) - 
Adjacent structure invasion Yes vs. no 0.28 (0.26-0.31) 0.09 (0.08-0.11) 0.22 (0.17-0.29) 0.24 (0.19-0.31)
With metastasis      
Year of diagnosis Per 1 year 0.91 (0.90-0.92) 0.98 (0.96-1.00) 0.93 (0.90-0.96) 0.95 (0.91-0.99)
Sex Female vs. male 1.07 (0.99-1.16) 1.06 (0.93-1.21) 1.15 (0.94-1.41) 1.16 (0.88-1.52)
Age group 60-69 years 0.97 (0.88-1.07) 0.97 (0.80-1.15) 0.68 (0.53-0.89) 0.84 (0.58-1.24)
    < 60 years as reference 70-79 years 0.89 (0.81-0.99) 0.90 (0.76-1.07) 0.70 (0.55-0.90) 0.73 (0.50-1.06)
 ≥ 80 years 0.73 (0.65-0.83) 0.74 (0.60-0.91) 0.59 (0.44-0.78) 0.44 (0.28-0.68)
Tumor location Gastric fundus/body 1.75 (1.52-2.02) 1.49 (1.21-1.82) 0.93 (0.65-1.32) 1.55 (1.04-2.31)
    Gastric cardia as reference Gastric antrum/pylorus 4.09 (3.64-4.60) 2.26 (1.88-2.71) 1.93 (1.43-2.62) 4.41 (3.05-6.37)
 Other2 2.12 (1.90-2.36) 1.38 (1.16-1.63) 1.01 (0.80-1.26) 0.93 (0.61-1.40)
Tumor histology SRC vs. non-SRC 1.11 (1.02-1.22) 1.18 (1.00-1.38) 1.51 (1.18-1.93) -
Adjacent structure invasion Yes vs. no 0.56 (0.51-0.61) 0.39 (0.31-0.48) 0.80 (0.60-1.07) 0.28 (0.20-0.39)
1Odds ratios and 95% confidence intervals for resection versus non-resection were calculated using multivariable logistic regression models 
adjusting for year of diagnosis, sex, age group, tumor location, and histology. For the association with adjacent structure invasion, this factor 
was additionally added into the main model. Previous cancer was available and also adjusted for in the US, the Netherlands, and Belgium. 
ORs shown in bold are statistically significant.  
2Lesser curvature, greater curvature, and overlapping lesion of stomach, and stomach (not otherwise specified). 
OR, odds ratio; CI, confidence interval; SRC, signet ring cell carcinoma; -, not available.
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Table 60. Association of demographic and clinical parameters with resection for gastric cancer without and with 
distant metastasis using multivariable logistic regression (continued) 
Variable Category Norway Slovenia Estonia 
  OR (95% CI)1 OR (95% CI)1  OR (95% CI)1
Without metastasis     
Year of diagnosis Per 1 year 0.89 (0.87-0.91) 0.95 (0.93-0.98) 0.86 (0.78-0.94) 
Sex Female vs. male 0.84 (0.71-0.99) 1.04 (0.85-1.26) 1.22 (0.89-1.68) 
Age group 60-69 years 0.99 (0.76-1.28) 0.67 (0.48-0.93) 0.65 (0.39-1.07) 
    < 60 years as reference 70-79 years 0.70 (0.55-0.89) 0.42 (0.32-0.56) 0.50 (0.31-0.81) 
 ≥ 80 years 0.25 (0.19-0.32) 0.11 (0.08-0.15) 0.25 (0.15-0.43) 
Tumor location Gastric fundus/body 1.90 (1.48-2.44) 5.14 (3.50-7.55) 1.70 (1.00-2.88) 
    Gastric cardia as reference Gastric antrum/pylorus 3.84 (3.05-4.84) 3.25 (2.41-4.38) 1.79 (1.03-3.12) 
 Other2 1.17 (0.96-1.42) 1.14 (0.89-1.46) 1.01 (0.58-1.76)
Tumor histology SRC vs. non-SRC 0.74 (0.56-0.97) 0.43 (0.25-0.72) 0.73 (0.51-1.04) 
Adjacent structure invasion Yes vs. no 0.45 (0.33-0.62) 0.09 (0.06-0.13) 0.25 (0.13-0.51) 
With metastasis     
Year of diagnosis Per 1 year 0.88 (0.84-0.92) 0.97 (0.93-1.01) 1.04 (0.93-1.17) 
Sex Female vs. male 1.21 (0.90-1.63) 1.19 (0.92-1.55) 1.16 (0.77-1.74) 
Age group 60-69 years 0.70 (0.46-1.07) 0.78 (0.57-1.08) 0.75 (0.44-1.28) 
    < 60 years as reference 70-79 years 0.70 (0.47-1.04) 0.58 (0.42-0.79) 0.65 (0.39-1.10) 
 ≥ 80 years 0.57 (0.37-0.87) 0.25 (0.15-0.42) 0.45 (0.23-0.89) 
Tumor location Gastric fundus/body 2.38 (1.41-4.00) 3.48 (2.09-5.81) 2.20 (0.83-5.83) 
    Gastric cardia as reference Gastric antrum/pylorus 4.65 (2.89-7.49) 3.16 (1.94-5.16) 4.75 (1.74-12.97)
 Other2 1.78 (1.14-2.77) 1.59 (1.04-2.43) 2.15 (0.81-5.70)
Tumor histology SRC vs. non-SRC 1.01 (0.64-1.59) 0.75 (0.44-1.28) 0.86 (0.55-1.34) 
Adjacent structure invasion Yes vs. no - 0.25 (0.17-0.37) 0.76 (0.38-1.55) 
1Odds ratios and 95% confidence intervals for resection versus non-resection were calculated using multivariable logistic regression models 
adjusting for year of diagnosis, sex, age group, tumor location, and histology. For the association with adjacent structure invasion, this factor 
was additionally added into the main model. Previous cancer was available and also adjusted for in the US, the Netherlands, and Belgium. 
ORs shown in bold are statistically significant.  
2Lesser curvature, greater curvature, and overlapping lesion of stomach, and stomach (not otherwise specified). 
OR, odds ratio; CI, confidence interval; SRC, signet ring cell carcinoma; -, not available. 
 
For non-metastatic cancers, while resection was less frequently conducted in females in the 
Netherlands (OR=0.85), Belgium (OR=0.87), and Norway (OR=0.84), it was less often done with 
older age and for cardia cancer in all countries. Specifically, compared to patients <60 years, ORs for 
resection in patients aged 70-79 and ≥80 years were 0.42-0.70 and 0.11-0.25, respectively. Compared 
to cardia cancers, ORs for resection of fundus/body and antrum/pylorus cancers were 1.39-5.14 and 
1.79-3.84, respectively. Resection was less often conducted for SRCs in the US (OR=0.80), Norway 
(OR=0.74), and Slovenia (OR=0.43). Adjacent structure invasion was associated with less frequent 
resection in all countries with available information (OR=0.09-0.45).  
In metastatic GC, no significant associations of resection with sex were observed, and resection 
was more often performed for SRCs in the US (OR=1.11), the Netherlands (OR=1.18), and Belgium 
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(OR=1.51). For the other variables, compared to non-metastatic cancers, while the association patterns 
were similar, the strengths differed. Older age (versus <60 years, OR70-79 years=0.58-0.90; OR≥80 
years=0.25-0.74) and adjacent structure invasion (OR=0.25-0.80) were less strongly associated, but 
pylorus/antrum cancers were more strongly associated with more frequent resection (versus cardia 
cancers, OR=1.93-5.77) in most countries. 
Associations of resection with further variables available in certain countries for non-metastatic 
cancers are shown in Table 61. Management in academic hospitals was associated with more frequent 
resection in the Netherlands (OR=2.59), Belgium (OR=1.49), and Sweden (OR=1.43). In the 
Netherlands and Sweden, a smaller hospital volume was associated with less frequent resection (OR<10 
vs. ≥20 resections/year=0.48 and 0.64, respectively). In the US, resection was more frequently performed for 
smaller tumors (e.g., OR<2 vs. ≥4 cm=1.80). With higher ECOG (e.g., ≥3 vs. 0-1, ORBelgium=0.15; 
ORSweden=0.06) and ASA scores (e.g., ≥4 vs. 1-2, ORSweden=0.13), resection was much less often 
performed. Cardiac disease (OREindhoven=0.73), vascular disease (OREindhoven=0.65), diabetes 
(OREindhoven=0.77), and pulmonary disease (OREindhoven=0.73, ORBelgium=0.73) were significantly 
associated with less frequent resection. More than 2 comorbidities were associated with 39% reduced 
resection odds in Eindhoven. The decreasing resection trends over time remained after incorporating 
these factors (data not shown). 
 
Table 61. Association of hospital type, volume, tumor size, performance status, and comorbidities with resection 
in non-metastatic gastric cancer in registries with available information using multivariable logistic regression 
Variable Category the US The Netherlands 
  n OR (95% CI)1 n OR (95% CI) 
Hospital type Non-academic - - 7857 1.00 (reference) 
 Academic - - 1875 2.59 (2.25-2.98) 
Hospital volume 
(resections/year) 
< 10  - - 1232 0.48 (0.39-0.60) 
10-20  - - 1374 0.51 (0.42-0.63) 
 ≥ 20 - - 1000 1.00 (reference) 
Tumor size (cm) < 2  1694 1.80 (1.63-1.99) - - 
 2-4  2747 1.26 (1.17-1.36) - - 
 ≥ 4  5056 1.00 (reference) - - 
Comorbidity Cardiac disease - - 615/1437 0.73 (0.59-0.91) 
 Vascular disease - - 349/1703 0.65 (0.50-0.84) 
 Hypertension - - 588/1464 0.99 (0.79-1.23) 
 Diabetes - - 336/1716 0.77 (0.59-1.00) 
 Pulmonary disease - - 255/1797 0.73 (0.55-0.98) 
Comorbidity no. 0 - - 609 1.00 (reference) 
 1 - - 548 0.87 (0.65-1.16) 
 ≥ 2 - - 895 0.61 (0.47-0.80) 
1Odds ratios and 95% confidence intervals for associations of hospital type, tumor size, ECOG score, and comorbidity with resection versus 
non-resection were calculated by adding these variables one by one into the main multivariable logistic regression models adjusting for year 
of diagnosis, sex, age group, tumor location, and histology. The reference categories for each comorbidity were those without the 
corresponding comorbidity. Previous cancer was available and also adjusted for in the US, the Netherlands, and Belgium. Statistically 
significant odds ratios are shown in bold. Numbers for comorbidities were shown for with/without the respective comorbidity. 
OR, odds ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; ASA, American Society of Anesthesiologists; -, not 
available. 
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Table 61. Association of hospital type, volume, tumor size, performance status, and comorbidities with resection 
in non-metastatic gastric cancer in registries with available information using multivariable logistic regression 
(continued) 
Variable Category Belgium Sweden 
  n HR (95% CI) n HR (95% CI) 
Hospital type Non-academic 3906 1.00 (reference) 2515 1.00 (reference) 
 Academic 2510 1.49 (1.30-1.70) 1971 1.43 (1.25-1.64) 
Hospital volume 
(resections/year) 
< 10  - - 872 0.64 (0.51-0.80) 
10-20  - - 931 0.88 (0.71-1.09) 
 ≥ 20 - - 1373 1.00 (reference) 
ECOG score 0-1 4285 1.00 (reference) 3194 1.00 (reference) 
 2 510 0.52 (0.42-0.64) 763 0.27 (0.22-0.32) 
 ≥ 3 159 0.15 (0.11-0.22) 287 0.06 (0.04-0.09) 
ASA score 1-2 - - 2949 1.00 (reference) 
 3 - - 1166 0.46 (0.39-0.53) 
 ≥ 4 - - 236 0.13 (0.09-0.19) 
Comorbidity Cardiac disease 3405/3063 0.90 (0.79-1.03) - - 
 Diabetes 980/5488 0.87 (0.73-1.02) - - 
 Pulmonary disease 370/6098 0.73 (0.57-0.93) - - 
1Odds ratios and 95% confidence intervals for associations of hospital type, tumor size, ECOG score, and comorbidity with resection versus 
non-resection were calculated by adding these variables one by one into the main multivariable logistic regression models adjusting for year 
of diagnosis, sex, age group, tumor location, and histology. The reference categories for each comorbidity were those without the 
corresponding comorbidity. Previous cancer was available and also adjusted for in the US, the Netherlands, and Belgium. Statistically 
significant odds ratios are shown in bold. Numbers for comorbidities were shown for with/without the respective comorbidity. 
OR, odds ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; ASA, American Society of Anesthesiologists; -, not 
available. 
 
Subgroup analyses were performed for non-metastatic cancers according to age (Table 62) and 
tumor location (Table 63). While association patterns were mostly similar between subgroups, in all 
countries except Slovenia and Estonia, associations of resection with tumor location were stronger in 
patients ≥70 years than those <70 years, and associations with age were stronger in cardia than 
non-cardia cancers. In the Netherlands and Slovenia, the association of year of diagnosis with 
resection became insignificant in patients <70 years after multivariable adjustment. In SRCs and in 
cancers invading adjacent structures, association patterns and strengths were mostly similar with those 
for total non-metastatic cancers (data not shown). 
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Table 62. Association of demographic and clinical characteristics with resection in non-metastatic gastric cancer 
patients aged < and ≥ 70 years using multivariable logistic regression 
Variable Category the US The Netherlands Belgium Sweden 
  OR (95% CI)1 OR (95% CI) OR (95% CI) OR (95% CI) 
< 70 years      
Resected/total no.  13162/17537 3238/3979 2301/2664 1226/1757
Year of diagnosis Per 1 year 0.95 (0.94-0.96) 0.99 (0.96-1.02) 0.92 (0.88-0.95) 0.92 (0.89-0.95)
Sex Female vs. male 1.09 (1.01-1.18) 0.89 (0.74-1.06) 1.07 (0.83-1.39) 1.07 (0.85-1.33)
Age group 60-69 vs. < 60 years 0.94 (0.88-1.01) 0.75 (0.64-0.89) 0.92 (0.74-1.16) 0.92 (0.75-1.14)
Tumor location Gastric fundus/body 1.41 (1.25-1.58) 1.75 (1.35-2.27) 1.16 (0.72-1.88) 1.22 (0.92-1.62)
    Gastric cardia as reference Gastric antrum/pylorus 2.25 (2.03-2.49) 2.19 (1.74-2.76) 1.46 (1.01-2.10) 1.41 (1.07-1.87)
 Other2 1.43 (1.31-1.56) 0.92 (0.75-1.13) 1.16 (0.90-1.51) 0.85 (0.63-1.14)
Tumor histology SRC vs. non-SRC 0.86 (0.79-0.94) 0.99 (0.81-1.21) 1.38 (1.00-1.90) - 
Adjacent structure invasion Yes vs. no 0.26 (0.23-0.29) 0.08 (0.06-0.10) 0.18 (0.11-0.28) 0.29 (0.21-0.42)
≥ 70 years      
Resected/total no.  11908/20292 3367/5766 2795/3804 1275/2729
Year of diagnosis Per 1 year 0.93 (0.92-0.94) 0.94 (0.92-0.96) 0.96 (0.93-0.98) 0.90 (0.87-0.93)
Sex Female vs. male 0.90 (0.85-0.96) 0.84 (0.74-0.94) 0.81 (0.69-0.95) 0.88 (0.74-1.04)
Age group ≥ 80 vs. 70-79 years 0.35 (0.33-0.37) 0.30 (0.26-0.33) 0.36 (0.31-0.42) 0.30 (0.25-0.35)
Tumor location Gastric fundus/body 2.10 (1.91-2.33) 2.37 (1.97-2.84) 1.54 (1.15-2.05) 1.98 (1.57-2.50)
    Gastric cardia as reference Gastric antrum/pylorus 3.30 (3.04-3.58) 3.21 (2.74-3.76) 2.40 (1.91-3.01) 2.54 (2.03-3.18)
 Other2 2.13 (1.97-2.30) 1.58 (1.36-1.85) 2.09 (1.74-2.51) 0.92 (0.72-1.17)
Tumor histology SRC vs. non-SRC 0.77 (0.71-0.84) 1.01 (0.87-1.18) 0.89 (0.70-1.12) -
Adjacent structure invasion Yes vs. no 0.31 (0.28-0.35) 0.10 (0.08-0.13) 0.25 (0.18-0.35) 0.21 (0.15-0.29)
1Odds ratios and 95% confidence intervals for resection versus non-resection were calculated using multivariable logistic regression models 
adjusting for year of diagnosis, sex, age group, tumor location, and histology. For association with adjacent structure invasion, this factor was 
additionally added into the main model. Previous cancer was available and also adjusted for in the US, the Netherlands, and Belgium. ORs 
shown in bold are statistically significant. 
2Lesser curvature, greater curvature, and overlapping lesion of stomach and stomach (not otherwise specified). 
OR, odds ratio; CI, confidence interval; SRC, signet ring cell carcinoma; -, not available. 
 
Table 62. Association of demographic and clinical characteristics with resection in non-metastatic gastric cancer 
patients aged < and ≥ 70 years using multivariable logistic regression (continued) 
Variable Category Norway Slovenia Estonia 
  OR (95% CI) OR (95% CI) OR (95% CI) 
< 70 years     
Resected/total no.  909/1245 1120/1304 416/496
Year of diagnosis Per 1 year 0.85 (0.81-0.88) 1.00 (0.95-1.05) 0.81 (0.70-0.94)
Sex Female vs. male 0.86 (0.65-1.15) 0.99 (0.69-1.41) 1.11 (0.66-1.85)
Age group 60-69 vs. < 60 years 0.99 (0.76-1.30) 0.69 (0.50-0.95) 0.68 (0.41-1.13)
Tumor location Gastric fundus/body 1.43 (0.95-2.14) 6.85 (3.38-13.88) 1.80 (0.81-3.99)
    Gastric cardia as reference Gastric antrum/pylorus 2.57 (1.72-3.86) 3.39 (2.07-5.55) 1.72 (0.73-4.04)
 Other2 0.73 (0.53-1.01) 1.38 (0.94-2.02) 0.92 (0.40-2.14)
Tumor histology SRC vs. non-SRC 0.85 (0.54-1.33) 0.32 (0.17-0.63) 1.02 (0.60-1.72)
Adjacent structure invasion Yes vs. no 0.39 (0.23-0.67) 0.08 (0.05-0.13) 0.26 (0.10-0.71)
≥ 70 years     
Resected/total no.  1148/2013 1052/1589 391/532
Year of diagnosis Per 1 year 0.90 (0.88-0.93) 0.93 (0.90-0.96) 0.90 (0.80-1.01)
Sex Female vs. male 0.82 (0.68-1.00) 1.06 (0.83-1.34) 1.30 (0.86-1.95)
Age group ≥ 80 vs. 70-79 years 0.34 (0.28-0.42) 0.27 (0.21-0.34) 0.48 (0.32-0.72)
Tumor location Gastric fundus/body 2.40 (1.74-3.31) 4.37 (2.73-7.01) 1.69 (0.83-3.43)
    Gastric cardia as reference Gastric antrum/pylorus 5.00 (3.74-6.67) 3.01 (2.05-4.40) 1.85 (0.89-3.86)
 Other2 1.57 (1.22-2.04) 0.99 (0.71-1.38) 1.07 (0.51-2.28)
Tumor histology SRC vs. non-SRC 0.70 (0.49-1.02) 0.64 (0.27-1.52) 0.53 (0.32-0.86)
Adjacent structure invasion Yes vs. no 0.48 (0.32-0.70) 0.10 (0.06-0.16) 0.22 (0.08-0.59)
1Odds ratios and 95% confidence intervals for resection versus non-resection were calculated using multivariable logistic regression models 
adjusting for year of diagnosis, sex, age group, tumor location, and histology. For association with adjacent structure invasion, this factor was 
additionally added into the main model. Previous cancer was available and also adjusted for in the US, the Netherlands, and Belgium. ORs 
shown in bold are statistically significant. 
2Lesser curvature, greater curvature, and overlapping lesion of stomach and stomach (not otherwise specified). 
OR, odds ratio; CI, confidence interval; SRC, signet ring cell carcinoma; -, not available. 
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Table 63. Association of demographic and clinical characteristics with resection in non-metastatic gastric cancer 
located in cardia and non-cardia using multivariable logistic regression 
Variable Category the US The Netherlands Belgium Sweden 
  OR (95% CI)1 OR (95% CI)1 OR (95% CI)1  OR (95% CI)1
Cardia      
Resected/total no.  7387/12731 1622/2630 1520/2024 737/1387
Year of diagnosis Per 1 year 0.95 (0.94-0.96) 0.94 (0.91-0.97) 0.97 (0.93-1.01) 0.93 (0.89-0.96)
Sex Female vs. male 0.93 (0.85-1.02) 0.96 (0.78-1.17) 0.90 (0.70-1.17) 0.87 (0.66-1.14)
Age group 60-69 years 0.82 (0.74-0.91) 0.65 (0.49-0.85) 0.89 (0.64-1.24) 0.90 (0.64-1.25)
    < 60 years as reference 70-79 years 0.55 (0.50-0.61) 0.33 (0.25-0.43) 0.52 (0.38-0.70) 0.54 (0.39-0.74)
 ≥ 80 years 0.17 (0.15-0.19) 0.07 (0.06-0.10) 0.18 (0.13-0.25) 0.10 (0.07-0.15)
Tumor histology SRC vs. non-SRC 0.75 (0.67-0.85) 0.80 (0.62-1.03) 0.99 (0.68-1.45) - 
Adjacent structure invasion Yes vs. no 0.29 (0.24-0.34) 0.09 (0.06-0.14) 0.44 (0.23-0.85) 0.26 (0.16-0.41)
Non-cardia      
Resected/total no.  10200/14039 3368/4533 1307/1635 1373/2215
Year of diagnosis Per 1 year 0.93 (0.92-0.94) 0.97 (0.94-0.99) 0.91 (0.87-0.96) 0.89 (0.86-0.92)
Sex Female vs. male 0.98 (0.91-1.06) 0.83 (0.72-0.96) 0.73 (0.56-0.94) 0.99 (0.82-1.19)
Age group 60-69 years 0.99 (0.87-1.13) 0.88 (0.66-1.18) 0.73 (0.43-1.24) 1.00 (0.72-1.38)
    < 60 years as reference 70-79 years 0.79 (0.70-0.89) 0.53 (0.41-0.68) 0.59 (0.37-0.94) 0.80 (0.59-1.07)
 ≥ 80 years 0.28 (0.25-0.31) 0.15 (0.11-0.19) 0.23 (0.15-0.37) 0.26 (0.19-0.35)
Tumor location Fundus/body vs. antrum/pylorus 0.64 (0.59-0.69) 0.74 (0.64-0.86) 0.68 (0.52-0.89) 0.81 (0.67-0.97)
Tumor histology SRC vs. non-SRC 0.76 (0.69-0.84) 1.04 (0.87-1.24) 1.18 (0.83-1.67) -
Adjacent structure invasion Yes vs. no 0.27 (0.23-0.30) 0.07 (0.06-0.09) 0.26 (0.15-0.45) 0.27 (0.19-0.37)
1Odds ratios and 95% confidence intervals for resection versus non-resection were calculated using multivariable logistic regression models 
adjusting for year of diagnosis, sex, age group, tumor location, and histology. For associations with tumor adjacent structure invasion, this 
factor was additionally added into the main model. Previous cancer was available and also adjusted for in the US, the Netherlands, and 
Belgium. Results were not shown for countries with <50 resected and/or <100 total cases (resected/total no.: cardia: Estonia, 70/96). ORs 
shown in bold are statistically significant. 
OR, odds ratio; CI, confidence interval; SRC, signet ring cell carcinoma; -, not available; \, not shown due to small case number. 
 
Table 63. Association of demographic and clinical characteristics with resection in non-metastatic gastric cancer 
located in cardia and non-cardia using multivariable logistic regression (continued) 
Variable Category Norway Slovenia Estonia 
  OR (95% CI)1 OR (95% CI)1  OR (95% CI)1
Cardia     
Resected/total no.  480/857 314/461 70/96
Year of diagnosis Per 1 year 0.91 (0.87-0.95) 0.94 (0.88-1.01) \
Sex Female vs. male 0.84 (0.60-1.18) 0.95 (0.58-1.56) \
Age group 60-69 years 0.98 (0.64-1.49) 1.24 (0.68-2.27) \
    < 60 years as reference 70-79 years 0.47 (0.31-0.71) 0.72 (0.42-1.25) \
 ≥ 80 years 0.17 (0.11-0.27) 0.18 (0.09-0.36) \
Tumor histology SRC vs. non-SRC 0.53 (0.30-0.95) 0.38 (0.11-1.29) \
Adjacent structure invasion Yes vs. no 0.37 (0.21-0.65) 0.06 (0.02-0.14) \
Non-cardia     
Resected/total no.  1000/1351 1068/1238 579/714
Year of diagnosis Per 1 year 0.89 (0.86-0.92) 0.92 (0.87-0.97) 0.83 (0.74-0.93)
Sex Female vs. male 0.80 (0.61-1.03) 1.00 (0.70-1.42) 1.40 (0.94-2.08)
Age group 60-69 years 0.85 (0.52-1.39) 0.47 (0.23-0.93) 0.36 (0.18-0.72)
    < 60 years as reference 70-79 years 0.82 (0.52-1.30) 0.35 (0.19-0.66) 0.32 (0.17-0.63)
 ≥ 80 years 0.25 (0.16-0.38) 0.09 (0.05-0.17) 0.16 (0.08-0.33)
Tumor location Fundus/body vs. antrum/pylorus 0.50 (0.38-0.65) 1.56 (1.07-2.29) 0.96 (0.65-1.42)
Tumor histology SRC vs. non-SRC 0.77 (0.49-1.22) 0.57 (0.18-1.77) 0.66 (0.42-1.02)
Adjacent structure invasion Yes vs. no 0.57 (0.32-1.01) 0.07 (0.04-0.13) 0.27 (0.11-0.68)
1Odds ratios and 95% confidence intervals for resection versus non-resection were calculated using multivariable logistic regression models 
adjusting for year of diagnosis, sex, age group, tumor location, and histology. For associations with tumor adjacent structure invasion, this 
factor was additionally added into the main model. Previous cancer was available and also adjusted for in the US, the Netherlands, and 
Belgium. Results were not shown for countries with <50 resected and/or <100 total cases (resected/total no.: cardia: Estonia, 70/96). ORs 
shown in bold are statistically significant. 
OR, odds ratio; CI, confidence interval; SRC, signet ring cell carcinoma; -, not available; \, not shown due to small case number. 
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3.2.5 Rates of non-surgical therapies in addition to resection 
The trends of non-surgical therapies in addition to resection were further investigated for all patients 
irrespective of distant metastasis status (Figure 29). Relevant information was available in all 
countries except Sweden, and had low sensitivity in the US and Estonia where results are not shown. 
Regarding rates of ≥1 therapy (resection, chemotherapy, and/or radiotherapy), they mostly showed 
increasing trends (the Netherlands (2005-2006 to 2013-2014: 61% to 64%; Ptrend=0.003); Belgium 
(2003-2004 to 2013-2014: 74% to 77%; Ptrend=0.024)) or remained stable (ORSlovenia=0.828). In 
Norway, still a slight decreasing trend was observed (2003-2004 to 2013-2014: 66% to 60%; 
Ptrend=0.007). 
 
 
Figure 29. Proportions of gastric cancer patients undergoing ≥1 treatment modality (resection, chemotherapy, 
and/or radiotherapy) in overall patients, of resected cancer patients in those receiving ≥1 treatment, and of 
patients receiving non-surgical therapies in overall and unresected patients. 
 
The proportion of resected patients in those receiving ≥1 treatment significantly decreased in all 
countries. The strongest decrease was observed in the Netherlands (2005-2006 to 2013-2014: 75% to 
64%; Ptrend=0.001), and the slightest decrease occurred in Belgium (2003-2004 to 2013-2014: 71% to 
67%; Ptrend=0.002). Norway (2003-2004 to 2013-2014: 79% to 67%; Ptrend=0.014) and Slovenia 
(2003-2004 to 2013-2014: 90% to 77%; Ptrend=0.003) showed moderate decreasing proportions. 
Rates of non-surgical therapies significantly increased in all countries. The largest increase was 
observed in the Netherlands (2005-2006 to 2013-2014: 23% to 47%; Ptrend=0.001), followed by 
Norway (2003-2004 to 2013-2014: 19% to 36%; Ptrend<0.001). Belgium (2003-2004 to 2013-2014: 40% 
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to 54%; Ptrend<0.001) and Slovenia (2003-2004 to 2013-2014: 22% to 36%; Ptrend<0.001) showed 
moderate increases. For unresected cancer patients, while the changes were insignificant in Norway 
(Ptrend=0.552) and Slovenia (Ptrend=0.051), increasing rates were observed in the Netherlands 
(2005-2006 to 2013-2014: 32% to 43%; Ptrend=0.001) and Belgium (2003-2004 to 2013-2014: 48% to 
54%; Ptrend=0.001). 
Results were similar after stratifying patients by metastasis status (data not shown). 
DISCUSSION 
119 
 
4 DISCUSSION 
4.1 Pancreatic cancer 
4.1.1 Resection of pancreatic cancer in Europe and the US 
(This part has been published (Huang et al., 2017).) 
This part of the large international study described the use of surgical resection for PaC in Europe and 
the US in the early 21st century. Overall low resection rates were observed, albeit with major variations 
across countries. Various factors were found to be associated with resection application. 
Variations in resection rates between countries and over time have been rarely investigated for 
PaC. This study showed that the overall resection rates were low in all participating countries. Even 
within patients with stage I-II PaCs, who however only comprised 19%-36% of all diagnosed cases, 
only 35%-69% were resected in 2012-2014. Increases in resection rates over time were only detected 
in the US, the Netherlands, and Denmark. Compared with overall PaCs, variations in resection rates 
across countries were stronger for stage I-II cancers. Notably, centralization and/or specialization 
which potentially explains in part the observed geographical and temporal variations was implemented 
in all three countries showing increasing resection rates. Centralization could contribute to increases in 
resection rates (de Wilde et al., 2012). Centralization started in the Netherlands regionally in 2005 
(Gooiker et al., 2014; Lemmens et al., 2011) and nationally in 2011 (van der Geest et al., 2016a), and 
in Denmark in 2000 (Cronin-Fenton et al., 2011). Nationally, the number of hospitals performing 
pancreatoduodenectomy for PaC decreased from 39 to 23 during 2004-2009 in the Netherlands, and 
the proportion of patients operated at medium-/high-volume centers with >10 resections per year 
increased from 53% to 91%, which is accompanied by an increase in the number of 
pancreatoduodenectomy from 258 (11%) to 394 (18%) (de Wilde et al., 2012; Onete et al., 2015). In 
2011, an annual volume standard of 20 pancreatoduodenectomies per hospital was set by the Dutch 
Health Inspectorate (van der Geest et al., 2016b). In Eindhoven, the Netherlands, the number of 
hospitals conducting resection decreased from 6 to 3 during 2005-2008, and the annual number of 
resections per hospital increased from 5 to 16 (Lemmens et al., 2011). In western Netherlands, 
pancreatic surgery was centralized into two high-volume hospitals since 2006 (Gooiker et al., 2011). 
In the US, nationwide centralization in pancreatic surgery has also been occurring with state-specific 
variations (O'Mahoney et al., 2016; Ryan et al., 2015). Between 1992-1994 and 2010-2012 in Florida, 
the number of pancreatic surgeons decreased from 363 to 196, while the number of resections 
increased from 729 to 1,569 (Ryan et al., 2015). In Denmark, only 4 university hospitals are allowed 
to do pancreatectomy, two with ≥75 yearly resections and the other two with ≥25. In Belgium, a 
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population-based study (Topal et al., 2007) proposed centralization in 2007. While the number of 
treating hospitals decreased from 77 to 68 with the average number of resections per hospital 
increasing from 6 to 7 in 2009-2014, only 4 hospitals kept doing >15 pancreatectomies per year. In 
Slovenia, pancreatectomy is centralized in 3 centers. Patients undergoing resection in higher-volume 
centers had better survival (Ahola et al., 2017; Ryan et al., 2015). Morbidity and hospital duration 
could also be reduced by centralization (O'Mahoney et al., 2016; Topal et al., 2007; Young et al., 
2013).  
Although in countries with centralization the resection rates increased, they remained low. It was 
observed that resection was less frequently conducted with more advanced cancer stage, with larger 
lesion size, with older age, in pancreatic body cancer, and with poorer performance status. Notably, 
patients with stage III-IV cancers (64%-81%) and those ≥70 years (53%-60%) comprised the majority 
of all the PaC cases across all investigated countries, which largely contributed to the low resection 
rates on the basis of the strong associations of resection application with patient age and cancer stage. 
Patients aged ≥70 years remained the majority among those with stage I-II PaCs (53%-61%). 
Advanced cancer stage is a negative prognostic factor and is often regarded as contraindicative to 
resection (Swanson et al., 2014). Tumor size was found to be negatively associated with the frequency 
of resection, possibly in part because larger tumors are more prone to vessel involvement and are thus 
often associated with more advanced cancer stages. Pancreatologists’ consensus states that localized 
PaCs without major vessel involvement (mostly TNM stage I-II) are mostly clearly resectable 
(Ducreux et al., 2015b; Tempero et al., 2014). For ‘unresectable’ tumors, resection is seldom 
recommended (Balaban et al., 2016; Sohal et al., 2016). Per guidelines (Ducreux et al., 2015b; 
Tempero et al., 2014), cancers which circumferentially encase celiac axis or superior mesenteric artery 
(T4/stage III) and metastatic tumors (M1/stage IV) are deemed to be unresectable, largely because of 
the high possibility of incomplete resection, which is associated with worse survival (Conroy et al., 
2011). Many resected ‘unresectable’ cancers are detected unsuspectedly during surgery (Kim et al., 
2016). With increasing experience in vascular surgery, vessel involvement which characterizes 
T4/stage III cancers is less frequently regarded as resection-contraindicative (Hartwig et al., 2013). 
The term ‘borderline resectable’ was brought about to define a specific subgroup within 
locally-advanced PaCs for which curative resection is potentially applicable. While borderline 
resectable PaCs might be associated with resection rates higher than the other stage III cancers, they 
could not be investigated here due to the newly-emerged, continuously-evolving, and non-uniform 
definition (Katz et al., 2013; Khorana et al., 2016).  
Resectability criteria are a key and hot issue in PaC treatment. While there might be differences in 
the management guidelines across countries, concerning resectability the participating countries all 
follow the NCCN guidelines (Tempero et al., 2014). While there remain differences, major progresses 
have been made in the definition which is becoming more and more uniform and standardized in 
recent years (Balaban et al., 2016; Bockhorn et al., 2014; Ducreux et al., 2015b; Tempero et al., 2017; 
DISCUSSION 
121 
 
Wolfgang et al., 2013). However, since the criteria are relatively complicated for routine registration 
practice especially at the population-based level and were mostly evolving during the study period, 
resectability status was mostly not readily registered in the participating countries. Subgroup analyses 
were performed according to TNM stage, which is commonly used and which could hopefully help to 
identify a subgroup of patients for which resection is more likely. Notably, the resectability criteria 
could not be substituted by the TNM staging system. Locally advanced, unresectable PaCs defined by 
the ISGPS and the NCCN are different from T4/stage III cancers according to the AJCC/UICC. Even 
some TNM stage II cancers can be locally-advanced and/or unresectable according to the ISGPS and 
the NCCN guidelines. A uniform and standardized resectability definition is hopefully to be 
implemented in the clinical and registry practice in the near future. 
Older age is also a negative prognostic factor (Swanson et al., 2014), and is associated with 
higher prevalence of comorbidities (Kimura et al., 2014) and complications (Sukharamwala et al., 
2012). Whether older age should be regarded as contraindicative to resection remains controversial. 
Some small studies suggested that resection was associated with higher survival in elderly patients (He 
et al., 2015; Marmor et al., 2016), which however could be at least in part explained by the selection 
of fitter patients for resection. Some studies showed that compared to younger people, fit elderly 
patients might gain similar survival benefits from resection, which could be safely performed for the 
group of patients (Barbas et al., 2012; van der Geest et al., 2016a). However, some other large 
monocentric studies have identified age as a risk factor for operative mortality in scores predicting 
post-pancreatoduodenectomy mortality (Kimura et al., 2014; Venkat et al., 2011). The operative 
mortality in octogenarians was 4% in a series of 2,000 pancreatoduodenectomies (Cameron and He, 
2015). Thus, the general pre-treatment condition of elderly patients should be carefully assessed to 
ensure that it allows pancreatectomy to be safely performed with an acceptable perioperative risk. As 
more than half of the PaC patients were 70 years or older at diagnosis, further studies are needed to 
investigate the benefit and harm of PaC resection for elderly patients, which should be well balanced 
(van der Geest et al., 2016a).  
Tumor location was another factor associated with PaC resection. Pancreatic body cancers were 
less often resected, which could be potentially explained by that pancreatic body lesions might be most 
challenging to manage, due to the common involvement of major vasculatures and accordingly the 
advanced stage at diagnosis (Hartwig et al., 2013; Wolfgang et al., 2013). It was also observed that 
higher ECOG scores, which are associated with higher perioperative morbidity and mortality risks, 
were negatively associated with the frequency of resection. Specific comorbidities were also inversely 
associated with resection frequencies. 
The aspects discussed above potentially explain in part surgeons’ option of resection for PaC and 
the low resection rates. Further reasons especially for the low resection rates for stage I-II cancers 
remain to be revealed. Notably, resectability might be largely impacted by surgeons’ abilities and 
experience, surgical techniques, equipment, skills, and procedure (Hartwig et al., 2013). Tumor 
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biology, symptom burden, patient preferences, operative tolerance, support systems, and quality of life 
(QoL) are important aspects to consider beyond standard resectability classification. Based on 
SEER-18, for 96.8% of unresected cancer patients, resection was not recommended by doctors. QoL 
decreases considerably in the early postoperative phase and its full recovery might take up to half a 
year (Heerkens et al., 2016). However, in the longer term resection overall does not worsen and even 
benefits QoL in most PaC survivors (Laitinen et al., 2017). Patient choice might be influenced by the 
health insurance coverage, his/her socioeconomic status, marriage status, and trust in doctor 
(Schildmann et al., 2013). Notably, some people might have limited access to medical care because of 
the distance from care facilities. Future studies especially on patient preferences and access to care are 
warranted. 
There are some limitations for this study. Due to the retrospective design, some important 
variables (e.g., performance status, comorbidities, and tumor size) were not available in some 
registries or the missing number was too high to be included in the main analyses. Furthermore, the 
heterogeneity in the available variables across registries might lead to information bias which 
potentially impacts robust inferences of the data. This highlights the need for improving the level of 
standardization and comprehensiveness in the registration practice. Another limitation was that the 
proportions of patients with unknown TNM stages were relatively high. Nevertheless, patterns 
remained the same after multiple imputations. Furthermore, treatment patterns in other European 
countries (e.g., the United Kingdom and France) were not investigated in this study, and no Asian or 
African registries were included. The treatment patterns in these countries or continents need to be 
clarified in future investigations. Notably, the US and the Netherlands registries contributed the largest 
numbers of cases among participating registries. However, results for each registry were presented 
separately, and no pooled-analysis was conducted, which reduces the concern of the potential impact 
of these large registries on the interpretation of the results.  
Differences in cancer stage across registries were detected, which potentially highlights the 
variation in the quality of PaC staging, since it is often difficult to correctly stage T4 cancers with 
arterial invasion compared with T1-3 cancers, and there could be relevant inter-observer variations. 
There could even be relevant differences at the national level (Minicozzi et al., 2017). In most of the 
investigated countries, many of those patients are discussed by multidisciplinary teams (MDTs), which 
is required by law. In Denmark and Estonia, almost all patients are evaluated by MDTs. In Belgium, 
the proportion of MDT-discussed patients increased from 57.8% in 2005 to 84.5% in 2012. In the 
Netherlands, about two-third of the patients were discussed by MDTs in 2012 (van Rijssen et al., 
2016).  
Strengths of this study include the use of high-quality data from multiple population-based cancer 
registries, the large sample size, the strict inclusion criteria, the careful case selection, and the 
uniformly defined and standardized variables across registries. 
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4.1.2 Non-surgical therapies for resected and unresected pancreatic cancer in Europe and the 
US 
(This part has been published (Huang et al., 2018b).) 
This part of the large international study with a focus on the administration of non-surgical therapies 
for resected and unresected PaCs highlighted the geographical and temporal variations and revealed 
the factors associated with the administration. The rates of the non-surgical treatment remained 
generally low and varied greatly across the European countries and the US. Most of the resected and 
unresected patients did not receive any non-surgical treatment. Major increases in the use rate were 
observed for chemotherapy, but not for radiotherapy. 
 The NCCN (Tempero et al., 2014), American Society of Clinical Oncology (ASCO) (Khorana et 
al., 2016), and ESMO guidelines (Ducreux et al., 2015b) recommend that patients with resectable 
PaCs undergo resection and receive adjuvant chemotherapy with or without radiotherapy, and that 
those with unresectable tumors receive palliative chemotherapy or chemoradiation. Although resection 
can markedly improve survival for patients with resectable PaC, locoregional disease relapses after 
surgery in about three-fourth of patients as a result of occult metastasis and residual cancer cells, 
which necessitates the use of adjuvant therapy (Ferrone et al., 2012). Although RCTs have 
demonstrated better survival in patients with resected localized cancers who have received 
postsurgical chemotherapy (Mukherjee et al., 2013; Neoptolemos et al., 2001; Neoptolemos et al., 
2004; Oettle et al., 2013; Oettle et al., 2007; Uesaka et al., 2016), the use of adjuvant therapy could be 
limited by poor tolerance. Neoadjuvant therapy might be offered as an alternative to upfront surgery 
and has been indicated to be well-tolerated and effective for PaC patients (Khorana et al., 2016), but 
prospective evidence which supports survival benefits is very limited (Crane et al., 2011; Kim et al., 
2013; Mokdad et al., 2016). Neoadjuvant therapy was rarely administered in Europe. Side effects 
associated with the use of chemotherapy and radiotherapy require special attention when planning 
these treatment modalities. 
 While guidelines are comparable across countries regarding chemotherapy use, great 
geographical variation in chemotherapy administration were found across Europe. A nationwide Dutch 
study focusing on resected PaCs during 2008-2013 further reported great inter-center variations 
(26%-74%) (Bakens et al., 2016). These variations are not very likely explainable by differences in 
patient or tumor characteristics, which were mostly similar across registries. Potential reasons for the 
variations include differences in patient and/or clinician preferences, socioeconomic factors, 
healthcare system, and health insurance coverage. All patients in the Netherlands and most of the 
patients in Estonia are covered by insurance. 
 Despite the disparities, chemotherapy use increased strongly over time, particularly for resected 
cancer patients. The strongest increase was observed in the Netherlands, where reimbursement for 
gemcitabine was possible since November 2008 (Bakens et al., 2016), with use rates increasing from 
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10% in 2003-2005 to 56% in 2012-2014 among resected cancer patients. The observed trends and 
disparities might also be associated with centralization and/or specialization of PaC care (Faluyi et al., 
2017), and management in academic hospitals was associated with more frequent adjuvant 
chemotherapy use. In the Netherlands, all hospitals are eligible to prescribe the chemotherapey drugs. 
In Estonia, chemotherapy is provided in three hospitals, and radiotherapy in two hospitals. These 
hospitals are distributed adequately in the country. The characterization of PaC as a chemoresistant 
cancer has been greatly challenged through the past years (Conroy et al., 2016). A decade ago, a 
meta-analysis on adjuvant chemotherapy for PaC revealed a benefit of only a 3-month prolongation of 
median survival (Boeck et al., 2007). However, a recent network meta-analysis showed that adjuvant 
chemotherapy reduced mortality by nearly one third after resection (Liao et al., 2013). Several 
landmark RCTs were key in establishing the standard and might explain the trends. The results of the 
ESPAC-1 trial (Neoptolemos et al., 2004) showed that 5-year overall survival (OS) nearly tripled 
among resected cancer patients receiving adjuvant 5-flourouracil-based chemotherapy compared to 
those who did not (21% vs. 8%). The absolute clinical benefits of adjuvant gemcitabine versus placebo 
to median OS (23 vs. 20 months) and 5-year survival rate (21% vs. 10%) were shown in the phase III 
CONKO-001 trial (Oettle et al., 2007). Westerners tend to be more sensitive to gemcitabine-based 
therapies (Khorana et al., 2016). Notably, chemotherapy-associated survival improvement does not 
compromise QoL or pain control (Kristensen et al., 2016). A RCT even showed better QoL with 
adjuvant treatment (Morak et al., 2010).  
 Radiotherapy was mostly used as an addition to chemotherapy. The role of radiotherapy remains 
uncertain for resectable PaC, and combination of chemotherapy with radiotherapy has shown 
controversial results for locally-advanced unresectable PaC (Chauffert et al., 2008; Loehrer et al., 
2011). The geographical disparity might be explained by the conflicting evidence from RCTs 
regarding the addition of radiotherapy on the two sides of the Atlantic, which makes 
chemoradiotherapy considered as the optimal approach in the US, but chemotherapy alone as the 
standard of care in Europe (Herreros-Villanueva et al., 2012). European trials on adjuvant radiotherapy 
for PaC mostly revealed non-superior or even harmful effects, which is in contrast to the beneficial 
effects according to the US reports (Chauffert et al., 2008; Klinkenbijl et al., 1999; Loehrer et al., 
2011; Neoptolemos et al., 2004). The small EORTC trial (Klinkenbijl et al., 1999) suggested potential 
survival benefits of concurrent chemoradiotherapy compared with observation for resected PaC. For 
locally-advanced PaCs which are mostly considered to be unresectable, the ECOG-4201 trial (Loehrer 
et al., 2011) showed that chemoradiotherapy was associated with higher OS compared to 
chemotherapy alone (11 vs. 9 months), albeit with more toxicity. However, the FFCD-SFRO study 
(Chauffert et al., 2008) showed reverse survival outcomes, and the ESPAC-1 trial (Neoptolemos et al., 
2004) likewise did not reveal any benefit. The ESMO does not recommend the routine use of adjuvant 
chemoradiotherapy (Ducreux et al., 2015b).  
Consistent with these discrepancies, it was observed that for resected PaC radiotherapy use rates 
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were markedly higher in the US than the European countries. When focusing on the period 2012-2013, 
great disparities across SEER-18 sub-registries were found, and a pattern consistent with an earlier 
SEER-based study that patients treated in the western US had a lower likelihood of undergoing 
non-surgical therapy was shown (Krzyzanowska et al., 2003). Interestingly, even in the US, adjuvant 
radiotherapy rates decreased, which might be accompanied with the more frequent use of intensified 
chemotherapy (Conroy et al., 2011; Kamisawa et al., 2016; Uesaka et al., 2016; Von Hoff et al., 2013). 
Within the subset of unresected cancer patients, both the US and the European countries were 
conservative in radiotherapy use. In unresected cancer patients who often have more advanced tumors, 
chemotherapy might be preferred over radiotherapy for systemic control, as radiotherapy as a local 
procedure more often causes serious complications especially fibrosis and does not address the 
systemic disease (Wo et al., 2014). Given the lack of consistent findings across clinical trials, further 
trials on radiotherapy might be warranted to establish the optimal treatment modality. 
Cancer stage, location, patient age, performance status, certain comorbidities, and hospital type 
were associated with chemotherapy use. Older ages were associated with lower rates in both resected 
and unresected cancer patients. While it has been shown that chemotherapy is safe for elderly patients 
with resectable or unresectable PaC, with survival benefits similar to those for younger patients 
(Berger et al., 2014; Nagrial et al., 2014; Sehgal et al., 2014), it is important to well balance benefits 
and harms for the elderly patients, a heterogeneous population who might have poorer performance 
status and more frequent and serious comorbidities and who might be more prone to toxicity. Older 
patients are often neglected in clinical trials, which makes the determination of the optimal therapy for 
this population difficult. The preferred treatment for patients with early-stage PaC is resection, after 
which patients’ physical and mental statuses might not allow for further aggressive therapy (Khorana 
et al., 2016). In patients with advanced unresectable cancers, palliative chemotherapy is considered to 
be the first and possibly only effective option (Balaban et al., 2016; Sohal et al., 2016). Interestingly, 
within resected cancer patients, no prominent associations between cancer stage and chemotherapy use 
were observed, which is probably due to the small case numbers; while in unresected cancer patients, 
chemotherapy was more often used for stage III and IV PaCs than for stage I-II tumors. Tumor 
location was not significantly associated with chemotherapy administration within resected cancer 
patients, while among unresected cancer patients, both pancreatic body and tail cancer patients 
received more frequently chemotherapy. This could be possibly explained in part by the attempt to 
downstage body/tail cancers which are more often advanced in stage with major vessel involvement 
due to the usual late detection, and to render them resectable (Balaban et al., 2016).  
Radiotherapy use was associated with patient age, performance status, cancer stage, hospital type, 
and resection type (in resected PaC). Among both resected and unresected cancer patients, 
radiotherapy was less frequently administered with increasing age, although chemoradiotherapy in 
both the adjuvant and palliative settings was found to be non-inferior to observation concerning 
survival among the very old patients (Horowitz et al., 2011; Mattiucci et al., 2015; Miyamoto et al., 
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2010). However, tolerance in the heterogeneous aged patient groups with more frequent comorbidities 
should be of note. Compared with stage I-II PaCs, radiotherapy was more often used for stage III 
cancers, but less frequently for metastatic cancers. The higher rate for stage III cancer might be based 
on the attempt to downstage cancers which could facilitate the subsequent resection and to achieve 
local control which would be complimentary to surgery (Balaban et al., 2016). Notably, radiotherapy 
use might be largely at clinicians’ disposal. According to the SEER-18, only 1.2% of unresected and 
0.8% of resected PaC patients did not receive radiotherapy because of patient and/or guardian refusal. 
This study has some limitations. Firstly, some potentially treatment-associated factors were not 
studied due to being unavailable in some registries. Particularly, data on comorbidities were only 
available in Eindhoven, the Netherlands. Patients’ socioeconomic and marital statuses, access to care, 
tolerance, recovery from resection, and treatment response are important factors that should be studied 
in future investigations. No reliable data on chemotherapy use are available in the SEER dataset 
(Noone et al., 2016). Since data on the time intervals between diagnosis/surgery and 
chemotherapy/radiotherapy use was not available in all registries, a cut-off for the time intervals was 
applied in the sensitivity analyses rather than in the main analyses. Furthermore, treatment patterns in 
other countries should be investigated in future studies.  
The main strengths of this study include the international population-based design, the large 
sample sizes, and the strict inclusion criteria and methodology, which enable this work to well reflect 
the status quo of the use of non-surgical therapies for PaC in Europe and the US, warranting caregivers’ 
and policymakers’ attention. 
4.1.3 Stratified survival of resected and overall pancreatic cancer patients in Europe and the US 
(This part has been published (Huang et al., 2018a).) 
This part of the large international population-based study comprehensively provided the overall 
survival estimates for overall and resected PaC patients by cancer TNM stage and patient age. 
Furthermore, the temporal trends of survival for the overall and resected cancer patients with 
clearly-resectable (stage I-II) and mostly-unresectable (stage III-IV) PaCs in four European countries 
and the US were shown separately. In both stage I-II and III-IV cancers, survival rates decreased 
prominently with increasing age. Limited but encouraging progresses in survival over time were 
detected. 
 According to the EUROCARE-5 study (De Angelis et al., 2014; Lepage et al., 2015b), overall, 
the 1-, 3-, and 5-year survival rates of European PaC patients diagnosed in 1999-2007 were only 26%, 
9%, and 7%, respectively. For the European countries participating in this study, the 1-year survival 
was 19%-34% and the 5-year survival was 4%-11%. In the US, the overall 5-year survival was 7% to 
10% (Brenner et al., 2007; Sirri et al., 2016). Stage- and treatment-specific survival was not provided 
by the previous studies (De Angelis et al., 2014; Lepage et al., 2015b). This study provided more 
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up-to-date estimates by including patients diagnosed in 2003-2014 and further showed survival by 
cancer TNM stage and patient age. Survival decreased with advancing stage and older age. It is 
important to provide stratified survival for clinical counseling. 
It is stated by guidelines (Balaban et al., 2016; Ducreux et al., 2015b; Khorana et al., 2016; Sohal 
et al., 2016; Tempero et al., 2014) that localized (stage I-II) PaCs are mostly resectable, while T4/stage 
III and M1/stage IV cancers are largely unresectable. The results showed that resected patients with 
stages I-II PaCs had higher survival estimates through all age groups compared with the usually 
reported and widely available overall survival. For instance, resected cancer patients aged <60 years 
had 3%-19%, 1%-13%, and 1%-9% units higher 1-, 3-, and 5-year survival than the overall patients 
across countries, respectively. These differences may reflect the effects of both resection and selection 
of fitter patients for surgery. Given that most patients would perceive the overall PaC prognosis as 
dismal and thus feel extremely distressed, which also generates great burdens to their family and 
caregivers, it would be important to show the objective survival estimates especially for the resected 
cancer patients to them, which potentially helps to rebuild the hope of life. 
Survival of patients with stage III-IV PaCs, who took up the majority of the diagnosed cases, was 
much lower than that of those with stage I-II cancers, especially in the longer term. For 
locally-advanced PaC, the average overall survival remains <12 months (Loehrer et al., 2011), and for 
metastatic cancers, the median survival is <6 months (Hammel et al., 2016), with 5-year survival of 
only about 2% (Wolfgang et al., 2013). It was shown that even for those aged <60 years, the overall 3- 
and 5-year survival was as low as 2%-5% and 1%-4%, respectively. Most patients with stage III-IV 
PaCs are considered to be unresectable (Balaban et al., 2016; Sohal et al., 2016). This may, however, 
improve in the years to come with the increasing administration of the FOLFIRINOX regimen (Suker 
et al., 2016). In many of the cases in which patients with metastatic PaCs underwent resection, the 
metastasis was unexpectedly found only during resection (Kim et al., 2016). Although resection rates 
for advanced cancers were low, notably, in patients with stage III-IV PaCs substantially higher 
survival was observed for resected cancer patients compared to overall patients in all age groups, and 
resected cancer patients aged <70 years could have 3-year survival of 5%-34%. Even in those aged 
≥70 years, higher survival estimates for the resected cancer patient subgroup were observed (1-year, 
16%-42% vs. 5%-14%; 3-year, 2%-14% vs. 1%-1%). While this difference might again at least in part 
reflect patient selection, i.e., inclusion of fitter and healthier patients or those with more favorable 
cancer characteristics for surgery, the results indicated that not all stage III-IV PaC patients had such 
dismal prognosis as indicated by the overall survival estimates. These strong differences again 
underline the importance of showing respective outcomes for stratified resected cancer patients for 
enhanced counseling of these patients. 
The perioperative survival should be of note, especially for elderly patients. It is 
volume-dependent, and is mainly impacted by surgical expertise and failure to rescue (Krautz et al., 
2018). While resection could be performed safely for some proportion of the usually more vulnerable 
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elderly patients (Barbas et al., 2012; van der Geest et al., 2016a), at the population level, it was found 
that in patients with stage III-IV PaCs, which is associated with inferior general status, the 1-month 
survival dropped from 94%-99% in patients aged <70 years to 81%-96% in those aged ≥70 years, 
which was more dramatic compared with stage I-II cancers. Age was inversely associated with 
survival, which necessitates it to be a stratification factor when showing survival outcomes. Increasing 
ages are associated with more frequent comorbidities and complications, which decreases the potential 
survival benefits of resection. However, some studies indicated that compared with younger 
individuals, fit elderly patients might obtain comparable survival benefits from resection (Barbas et al., 
2012; van der Geest et al., 2016a). The higher survival observed for the younger patients might be 
partly explained by the more aggressive treatment strategies used, which might contribute to 
improvements in survival of the fit elderly patients too (Lepage et al., 2015b). These highlight the 
importance of geriatric assessment before treatment. 
No substantial survival alterations (5-year, 5%-6%) were shown for PaC in the EUROCARE-5 
study (Lepage et al., 2015b) during the period 1999-2007. In the US, the 5-year survival increased 
from 6% in 1992-1996 to 8% in 2002-2006 (Pulte et al., 2012) and from 8% in 2002-2004 to 12% in 
2008-2010 (Sirri et al., 2016); especially for localized cancers, strong improvement in 5-year survival 
by 7% units from 1998 through 2003 was detected (Brenner et al., 2007). Modest but nevertheless 
encouraging improvements in survival of patients both with stage I-II and with III-IV cancers from 
2003-2005 to 2009-2011 were observed, which potentially reflects the advancement in surgical skill, 
technique, and perioperative care. In the US, the 3-year survival increased by 4% units in patients with 
stage I-II PaCs overall, but by only <1% units in those with stage III-IV tumors. For resected PaCs, 
survival increased by 5% units among patients with stage I-II cancers. In Europe, the 3-year survival 
for both overall and resected patients with stage I-II PaCs increased in all participating countries, and a 
large increase was detected in the Netherlands (overall, 8% units; resected, 11% units), in which 
postoperative mortality is decreasing (de Wilde et al., 2012). Notably, the centralization agreement 
was implemented in the Netherlands since 2005, and it promoted more resections (Lemmens et al., 
2011), which might be associated with the continuous improvement in survival (van der Geest et al., 
2016b). While further major survival improvement in resected cancer patients could be limited even 
with modification of surgical technique, better outcomes are likely to come from more effective 
systemic therapies (e.g., FOLFIRINOX) combined with resection. The discrepant trends between 
overall and resected cancer patients further highlight the need to provide survival data in specific 
patient subgroups. 
This study covered the periods when the sixth and seventh TNM staging systems were in effect, 
and both are compatible/identical with each other (Ducreux et al., 2015b). While potentially improved 
imaging technique might result in a shift in stage categorization, the proportions of each stage 
remained relatively stable in the participating countries (data not shown). In the era of the eighth TNM 
staging, in which the definitions of the T4 and M1 categories suggesting mostly unresectable tumors 
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remain unchanged (Shi et al., 2018), the results would still be applicable for survival counselling. 
This study was limited by the relatively small case numbers in some subgroups. Further 
potentially prognostically-important factors (e.g., comorbidities) were not considered due to being 
unavailable or unknown in the national registries of most participating countries. Although older 
patient ages and more advanced cancer stages herein studied were the most outstanding negative 
prognostic factors and might contraindicate surgery, precise and personalized factors should be 
considered for the evaluation of individual patient prognosis. Some survival-predicting tools (e.g., 
nomogram) might offer more precise prognostic data for a given patient. Non-surgical therapies were 
not incorporated considering the low sensitivity in recording in some participating registries and the 
varying regimens administered. Data from more countries would increase the comprehensiveness of 
the study. However, data on TNM staging or treatment were mostly not readily available in the other 
national population-based registries. This study was based on complete-case analysis. Some 
differences in data recording especially of TNM stage should be of note, and the proportion of stage 
I-II cancers varied from 25% (Norway and Slovenia) to 38% (Belgium). There could be 
underreporting especially of advanced-stage cancers with various extents, besides the potential impact 
of unknown staging data. These differences highlight the need for standardization in the registration 
practice. Potential variation in the registration practice especially for stage might influence outcomes, 
and inter-country comparisons were not made considering the probable heterogeneity. Results were 
only analyzed and interpreted separately in the respective country without pooling or comparison with 
other countries. Results from a specific national population-based registry might not be generalizable 
to another country. For counselling for patients from other countries, other aspects (e.g., treatment 
profiles and health care systems) should be considered. 
In the main analyses, PaC cases regardless of microscopic confirmation were included, which is 
in accordance with the real-world situation (Asbun et al., 2014), and which is also consistent with the 
approach used in the EUROCARE studies (De Angelis et al., 2014; Lepage et al., 2015b). While 
resected cases were mostly microscopically confirmed, the confirmation rates for overall cases varied. 
The rates of microscopic confirmation for PaC have been relatively low (Lepage et al., 2015b), and it 
has always been difficult to microscopically verify especially unresectable PaC. In this complete-case 
analysis, inclusion of patients with known stage might influence the observed rates of confirmation. 
After restricting the overall cases to the microscopically confirmed ones in sensitivity analyses, the 
survival estimates mostly became higher in all included countries except in Belgium, where the rates 
of microscopic confirmation were high. Furthermore, the survival increase was most prominent in 
patients aged ≥70 years, who are generally frailer and for whom the selection of treatment is 
commonly more cautious. While including microscopically-confirmed cases only could help to further 
increase the probability of selecting the real PaC patients, those not receiving any treatment and 
usually having inferior patient and/or cancer characteristics might be more likely excluded, which 
potentially explains in part the higher observed survival estimates in the sensitivity analyses. 
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It was shown that it is important to provide survival estimates to resected patients separately for 
counseling, as the resected PaC patient subgroup has substantially higher survival than the overall 
estimation. The results for unresected cancer patients were not shown and direct comparisons between 
the resected and the unresected cancer patients were avoided, as they may to a large extent reflect the 
selection effects which are related to various factors including patients’ health status and hospital 
characteristics. In the resected cancer patient subgroup, curative and palliative resections were not 
differentiated from each other, considering the greatly geographically and temporally varying 
standards for defining clear resection margins in PaC resection.  
Nevertheless, the large international population-based nature of this study with the 
country-specific respective analysis adds important new survival data to the literature. In particular, 
results stratified by cancer TNM stage and patient age for resected and overall cancer patients will 
further aid patient counseling in clinical practice, which provides more specific survival information 
for specific PaC patient populations.  
4.1.4 Prognostic factors and development and international validation of a benchmark 
population-based survival-predicting model in patients with resected stage I-II pancreatic 
adenocarcinoma receiving chemotherapy 
In this part of the large population-based study, various factors independently associated with survival 
after resection of PaC were identified, and for the first time a population-based nomogram for 
predicting survival in resected PaC patients receiving chemotherapy was established and 
internationally validated, which is robust, accurate, reliable, and practical. 
Through multivariable analyses, it was revealed that older age, more advanced T and N stages, 
and poorer differentiation were independently associated with lower overall survival in resected PaC 
across most countries. These findings are mostly consistent with previous literature (Kuhlmann et al., 
2004; Schnelldorfer et al., 2008). In registries with available information, resection margin, hospital 
type, tumor size, metastatic and harvested lymph node numbers, lymph node ratio, and comorbidity 
number were also associated with prognosis. While previous studies differ in conclusion regarding 
association between resection type and survival (Kuhlmann et al., 2004; Schnelldorfer et al., 2008), 
this population-based investigation of chemotherapy-treated resected cases did not show a significant 
association. Furthermore, mostly insignificant associations of survival with tumor location were found. 
Notably, overall the contribution of T or N stage to postoperative survival was mostly not greater 
than differentiation. Categorization of tumor size and number of metastatic lymph nodes following the 
8th TNM staging system (Allen et al., 2017; Schlitter et al., 2017) well discriminated survival, 
supporting the implementation of the new system. Notably, harvested lymph node number was 
positively associated with survival. Its relevance for survival has remained controversial in PaC 
(Huebner et al., 2012; Murakami et al., 2010). Possible reasons supporting the favorable association 
include that potentially more metastasized lymph nodes will be removed with more extensive 
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sampling, which also results in more precise staging, guiding appropriate postsurgical treatment.  
Estimating mortality risk might impact treatment planning, and provide information helpful for 
patient stratification in study design, contributing to better equivalence between study arms (Hammel 
et al., 2016). PaC is remarkably heterogeneous concerning postsurgical survival of individual patients, 
even with the same TNM stage (Benassai et al., 2015; Jouffret et al., 2015; Luberice et al., 2017). The 
nomogram developed is the first one derived from a large population-based database with long-term 
follow-up for predicting overall survival in patients with resected stage I-II PaC receiving 
chemotherapy, with international validations in multiple European national datasets. There is a 
previous institutional nomogram (Brennan et al., 2004) developed by Memorial Sloan-Kettering 
Cancer Center (MSKCC) in 2004 for predicting postsurgical survival in Western PaC patients not 
accounting for chemotherapy, with three external institutional validation attempts (Clark et al., 2008; 
de Castro et al., 2009; Ferrone et al., 2005). Based on institutional patient cohorts diagnosed many 
years ago (Brennan et al., 2004; Clark et al., 2008; de Castro et al., 2009; Ferrone et al., 2005), the 
score assignment of several variables might not be optimal currently using the MSKCC nomogram, 
which might also be limited in generalizability. It did not employ a backward selection process, and 
incorporated some detailed surgical (e.g., portal vein resection and splenectomy) and symptom 
parameters (back pain and weight loss). Notably, portal vein resection and splenectomy might not be 
routine procedures during pancreatectomy, and reporting of symptoms might show great interpersonal 
variations. The population-based nomogram thus represents a more updated prognostic model 
compared to the MSKCC nomogram (Table 64). The wide geographical distribution of patients and 
large sample size further enhanced the international representativeness and generalizability of the 
nomogram. 
 
Table 64. Comparison of the Memorial Sloan-Kettering Cancer Center nomogram with the newly developed one 
for survival for Western patients with resected pancreatic cancer 
Nomogram Dataset Authors Cohort origin Publication year Study design 
Resection 
period 
Follow-up 
end 
Sample 
size 
The newly 
developed Training 
Huang 
et al. The US - Population-based 2004-2015 2015 9519 
 Validation Huang 
et al. 
Belgium, The 
Netherlands, 
Norway, Slovenia
- Multinational population-based 2003-2014 2016 2318 
Memorial 
Sloan-Kettering 
Cancer Center 
Training Brennan 
et al. The US 2004 
Single 
institutional 1983-2000 2002 555 
 Validation I 
Ferrone 
et al. The US 2005 
Single 
institutional 1985-2003 
Not 
reported 375 
 Validation II 
Clark et 
al. UK 2008 
Single 
institutional 1995-2005 
Not 
reported 63 
 Validation III 
de 
Castro 
et al. 
The Netherlands 2009 Single institutional 1985-2004 2007 263 
-, not available. 
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Table 64. Comparison of the Memorial Sloan-Kettering Cancer Center nomogram with the newly developed one 
for survival for Western patients with resected pancreatic cancer (continued) 
Nomogram Dataset Authors Survival index Additional factors Backward selection 
Concordance 
index 
95% 
confidence 
interval 
External 
validation
The newly 
developed Training 
Huang et 
al. 
Median 
survival time, 
1-/2-/3-/5-year 
survival rate 
- Yes 0.60 0.59-0.61 - 
 Validation Huang et 
al. 
Median 
survival time, 
1-/2-/3-/5-year 
survival rate 
- - 0.58-0.63 Shown in Table 48 Accurate
Memorial 
Sloan-Kettering 
Cancer Center 
Training Brennan et 
al. 3-year survival
Portal vein 
resection, 
splenectomy, 
resection margin, 
back pain, weight 
loss, maximum 
pathologic axis 
Unspecified 0.64 Not reported - 
 Validation I 
Ferrone et 
al. 3-year survival - - 0.62 Not reported Accurate
 Validation II 
Clark et 
al. 3-year survival - - Not reported Not reported 
Not 
accurate
 Validation III 
de Castro 
et al. 3-year survival - - 0.61 Not reported Accurate
-, not available. 
 
Resection margin has not received a universal standard definition in PaC (Konstantinidis et al., 
2013; Tempero et al., 2014), and has highly controversial survival relevance (Butturini et al., 2008; 
Chandrasegaram et al., 2015). A meta-analysis (Butturini et al., 2008) even showed overall no 
significant postsurgical survival differences between patients with negative and positive margins. 
While a positive association of survival with negative margin in the Netherlands was shown, the 
strength was not greater than T, N stage, or differentiation, and the association was insignificant in 
Slovenia. This variable was not incorporated in the nomogram for better generalizability. It is 
encouraged to incorporate margin status into the nomogram when a standard definition comes. 
Calibration plots demonstrated very good agreement between nomogram-predicted and actual 
survival, which assures the repeatability and reliability of the nomogram. Importantly, the model based 
on the US dataset also fits the multiple European national cohorts well, which supports the potential 
for the generalization and international utilization of the nomogram, irrespective of the potential 
health care disparity across countries. Discrimination of the nomogram, as highlighted by the C-index, 
was significantly and markedly higher compared to the model based on T and N stages only. In the 
external validation cohorts, the discriminative potency only slightly changed. The model performed 
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similarly well across countries, potentially facilitating patient allocation in international studies. 
In sensitivity analyses, various alternative models were tried via for instance incorporating 
positive lymph node number or lymph node ratio as a continuous variable in place of N stage into the 
nomogram, and the discrimination ability basically remained the same, supporting the robustness of 
the model.  
Notably, the eighth edition of TNM staging system has been implemented since 2018 (Allen et al., 
2017; Schlitter et al., 2017). Compared to the sixth/seventh version, in the eighth version new 
categories of tumor size (≤2, 2-4, and >4 vs. ≤2 and >2 cm) and positive node number (0, 1-3, and ≥4 
vs. 0 and ≥1) are incorporated into T and N staging, respectively (Allen et al., 2017; Kamarajah et al., 
2017; Schlitter et al., 2017). However, after integrating these factors either as continuous or 
corresponding categorical variables into the nomogram, the performance did not markedly change. 
After transforming the SEER-18 staging data according to the eighth edition following Kamarajah et 
al. (Kamarajah et al., 2017), the performance also remained very similar. Moreover, it will take 
considerable follow-up time for the survival associated with the new staging system to be adequately 
assessed. Therefore, the nomogram will still be applicable without compromised accuracy in the 
coming years.  
Strengths of this study include the international population-based design, the largest number of 
resected PaC patients ever investigated, the extensive potential prognostic factors studied, the 
uniformly- and consistently-defined variables especially TNM stage across countries, and the 
consistency and quality control in reporting through applying rigorous registry data standards. 
Analyses were performed separately in each respective country without pooling, which avoids the 
impact of the potential heterogeneity across countries. 
Resected PaC patients do not respond equally to chemotherapy, and accordingly, the calibration 
plots also suggest that individual survival varied greatly despite the relatively consistent 
comprehensive survival across countries. This study will help to initially stratify this patient 
population into subgroups with discrepant survival, and might potentially serve as a platform for 
developing further endeavors to understand factors associated with chemotherapy responses and 
survival in resected PaC, including precise, individualized, and personalized genomic and proteomic 
survivorship investigations. 
Like any observational registry-based investigation, this study also has some limitations. The 
model predicts survival at the average population level, and when applying this model in specific 
centers or regions with different care patterns, there could be some inconsistencies between predicted 
and actual survival. Nevertheless, as revealed by the calibration plots, the real-world survival was still 
in good accordance with the prediction for a single individual. Residual confounding is a concern. 
Some significant variables (e.g., tumor size) were only registered in certain databases. Differences in 
survival pattern across countries might be partly associated with variation in the prescription of 
chemotherapy and/or the underlying ethnic/racial distribution, even though association results 
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remained similar after limiting the US cohort to white. Notably there were some differences in patient 
and tumor characteristics across registries. For instance, in Slovenia, tumors were generally more 
advanced and poorly-differentiated, and the actual survival was the lowest. Nevertheless, these 
variables were adjusted for in the multivariable analyses. 
Furthermore, population-based registries collected limited information on variables including 
family and patient health history and individual-level socioeconomic status, and the molecular or 
genetic subtype of PaC could not be determined (Cancer Genome Atlas Research Network. Electronic 
address and Cancer Genome Atlas Research, 2017), which probably plays a role in prognosis and 
explains the moderate C-index of the nomogram. Accordingly, the nomogram is limited by failure to 
incorporate these and other recognized prognostic parameters (e.g., lymphatic and neurovascular 
invasion and type of chemotherapy). Further efforts on collection and incorporation of more relevant 
variables are encouraged to improve this model. 
Notably, all known models predicting PaC survival perform very modestly (Brennan et al., 2004; 
Clark et al., 2008; de Castro et al., 2009; Ferrone et al., 2005; Tol et al., 2015). This nomogram with 
selection of only chemotherapy-treated resected PaC patients does not perform better compared to 
previous models with selection of all patients undergoing resection (Brennan et al., 2004; Clark et al., 
2008; de Castro et al., 2009; Ferrone et al., 2005; Tol et al., 2015), which might limit the added value 
of the selection for the current nomogram. Furthermore, during the study period, the type of 
chemotherapy is mainly gemcitabine monotherapy, while the landscape of systemic treatment and 
treatment sequence for PaC are rapidly changing, which might limit the possible use of this 
nomogram. 
Despite the moderate C-index, the agreement between predicted and actual survival was almost 
excellent. All variables included in the practical easy-to-use nomogram are easily-available in clinics, 
compared to the not-routinely-measured and costly molecular markers. It is herein the first time that 
the contributions of these risk factors are quantified and integrated into a single model for survival 
prediction in resected and chemotherapy-treated PaC with international validations. 
4.1.5 Significance of examined lymph node number in accurate staging and long-term survival in 
resected stage I-II pancreatic cancer 
In this part of the large population-based study, the association of ELN number with stage migration 
and long-term survival in resected PaC was analyzed. Stage migration analysis suggested that more 
ELNs were associated with a larger proportion of observed node-positive diseases in the entire 
resected PaC population of both the US and the Netherlands cohorts, after multivariable adjustment. 
This association was further confirmed by the trends of the mean PLN number and the probability of 
accuracy for observed node-negative disease with increasing ELN count. In both cohorts, associations 
between more ELNs and higher survival in both overall and node-positive diseases were observed. A 
minimal (12 ELNs) and optimal cut-point (19 ELNs) was then determined based on the associations 
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with stage migration and survival, respectively, in the derivative US cohort, and validated in both 
cohorts with the ability to well discriminate different probabilities of both survival and stage 
migration. 
The ISGPS has recommended that the ELN number be reported in PaC pathologic analysis (Tol et 
al., 2014b). However, there is no uniform conclusion yet on the association of ELN count with 
survival or on the threshold ELN number that could best address both stage migration and long-term 
survival in PaC (Ashfaq et al., 2014; Hellan et al., 2008; Huebner et al., 2012; Lahat et al., 2016; 
Michalski et al., 2007; Pedrazzoli et al., 1998; Riall et al., 2005; Slidell et al., 2008; Sun et al., 2014; 
Tol et al., 2014b; Valsangkar et al., 2013; Wu et al., 2014; Yeo et al., 2002; Yeo et al., 1999). Even the 
latest edition of TNM staging could not account for the heterogeneity of patient populations, surgical 
practice, and LN distribution maps. The PLN number at each ELN count was lower in the US than in 
the Netherlands, and the different ELN numbers observed in this study might reflect the discrepancy in 
practice patterns of surgeons and pathologists between the US and the Netherlands. The differences 
might be possibly explained by pathologists’ practice, since the minimum requirement of 10 ELNs in 
the Netherlands could preclude some pathologists from searching for more, which would actually be 
associated with more accurate staging further. 
In this observational hypothesis-generating analysis, while the association of more ELNs with 
higher survival was significant in multivariable-adjusted models both overall and in extensive 
stratifications, and ELN number was prognostically significant irrespective of the PLN number in 
patients with node-positive disease, these do NOT suggest any causal relationship between ELN 
number and survival. Several reasons potentially explain the observed survival association. First, more 
ELNs were associated with more accurate staging. Second, sampling of more LNs might reduce the 
risk of undetected PLNs. More ELNs were associated with better survival in patients with resectable 
node-positive disease where no stage migration would occur. Third, patients with observed 
node-negative disease and with fewer ELNs may include some who actually had node-positive disease. 
While evidence on the association of ELN number with long-term survival in resected PaC remains 
contradictory (Ashfaq et al., 2014; Hellan et al., 2008; Huebner et al., 2012; Lahat et al., 2016; 
Michalski et al., 2007; Pedrazzoli et al., 1998; Riall et al., 2005; Slidell et al., 2008; Sun et al., 2014; 
Tol et al., 2014b; Valsangkar et al., 2013; Wu et al., 2014; Yeo et al., 2002; Yeo et al., 1999), the 
results suggest the hypothesis of a positive association at the large population level. This hypothesis 
should be tested and validated in prospective studies. Importantly, the survival association does not 
suggest causality, and might be largely due to stage migration. 
A minimal (12) and optimal cutoff of ELNs (19) for overall resected PaC were then identified, 
which might serve as an effective quality reference and metric to determine adequate LN sampling. So 
far, recommendations on ELN number have not been uniform in PaC, although some retrospective 
analyses have tried to set a benchmark, with proposed ELN number ranging from 11 to 17 for overall 
PaC (Ashfaq et al., 2014; Huebner et al., 2012; Valsangkar et al., 2013). For correct staging of 
DISCUSSION 
136 
 
pancreas body/tail cancers, an institutional report even suggested ≥20 LNs to be examined (Malleo et 
al., 2018). A significant and independent association of ≥12 or ≥19 ELNs with decreased risk of 
mortality were further shown, especially in node-positive disease, in both cohorts. In standard 
lymphadenectomy for pancreatoduodenectomy where 12 LN stations are recommended to be resected 
(Tol et al., 2014a), twelve ELNs could be achievable, while 19 ELNs might be somehow challenging. 
The recommendation of 12 ELNs was close to the suggestion by the AJCC/UICC which emphasized 
stage migration only. Although mostly slightly, the recommendation could vary with different 
demographic, clinical, and pathologic characteristics as shown in the stratified analyses. For some 
stratifications, associations were less uniform across cohorts, most likely due to the paucity of cases or 
because node status did not influence treatment. Notably, it was further found that younger patients 
achieved these thresholds in higher proportions in both cohorts (data not shown).  
Notably, in the Netherlands, ≥19 ELNs were not associated with higher survival in node-negative 
disease, which was different from the case in the US. While this could be partly due to the much 
smaller proportion of patients with ≥19 ELNs among those with declared “N0” disease in the 
Netherlands compared to the US (8% vs. 23%), for early-stage lesions, limited resection might already 
provide sufficient favorable benefits, and it remains uncertain whether the stage migration benefit 
could be translated directly into improved patient outcomes. Attention should be exerted when 
applying the 19-ELN threshold to node-negative disease, for which the threshold could be lower. 
Notably, accuracy of a declared node-negative disease could also be affected by other factors beyond 
ELN count, and could vary across countries. It has always been difficult to identify the real “N0” 
disease before resection. More efficacious approaches to pre- or intra-operatively predict LN 
metastasis (e.g., laparoscopic ultrasound) could be preferred. 
Results from earlier randomized studies suggested that compared to standard lymphadenectomy, 
extended lymphadenectomy with largely varying ELNs and definitions was not associated with 
improved survival overall. Most of these studies were, however, insufficiently powerful due to 
immature survival data and/or small case number (Michalski et al., 2007; Pedrazzoli et al., 1998; Riall 
et al., 2005; Sun et al., 2014; Tol et al., 2014b; Yeo et al., 2002; Yeo et al., 1999). While extended 
lymphadenectomy did not increase postoperative mortality, it tended to increase morbidity (Michalski 
et al., 2007; Pedrazzoli et al., 1998; Riall et al., 2005; Sun et al., 2014; Tol et al., 2014b; Yeo et al., 
2002; Yeo et al., 1999). Extended lymphadenectomy has thus not been recommended by the NCCN, 
ESMO, or ISGPS as a routine procedure, while it has been commonly performed in the US (Ducreux 
et al., 2015b; Tempero et al., 2017; Tol et al., 2014b). A randomized controlled trial (RCT) (Pedrazzoli 
et al., 1998) reported that compared to standard lymphadenectomy (mean ELN=13), extended 
lymphadenectomy (mean ELN=20) prolonged survival in node-positive but not in node-negative 
disease. Another RCT (Riall et al., 2005; Yeo et al., 2002; Yeo et al., 1999) comparing extended (mean 
ELN=29) with standard lymphadenectomy (mean ELN=17) showed a trend toward overall higher 
5-year survival in pancreatic adenocarcinoma patients undergoing extended lymphadenectomy (29% 
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vs. 13%). A later RCT (Farnell et al., 2005) with a mean of 36 nodes resected during extended 
lymphadenectomy showed no survival difference. Notably, the mean ELN number would be too large 
in the extended group in most previous studies (Michalski et al., 2007; Pedrazzoli et al., 1998; Riall et 
al., 2005; Sun et al., 2014; Tol et al., 2014b; Yeo et al., 2002; Yeo et al., 1999), compared to the 
thresholds determined. Excessive ELNs might even reduce survival, and there could be an upper 
threshold for ELN number after which the HR might markedly increase. However, this could not be 
determined in this study because of the small number of patients with relatively large ELN numbers. 
Further prospective/randomized studies on the extent of lymphadenectomy with more adequate ELN 
number and with nodal status-stratified analyses might be warranted, and the increase in morbidity and 
potential survival benefits should be well-balanced. 
This study is limited by its observational nature. Data from observational studies can only detect 
associations, but cannot infer causality, and it cannot be concluded that examination or dissection of 
more LNs improves survival. The ultimate ELN number results from a collaboration between surgeons 
responsible for LN dissection and pathologists responsible for specimen examination and node 
identification. The reported ELN number might also be impacted by other confounders not available 
and not accounted for in this study, such as patient body mass index, immune status, surgical standards, 
difficulty in separating individual LN in dissected specimens, evaluators’ expertise, and tumor biologic 
behaviors. Notably, reaching the threshold might not be possible for some patients with specific 
features, despite optimal surgery and pathologic assessment. 
While clinical practice might have changed during the investigation period, year of diagnosis was 
included in multivariable analyses and subgroup analyses by limiting patients to those diagnosed in 
2010 or later was performed, revealing very similar results. Multivariable analyses by accounting for 
every additional LN would reduce the impact of varying clinical practice. Multiple cancer histology 
types were initially included, considering the real-world practice and the consensus by the ISGPS that, 
in the presence of a solid mass suspicious for malignancy, biopsy proof has not been and is not 
required before proceeding with resection (Asbun et al., 2014). Subgroup analyses according to tumor 
histology were further performed. Since it is hardly possible to fully confirm an N0 disease before 
resection, patients regardless of LN status were initially included, with further subgroup analyses 
according to N stage conducted. 
Other important aspects including LN station and location could not be investigated, the 
understanding of which might contribute to precise LN dissection. The ELN number is determined by 
both the stations and extent of LNs dissected. It needs to be further investigated whether the number of 
ELNs or the distribution of dissected LN stations is more prognostically significant in specific patient 
populations. While there was no information on dissected nodal stations, it would be difficult to 
incorporate this information into the models as an independent variable, given its strong correlation 
with nodal yield. 
This study is the largest on the clinical significance and cut-point determination of ELNs in PaC 
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using multinational real-world cohorts with robust statistics and representative and generalizable 
results. The ELN number could be one of the quality assessment criteria and metrics. The 
recommendation potentially contributes to the consensus between surgeons and pathologists, 
especially regarding the degree of en bloc resection. The results should NOT encourage surgeons to do 
more extended lymphadenectomies. 
4.2 Gastric cancer 
This part of the large international population-based study reported the patient and tumor 
characteristics, resection trends, and treatment-associated factors for GC across Europe and the US in 
the early 21st century. Surprisingly, resection rates decreased for both non-metastatic and metastatic 
cancers. In non-metastatic cancers, for which resection remains the only curative treatment, this 
decreasing trend was consistently seen in various subgroups and could not be explained by several 
tumor and patient characteristics. Notably, overall patients were not less frequently treated in most 
countries, with increasing rates of non-surgical therapies.  
The observed decreasing trends are consistent with some previous national studies from the US 
and the Netherlands in earlier periods. In the US, 63% of patients with non-cardia GC underwent 
resection during 1983-2002. During that period, resection rates declined by 6% units in all stages, and 
by even 20% units in local stages (Le et al., 2007; McGhan et al., 2012). Using the Nationwide 
Inpatient Sample in 1988-2000, a 20% stratified random sample representative of all US hospitals, 
gastric resection rate showed a 20% decline (Wainess et al., 2003); however, rates of reduction 
operations for GC increased from 5% to 34% during 1990-2001 (Espat et al., 2004). In the 
Netherlands, resection rates for stage I-III non-cardia cancer decreased from 71% (1989-1992) to 62% 
(2005-2008), while rates for cardia cancer remained relatively stable during that period (Dassen et al., 
2013); palliative resection rates for patients <70 (25% to 3%) and ≥70 years (26%-5%) both decreased 
from 1989-1993 to 2009-2013 (Nelen et al., 2017). Resection trends in the other European countries 
have been rarely reported.  
In Western countries, there is consensus that medically fit patients with non-metastatic resectable 
GC should undergo standardized resection in specialized, high-volume centers with appropriate 
surgical expertise and perioperative care (Begg et al., 1998; Birkmeyer et al., 2002; Dikken et al., 
2013). Volume-outcome associations have motivated centralization of surgical care worldwide 
(Coupland et al., 2013), and morbidity and mortality have markedly decreased after GC resection 
(Lepage et al., 2010). Still, many Western surgeons do not see sufficient GC patients to improve the 
surgical skills, and are more often faced with hurdles including more challenging body habitus, more 
comorbidities, and older ages (Bunt et al., 1995). While the degree and the start time vary across 
countries, GC surgery has shown increasing trends towards centralization to high-volume specialized 
unites. It was found that the proportions of patients managed and of resections performed in academic 
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hospitals increased moderately in the Netherlands (2005-2014: 14%-22% and 17%-34%) and Belgium 
(2004-2013: 38%-43% and 40%-47%), and strongly in Sweden (2006-2016: 34%-70% and 38%-84%). 
In the US, proportions of gastrectomies performed at centers with ≥9 resections per year increased 
from 43% in 1988-1989 to 48% in 1999-2000 (Wainess et al., 2003), although the number of gastric 
surgery per chief resident decreased from 12 in 1990 to 11 in 2001 (Espat et al., 2004). It was found 
that the proportions of patients managed (27%-29%) and of resections performed (33%-33%) in 
hospitals with ≥20 annual gastric/esophageal resections remained relatively stable during 2005-2014 
in the Netherlands, where centralization of GC surgery has essentially been imposed since 2012 only 
(Claassen et al., 2018a; Claassen et al., 2018b). Proportions of resections done in hospitals with ≥20 
yearly resections increased moderately in Belgium (2004-2013: 18%-28%). In Sweden, proportions of 
patients treated (30%-72%) and of resections (32%-68%) performed in hospitals with ≥20 resections 
per year increased strongly in 2006-2016. It is expected that further centralization might retard or even 
reverse the decreasing trends in the years to come.  
Palliative (R1/2) resection might not bring any benefit compared with exclusive medical 
treatment, but only increase posttreatment morbidity and mortality (Ajani et al., 2016; Japanese 
Gastric Cancer, 2017; Smyth et al., 2016). The fear of margin-positive resection might impede more 
and more surgeons from conducting resection especially in challenging situations. Increasing 
clear-margin (R0) resection rates have been observed among all resections for non-metastatic cancer in 
the Netherlands (2005-2014: 83%-88%) and Sweden (2006-2016: 83%-92%). Furthermore, 
proportions of resections with ≥15 examined lymph nodes for non-metastatic disease increased in the 
US (2004-2014: 36%-51%), the Netherlands (2005-2014: 32%-67%), and Sweden (2006-2016: 
42%-82%). While these trends could partly reflect the surgical advances, they might also indicate the 
increasingly stricter selection criteria of resection candidates.  
Some patients with metastatic GC underwent resection, albeit with decreasing trends observed in 
most countries. Patients with metastatic cancers are typically not suitable for curative surgical 
treatment (Thrumurthy et al., 2013). The role of gastrectomy remains unclear in patients with 
technically operable metastatic GC (Japanese Gastric Cancer, 2017). Recent advances in 
chemotherapy have resulted in considerable tumor regression in many cases of inoperable GC, and 
might render them operable (Bouche et al., 2004; Wagner et al., 2010). Observational studies (de Gara 
et al., 2003; Zhang et al., 2011) showed that palliative resection might improve survival and quality of 
life in selected patients with advanced GC. There might be a subgroup of patients with metastatic GC 
for whom primary tumor resection with chemotherapy might improve survival (Warschkow et al., 
2018). In particular, selected patients with peritoneal carcinomatosis or positive peritoneal cytology 
might benefit from aggressive surgery in expert centers. A meta-analysis (Coccolini et al., 2014) of 20 
randomized trials suggested that cytoreductive surgery for GC with peritoneal carcinomatosis was 
associated with improved survival up to 3 years, but not at 5 years. Notably, no evidence in support of 
reduction gastrectomy for patients with limited metastatic disease, which aims to enhance survival by 
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reducing tumor volume, was found in the international REGATTA randomized trial (D'Ugo et al., 
2016; Fujitani et al., 2016). However, in the phase II AIO-FLOT3 trial (Al-Batran et al., 2017), 
patients with limited metastasis receiving neoadjuvant chemotherapy and proceeding to resection 
showed favorable survival. Until further evidence is presented, resection should be considered only 
experimental for metastatic GC patients or for palliative reasons in gastric outlet-obstructive tumors.  
It was found that GC was most commonly diagnosed in patients ≥70 years and at stomach cardia, 
two factors that were associated with significantly less frequent resection. For elderly patients who are 
generally more frail the resection-upfront approach might be suboptimal unless specifically tailored 
(Cunningham and Chua, 2007). Geriatric evaluation would be helpful before initiating treatment for 
older patients. However, GC patients were getting increasingly younger in the investigated period. 
Cardia cancer often requires total gastrectomy and might be more surgically challenging (Sasako et al., 
2006). While its recent increasing incidence potentially impedes resection (Colquhoun et al., 2015; 
Smyth et al., 2016), resection rates for non-cardia cancer were also decreasing. Interestingly, 
compared to those with non-cardia cancers, the magnitude of decrease in resection rates with 
increasing age was markedly greater in patients with cardia cancers. Within non-metastatic tumors, 
cancers invading adjacent structures had lower R0 resection rates, which potentially bars resection. 
Recent advances in diagnostics have made the detection of patients with incurable advanced disease 
more efficient and thus made them less often referred for aggressive treatment (Ajani et al., 2016; 
Kwee and Kwee, 2007). Patients with SRC GC, who are a rapidly increasing population and have a 
poor prognosis, have been shown to be inherently more resistant to chemotherapy, and might even be 
harmed by the delay in resection (Charalampakis et al., 2016; Heger et al., 2014; Messager et al., 
2011). Total gastrectomy is often required for SRC carcinoma (Sasako et al., 2006). Notably, 
non-metastatic SRC cancers were less often surgically managed in some countries, and the differences 
between countries could be biased by differences in classification of SRC across countries. The 
different patterns and strengths of associations of resection with patient and tumor characteristics 
across countries and between non-metastatic and metastatic cancers highlight the variation in clinical 
practice and the need for standardization. The aforementioned factors could not fully explain the 
decreasing trends as indicated by multivariable analyses. 
The rates of non-surgical therapies were further explored, which were increasing compared to the 
declining resection rates. Overall, patients did not receive markedly less frequent management. 
Following the pivotal MAGIC trial (Cunningham et al., 2006), perioperative therapy is recommended 
as standard of care for most resectable GC planned for resection throughout many parts of Europe, and 
is increasingly favored over adjuvant treatment (Cunningham et al., 2006; Ychou et al., 2011). It is 
especially recommended for cardia cancer with invasion of serosa and/or adjacent structures and/or 
with positive nodes (Cunningham et al., 2006; Ychou et al., 2011). Two subsequent multicenter 
randomized trials (2008 (Cunningham et al., 2008) and 2011 (Ychou et al., 2011)) further reported 
benefits from perioperative chemotherapy and potentially resulted in wider application of neoadjuvant 
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treatment. While the preoperative approach might enhance resectability by down-staging tumor, it also 
allows substantial time for further growth of advanced cancers or metastases, which potentially 
impeded the application of resection. Greater access to and wider use of non-surgical care and 
pre-surgical chemotherapy-associated toxicity might also preclude some patients from receiving 
further resection (Macdonald, 2004; Stahl et al., 2009). These factors may have implicated an overall 
increasingly less aggressive approach toward GC. However, it is unclear whether this change is due to 
a superior patient selection strategy, and the associated survival warrants further investigation. 
Proper patient selection for treatment is paramount. Physician recommendation and expertise, and 
patient preference and adherence importantly impact treatment choice. In patients with unresected 
non-metastatic GC in the SEER-18, the proportion of those recommended for surgery decreased from 
12% in 2004 to 11% in 2014. The aggressive nature of GC and historically poor outcomes even in the 
setting of operable disease should be discussed with patients before treatment. Patient performance, 
nutrition, and psychosocial statuses, organ function, medical history, tolerability, therapeutic burden 
especially cost, potential benefit from resection, postoperative morbidity and mortality, and quality of 
life should also be factored into treatment decisions. Combined modality therapy optimized by 
multidisciplinary teams is effective and essential for GC patients (Brar et al., 2014; Cunningham et al., 
2006; Macdonald et al., 2001).  
This study was firstly limited by its observational nature. Some important variables were not 
recorded in certain countries, and the quality of registration might vary. While variables included in 
the main models were complete, some variables were not included in modeling due to the relatively 
high proportions of missing values (e.g., differentiation). Proportions of unknown metastasis were 
particularly high in Belgium (22%) compared to the other countries (4%-10%). Data were not pooled 
or compared between countries, considering the potential heterogeneity, but were analyzed, presented, 
and interpreted for each country separately. It is noteworthy that in non-metastatic cancers the 
proportion of cardia cancer was very low in Slovenia (27%) and Estonia (12%), and SRC carcinoma 
was very often diagnosed in Estonia (28%). While this could be partly explained by differences in 
dietary and obesity patterns and the prevalence of Helicobacter pylori infection, potential variation in 
clinical and registry practice might also play a role which underlines the importance of further 
standardization. The investigated time periods were not totally identical. Nevertheless, they mostly 
covered the period 2003/2004-2013/2014, and year of diagnosis was adjusted for in all multivariable 
models.  
Nevertheless, the largest sample size ever investigated, uniformly defined variables across 
nationwide population-based registries from multiple countries with potentially different health care 
systmes, careful case selection and quality control, and valid statistical methods enabled this report to 
show important results regarding treatment for GC that warrants clinicians’ and policymakers’ 
attention. 
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4.3 Conclusions 
These large international population-based cohort study series in this dissertation/thesis show that: 
4.3.1 Pancreatic cancer 
The resection rates for PaC are generally low in Europe and the US with large international variations. 
Further investigations are warranted to further explore the reasons for these variations. Although the 
role of chemotherapy has been well established, its use remained very heterogeneous and of mostly 
low rates for both resected and unresected PaCs in Europe, despite major increases especially for 
resected tumors from 2003-2005 to 2012-2014. The benefit remaining controversial, radiotherapy was 
rarely administered, and its role needs to be clarified in further RCTs. 
Comprehensive data on survival expectations of patients with resected PaCs are then provided, 
which are substantially higher than the widely available and known dismal survival of overall patients. 
Benefits of resection cannot be concluded from the observational study. However, the cancer TNM 
stage- and patient age group-stratified survival might be of help for clinical counselling. The estimated 
survival for advanced-stage cancers should be interpreted with caution due to potential underreporting. 
Patients with advanced stage and/or old age should undergo careful assessment before treatment. 
Limited but encouraging survival improvement is observed. 
Independent factors associated and not associated with survival in patients with resected stage I-II 
PaC receiving chemotherapy are further revealed, with country-specific association patterns and 
strengths. A novel, robust, and reliable survival-predicting model was further established and 
internationally validated, which may provide the basis for more precise individualized survival 
estimation and which could be useful for clinical counselling for both doctors and patients. While with 
very good calibration, this nomogram together with all known models predicting survival in resected 
PaC performs modestly. 
More ELNs are associated with more accurate nodal staging, which might to a great extent 
explain the association with higher survival in resected PaC in the observational study, and no 
definitive conclusions on causality or benefits should be drawn. The analysis suggests 12 and 19 ELNs 
as potential minimal and optimal cut-points for the overall quality assessment regarding LN 
examination in clinical practice and for postoperative prognosis stratification especially in 
node-positive disease. These findings should be further validated in prospective studies. 
4.3.2 Gastric cancer 
Both non-metastatic and metastatic GCs were less frequently surgically managed in Europe and the 
US in the early 21st century. While the decreasing trends could not be explained by various variables 
associated with resection, they were accompanied by increasing non-surgical therapy use. Since 
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resection remains the only potentially curative treatment for most non-metastatic resectable GCs, the 
appropriateness of such trends warrants further investigation. Further centralization might be needed 
to weaken or reverse the decreasing resection trends. 
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5 SUMMARY 
In this dissertation large international population-based cohorts of pancreatic cancer (PaC) and gastric 
cancer (GC) patients registered in multiple European national population-based cancer registries from the 
Netherlands, Belgium, Norway, Denmark, Sweden, Slovenia, and Estonia and the US Surveillance, 
Epidemiology, and End Results (SEER-18) Program database in the early 21st century were analyzed. 
For pancreatic cancer: 
Resection can potentially cure resectable PaC and significantly prolong survival in some patients. The role 
of chemotherapy in the management of PaC has been well established, while radiotherapy plays ambiguous 
roles. The prognosis of resected and overall (resected and unresected) PaC varies strongly across different 
stages and age groups. Prognostic factors for resected PaC receiving chemotherapy at the population level 
remains largely unexplored, and there lacks a corresponding population-based tool to predict survival. 
Examined lymph node (ELN) number is an important quality metric in cancer care. 
The PaC part of this thesis aimed to investigate the variations in resection for PaC, the real-world use 
of chemotherapy and radiotherapy for resected and unresected PaC, and the determinants for the use of the 
treatment modalities, to provide TNM stage- and age group-specific survival estimates and trends in 
resected and overall PaC, to explore factors associated with survival in patients with resected TNM stage 
I-II PaC receiving chemotherapy, to develop and internationally validate a population-based 
survival-predicting model for this patient group, to investigate the associations of ELN number with 
accurate staging and long-term survival, and to determine the ELN thresholds. 
In 2012-2014, age-standardized resection rates ranged from 13.2% (Estonia) to 21.2% (Slovenia) 
overall and from 34.8% (Norway) to 68.7% (Denmark) for stage I-II cancers, with large international 
variations. During 2003-2014, resection rates only increased in the US, the Netherlands, and Denmark. 
Using multivariable logistic regression, resection was found to be significantly less frequently performed 
with more advanced tumor stage and increasing age. Patients with stage III-IV tumors and aged ≥70 years 
comprised the majority. Performance status, location, and size were also associated with resection use. 
From 2003 to 2014, age-standardized chemotherapy use rates increased in most countries and more 
strongly for resected patients, while radiotherapy use was generally rare with a slight decline or no obvious 
trend. In 2012-2014, 12.5% (Estonia) to 61.7% (Belgium) of resected and 17.1% (Slovenia) to 56.9% 
(Belgium) of unresected patients received chemotherapy. Radiotherapy was used for 2.6% (the Netherlands) 
to 32.6% (the US) of resected and 1.0% (the US) to 6.0% (Belgium) of unresected patients. Strong 
temporal and geographical variations were observed. Patterns and strengths of associations of treatment use 
with various demographic and clinical factors differed substantially between resected and unresected 
cancers and varied greatly across countries. 
Overall, age-stratified 3-year survival was 20%-34% (<60 years), 14%-25% (60-69 years), and 9%-13% 
(≥70 years) in stage I-II PaC, and 2%-5% (<60 years), 1%-2% (60-69 years), and <1%-1% (≥70 years) in 
stage III-IV cancer. Operated patients had higher 3-year survival in each stage and age group (stage I-II: 
23%-39% (<60 years), 16%-31% (60-69 years), and 17%-30% (≥70 years); stage III-IV: 5%-19% (<70 
years) and 2%-14% (≥70 years)). Perioperative survival also decreased with advancing stage and older age. 
In 2003-2011, for overall PaC, both short-term and long-term survival improvements were observed in all 
countries except Belgium; for resected disease, short-term improvements were present only in the US and 
Slovenia, but long-term improvements in all countries except Slovenia, with stage-specific variations. 
In patients with resected stage I-II PaC receiving chemotherapy, the median survival time was 18-23 
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months with 3-year survival rates of 21%-31%. In the main analysis, patient age, tumor T stage, N stage, 
and differentiation were independently associated with survival across most countries, with 
country-specific patterns and strengths. Resection margin, hospital type, tumor size, positive and harvested 
lymph node number, lymph node ratio, and comorbidity number were associated with survival in countries 
with available information. A median survival time- and 1- to 5-year survival probability-predictive 
nomogram incorporating the backward-selected prognostic variables in the main analysis of SEER-18 was 
built. It fits the European cohorts similarly well. Calibration curves showed very good agreement between 
nomogram-prediction and actual observation. The concordance-index of the nomogram was significantly 
higher than that of the T and N stage-based model for predicting survival. It was validated both internally 
using bootstrap and externally in the European datasets. 
In patients with resected stage I-II PaC registered in the US SEER-18 Program and the Netherlands 
National Cancer Registry (NCR), with increasing ELN number, both cohorts exhibited significant 
proportional increases from node-negative to node-positive disease and serial improvements in survival 
after controlling for confounders, in both overall and most stratified analyses. Cut-point analyses of the 
series of the odds ratios for stage migration and the hazard ratios for survival with more ELNs in the 
derivation SEER-18 cohort suggested a minimal threshold ELN number of 12 and an optimal number of 19, 
respectively, which were validated both internally and externally. 
In conclusion, in Europe and the US in the early 21st century, rates of PaC resection remain low with 
large international variations. Use of chemotherapy but not radiotherapy increased, but treatment rates were 
low and the uptake varied strongly across countries. These highlight the need for standardization in PaC 
treatment to improve patient care, and further studies are warranted to explore reasons for these variations. 
TNM stage- and age-specific population-based survival in overall and resected PaC are further provided, 
which will facilitate clinical counseling. Patients with advanced-stage disease and/or older age should 
undergo careful risk assessment before treatment. Some limited but encouraging improvement in survival 
was observed. Resected PaC patients receiving chemotherapy have distinct characteristics independently 
associated with survival, with country-specific patterns and strengths. A robust benchmark 
population-based personalized survival-predicting model was established and internationally validated, 
which would be easy-to-use, practical, and helpful clinically and aid to patient allocation in international 
studies. More ELNs are associated with more precise nodal staging, which might largely explain the 
survival association. 12 and 19 ELNs are suggested as the minimal and optimal cut-points, respectively, for 
evaluating quality of lymph node examination and possibly for stratifying postoperative prognosis. 
For gastric cancer: 
Resection is potentially curative for many resectable non-metastatic GCs, and some metastatic GCs are 
technically resectable. The GC part of this thesis aimed at investigating the resection trends for 
non-metastatic and metastatic GCs and at exploring the underlying reasons for the trends. 
Resection rates significantly decreased in all countries for non-metastatic cancers and in all countries 
except the Netherlands, Slovenia, and Estonia for metastatic cancers. Patients with increasing ages, cardia 
cancers, or cancers invading adjacent structure were significantly less often resected. Resection was also 
associated with patient sex, performance status, comorbidities, tumor histology, size, hospital type and 
volume. Association patterns and strengths varied across countries. After adjusting for the associated 
factors, resection rates remained decreasing for both non-metastatic and metastatic cancers. Rates of 
non-surgical therapies increased, making the overall treatment rates mostly stable or slightly increasing. 
In conclusion, both non-metastatic and metastatic GCs were less frequently surgically managed in 
Europe and the US in the early 21st century. While the decreasing trends could not be explained by various 
variables associated with resection, they were accompanied by increasing non-surgical therapy use. The 
survival relevance of such trends warrants further investigation.  
ZUSAMMENFASSUNG 
146 
 
6 ZUSAMMENFASSUNG 
In dieser Dissertation wurden große internationale bevölkerungsbezogene Kohorten von Bauchspeicheldrüsenkrebs- (PaC) und 
Magenkrebspatienten (GC), die in europäischen nationalen bevölkerungsbezogenen Krebsregistern aus den Niederlanden, 
Belgien, Norwegen, Dänemark, Schweden, Slowenien und Estland sowie der SEER-18 (US Surveillance, Epidemiology, and 
End Results) Datenbank aus der USA im frühen 21. Jahrhundert registriert wurden, analysiert. 
Für Bauchspeicheldrüsenkrebs (PaC): 
Eine Resektion hat das Potenzial, resezierbare PaC zu heilen und bei einigen Patienten das Überleben signifikant zu verlängern.  
Die Rolle der Chemotherapie bei der Behandlung von PaC ist gut belegt, während die Strahlentherapie eine unklare Rolle 
spielt. Die Prognose nach resezierten PaC und nach PaC ingesamt (reseziert und nicht-reseziert) variiert stark zwischen den 
verschiedenen Stadien- und Altersgruppen. Auf Bevölkerungsebene sind prognostischen Faktoren bei resezierten PaC nach 
Erhalt einer Chemotherapie noch weitgehend unerforscht, und es fehlt ein entsprechendes populationsbasiertes Werkzeug zur 
Vorhersage des Überlebens. Die Zahl der untersuchten Lymphknoten (ELN) ist eine wichtige Qualitätskennzahl in der 
Krebsbehandlung. 
Der Abschnitt dieser Arbeit zu PaC zielte darauf ab, zeitliche und regionale Unterschiede der Nutzung einer Resektion bei 
PaC und der Administration von Chemotherapie und Strahlentherapie für resezierte und nicht-resezierte PaC zu beschreiben. 
Darüber hinaus wurden Determinanten für die Verwendung dieser Behandlungsmodalitäten untersucht. Auch wurden Stadien- 
und altersspezifische Überlebensschätzer und Trends bei resezierten PaC und der Gesamtgruppe von PaC Patienten berechnet. 
Es wurden Faktoren untersucht, die potentiell mit dem Überleben in Stadium I-II PaC Patienten, die eine Chemotherapie 
erhalten haben, assoziiert sind. Ein weiteres Ziel war die Entwicklung und internationale Validierung eines 
bevölkerungsbezogenen Modells zur Vorhersage des Langzeitüberlebens in dieser Patientengruppe. Außerdem wurde die 
Assoziation zwischen der Anzahl der ELN und einer akkuraten Stadienvergabe und dem Langzeitüberleben untersucht und ein 
Schwellenwert für die Anzahl der ELN ermittelt.  
Im Zeitraum 2012-2014 schwankten die altersstandardisierten Resektionsraten von 13,2% (Estland) bis 21,2% 
(Slowenien) insgesamt und von 34,8% (Norwegen) bis 68,7% (Dänemark) für Stadium I-II PaC. Steigende Resektionsraten im 
Zeitraum 2003-2014 waren nur in den USA, den Niederlanden und Dänemark sichtbar. Mit Hilfe der multivariablen 
logistischen Regression wurde gezeigt, dass eine Resektion signifikant seltener mit fortgeschrittenem Tumorstadium und 
steigendem Alter durchgeführt wurde. Die meisten Patienten hatten Tumoren im Stadium III-IV und waren ≥70 Jahren. 
Performancestatus, Lokalisation und Tumorgröße waren auch mit der Durchführung einer Resektion assoziiert. 
Von 2003 bis 2014 stieg die altersstandardisierte Nutzungsrate der Chemotherapie in den meisten Ländern an, mit größten 
Steigerungen bei resezierten Patienten, während die Strahlentherapie im Allgemeinen selten durchgeführt wurde, mit einem 
leichten Rückgang oder keinem offensichtlichen Trend. Im Zeitraum 2012-2014 erhielten 12,5% (Estland) bis 61,7% (Belgien) 
der resezierten und 17,1% (Slowenien) bis 56,9% (Belgien) der nicht resezierten Patienten eine Chemotherapie. Die 
Strahlentherapie wurde bei 2,6% (Niederlande) bis 32,6% (USA) der resezierten und 1,0% (USA) bis 6,0% (Belgien) der nicht 
resezierten Patienten eingesetzt. Starke zeitliche und geografische Unterschiede wurden beobachtet. Die Muster und Stärken 
der Assoziationen zwischen der Durchführung dieser Behandlungen und verschiedenen demographischen und klinischen 
Faktoren unterschieden sich erheblich zwischen resezierten und nicht resezierten PaC und waren in den einzelnen Ländern sehr 
unterschiedlich. 
Insgesamt betrug das altersstandardisierte 3-Jahres-Überleben 20%-34% (<60 Jahre), 14%-25% (60-69 Jahre) und 9%-13% 
(≥ Jahre) in Stadium I-II PaC, und 2%-5% (<60 Jahre), 1%-2% (60-69 Jahre) und <1%-1% (≥ Jahre) in Stadium III-IV PaC. 
Die operierten Patienten hatten in jeder Phase und Altersgruppe eine höhere 3-Jahres-Überlebensrate (Stadium I-II: 23%-39% 
(<60 Jahre), 16%-31% (60-69 Jahre) und 17%-30% (≥70 Jahre); Stadium III-IV: 5%-19% (<70 Jahre) und 2%-14% (≥70 
Jahre)). Das perioperative Überleben nahm mit fortschreitendem Stadium und höherem Alter ebenfalls ab. Im Zeitraum 
2003-2011 wurden in allen Ländern mit Ausnahme Belgiens Verbesserungen im Kurz- und Langzeitüberleben beobachtet; bei 
resezierten PaC hat sich das Kurzzeitüberleben nur in den USA und Slowenien verbessert, wogegen das Langzeitüberleben in 
allen Ländern mit Ausnahme Sloweniens anstieg, wobei es unterschiedliche Trends in den einzelnen Stadiengruppen gab. 
Bei Patienten mit reseziertem Stadium I-II PaC, die eine Chemotherapie erhalten haben, betrug die mediane 
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Überlebenszeit 18-23 Monate mit 3-Jahres-Überlebensraten von 21%-31%. In der Hauptanalyse waren Patientenalter, 
Tumor-T-Stadium, N-Stadium und Differenzierung unabhängig voneinander in den meisten Ländern mit dem Überleben 
assoziiert, wobei es Unterschiede zwischen den Ländern gab. Resektionsrand, Krankenhaustyp, Tumorgröße, Anzahl der 
positiven und entnommenen Lymphknoten und die Anzahl der Komorbiditäten waren in Ländern mit verfügbaren 
Informationen mit dem Überleben assoziiert. Es wurde ein Nomogramm zur Vorhersage der medianen Überlebenszeit und der 
1- bis 5-Jahres-Überlebenswahrscheinlichkeit auf den SEER-18 Daten erstellt, welches auf prognostischen Faktoren beruht, die 
mithilfe von backward-selection ausgewählt wurden. Dieses Nomogramm erreichte auch gute Vorhersagen in anderen 
europäischen Kohorten. Die Kalibrierungskurven zeigten eine sehr gute Übereinstimmung zwischen Nomogramm-Vorhersage 
und tatsächlicher Beobachtung. Der Konkordanzindex des Nomogramms war signifikant höher als bei einer Vorhersage 
basierend auf T- und N-Stadium. Das Nomogramm wurde sowohl intern mittels Bootstrap als auch extern in den europäischen 
Datensätzen validiert. 
Bei Patienten mit reseziertem Stadium I-II PaC, die im SEER-18 Programm oder im nationalen niederländischen 
Krebsregister registriert wurden, zeigte sich nach Adjustierung für Störfaktoren mit steigender ELN-Zahl signifikante 
Erhöhungen von dem Anteil Lymphknoten-negativer zu Lymphknoten-positiver Erkrankung und kontinuierliche 
Überlebenszeitverbesserungen, sowohl in der Gesamtgruppe als auch in den meisten Subgruppen.  Analysen der SEER-19 
Daten zur Bestimmung der optimalen Anzahl der ELN im Hinblick auf die Stadienvergabe und des Überlebens ergaben einen 
minimalen Schwellenwert von 12 und einen optimalen Schwellenwert von 19 ELN. Diese Schwellenwerte wurden sowohl 
intern als auch extern validiert. 
Zusammenfassend lässt sich sagen, dass in Europa und den USA zu Beginn des 21. Jahrhunderts die Rate der 
PaC-Resektion niedrig bleibt und große internationale Unterschiede aufweist. Der Einsatz von Chemotherapie (aber nicht der 
Radiotherapie) nahm zu, aber die Behandlungsraten waren niedrig und sehr unterschiedlich in den einzelnen Ländern. Diese 
Ergebnisse zeigen die Notwendigkeit einer Standardisierung der PaC-Behandlung zur Verbesserung der Patientenversorgung. 
Außerdem sollten in weiteren Studien die Gründe für diese Unterschiede im Detail untersucht werden. Die Bereitstellung von 
Stadien- und altersspezifischen bevölkerungsbezogenen Überlebensraten für PaC insgesamt und reseziertes PaC wird die 
klinische Beratung erleichtern. Bei Patienten mit Erkrankungen im fortgeschrittenen Stadium und/oder im höheren Lebensalter 
sollte vor der Behandlung eine sorgfältigen Risikobewertung durchgeführt werden. Kleine aber vielversprechende 
Verbesserungen des Überlebens wurden beobachtet. Bei resezierten PaC-Patienten, die eine Chemotherapie erhalten haben, 
sind spezielle Faktoren mit dem Überleben assoziiert, aber die Assoziationen unterscheiden sich zwischen den Ländern. Ein 
robustes Modell zur populationsbasierten personalisierten Überlebensvorhersage, das einfach zu nutzen ist und die 
Patientenauswahl für internationalen Studien erleichtert, wurde mit dieser Arbeit erstellt und international validiert. Mehr 
ELNs sind mit einer präziseren Lymphknoten-Stadienvergabe assoziiert, was die Überlebensassoziation weitgehend erklären 
könnte. 12 und 19 ELNs werden als minimale bzw. optimale Schwellenwerte vorgeschlagen, um die Qualität der 
Lymphknotenuntersuchung zu bewerten und eventuell die postoperative Prognose zu stratifizieren. 
Für Magenkrebs (GC): 
Bei resektablen nicht-metastasierten GCs ist eine Resektion potenziell heilend. Einige metastatische GCs sind technisch 
resektabel. Der GC-Teil dieser Arbeit zielte auf die Untersuchung der Trends in den Resektionsraten bei nicht-metastasierte 
und metastasierte GCs und auf die Erforschung der zugrundeliegenden Gründe für die Trends ab. 
Die Resektionsraten sind bei nicht-metastasierende GC in allen Ländern und bei metastasierende GC in allen Ländern mit 
Ausnahme der Niederlande, Sloweniens und Estlands deutlich gesunken. Patienten mit zunehmendem Alter, mit Kardiakrebs 
oder GC, der in die angrenzende Struktur eingedrungen ist, wurden deutlich seltener operiert. Die Resektion war auch mit dem 
Geschlecht des Patienten, dem Leistungsstatus, den Komorbiditäten, der Tumorhistologie, der Tumorgröße, dem 
Krankenhaustyp und dem Krankenhausvolumen assoziiert. Die Assoziationsmuster und -stärken waren in den einzelnen 
Ländern unterschiedlich. Nach Adjustierung für diese Faktoren blieben die Resektionsraten sowohl bei nicht-metastasierenden 
als auch bei metastasierenden GC jährlich rückläufig. Die Rate der nicht-chirurgischen Therapien stieg, so dass die 
Gesamtbehandlungsraten weitgehend stabil oder leicht ansteigend waren. 
Zusammenfassend lässt sich sagen, dass sowohl nicht-metastasierte als auch metastasierte GCs im frühen 21. Jahrhundert 
in Europa und den USA weniger häufig operativ behandelt wurden. Während die rückläufigen Trends nicht durch die mit der 
Resektionsdurchführung assoziierten Variablen erklärt werden konnten, gingen sie mit einer Zunahme der nicht-chirurgischen 
Therapien einher. Der Einfluss dieser Trends auf Überleben muss in weiteren Studien untersucht werden. 
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